Electronic cigarettes for smokers with schizophrenia spectrum disorders by Caponnetto, Pasquale
1 
 
 
 
 
 
 
ELECTRONIC CIGARETTES FOR 
SMOKERS WITH 
SCHIZOPHRENIA SPECTRUM 
DISORDERS 
 
Pasquale Caponnetto 
Student number: 2431558 
Submitted for the degree of Doctor of Philosophy 
Faculty of Health Sciences and Sport 
University of Stirling 
3 September 2019 
 
 
 
 
 
  
2 
 
ABSTRACT  
Tobacco use is the greatest threat to public health worldwide, killing more than 
seven million people annually. Globally, people with schizophrenia smoke 
disproportionately more than the general population and those with other mental 
illnesses. Consequently, they carry the burden of smoking-attributable morbidity and 
premature mortality. The risk of serious disease diminishes rapidly after stopping 
smoking and life-long abstinence is known to reduce the risk of lung cancer, heart 
disease, stroke, chronic lung disease and other cancers. 
 
This research involved three novel contributions to the literature. First, a qualitative 
study was conducted with 30 current smokers with schizophrenia spectrum 
disorders, some motivated to stop smoking and others with no intention to quit. This 
study explored their views regarding traditional cigarettes compared with e-
cigarettes and licensed cessation aids or e-cigarettes for smoking cessation or 
smoking reduction. In interviews, about half of participants (16 of 30) reported an 
interest in using e-cigarettes to quit or reduce smoking. Of these, four were from the 
less motivated group, suggesting that e-cigarettes may appeal to schizophrenic 
smokers not currently considering cessation.  
 
Secondly, a quantitative, prospective single-arm pilot study was conducted that 
investigated the role of e-cigarettes in smoking cessation or reduction for smokers 
with schizophrenia spectrum disorders. Forty smokers were recruited and 37 of 
these completed the study. Sixteen participants were CO verified as abstinent from 
smoking at the end of the study (40%) and 21 (52.5%) significantly reduced their 
cigarette consumption. The e-cigarette and study procedures were deemed feasible 
and acceptable to participants. Some adverse events were noted but were rare.  
 
Finally, building on these earlier studies, a full protocol for a large multicenter 
randomised controlled study with long term follow-up was prepared. This protocol 
could guide the development of a research proposal for a future trial.   
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CHAPTER 1: INTRODUCTION TO MENTAL HEALTH AND 
SMOKING 
 
This thesis focuses on the topic of electronic cigarettes (e-cigarettes) for smokers 
with schizophrenia spectrum disorders. This introductory chapter on mental health 
and smoking outlines the aim and objectives of the research, introduces the 
research methods employed and outlines the structure of the thesis. It provides the 
background to the topic in terms of a) epidemiology of tobacco smoking and related 
harm amongst the general population; b) epidemiology of tobacco use and related 
harm in the mental health population; c) symptomatology, diagnostic criteria, 
prognosis, aetiology and principal treatments of schizophrenia; d) theory explaining 
high smoking rates and high nicotine dependence in smokers with schizophrenia; 
e) motivation to quit smoking in both the general population and people with 
schizophrenia spectrum disorders; f) smoking cessation treatments in the general 
population and g) smoking cessation treatments for people with schizophrenia 
spectrum disorders. It concludes with comments on the significance of the research 
and why it constitutes an original contribution.   
 
1.1 Aim and objectives 
The main aim of this thesis is to inform the development of future studies to assess 
the potential role of e-cigarettes for smoking cessation or reduction for smokers with 
schizophrenia spectrum disorders. The research studies in the thesis aimed to 
explore whether e-cigarettes are acceptable and feasible for smoking cessation in 
this high priority group.  
 
The objectives of this thesis are to: 
1: Examine the existing literature to inform the design, conduct and interpretation of 
research on e-cigarettes for smoking cessation or reduction in smokers with 
schizophrenia spectrum disorders. 
2. Explore the perceptions of smokers with schizophrenia spectrum disorders 
regarding licensed smoking cessation treatments and e-cigarettes.  
3: Investigate the feasibility and acceptability of e-cigarettes for smoking cessation 
or reduction in smokers with schizophrenia spectrum disorders  
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4: Develop plans for future research on this topic, including a protocol for a future 
multi-site randomised controlled trial (RCT) with longer term follow up. 
 
1.2 Methodology 
The present research employed a mixed design, involving both qualitative and 
quantitative methods. In stage one, using qualitative structured interviews, the 
perceptions of licenced treatments and e-cigarettes for smoking cessation or 
smoking reduction were explored amongst 30 people with schizophrenia spectrum 
disorders who were current smokers. In stage two, a quantitative single-arm pilot 
study with 40 smokers with schizophrenia spectrum disorders, who were not 
motivated to quit, explored the efficacy, acceptability and feasibility of an e-cigarette 
intervention. Both studies were conducted with patients who were receiving care 
from the local Department of Mental Health of the Italian National Health System 
(Servizio Sanitario Nazionale (SSN)). Stage three involved reflecting on this 
research and developing a protocol for a future RCT.  
 
1.3 Structure of the thesis 
This PhD thesis includes six chapters. Details of the remaining chapters are as 
follows.  
 
Chapter two introduces the concepts of tobacco harm reduction (THR) and includes 
a review of relevant literature on e-cigarettes and on the potential effectiveness of 
e-cigarettes as an emerging approach to smoking cessation in the general 
population and amongst patients with schizophrenia. 
 
Chapter three focuses on the first empirical study in the PhD. It describes the 
methods and findings of a qualitative study with 30 smokers with a schizophrenia 
spectrum disorder. It examines their perceptions of smoking traditional cigarettes, 
the appeal of licensed aids for smoking cessation or smoking reduction, and the 
appeal of e-cigarettes for smoking cessation or smoking reduction. The experiences 
of participants who are motivated to quit are compared with those who are not 
motivated to quit.  The chapter includes a discussion about researcher reflexivity 
and limitations of the study.  
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Chapter four describes methods and findings from a (quantitative) single arm pilot 
study with 40 smokers with a schizophrenia spectrum disorder to evaluate the 
feasibility and acceptability of e-cigarettes for smoking cessation or reduction. It 
details the approach to the research and the hypotheses tested. The chapter also 
includes a discussion of the study hypotheses and significance, the contribution of 
the PhD candidate, limitations of the study and indications for future research. 
Chapter five includes a full protocol for a future large RCT to evaluate the efficacy 
of e-cigarettes on smoking cessation or reduction for smokers with schizophrenia 
spectrum disorders. The chapter has the main elements of a standard protocol, 
including title and abstract, introduction, objectives, and methods.  Methods include 
trial design, participants, ethics, interventions, products tested, outcomes, sample 
size, randomisation and statistical methods. 
Finally, chapter six discusses and aims to interpret the findings of this research in 
the context of the wider literature. Strengths and limitations of the present work are 
also presented here. The chapter concludes with implications of the thesis findings 
for clinical practice in the area of mental health tobacco control and suggestions 
for related future research.   
 
1.4 Epidemiology of tobacco smoking and related harm amongst the general 
population 
Amongst the World Health Organization (WHO) regions, in 2015, over 1.1 billion 
people smoked tobacco. Far more males (36.1%) than females (6.8%) smoked 
tobacco. Although it is declining worldwide and in many countries, the prevalence 
of tobacco smoking appears to be increasing in the WHO Eastern Mediterranean 
Region and the African Region. Amongst the WHO regions (Europe, Western 
Pacific, Eastern Mediterranean, America, South-East Asia, and Africa) Europe has 
the highest prevalence of tobacco smoking amongst adults (28%) (WHO, 2018).  
 
In Italy, adult smoking prevalence has consistently decreased since recording 
started in 1957 (Gallus et al., 2013). From 2013 to 2014, Lugo et al. (2015) found 
an overall  smoking  prevalence  amongst  Italian  adults of  21%  (26% of men and 
17% of    women).  This  agrees  with recent data  from a  large   household  survey 
(based  on  60,000  families  and  130,000  individuals)  conducted  in  2013  by the 
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National Institute of Statistics (ISTAT), showing an adult smoking rate of 21% (26% 
in men and 16% in women) (ISTAT, 2015). Another study confirmed the decreasing 
trend observed over the last five decades in men and over the last two decades in 
women (Gallus et al., 2013). However, no significant decrease in terms of smoking 
prevalence has been observed in men or women between 2007 and 2014. This 
likely reflects the lack of adoption of effective and relevant additional antismoking 
measures after the successful ban introduced in 2005 (Joossens & Raw, 2013) and 
smoking prevalence has levelled off over the last few years (OSSFAD (Osservatorio 
Droga Alcol e Fumo), 2016). In 2005 the Italian government banned smoking in all 
indoor public places, including offices, cafes, restaurants (except for a few with 
separate and regulated smoking areas), airports, and railway stations. Italy was the 
first large country in Europe to introduce a comprehensive smoking ban, which 
resulted in a further acceleration of the decreasing trend of smoking prevalence in 
both sexes (Gallus et al., 2006; Tramacere et al., 2009; ISTAT, 2015). In February 
2016, the Italian government established new legislation regarding tobacco 
smoking. New anti-smoking laws have imposed large fines for several offences and 
make it illegal to smoke in a car carrying children or pregnant women. The laws 
require cigarette packs to carry health warnings about the effects of smoking. 
Smoking is also prohibited outdoors near schools and hospitals. Tobacconists 
caught selling cigarettes to minors risk heavy fines and losing their license. Throwing 
cigarette butts on the pavement could cost an offender up to 300 Euros (OSSFAD, 
2016). However, after the positive initial effects of the law of 2005, the prevalence 
of smokers in Italy has not decreased further and has instead remained static 
(OSSFAD, 2018). 
 
Smoking traditional cigarettes is one of the largest risk factors for premature 
mortality from non-communicable diseases in the general population (Stringhini et 
al., 2017). Tobacco use is the greatest threat to public health worldwide, killing more 
than seven million people each year (WHO, 2017). Cigarette smoking is the single 
most preventable cause of death and disease. Smoking-related death is principally 
caused by lung and other cancers, ischemic heart disease and chronic obstructive 
pulmonary disease (COPD) (WHO, 2012; Doll et al., 2004). The risk of serious 
disease   has    been   shown   to    diminish   rapidly   after    smoking   cessation – 
‘quitting’  –  and  permanent  abstinence  markedly  reduces  the risk of lung cancer 
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and other cancers, ischemic heart disease and COPD. Considering that the main 
types of these non-communicable diseases are cardiovascular diseases (CVDs), 
cancers and chronic respiratory diseases, helping traditional cigarette smokers quit 
and remain abstinent is one of the most effective ways we can improve the public 
health of Italy, UK and the rest of the world. The associations between traditional 
cigarette smoking and hazards to physical health are described below. 
 
Cigarette smoking is probably the most complex and the least understood amongst 
the risk factors for CVDs. Cigarette smoke contains several thousand chemicals, 
though there isn’t concordance about the exact number of chemicals. Two studies 
report traditional cigarettes contain ≈4000 different chemicals with sizes ranging 
from atoms to particulate matter (Burns, 1991; Zemann, 2011) and other two more 
recent papers demonstrate tobacco smoke contains more than 7000 chemicals 
(Perfetti & Rodgman, 2013; Tobacco Atlas, 2015). Individual smoking behaviour, 
intensity of smoking and the brand of cigarettes smoked further modulate the 
amount, number, and type of chemicals in tobacco smoke to which an individual is 
exposed (Conrad, 2011). Importantly, it is likely that it is not just a single compound 
or a compound class, such as oxidants, but rather a highly complex and changing 
mixture of compounds that is responsible for disease initiation, progression, and 
cardiovascular outcome. The interplay of these compounds with the individual’s 
genetic background and the environment defines the onset, location, and pace of 
CVDs. For the past few decades, it has been clear that smoking is an important (and 
modifiable) risk factor for CVDs; according to WHO data, smoking is responsible for 
10% of all CVD cases (WHO, 2012). However, for a long time it remained unclear 
how smoking causes CVDs. In 1993, Celermajer et al. (1992) published a study 
showing that smoking reduces flow-mediated dilatation (FMD) in systemic arteries 
in healthy young adults. Smoking not only plays a strong role in CVD initiation, but 
also significantly contributes to and causes disease progression and fatal 
cardiovascular outcomes. Current data clearly show that secondhand smoking can 
also trigger life-threatening conditions. Management and prevention of CVDs is a 
public health priority, and a simple intervention such as smoking cessation could 
lead to reduced prevalence of cardiovascular risk factors and, therefore, CVD itself. 
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There is a clear link between smoking initiation and cancer in later life. Smoking 
causes more than 48% of deaths from the 12 types of cancer caused by smoking. 
Smoking causes more than 80% of lung cancer deaths as well as 77% of larynx 
cancer deaths (Siegel et al., 2015). Approximately 168,000 people in the United 
States are estimated to die of cancer due to smoking each year. Continued progress 
in reducing cancer mortality will require more comprehensive tobacco control, 
including targeted cessation support (de Marco et al., 2004; Siegel et al., 2015). In 
Europe, the incidence of lung cancer ranges from eight to 62 per 100,000 persons, 
while prevalence ranges from 26 to 242 per 100,000 persons (Jimenez-Ruiz et al., 
2011). In Europe, death rates from lung cancer increased by 58% between 1960 
and 1988, but they declined by 14% in 1998, mainly due to the decreased incidence 
and mortality in males (Ezzati et al., 2003). The risk of developing lung cancer 
seems to be affected by the duration of smoking and the number of cigarettes (or 
cigars, or pipes) smoked daily (La Vecchia et al., 2003). The relative risk (RR) ratio 
between the occurrence of lung cancer amongst smokers and nonsmokers is 15 
overall and 25 for heavy smokers (Doll et al., 2004). Reducing the intake of 
traditional cigarettes smoked per day may support a harm reduction approach but 
the US Cancer Prevention Study II has shown that the number of years of tobacco 
smoking is far more critical in predicting lung cancer risk than the number of 
cigarettes smoked daily (Alberg & Samet, 2003). The age of starting smoking 
increases lung cancer risk (Flanders et al., 2003); hence, promoting interventions to 
avoid smoking initiation (typically during the adolescence) are important. 
 
Smoking is also the main cause of many respiratory diseases (UCDC, 2004). COPD 
is predicted to become the third leading cause of death in 2030 (WHO, 2008). 
Cigarette smoking is the most important risk factor for COPD and it can also promote 
the onset of exacerbations (Wedzicha & Donaldson, 2003). Data collected in 
European countries show that self-reported diagnosis of chronic 
bronchitis/emphysema (Viegi et al., 1999) or spirometry signs of airflow obstruction 
(Lundback et al., 2003) are more frequent in smokers than nonsmokers. The risk of 
developing COPD may be increased not only by the average daily number of 
cigarettes smoked but even more by cumulative pack-years (Viegi et al., 1999). 
Moreover, a study has shown that smokers with COPD have higher tobacco  
consumption, higher CO levels in exhaled air and higher dependence on nicotine 
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than healthy smokers (Lundback et al., 2003). However, despite COPD being 
considered as a smoking-related lung disorder, not all traditional cigarette smokers 
develop this disease. Faner et al. (2014) showed that some smokers may develop 
irreversible lung obstruction, which is linked with their epigenetic and genetic 
background (DeMeo et al., 2004) but smoking cessation plays a central role in 
COPD avoidance. 
 
Cigarette smoking is also a risk factor for male and female sexual and reproductive 
dysfunctions. In particular, it is a risk factor for the onset of erectile dysfunction and 
traditional cigarettes contain elements that exert a direct harmful effect on male and 
female germ cells and embryos (Zenzes et al., 2000). Tobacco use amongst women 
during their reproductive years is especially dangerous because of the potential for 
multi-generational harm. Smoking is associated with poorer pregnancy outcomes 
including infertility, ectopic pregnancy, increased rates of spontaneous abortion and 
still births. Smoking contributes to preterm birth, low birth weight, increased rates of 
infant chronic lung disease, wheezing, and an increased risk for Sudden Infant 
Death Syndrome (DiFranza & Lew, 1996). 
 
1.5 Epidemiology of tobacco smoking and related harm in the mental health 
population  
 
1.5.1 Prevalence of smoking  
Around 60-90% of people with schizophrenia are estimated to smoke, compared 
with 15-24% of the adult general population (Keltner & Grant, 2006; Ziedonis et al., 
2008; Diaz et al., 2009; Kotov et al., 2010; Dickerson et al., 2013; Smith et al., 2014, 
Davies 2014). The difference of 30 percentage points from 60% to 90% is large and 
may reflect the geographic location of the study or a different classification system 
used for schizophrenia spectrum disorders diagnosis, for example DSM 
classification used by the American Psychiatric Association (APA) or International 
Classification of Diseases (ICD) classification used by the WHO.  
Alternatively, the wide range in prevalence may be due to methodological 
differences between studies. As in the general population, in the study of de Leon 
& Diaz (2005), more males than females with schizophrenia were smokers (76% of 
males vs 50% of females). 
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The association between smoking and mental health conditions becomes stronger 
relative to the severity of the mental condition, with the highest levels of 70% 
smoking found in psychiatric in-patients (RCP, 2013; Jochelson et al., 2007). It was 
estimated in 2013 that of the ten million smokers in the UK about three million had 
a mental health condition (RCP, 2013).  
 
DSM-V (APA, 2013) describes 157 specific diagnoses. It is therefore important not 
to view ‘mental health conditions’ as one group, just as one would not consider 
‘physical health’ as one condition.  It is true that there is a high level of smoking 
prevalence amongst individuals with mental health conditions but it varies according 
to the actual mental health conditions, e.g. schizophrenia, anxiety disorders, major 
depression, bipolar disorder (Caponnetto, 2014). Rates of cigarette smoking 
amongst adults in the United States and United Kingdom are two to four times higher 
in people with current mood, anxiety, and psychotic disorders than in those without 
mental illness (Lasser et al., 2000; Lawrence et al., 2009). Between 2004 and 2011, 
after controlling for risk factors such as income, education, and employment, current 
smoking rates dropped from 19.2% to 16.5% in US residents without mental illness 
but not in those with mental illness (Cook et al., 2014).  
 
1.5.2 Smoking behaviour 
A study with more than 9000 people with severe psychotic disorders found that 
these people had a higher risk of having ever smoked 100 cigarettes (odds ratio 
(OR) 4.61, 95% confidence interval (CI) 4.3 to 4.9) relative to the general population 
after controlling for sex, race, age, and geographical region (Hartz et al., 2014). 
Hughes et al. (1986) reported that people with chronic mental illness had 
substantially higher smoking rates than control samples across age, sex, marital, 
socioeconomic, and alcohol use subgroups, and the smoking rate was particularly 
high (88%) in patients with schizophrenia.  
 
 
A meta-analysis of five studies across four countries established that tobacco 
smoking was associated with a schizophrenia diagnosis (OR = 5.9), heavier 
smoking (ORs ranged 1.9–6.4), higher nicotine dependence and lower cessation 
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rates compared with general population controls (de Leon & Diaz, 2005). Even 
patients with first-episode psychosis are much more likely to smoke than age-
matched controls, as confirmed in a meta-analysis (OR = 6.04) (Myles et al., 2012).  
 
In 2013, Zhang et al. enrolled 244 drug-naive smokers with schizophrenia and 256 
healthy controls matched for gender, age and education, completed the Fagerström 
Test for Nicotine Dependence and showed that smokers with schizophrenia 
spectrum disorders are heavier smokers than those without a mental health 
condition (Zhang et al., 2013). However, it is important to outline that the study 
conducted by Zhang et al., (2013) included exclusively never-medicated participants 
presenting with first episode of schizophrenia.  
 
In 2005,  Tidey  et  al.  enrolled  20  smokers with schizophrenia spectrum disorder 
and 20 smokers without psychiatric disorders and measured their smoking 
topography.  The participants were matched on age, gender, daily cigarette rate, 
years of  regular  smoking  and  nicotine  dependence. Tidey et al. (2005) reported 
that smokers with schizophrenia spectrum disorders take more frequent puffs and 
inhale more carbon monoxide (CO) per traditional cigarette and are highly 
dependent on nicotine compared with people in the general population. However, 
this   study   is   limited   by the  small  sample  size.  Smokers  with  schizophrenia 
spectrum disorders also extract more nicotine from their cigarettes compared with 
controls without schizophrenia spectrum disorders and have higher levels of nicotine 
in their blood after smoking one cigarette (Williams et al., 2010a).   
However, this study was limited by a small sample size of 21 participants (11 with 
schizophrenia spectrum disorders and 10 without) who smoked 20-30 traditional 
CPD. A further study by Williams et al. (2011), using a larger sample, measured 
serum nicotine levels and ad libitum smoking behaviour for 24 + two hours using a 
topography device in 75 smokers with schizophrenia compared with 86 control 
smokers without mental illness. They reported that  smokers with   schizophrenia   
differed  from smokers without schizophrenia in that they took more frequent puffs 
per traditional cigarettes smoked, which was associated with greater nicotine intake, 
and waited less time between puffs. 
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1.5.3 Effect of smoking on the mortality and physical health of people with 
schizophrenia spectrum disorders 
As a result of high smoking rates, people with a mental health condition also have 
high mortality rates compared with the general population. Therefore, quitting 
smoking is particularly important for this group since smoking is the single largest 
contributor to their reduced life expectancy (Campion et al., 2014). The deleterious 
effects of smoking seem particularly pronounced and burdensome amongst people 
with schizophrenia (Brown et al., 2000; Kelly et al., 2011). Smokers with 
schizophrenia die early from diseases associated with smoking (15-20 years earlier 
than the general population) and this is often due to preventable smoking-related 
health conditions rather than suicide (Saha et al., 2007).  
 
In the United States, results from a recent retrospective longitudinal national review 
of premature mortality amongst 1,138,853 adults with schizophrenia demonstrated 
excess deaths from lung cancer, cardiovascular and respiratory diseases (Olfson et 
al., 2015). It is important to note that the findings from this research showed an 
excess of deaths especially due to cardiovascular and respiratory disease for which 
traditional cigarette use is a fundamental risk factor (but not the only one, because 
the use of other substances, such as alcohol, was also involved. The authors 
highlight a number of limitations in their study without considering the side effects of 
some antipsychotics, such as Clozapine, on cardiovascular parameters. 
 
In people with schizophrenia spectrum disorder, the risk of mortality is doubled 
(Heiberg et al., 2018). About 50% of deaths in patients with chronic mental illness 
are due to tobacco-related cancers, respiratory diseases, and cardiovascular 
conditions (Kelly et al., 2011; Callaghan et al., 2014). Callaghan et al. (2014) found 
in a large-scale follow-up study that tobacco-related conditions comprised 
approximately   53%  (23.620/44.469)  of  total  deaths  in  the  schizophrenia  cohort, 
48%  (6.004/12.564)  in the   bipolar   cohort,   and   50%   (35.729/71.058)   in   the 
depression cohort. This included an increased risk  of tobacco-related deaths  from 
cancer (standardised mortality ratio (SMR) 1.30, 95% CI 1.3–1.4), cardiovascular 
disease (SMR 2.46, 95% CI 2.41–2.50) and respiratory diseases (SMR 2.45, 95% 
CI 2.41–2.48) (Callaghan et al., 2014). However, these data refer exclusively to 
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smokers who received in-patient treatment and cannot be generalized to other 
smokers treated as outpatients.  
 
Moreover, people with schizophrenia who smoke have poorer health compared with 
people with schizophrenia who do not smoke (Aubin et al., 2012).  
An increased rate of smoking amongst subjects with schizophrenia spectrum 
disorders contributes to multiple negative health effects compared with the general 
population (Beary et al., 2012).  
Specifically, several studies have shown that people with schizophrenia spectrum 
disorders have a significantly higher prevalence of cancer (Sokal et al., 2004), 
respiratory diseases (Sokal et al., 2004; Carney et al., 2006; Batki et al., 2009; Partti 
et al., 2015), and CVDs (Sokal et al., 2004; Carney et al., 2006;  Batki et al., 2009) 
compared with the general population (Sokal et al., 2004; Carney et al., 2006;  Batki 
et al., 2009).  
A recent study conducted by Partti et al. (2015), showed smokers with schizophrenia 
had a greater likelihood of suffering from comorbid COPD compared with the 
general population, reporting an OR of 4.23 (1.61, 11.10). Based on these findings, 
COPD is more common in smokers with schizophrenia spectrum disorders 
compared with the general population. Other studies have also shown an increased 
risk of death from cancer (Tran et al., 2009; Partti et al., 2015) and cardiovascular 
disease (Druss et al., 2001; Osborn et al., 2007; Lawrence et al., 2013) with an 
approximately 12-fold increased risk of cardiovascular death in smokers compared 
with non-smokers (Kelly et al., 2011). 
 
1.5.4 Effect of smoking on the mental health of people with schizophrenia 
spectrum disorders 
Amongst smokers with schizophrenia spectrum disorders, smoking is associated 
with depressive symptoms, increased hospitalizations, stress, poor treatment 
outcomes, low quality of life, and enhanced psychotic symptoms (Dixon et al., 2007). 
 
The association between tobacco addiction and neurocognitive performance in 
smokers with schizophrenia spectrum disorders is unclear. Several studies have 
demonstrated that nicotine administration has a role in enhancing cognition in 
schizophrenia, particularly for the attention/vigilance domain (Harris et al., 2004; 
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Smith et al., 2005; Hahn et al., 2013). Furthermore, the studies assessed several 
cognitive tests with different outcomes but the majority failed to control for multiple 
comparisons on cognitive assessment and the brief duration of these studies have 
not confirmed the long-term benefits to attention/vigilance. Recently, evidence has 
demonstrated that smoking may have a detrimental effect on the working memory 
(Lee et al., 2015) and hippocampal volume (Schneider et al., 2014) of people with 
schizophrenia. A recent systematic review and meta-analysis of comparative 
studies conducted by Wang et al. (2019) explored cognitive functions in smokers 
and non-smokers with schizophrenia spectrum disorders and found that smokers 
with schizophrenia spectrum disorders had lower neurocognitive performance in 
cognitive tasks than non-smokers with schizophrenia spectrum disorders. 
 
In a recent systematic review and meta-analysis, Huang et al. (2019) explored the 
effect of traditional cigarette smoking on different psychopathological positive and 
negative symptoms of schizophrenia. Their meta-analysis of 24 studies examined 
positive and negative symptoms scores as assessed by the Positive and Negative 
Syndrome Scale (PANSS) or the Scale for the Assessment of Positive Symptoms 
(SAPS)  and the Scale for the Assessment of Negative Symptoms (SANS) in 2322 
smokers and 2319 non-smokers with schizophrenia spectrum disorders and showed 
that smokers had more severe positive symptoms than non-smokers (SMD = 0.33, 
95% CI: 0.16 to 0.50, P < 0.001) but the same study did not find any significant 
difference between smokers and non-smokers for negative symptoms (SMD = 0.11, 
95% CI: −0.06 to 0.28, P = 0.21). This systematic review and meta-analysis (Huang 
et al., 2019) also investigated extrapyramidal side effects of smokers and non-
smokers with schizophrenia spectrum disorders and showed less severe 
extrapyramidal side effects in smokers than non-smokers (SMD = −0.20, 95% CI: 
−0.38 to −0.02, P = 0. 03). The strength of this systematic review and meta-analysis 
is that it included a large number of studies; however, it is important to consider that 
different diagnostic scales (using different items and therefore producing different 
scores) were used. 
 
In schizophrenia spectrum disorders, smoking traditional cigarettes is associated 
with increased psychopathological symptoms and increased hospitalizations 
(Ziedonis et al., 1994). Kobayashi et al. (2010) conducted a retrospective study with 
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460 discharged patients with schizophrenia spectrum disorders in Japan. Smoking 
status and hospital psychiatric readmissions were reviewed and it was observed 
that psychiatric hospital readmission rates were significantly higher in smokers with 
schizophrenia compared with smokers without schizophrenia (HR = 1.78). 
Participants were voluntarily admitted to psychiatric hospitals for the first time and 
findings cannot be generalized to other populations or people in different stages of 
this illness. Smoking is also associated with an increased need for higher psychiatric 
medication doses. Cigarette smoking increases the activity of the cytochrome P450 
1A2 (CYP1A2) liver enzyme system, thus reducing the blood concentrations of 
many drugs (Sagud et al., 2009) and this process can also have an impact on 
antipsychotic medication. A recent meta-analysis conducted by Tsuda et al. (2014) 
found that two commonly used antipsychotics in the treatment of schizophrenia 
spectrum disorders, olanzapine and clozapine, should be increased by 30% and 
50%, respectively, in smokers compared with non-smokers in order to obtain an 
equivalent olanzapine or clozapine blood levels. 
 
It has been suggested that smoking could act as a trigger for mental ill-health (West 
& Jarvis, 2005). Two recent meta-analyses conducted respectively by Gurillo et al. 
(2015) and Hunter et al. (2018) showed that smokers of traditional cigarettes have 
an ~two-fold increased risk of developing schizophrenia spectrum disorders. Gurillo 
et al. (2015) included five studies and reported an increased risk of developing a 
schizophrenia spectrum disorder in smokers compared with non-smokers (RR = 
2.18; 95% CI 1.23–3.85). Also, Hunter et al. (2018) included five studies and 
reported a similar result (RR = 1.99; 95% CI 1.10–3.61), but in conclusion, further 
studies are needed to explore the association between traditional cigarette smoking 
as a predictor of developing a schizophrenia spectrum disorder. 
 
1.6 Schizophrenia spectrum disorders: symptomatology, diagnostic criteria, 
prognosis, aetiology and principal treatments  
Mental health conditions comprise a broad range of psychological conditions, with 
varying symptoms, characterized by a combination of abnormal thoughts, emotions, 
behaviour and relationships with others (WHO, 2010). As mental conditions are 
often defined as much by the severity of their symptoms as by the occurrence of 
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specific symptoms, diagnosis frequently relies on an assessment of the impact of 
symptoms on functioning (RCP, 2013).  
 
Schizophrenia spectrum disorders are a range of linked conditions sometimes 
extending to include singular symptoms and disorders as they relate to psychology; 
they also refer to patterns of behaviour that impact multiple life areas and create 
distress for the person suffering them. Schizophrenia spectrum disorders are a 
range of disorders with the same symptoms as schizophrenia. Some of these 
disorders are delusional disorder, schizoaffective disorder, schizophreniform 
disorder, schizotypal personality disorder, and schizoid personality disorder (APA, 
2013). 
 
Schizophrenia is one type of chronic and severe mental illness. It is a 
heterogeneous mental disorder characterized by disturbances in emotion, 
behaviour and thought (WHO, 2001). The National Institute of Mental Health (NIMH, 
2016) describes this disorder as a chronic and severe mental illness affecting how 
someone thinks, feels, and behaves. People affected by schizophrenia experience 
some of the most challenging clinical signs and symptoms evidenced by any mental 
disorders.   
A review of 41 studies by Tajima-Pozo and colleagues suggested that schizophrenia 
is associated with a particularly high burden to society as many affected individuals 
are unable to work, and a substantial proportion may need additional help from 
caregivers (Tajima-Pozo et al., 2015). Schizophrenia is a mental disorder 
characterized by reduced emotional expression, abnormal social behaviour and the 
inability to distinguish what is real from what isn’t. Persons with schizophrenia might 
talk about hearing voices, experience hallucinations, and suffer delusions. 
According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-V) (APA, 2013), schizophrenia affects men slightly more than women and 
typically begins in late adolescence or early adulthood. A diagnosis of schizophrenia 
requires two or more DSM-V Criterion A symptoms to be present for at least one 
month. The symptoms must include a delusion, hallucination, or disorganized 
speech. Other clinical signs and symptoms might include grossly disorganized or 
catatonic behaviour and negative symptoms (APA, 2013). Additionally, there must 
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be a decrease in the individual’s level of functioning and signs of the illness must 
persist for at least six months (APA, 2013).  
 
The DSM-V diagnostic criteria for schizophrenia are: 
• Two or more of the following symptoms for a significant portion of 
time for at least one month; at least one symptom should be either 
1, 2, or 3: 
(1) Delusions 
(2) Hallucinations 
(3) Disorganized speech 
(4) Grossly abnormal psychomotor behavior (e.g., catatonia) 
(5) Negative symptoms (i.e., restricted affect or 
avolition/asociality) 
• Functioning in work, relationships, or self-care have declined since 
onset 
• Signs of disturbance for at least six months; at least one month of 
symptoms above; or, if during a prodromal or residual phase, 
negative symptoms or two or more of the symptoms in attenuated 
form. 
 
The DSM-V diagnostic criteria for delusional disorder are: 
• An illness characterized by at least one month of delusions but no 
other psychotic symptoms.  
• Delusions are false beliefs based on incorrect inference about 
external reality that persist despite the evidence to the contrary; these 
beliefs are not ordinarily accepted by other members of the person's 
culture or subculture. 
• Delusions can be characterized as persecutory, referential, 
grandiose, erotomanic, nihilistic, or somatic.  
 
The DSM-V diagnostic criteria for schizoaffective disorder are:  
• Presence of a generally continuous psychotic illness plus intermittent 
mood episodes for at least one month.  
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• Mood episodes are present for the majority of the total duration of the 
illness, which can include either one or both of the following: Major 
depressive episode (must include depressed mood); Manic episode 
• The psychotic illness criteria resemble Criterion A of the 
schizophrenia diagnosis 
 
The DSM-V diagnostic criteria for schizophreniform disorder are characterized by 
the presence of the symptoms of schizophrenia, but it is distinguished from that 
condition by its shorter duration, which is at least one month but less than six 
months. 
 
The DSM-V essential features of the schizotypal personality disorder are: 
• Significant impairments in personality functioning manifest by: 
o Impairments in self functioning. 
o Impairments in interpersonal functioning. 
• Pathological personality traits in the following domains: 
o Psychoticism. 
o Detachment. 
o Negative Affectivity. 
 
 
The DSM-V essential features of the Schizoid personality disorder are: 
• A persistent pattern of disinterest from social interactions and a 
limited variety of expression of emotions in a close personal 
setting as shown by at least four (or more) of the subsequent: 
• neither wants nor likes close relationships, counting being part 
of a family 
• almost constantly picks introverted activities 
• has little if any, thought in engaging in any sexual experiences 
• seldom derives pleasure from any activities 
• has no close friends other than immediate relatives 
• appears apathetic to the admiration or disapproval of others 
• shows emotional coldness, detachment, or flattened affectivity 
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Symptoms can be distinguished by positive, negative, cognitive and disorganized 
symptoms (APA, 2013; NIMH, 2016). Positive symptoms include excesses and 
distortions, hallucinations, delusions, or thought disorders. Negative symptoms are 
associated with disruptions in normal emotions or behaviours, and include a 
flattened affect, avolition, alogia, anhedonia, and asociality reduced feelings of 
pleasure, difficulty beginning or sustaining activities, or reduced speech. Cognitive 
symptoms, which might be subtle or severe, include difficulties with executive 
functioning (i.e. planning and decision making), focus, attention, or memory. 
Disorganized symptoms include disorganized speech and disorganized behaviour 
(APA, 2013; NIMH, 2016).  
 
Schizophrenia has a lifetime prevalence of approximately 0.5 to 1%, though 
schizophrenia spectrum disorders and subclinical traits likely affect a much broader 
segment of the population (Lenzenweger, 2006; Owen et al., 2016). Once a 
diagnosis is made, a person living with schizophrenia spectrum disorders will 
fluctuate between three distinct phases: the acute phase, stabilization, and the 
stable (or chronic) phase (APA, 2013). The acute phase may develop gradually or 
suddenly. Symptoms are often severe and individuals require professional help. 
During stabilization, treatment is initiated (or re-initiated) and there is a reduction in 
acute symptoms. Finally, in the stable phase, acute symptoms are managed, but 
some functional disability may persist (APA, 2013). Despite advances in the 
treatment of schizophrenia spectrum disorders, many patients continue to show 
persistent negative (Chue & Lalonde., 2014) and positive symptoms of 
schizophrenia (Suzuki et al., 2012).  
 
It has been estimated that around two-thirds of patients still experience significant 
positive symptoms two years after initiation of antipsychotic treatment, and 
approximately 33% will continue to experience these symptoms six years after 
diagnosis of schizophrenia (Novick et al., 2009). Poorly controlled positive 
symptoms lead to poor patient outcomes such as relapse, rehospitalization, 
impaired functioning, and a reduced quality of life (Novick et al., 2009; Jordan et al., 
2014).  Many  patients  experience   persistent   negative   symptoms   even   after 
control of positive symptoms (Chue and Lalonde, 2014). Severe negative symptoms 
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are a predictor of poor patient functioning and also contribute to worse patient 
outcomes (Jordan et al., 2014).  
 
People with schizophrenia spectrum disorders with persistent symptoms represent 
a great challenge in their treatment management and, given the disorders’ 
complexity, scientific literature shows a number of causal factors are likely to 
contribute.  
 
The genetic evidence is strong, with much of the evidence coming from family, twin, 
and adoption studies. Learning what is inherited remains a challenge for molecular 
genetics studies (Walker et al., 2008). Linkage studies have found linkage on 
several chromosomes, but these studies need to be replicated.  
 
Neurotransmitters play a role in schizophrenia spectrum disorders. For years, 
dopamine was the focus of study, but later findings led investigators to conclude 
that this one neurotransmitter could not fully account for schizophrenia. Other 
neurotransmitters are also the focus of study, such as serotonin, gamma-
Aminobutyric acid (GABA), and glutamate (Volk et al., 2000; MacDonald et al., 
2006). A number of different brain areas have been implicated in schizophrenia. 
One of the most widely replicated findings is of enlarged ventricles (Hajima et al., 
2013). Other research supports the role of the prefrontal cortex, particularly reduced 
activation of this area, in people with schizophrenia spectrum disorders (Ohtani et 
al., 2014).  Some of these structural abnormalities could result from maternal viral 
infection during the second trimester of pregnancy or from damage sustained during 
a difficult birth (Walker et al., 2004).  
 
Early developmental studies looked back at the childhood records of adults with 
schizophrenia spectrum disorders and found that some adults with schizophrenia 
spectrum disorders had lower intelligence quotients (IQs) and were withdrawn and 
delinquent as children (Berry, 1967; Watt, 1974). Other studies found that adults 
who later developed schizophrenia spectrum disorders expressed a lot of negative 
emotion and had poor motor skills (Walker et al., 1993; Walker et al., 1994) and 
these studies have found that children at risk for adult schizophrenia spectrum 
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disorders have difficulties with attention and motor control, amongst other things 
(Woodberry et al., 2008). 
 
During the acute phases of the illness, treatment of schizophrenia spectrum 
disorders most often includes a combination of short-term hospital stays, medication, 
and psychosocial treatment. Antipsychotic drugs have been widely used to treat 
schizophrenia since the 1950s. Second-generation antipsychotic drugs, such as 
clozapine, olanzapine and risperidone, are effective and produce fewer motoric side 
effects compared with first generation drugs, though they have their own set of side 
effects (McEvoy et al., 2014). Drugs alone are not a completely effective treatment, 
though, as people with schizophrenia spectrum disorders need to be re-taught ways 
of dealing with the challenges of everyday life (Kreyenbuhl et al., 2010). 
 
Family psychotherapy aimed at reducing high levels of expressed emotion has been 
shown to be valuable in preventing relapse in people with schizophrenia spectrum 
disorders (Guo et al., 2010). Psychoeducation and social skills training have helped 
people with schizophrenia spectrum disorders meet the inevitable stresses of family 
and community living (Kopelowicz et al., 2002). Efforts to change the thinking of 
people with schizophrenia spectrum disorders by strategies emerging from cognitive 
behavioural therapy (CBT) are showing promise as well (Elis et al., 2013). In 
conclusion, the most promising approaches to treatment today emphasize the 
importance of both pharmacological and psychosocial interventions.  
 
1.7 Theory explaining high smoking rates and high nicotine dependence in 
smokers with schizophrenia spectrum disorders 
The reasons for the high frequency of both high nicotine dependence and high 
smoking prevalence in patients with schizophrenia spectrum disorders are 
incompletely understood. Explanations for the phenomenon of high rates of smoking 
are included in the next subsections. Illness-related factors, patient-related factors 
and health service-related factors have been considered in an attempt to find a 
reason for the relationship between high smoking rates and schizophrenia but have 
failed to arrive at decisive conclusions.  
 
1.7.1 Illness-related factors 
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Studies have presented a number of illness-related reasons for high smoking rates 
and high nicotine dependence in smokers with schizophrenia spectrum disorders. 
Nicotine evokes its physiological effects by binding with nicotine acetylcholine 
receptors (nAChRs) and strengthens rewards from brain stimulation. nAChRs also 
play an essential role in cognitive processes such as memory and learning (Yann et 
al., 2008) and researchers have shown abnormalities of nAChRs in people with 
schizophrenia (D’Souza & Markou, 2012; Parikh et al., 2014). 
Schizophrenia is linked to elevated dopamine levels in dorsal striatum and reduced 
cortical dopamine release (Howes et al., 2017).  Dopamine is a neurotransmitter 
system influenced by nAChRs (Albuquerque et al., 2009). All antipsychotic 
medications act on the dopaminergic system by blocking dopamine receptors of the 
D2-type family (Ellenbroek, 2012). Nicotine increases dopamine levels in the 
striatum by stimulating its release via nicotinic receptors and decreasing its 
degradation by inhibiting monoamine oxidase A and B. These produce a stimulation 
effect and a reduction of anti-psychotic extrapyramidal side effects (Sagud et al., 
2009). It has been suggested that in people with schizophrenia spectrum disorders, 
traditional cigarette smoking is a way to self-medicate by reducing problems 
associated with antipsychotic treatment (e.g extrapyramidal symptoms) and 
reducing positive and negative psychotic symptoms (Leonard & Adams, 2006), 
attempting to remediate cognitive performances as a result of the underlying 
schizophrenia spectrum disorders symptoms and stimulating attention and working 
memory (Sacco et al., 2005).  
However, some aspects of the above theories are questionable.  For example, if 
smoking traditional cigarettes reduces problems associated with antipsychotic 
treatment, tobacco consumption in smokers with schizophrenia should change with 
changes of antipsychotic drugs.  Also, smokers and non-smokers with 
schizophrenia should show significant differences in their behaviours in terms of 
positive and negative symptoms phenomenology.   
Kumari & Postma (2005) suggested the smoking rate in people with schizophrenia 
increased due to nicotine’s improving effect on schizophrenia symptoms. Studies 
have described positive neurocognitive effects of nicotine in principal cognitive 
domains (attention, processing speed, working memory, and psychomotor abilities) 
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in individuals with cognitively impaired people with schizophrenia. 
Research conducted by Barr et al. (2008a) examined the effect of transdermal 
nicotine (14 mg nicotine patches) and placebo in non-smoking individuals with 
schizophrenia (n=28) and healthy controls (n=32) in a within-subject study and 
showed that nicotine improved cognitive performance in both groups in terms of 
attention, but patients with schizophrenia showed greater improvement in inhibition 
and impulse control compared with healthy controls. In a second study, Jubelt et al. 
(2008) investigated the effect of transdermal nicotine on episodic memory 
performance in non-smoking individuals with (n=10) and without schizophrenia 
(n=12). Compared with placebo control conditions, both groups increased in 
processing speed and accuracy in recognising novel objects but there was a trend 
for a stronger nicotine-induced effect in schizophrenic patients in the reduction of 
false alarms and this is important considering that memory deficits are associated 
with functional impairment in schizophrenia and that impaired novelty detection has 
been linked to the positive symptoms of schizophrenia. However, it’s important to 
consider that these findings refer to non-smokers with schizophrenia using nicotine 
not delivered by traditional cigarettes.  
Further studies have assessed the impact of nicotine intake on cognitive function in 
people with schizophrenia spectrum disorders (D’Souza & Markou, 2012). Despite 
the differences in level of nicotine dependence, severity of nicotine withdrawal, 
craving and satiety and method of nicotine administration (gum, transdermal patch, 
nicotine nasal spray) amongst participants in several different research studies, 
findings suggest nicotine administration has a role to play in enhancing cognition in 
schizophrenia, particularly for attention/vigilance (Harris et al., 2004; Smith et al., 
2005; Hahn et al., 2013). However, none of these studies has used cognitive 
psychodiagnostic tools specifically designed for people suffering from schizophrenia 
spectrum disorders, such as the Brief Assessment of Cognition in Schizophrenia 
(BACS) (Kefee et al., 2004), or MATRICS Consensus Cognitive Battery (MCCB) 
scales (Nuechterlein et al., 2008), but have instead used psychodiagnostic tools 
created for the general population such as the Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS) (Randolph et al., 1998), Spatial 
Attentional Resource Allocation Task (SARAT) (Hahn et al., 2006), and Singleton 
Detection Task or  Continuous Performance Task (CPT) (Conner, 2000).  
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A Spanish study (Aguilar et al., 2005) explored the association between frequency 
of smoking and severity of positive symptoms and number of hospitalisations 
amongst 250 outpatients with schizophrenia. Patients were classified into three 
categories: highly dependent smokers, mildly dependent smokers and non-
smokers. High PANSS total scores and positive symptoms were less frequent in 
mildly dependent smokers than in non-smokers or highly dependent smokers. The 
highly dependent smokers had the worst outcomes.  Aguilar et al. (2005) argued 
that their data did not support the self-medication hypothesis but rather suggested 
a complex interaction between nicotine dependence and symptoms of 
schizophrenia. 
The self-medication theory has generated further criticism; for example Manzella et 
al. (2015) generated a list of predictions from the self-medication hypothesis applied 
to smoking traditional cigarettes in patients with schizophrenia spectrum disorders 
and concluded that further consideration of the neurophysiological data was needed 
to resolve the countering effects of nicotine-dopamine interactions on negative and 
positive symptoms of schizophrenia. Secondly, the evidence is contradictory that 
smokers with schizophrenia spectrum disorders have fewer signs and symptoms 
than non-smoking patients.  Thirdly, there is no information whether smoking 
traditional cigarettes reduces undesirable side effects of antipsychotic 
pharmacological treatments while leaving unmodified the positive effects of these 
drugs. Environmental and genetic aspects play roles in the aetiology and progress 
of nicotine addiction and schizophrenia. Patients affected by schizophrenia have 
abnormal expression of certain genes which are common to nicotine addiction and 
schizophrenia disorder (Riley et al., 2000; Mexal et al., 2010; Purcell et al., 2014; 
Owen et al., 2016). However, this does not completely explain the high smoking 
rates in smokers with schizophrenia spectrum disorders. 
  
1.7.2 Patient-related factors 
Another possible explanation could be that smokers with schizophrenia spectrum 
disorders have a subjectively more rewarding experience when smoking compared 
with others. For example, Spring et al. (2003) studied the reward value of smoking 
traditional cigarettes (compared with other pleasant activities, e.g., eating their 
favourite candy, seeing a movie, receiving a gift) in individuals with schizophrenia 
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(n=26) as well as healthy controls (n=26). All participants were nicotine-dependent, 
heavy smokers who had smoked since their teenage years and there were no 
differences between groups in the number of cigarettes smoked per day at baseline 
(BL). Their findings showed that participants did not differ in their perception of 
negative consequences related to smoking traditional cigarettes. However, smokers 
with schizophrenia differed significantly from controls in their evaluation of positive 
smoking-related effects. Although they recognized smoking related disadvantages 
to the same extent as the general population, they perceived more benefits and 
found traditional cigarettes more appealing than alternative rewards, indicating that 
their higher smoking rates are mediated by reward-related experiences. However, 
this study only considered that traditional cigarette smoking, and not exclusively 
nicotine, had greater reward value for smokers with schizophrenia. Future research 
should differentiate between nicotine and cigarette smoking and its reinforcing 
effects associated with sensorial and behavioural impact on reward perception. 
 
In 298 smokers with psychosis living in the community, Baker et al. (2007) reported 
that, compared with general population samples, patients with psychosis were more 
likely to indicate that addiction, stimulation and stress management were reasons 
for smoking traditional cigarettes. Dixon et al. (2007) examined the correlates and 
sequelae of smoking severity in 304 smokers with schizophrenia. Greater smoking 
severity was associated with poorer overall self-reported subjective quality of life, 
greater perceived stress, and lower satisfaction with relaxation activities, social 
relationships, finances and health amongst persons with schizophrenia. Greater 
smoking severity was also associated with greater perceived stress, poorer overall 
subjective quality of life, and lower satisfaction with finances, health, leisure 
activities, and social relationships (Dixon 2007). Some people with schizophrenia 
perceive that smoking traditional cigarettes helps to manage stress, whereas heavy 
smokers report increased stress levels. 
 
A study of Esterberg & Compton conducted in 2005 used semi-structured interviews 
to explore reasons for smoking amongst 12 smokers (ages 19 to 43 years, median 
25.5) with schizophrenia spectrum disorders. Their findings showed many reported 
perceived benefits associated with smoking traditional cigarettes, including that 
smoking traditional cigarettes was considered important to decrease anxiety, relieve 
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boredom and increase motivation and concentration. McCloughen et al. (2003) 
suggested that high smoking rates and high nicotine dependence in smokers with 
schizophrenia are explained by personal and social factors: many people with 
schizophrenia spectrum disorders are unemployed and inactive, and smoking was 
reported to relieve boredom and improve low self-esteem. 
 
Kelly et al. (2012) examined the perceived consequences and benefits of cigarette 
smoking and motivation for quitting in 100 nontreatment-seeking smokers who had 
schizophrenia or schizoaffective disorder and 100 people without a psychiatric 
disorder. People with schizophrenia reported that cigarette smoking made 
socialising easier compared with the control group. They also had a lower 
appreciation for health risks associated with cigarette smoking than controls. 
Potential health consequences were found to be a less compelling reason to quit 
smoking compared with the control group.   
 
1.7.3 Health service- and health professionals-related factors 
Smoking cigarettes is frequently socially accepted amongst smokers with 
schizophrenia spectrum disorders (Trainor & Leavey, 2017; Twyman et al., 2014) 
and many smokers with schizophrenia spectrum are not given smoking cessation 
treatment from health professionals providers (Goldberg, 2010; Trainor et al., 2017). 
Two studies found that smokers with schizophrenia spectrum disorders were less 
likely to be advised to quit compared with smokers without schizophrenia spectrum 
disorders (Briskman et al., 2012; Duffy et al. 2012). 
 
Brown et al. (2015) studied the perceptions of 49 mental health professionals in 
providing the “5 A's” (ask, advise, assess, assist, arrange) of smoking cessation to 
smokers with schizophrenia. Clinicians rated a perceived lack of interest amongst 
patients and the impact of delivering the intervention on staff time as the greatest 
barriers to smoking cessation in this population.  
 
Health service and mental health professionals have an important role in 
encouraging quit attempts and can guide the application of smoking cessation 
treatment in clinical practice (Prochaska, 2011) but several mental health 
professionals believe stopping smoking traditional cigarettes may worsen their 
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patients’ condition, and some mental health professionals feel that they are taking 
away one of their patients’ only pleasures in life (Ratschen et al., 2009; Johnson et 
al., 2010); hence, health service- and health professionals-related barriers are other 
possible reasons for high smoking rates in people affected by schizophrenia 
spectrum disorders. 
 
 
1.8 Motivation to quit smoking in the general population and motivation to quit 
smoking in people with schizophrenia spectrum disorders 
Generally, motivation is theorised as willingness to change (Biener & Abrams, 1991) 
and plays a central role in the smoking cessation process (Baker et al., 2004). Past 
and recent studies show that motivation to quit is a key factor in successful quit rates 
(Biener & Abrams, 1991; Jardin & Carpenter, 2012).  
In relapse prevention theory (Witkiewitz & Marlatt, 2004), motivation is an important 
element in quitting smoking and avoiding relapse. 
 
One theory regarding motivation to quit is “PRIME” theory (West., 2009). This theory 
of motivation considers plans, responses, impulses, motives and evaluations as 
important factors in motivation to quit.  
This theory suggests smokers’ evaluative beliefs about smoking traditional 
cigarettes, internal impulses and external triggers, have an important impact on the 
decision about smoking cessation.  
Another model used to explain motivation to quit smoking is the Transtheoretical 
Model (Prochaska & DiClemente, 1983), which assumes that a smoker goes 
through precontemplation, contemplation, preparation, action, and maintenance 
stages of behaviour, each having a different level of motivation, before quitting 
successfully. 
 
Data from general population studies indicate that motivation to quit is strongly 
related to quit attempts but not to successful smoking cessation (West et al., 2001; 
Zhou et al., 2009). However, other studies have found that higher levels of 
motivation increase the likelihood of maintaining smoking cessation (Boardman et 
al., 2005; Heppner et al., 2011), implying that there are different opinions about how 
motivation to quit relates to successfully quitting smoking in the general population. 
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A recent study addressed how motivation to quit smoking, assessed prior to a quit 
attempt in a sample of treatment-seeking smokers, predicted short-term quit rates 
at four weeks and medium-term at six or 12 months abstinence and showed that BL 
motivation to quit was not important in determining the success of quit attempts 
(Ussher et al., 2016). 
 
Studies on motivation to quit traditional cigarettes have been mainly undertaken with 
the general population and very few studies have focused on the motivation to quit 
in special populations such as patients affected by schizophrenia spectrum 
disorders. Siru et al. (2009) conducted a systematic review of motivation to quit in 
people with mental health disorders compared with the general population. Fourteen 
studies were identified and people with psychotic disorders were found to be less 
motivated to quit smoking than individuals with depression. Addington et al. (1997) 
showed, amongst a sample of 60 smokers with schizophrenia, that more than 50% 
of the sample were motivated to reduce or to quit smoking traditional cigarettes and 
showed the same reasons to reduce or to quit reported by the general population, 
principally health worries and social encouragement. Etter et al. (2004) evaluated 
the stages of change in 151 patients with schizophrenia spectrum disorders 
compared with 742 people in the general population.  The level of motivation to quit 
was similar in both groups. Amongst current smokers, the distribution of stages of 
change was similar in patients with schizophrenia or schizoaffective disorder 
(precontemplation 79%, contemplation 18%, preparation 3%) and in the general 
population sample (74%, 22%, and 4%, p = 0.6).   
 
As part of an RCT to test the efficacy of bupropion in 41 smokers with schizophrenia, 
Mann-Wrobel et al. (2011) assessed motivation and confidence to quit: 61.5% 
considered quitting in the next month and 85% in the following six months, with 70% 
motivated to quit forever.  However, half of the participants reported low levels of 
confidence in quitting.  
 
Therefore, even though there is evidence that motivation to quit in smokers with 
schizophrenia spectrum disorders is quite similar to those of smokers without mental 
illness, it is evident that it is more difficult to help them to quit  (Streck et al., 2018).  
43 
 
Therefore, additional effective strategies of traditional cigarette smoking cessation, 
reduction and THR approach are needed.  
 
1.9 Smoking cessation treatments in the general population 
Offering help to quit tobacco use in people dependent on tobacco is one of the six 
proven policies identified by the WHO Framework Convention on Tobacco Control 
(FCTC) to address the tobacco epidemic (WHO 2003; UCDC, 2004). Key barriers 
to developing national smoking cessation policies and tobacco-control supportive 
programmes are: inadequate training and lack of motivation amongst healthcare 
providers to undertake and deliver smoking cessation activities; lack of resources 
and government funding; unavailability and inaccessibility of pharmacotherapy 
products; the absence of mechanisms for financing or subsidising pharmacotherapy 
products by insurance companies; lack of coordination between various sectors 
involved in providing smoking cessation interventions; and, more importantly, the 
lack of integration of smoking cessation interventions into an overall policy on 
tobacco control. The FCTC came into force on February 27, 2005 and requires 
Parties to implement evidence-based measures to reduce tobacco use and 
exposure to tobacco smoke (WHO, 2013).  
 
Article 14 of the FCTC requires Parties to take effective measures to promote 
cessation and adequately treat tobacco dependence. Guidelines for the 
implementation of Article 14 recommend establishing specialized tobacco 
dependence treatment services, making medications widely available and 
considering emerging research evidence and novel approaches to cessation.  
 
The 2008 US Guide to Quitting Smoking recommends that, except for groups with 
contraindications or for whom smoking cessation drugs have uncertain efficacy 
(e.g., users of smokeless tobacco, light smokers, pregnant women, nursing women, 
and teenagers), clinicians should encourage all smokers intending to quit smoking 
to take smoking cessation medications combined with smoking cessation advice 
(Fiore et al., 2008). 
 
There is evidence regarding the efficacy of the drugs used in smoking cessation 
(Bauld et al., 2010; Cahill et al., 2013). The drugs are most effective when used in 
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combination with behavioural therapies and support. Cognitive and behavioural 
interventions, such as motivational interviewing and relapse prevention, are an 
essential adjunct for the efficacy of these treatments (Bauld et al., 2010; Cahill et 
al., 2013). 
 
In the general population there are three principal approved drug therapies, 
according to US International Guidelines:  Nicotine replacement therapy (NRT), 
varenicline, and bupropion (Fiore et al., 2008). 
 
Nicotine replacement therapy. NRT has an established evidence base in the 
general population. Multiple formulations are available – gum, lozenges, oral strips, 
sublingual tablets, inhalers, mouth and nasal sprays, and transdermal patches (16- 
or 24-hour release). All have comparable efficacy. These different formulations allow 
for better tailoring to individual requirements including the use of combinations if 
required. For example, a patient may be prescribed a transdermal nicotine patch 
and additionally use a nicotine inhaler to supplement blood nicotine concentrations 
at times of particular craving or risk of relapse (Stead et al., 2012). The OR of 
abstinence for any form of NRT compared with placebo is 1.84 (Cahil et al., 2013). 
Combined NRT formulations have been shown to result in higher abstinence rates 
than single NRT. The OR of abstinence for combination NRT compared with single 
NRT products is 1.43 (Cahil et al., 2013). 
 
Varenicline. Varenicline has comparable efficacy with combination NRT but has 
superior efficacy to nicotine replacement monotherapy. It is therefore recommended 
as an equal first-line drug for smoking cessation. Varenicline acts as a partial agonist 
at central nicotinic acetylcholinergic receptors, which are important in mediating the 
reinforcement associated with tobacco smoking. During treatment, drug binding 
partially activates these receptors thereby reducing withdrawal symptoms and 
cravings. If the patient lapses and smokes, varenicline reduces the access of 
nicotine to the receptors. By limiting nicotine binding, varenicline reduces its 
rewarding effect. It is recommended that varenicline is started a week or two before 
the patient quits smoking. This is because a continuous period of dosing is required 
before sufficient receptors are occupied and optimal drug efficacy is achieved. The 
recommended dosage is one mg twice daily (for 12 weeks) following a one week 
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up-titration (Fiore et al., 2008). In the most recent Cochrane review, Cahill et al. 
(2016) reported that the OR of continuous abstinence for varenicline compared with 
placebo was 2.24; varenicline was more effective when compared with bupropion 
(OR 1.39) and single-product NRT (OR 1.25), and was similarly effective compared 
with combination NRT. Varenicline is principally eliminated by the kidneys so 
reduced doses (or alternative treatments) are recommended for patients with renal 
impairment. Common adverse effects include nausea, headache and insomnia. 
 
Bupropion. Bupropion was originally developed as an antidepressant.  It has 
dopaminergic and adrenergic actions and is an antagonist at the nicotinic 
acetylcholinergic receptor; however, its precise mode of action in smoking cessation 
is uncertain. It has equivalent efficacy to nicotine replacement monotherapy but is 
less effective than varenicline and is therefore considered a second-line option 
(Fiore et al., 2008). The recommended dosage of bupropion is 150 mg twice daily. 
Several meta-analyses have conﬁrmed the efﬁcacy of bupropion (Hughes et al., 
2007; Fiore et al., 2008). In a network meta-analysis by Cahill et al. (2013), the OR 
of abstinence for bupropion compared with placebo was 1.82. Bupropion was of 
similar efficacy to single product NRT (RR 0.99) and less effective for quitting 
compared with varenicline and combination NRT. Bupropion has been shown to 
decrease nicotine/tobacco withdrawal symptoms and cigarette cravings (Mooney & 
Sofuoglu, 2006). Bupropion is contraindicated in patients with a history of seizures. 
Common adverse effects include difficulty concentrating, insomnia and nightmares. 
Bupropion undergoes significant hepatic CYP 2B6 metabolism to an active 
metabolite (hydroxybupropion), which is later excreted renally. Dose reduction is 
necessary in patients with hepatic or renal disease. There are potential interactions 
with other drugs metabolized by this system including antipsychotics and selective 
serotonin reuptake inhibitors. 
 
1.10 Smoking cessation treatments for people with schizophrenia spectrum 
disorders 
PubMed (National Library of Medicine), and PsycINFO (Ovid) were searched with 
the assistance of a trained librarian experienced in developing search strategies for 
reviews. Concepts that made up the search were: smoking cessation and 
schizophrenia. The search was not restricted by language or geographical region, 
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and was carried out by combining an exhaustive list of terms denoting schizophrenic 
disorder (schizophrenia or psychotic or psychosis or severe mental illness) AND 
smoking cessation treatment (smoking cessation treatment or varenicline or tobacco 
cessation or reduction or bupropion or NRT or behavioural treatment). Additionally, 
reference lists of all included papers were checked for any citations missed by 
electronic database searching.  Cohort and case-control study designs were 
considered eligible for inclusion.  
Cross-sectional studies, case series and case reports were included. The 
publication dates were limited to January 2006 to Febrary 2018. Relevant articles 
were also searched in Scopus (Elsevier) to determine if they were cited by studies 
that previous searches had not found. We identified 77 original studies from the 
electronic search of the databases (39 studies from PubMed and 38 from 
PsycINFO). 
 
These studies found evidence suggesting that pharmacotherapy for smoking 
cessation is effective amongst smokers with schizophrenia spectrum disorders, 
although more long-term research is required.  
Actual licensed aids to smoking cessation in smokers with schizophrenia spectrum 
disorders still yield low long-term abstinence rates (Cather et al., 2017) and a meta-
analytic study showed that for randomised controlled studies using bupropion or 
bupropion combined with NRT, the odds of smoking abstinence at six months were 
less than one in five participants (Tsoi et al., 2013). 
 
Nicotine replacement therapy 
Seven studies evaluated NRT for smoking cessation in smokers with schizophrenia 
spectrum disorders. 
 
Four observational studies of open label NRT plus psychosocial treatment with 
motivational interviewing and CBT components have been conducted in smokers 
with schizophrenia. Three studies in 24-65 outpatients found quit rates of 9-14% at 
six-month follow-up assessments (Ziedonis et al., 1997; Addington et al., 1998; 
George et al., 2000) and one study in 68 outpatients found a 23% continuous 
abstinence rate at three-month follow-up (Chou et al., 2004).  
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In the largest smoking study in this population, 298 outpatients with a psychotic 
disorder (57% with schizophrenia) were randomised to routine care or to 10 weeks 
of treatment with motivational interviewing and CBT plus NRT (Baker et al., 2006). 
At the 12 month follow-up assessment, abstinence was not significantly higher in 
the treatment group (10.9%) compared with the control group (6.6%) (OR 1.72, 99% 
CI 0.58 to 5.09), but significantly more people in the treatment group had reduced 
the number of cigarettes they smoked each day by half (2.09, 99% CI 1.03 to 4.27). 
In addition, authors affirmed that the study groups showed significant improvement 
as a whole on several mental health questionnaires and absence of exacerbations 
of psychotic symptoms, but they used mental health questionnaires not specifically 
validated for schizophrenia spectrum disorders. 
 
One placebo-controlled study investigated the efficacy of NRT for the prevention of 
relapse in smokers with schizophrenia (Horst et al., 2005). Fifty outpatients received 
nicotine patches that delivered 14-42 mg per day for 90 days along with weekly 
group motivational support. Those who quit (36%) were then randomised to 
continue receiving nicotine patches (same dose) or to receive placebo patches, 
along with biweekly group support, for another six months. At the end of this period, 
significantly more people receiving NRT remained abstinent compared with those 
receiving placebo (67% v 0%; P < 0.01). However, the use of a high-level nicotine 
patch at 42 mg, although it can guarantee high levels of efficacy, makes the 
symptoms of nicotine overdose highly probable in cases where the subject 
continues to smoke. 
 
In a Cochrane review that included 11 NRT studies, Tsoi et al. (2013) concluded 
that there is currently little evidence to support the effectiveness of NRT in people 
with schizophrenia despite the benefits in the general population. 
 
Bupropion  
Eight studies evaluated bupropion for smoking cessation in smokers with 
schizophrenia spectrum disorders. 
 
Two placebo-controlled trials in 32 and 57 smokers with schizophrenia found that 
bupropion significantly increased continuous abstinence during treatment (P < 
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0.05), although these effects were not maintained at the three to six-month follow-
ups (George et al., 2002; Evins et al., 2005). Two trials that compared bupropion 
plus NRT with placebo plus NRT in smokers with schizophrenia found that 
bupropion plus NRT significantly increased the odds of continuous abstinence 
during treatment but not at the three to 12 month follow-ups (D’Souza et al., 2012; 
Esterlis et al., 2013).  
 
In an observational study that examined the efficacy of extended open label 
bupropion plus NRT, 41 smokers with schizophrenia received bupropion plus NRT 
(patch plus gum or lozenge) and CBT for three months. At the end of this period, 
those who were abstinent (42%) entered a 12 month relapse prevention phase with 
bupropion plus NRT and CBT (Cather et al., 2013). At the 12 month assessment, 
59% had achieved four weeks of continuous abstinence. However, the four previous 
trials and the observational study based their conclusions on studies that used small 
sample sizes. 
 
A Cochrane review by Tsoi et al. (2013) found that bupropion was associated with 
a three-fold increase in cessation in smokers with schizophrenia (risk ratio 3.03, 
1.69 to 5.42 at end of treatment; 2.78, 1.02 to 7.58 at six months). In a recent 
systematic review and meta-analysis conducted by Peckham et al. (2017), eight 
trials comparing bupropion with placebo were pooled showing that bupropion 
improved quit rates significantly in the medium and long term but not the short term 
(short term RR = 6.42 95% CI 0.82–50.07; medium term RR = 2.93 95% CI 1.61–
5.34; long term RR = 3.04 95% CI 1.10–8.42).  
 
In the Evaluating Adverse Events in a Global Smoking Cessation (EAGLES) study 
(Anthenelli et al., 2016), the largest comparative study of licensed smoking 
cessation aids, 8,144 smokers of traditional cigarettes with or without a diagnosis of 
psychiatric disorder used three months of treatment or placebo with a further three 
months follow-up of non-treatment, showing that bupropion has superior continuous 
abstinence rates vs. placebo at weeks 9-12 and 9-24 in both cohorts. 4,116 smokers 
were in the psychiatric cohort and 9.5% were affected by schizophrenia spectrum 
disorders. However, the continuous success rates at week 12 and week 24 were 
larger for people without diagnosis of psychiatric disorders (week 12, 26.1%, week 
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24, 18.8%) compared with participants with psychiatric disorders (week 12, 22.6%, 
week 24, 16.2%) and success rates were not stratified according to the specific 
psychiatric diagnosis. 
 
Varenicline 
Seven studies evaluated varenicline for smoking cessation in smokers with 
schizophrenia spectrum disorders. 
 
A placebo-controlled trial (n = 9) found that three in four smokers with schizophrenia 
taking varenicline achieved continuous abstinence during the last four weeks of the 
treatment period compared with no patients taking placebo (P = 0.14) and no 
increases were seen in psychiatric symptoms or suicidal ideation (Weiner et al., 
2011). However, this research enrolled only nine participants, of which eight 
completed the study, and specific validated questionnaires for schizophrenia 
spectrum disorders, such as SAPS, SANS or PANSS, were not used to assess 
changes in schizophrenia symptoms. A multi-site placebo-controlled trial of 
varenicline with brief counseling in 128 smokers with schizophrenia found that 
varenicline significantly increased point prevalence abstinence at the end of 
treatment (19% v 4.7%; P < 0.05) but not at the six month follow-up (Barr et al., 
2008b). However, it is important to clarify that these patients undertook 12 weeks of 
treatment with varenicline and an extension of the use of varenicline up to 24 weeks 
would have probably reduced relapse rates at six month follow-up. In the study of 
Barr et al. (2008b), rates of adverse events (AEs) were similar across conditions, 
and schizophrenia symptoms, assessed by SAPS and SANS scales, were stable or 
decreased in both groups.  
 
Finally, a 10-site placebo-controlled trial investigated whether varenicline reduces 
smoking relapse (Evins et al., 2014). In total, 247 patients with schizophrenia 
spectrum or bipolar disorder were enrolled and 203, of which 185 (91%) with 
schizophrenia spectrum disorders, entered the open label treatment phase. Of 
these, 87 (43%) attained two weeks of continuous abstinence and entered the 
relapse prevention phase, in which they were randomised to varenicline or placebo 
with CBT. At week 52, point prevalence abstinence rates were significantly higher 
in people taking varenicline (60% vs. 19%; OR 6.2, 95% CI 2.2 to 19.2), and rates 
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of continuous abstinence from week 12 to 76 were also higher (30% vs. 11%; 3.4, 
1.02 to 13.6).  
Varenicline had no effect on psychiatric symptoms. Two patients in each group 
reported suicidal ideation during the maintenance phase but there were no suicide 
attempts. Thus, amongst smokers with schizophrenia who attained abstinence, 
varenicline was well tolerated and increased prolonged abstinence for as long as 76 
weeks (Evins et al., 2014). However as declared by the authors, smokers were 
enrolled from community mental health centers so that the findings should be 
generalizable to the large majority of patients with schizophrenia spectrum or bipolar 
disorders who are cured in this kind of setting.  
 
The EAGLES study showed that varenicline has superior continuous abstinence 
rates vs. bupropion, NRT patch and placebo at weeks 9-12 and 9-24 in smokers 
with and without a history of psychiatric disorders with no significantly increased 
neuropsychiatric safety risk vs. placebo (Anthenelli et al., 2016). However, the 
continuous success rates at week 12 and week 24 were larger for people without 
diagnosis of psychiatric disorders (week 12, 38%; week 24, 25.5%) compared with 
participants with psychiatric disorders (week 12, 33.5%; week 24, 21.8%) and 
success rates were not stratified according to the specific psychiatric diagnosis. 
The Cochrane review by Tsoi et al. (2013), found that varenicline is associated with 
an almost five-fold increase in cessation (4.74, 1.34 to 16.71 at end of treatment). 
In the review and meta-analysis by Peckham et al. (2017), five trials comparing 
varenicline with placebo showed that the addition of varenicline improved quit rates 
significantly in the medium term (RR = 4.13, 95% CI 1.36–12.53). A network meta-
analysis about the effectiveness and tolerability of adjunctive pharmacotherapy for 
smoking cessation in adults with serious mental illness (Roberts et al., 2016) 
suggests that varenicline and bupropion are effective and tolerable for smoking 
cessation in adults with serious mental illnesses. A review by Kishi and Iwata (2015) 
pooled ﬁve RCTs and found that varenicline performed no better than placebo in 
achieving smoking cessation (RR 0.79, 95% CI 0.58–1.08, n = 332); however, these 
authors combined findings of studies where participants were recruited into studies 
to test varenicline for health outcomes other than smoking cessation/reduction. 
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Behavioural interventions 
Bennett et al. (2013) identiﬁed 11 studies investigating behavioural therapies in 
people with schizophrenia and found that in the short term these had good post-
treatment abstinence rates of up to 42%.  
In addition, Bennett et al. (2013) found that these interventions were well tolerated 
by people with schizophrenia and found no evidence of deleterious impact on 
psychiatric symptoms.  
 
A study of 87 people compared higher versus lower intensity behavioural treatment 
delivered by trained mental health clinicians -- Treatment of Addiction to Nicotine in 
Schizophrenia (TANS) or Medication Management (MM) -- in smokers with 
schizophrenia who received NRT for 16 weeks and found no difference on 
abstinence (Williams et al., 2010b). TANS was a high intensity treatment of 24 
sessions (45 minutes) delivered over 26 weeks and MM was a moderate intensity 
treatment of nine sessions (20 minutes) delivered over 26 weeks that combined with 
NRT treatment significantly reduced smoking consumption in smokers with 
schizophrenia spectrum disorders.  This study showed that mental health 
professionals can be trained to help smokers with schizophrenia spectrum disorders 
to maintain traditional cigarette abstinence. 
 
Considering all these aspects, it is important to also investigate harm reduction 
approaches for smokers with schizophrenia spectrum disorders. 
 
Experiences of smoking cessation 
A study conducted by Tulloch and collaborators (2016) explored quitting experience 
and concerns of 732 smokers, 430 with psychiatric illness (18 with schizophrenia 
spectrum disorders), in comparison with 302 without psychiatric illness.  
Participants, enrolled between June 2010 and March 2013 to participate in the FLEX 
(Flexible and Extended Dosing of NRT and Varenicline in Comparison to Fixed-
Dose NRT for Smoking Cessation) trial, completed questionnaires assessing 
previously used cessation aids and concerns about their upcoming quit attempt. 
Smokers with schizophrenia spectrum disorders experienced distress and negative 
affect as the most common predictors of smoking relapse. The quit methods used 
by smokers with schizophrenia spectrum disorders were transdermal NRT (72.2%), 
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followed by NRT gum (11,1%), NRT lozenge (11,1%), NRT inhaler (11,1%), 
varenicline (11,1%) and bupropion (11.1%) compared with the following quit 
methods used by smokers without psychiatric illness: transdermal NRT (69.9%), 
followed by bupropion (43.6%), NRT gum (32,9%), varenicline (19,3%), NRT inhaler 
(12,9%),  and NRT lozenge (8,2%). 
 
Rae et al. (2015) interviewed 16 participants with serious mental illness (six with 
schizophrenia spectrum disorders) who had participated in a clinical trial comparing 
two smoking cessation interventions, the first using NRT alone and the second using 
NRT, motivational interviewing and a peer support group. Findings from semi-
structured interviews suggest smoking cessation experiences were influenced by 
positive experiences of NRT, though access to e-cigarettes or medications available 
in pill form (e.g., varenicline and bupropion) were considered more effective and 
easier to use. The intervention itself (such as the presence of smoking cessation 
aids and group support), Individual factors, (such as mental health, physical health, 
and substance use), and social-environmental factors (such as difficult life events 
and social relationships) influenced whether someone quit or not. The authors 
acknowledged several limitations in their study such as the small sample size, all 
participants coming from the same smoking cessation intervention, the researcher 
not being blind to the smoking cessation status of participants during the data 
collection and analysis, the interpretative nature of the results and the fact that the 
data were self-reported by participants and consequently subject to the effects of 
recall and social desirability, and the use of the seven-day period of abstinence and 
not continuous smoking abstinence criterion to differentiate quitters from smokers. 
Also, the authors did not differentiate the findings on the basis of the distribution of 
the mental pathology enrolled in the study (schizophrenia/schizoaffective disorder 
(n = 6, 38%), depression (n = 5, 31%), bipolar disorder (n = 4, 25%), and anxiety 
disorder (n = 1, 6%) and the thematic analysis did not give clear percentages of 
responses but used vague terms such as ‘many’ and ‘some’. 
 
Knowles et al. (2016) qualitatively explored the experiences of a small sample of 13 
participants with serious mental illnesses, of which eight had schizophrenia 
spectrum disorders, who used a ‘bespoke smoking cessation’ intervention, 
compared with their experience of standard smoking cessation services. The 
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authors, without specifying if participants were in a stable or unstable phase of their 
illness and without differentiating the findings on the basis of diagnosis, enrolled five 
people with bipolar disorder and eight with schizophrenia spectrum disorders). They 
found that this intervention was perceived positively because the bespoke 
intervention was more flexible and tailored compared with the previous standard 
smoking cessation programme.   
 
In addition to the medication used, tailoring the smoking cessation support to the 
individual needs of the smoker affected by schizophrenia spectrum disorders may 
result in better outcomes.  
 
1.11 Summary and conclusion 
This introductory chapter included literature about the epidemiology of tobacco 
smoking in people with schizophrenia spectrum disorders, examined the 
relationship between smoking and mental health and showed a higher prevalence, 
frequency and impact of both high nicotine dependence and its harmful effects in 
patients with schizophrenia spectrum disorders compared with the general 
population.  
 
People with schizophrenia spectrum disorders die on average earlier than the 
general population. Despite several existent theories, the reasons for high smoking 
rates are not fully understood. This chapter highlights the importance of increasing 
treatment options for this group of smokers, who find quitting difficult and have lower 
quit rates than the general population. Their high dependence on nicotine and 
severity of nicotine withdrawal symptoms suggest that a harm reduction approach 
may be more achievable and acceptable, particularly if this leads to eventual 
abstinence (McChargue et al., 2002; Hughes et al., 2006). E-cigarettes offer 
smokers with schizophrenia spectrum disorders an alternative to more well-
established approaches to smoking cessation or reduction. The next chapter 
provides a literature review of e-cigarettes and their potential for helping this group 
of smokers reduce their harm from tobacco smoking. 
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CHAPTER 2: INTRODUCTION TO E-CIGARETTES 
 
This chapter reviews key current literature on electronic cigarettes (e-cigarettes) to 
provide further background to the remainder of the thesis. It begins (Section 2.1) by 
describing the concepts of THR, which provides a framework for understanding e-
cigarette use as an alternative or addition to more well-established approaches to 
smoking cessation described in Chapter 1. The chapter then describes (Section 2.2) 
e-cigarettes as a product category, their development and key characteristics. This 
includes an introduction to the e-cigarette used in the primary research later in the 
thesis (JUUL). Section 2.3 of the chapter then describes and critically assesses 
available studies and reviews of e-cigarettes for smoking cessation in the general 
population. Section 2.4 outlines the available (and very sparse) literature on e-
cigarettes for smoking cessation in people with schizophrenia spectrum disorders 
and explains how the research conducted as part of the thesis contributes to 
addressing important research gaps. 
 
2.1 Tobacco harm reduction 
The history of THR may be traced back to at least 1974, with the publication of a 
special article in the Lancet by British tobacco addiction research expert Michael 
A.H. Russell (1974). In essence, harm reduction as part of a tobacco control strategy 
involves trying to separate the risk associated with inhaling smoke from that of taking 
nicotine.  As Russell noted 30 years ago, "There is little doubt that if it were not for 
the nicotine…people would be little more inclined to smoke than they are to blow 
bubbles or light sparklers" (Russell, 1974).  
 
More recently, the National Institute for Health and Care Excellence (NICE) in the 
UK has described THR as reducing the diseases and deaths caused by smoking 
traditional cigarettes (NICE, 2011). NICE produced the world’s first formal guidelines 
on THR between 2011 and 2013. These guidelines address reducing harm from 
smoking traditional cigarettes in order to help smokers, particularly those who are 
highly dependent on nicotine, and may not be able (or do not want) to stop smoking 
in one step; may want to stop smoking, without necessarily giving up nicotine; and 
may not be ready to stop smoking, but want to reduce the amount that they smoke 
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(NICE, 2013). 
 
Despite the NICE harm reduction guidelines, approved smoking cessation treatment 
in the UK and other countries normally requires nicotine addicted smokers to abstain 
from tobacco and nicotine entirely. Many smokers are unable – or at least unwilling 
– to achieve this goal, and so they continue smoking in the face of impending 
adverse health consequences. In effect, established approaches to smoking 
cessation present smokers with just two alternatives: stop smoking or suffer the 
harmful effects of continuing smoking. However, THR arguably provides a third 
choice for smokers. It involves the use of alternative sources of nicotine as a 
replacement for smoking. E-cigarettes as a product category can fit within a THR 
paradigm.  
They can deliver nicotine without the combustion products that are responsible for 
nearly all of smoking’s damaging effects. These products and key available 
evidence about their use is outlined in the next sections of this chapter.  
 
2.2 E-cigarettes 
E-cigarettes are a part of a series of emerging products often referred to as 
Alternative Nicotine Delivery Systems (ANDS) or Electronic Nicotine Delivery 
Systems (ENDS). The term ENDS was created by the WHO’s Study Group on 
Tobacco Regulation in 2009 to classify a collection of battery-powered devices that 
provide nicotine flavourings and other additives to the user in aerosol form.  
 
A first version of an e-cigarette was patented as early as 1965 in the USA by Gilbert 
(Gilbert 1965). The Gilbert e-cigarette resembled a traditional cigarette but instead 
of burnt tobacco, it allowed the user to draw warm flavoured vapour into the mouth 
or lungs. A cartridge held a chemical solution and an insulated tube or light bulb 
powered by a battery provided a heating element to heat the solution. However, 
despite this innovative idea, Gilbert was never able to bring this product successfully 
to market.  
 
Some years later, in 1986, the ‘Favor’ cigarette was developed as a non-
combustible nicotine-containing product that also resembled a cigarette in 
appearance (Ling and Glantz, 2005). The device was made of a plastic tube 
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containing a paper soaked with nicotine in order to simulate the traditional cigarette 
effect without vapour creation. The Food and Drug Administration (FDA) in the USA 
deemed this type of device to be a nicotine delivery system and as consequence 
classified Favor as a drug and banned it (Sleight, 2016).  
 
Following these very early designs, the modern e-cigarette was developed in 2003 
by a Chinese pharmacist, Hon Lik. He created an electronic atomizing cigarette for 
smoking cessation after his father (a smoker) died of lung cancer. This e-cigarette 
was composed of a battery-operated device designed to vaporize a liquid solution 
of propylene glycol and vegetable glycerine in which nicotine was dissolved. No 
tobacco was used in the device. Puffing activated a battery-operated heating 
element in the atomizer and the liquid in the cartridge was vaporized as a plume of 
a dense mist and inhaled (Hon 2003). This e-cigarette prototype showed promise, 
and as a result in 2004 it was introduced on the Chinese market under the company 
name Ruyan. From there many other companies began to develop similar devices 
building on this initial prototype. The technology and range of products rapidly 
evolved and the market grew considerably from 2010 onwards. These products 
have now spread rapidly across Europe, the USA and a number of other areas and 
countries (Sanford and Goebel, 2014).  
 
2.2.1 E-cigarette market and types 
As of 2014, it was estimated that over 460 e-cigarette brands were available on the 
global market (Zhu et al., 2014). However, despite the potential product differences, 
some characteristics of e-cigarettes appear to be consistent across products. These 
include: a cartridge containing propylene glycol or glycerine mixed with different 
nicotine concentrations and a battery powered heating component which transforms 
the liquid substance into an aerosol form when air is drawn through the device (Cobb 
et al., 2010). E-cigarettes are also sold as either disposable or reusable, refillable 
products.  E-cigarette devices vary from first generation, second generation, and 
third and fourth generation products.  
 
First-generation e-cigarettes appear similar to traditional cigarettes, usually with a 
white body made of plastic and a tan mouthpiece (other first-generation e-cigarettes 
were slightly longer or narrower than a traditional cigarette and were black or 
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coloured). These devices are described as “cigalikes.” First generation models 
included a cartridge designed for the part of the device that holds the e-liquid, which 
is either prefilled with the liquid or ready to be filled (Figure 1). The user then 
connects the cartridge to the heating element and atomizer that are themselves 
connected to the battery, and the “cigalike” is ready for use (Zhu et al., 2014).  
 
Second-generation e-cigarettes include devices that resemble fountain pens, are 
large and cylindrical, and are often described as e-cigarettes with “tank systems” in 
consideration of the transparent reservoir that holds larger amounts of e-liquid 
(about two or three ml) than previous first generation “cigalike” models (Figure 1).  
 
Third generation devices are a diverse product category, and they appear totally 
different from traditional cigarettes in their appearance, principally because many 
are square or rectangular and customizable by changing batteries and atomizers 
(Figure 1). Since the beginning of the availability of e-cigarettes’ component 
elements, users have been modifying their own e-cigarettes by building their own 
customized e-cigarettes, which are called “mods.”  Users can adjust the battery 
voltage and combine the e-liquid, choosing different flavours and nicotine levels 
(Richtel., 2014; Lee & Kim., 2015).  
 
Fourth generation devices are the most advanced and powerful and differ from third-
generation e-cigarettes in the following small details: they enable control over the 
temperature of the heating coil and can be used at much higher power levels (e.g., 
>200 W) compared with most earlier e-cigarettes (Strongin, 2019). 
 
  
58 
 
Figure 1. Evolution in e-cigarettes models  
 
 
2.2.2 The JUUL e-cigarette 
E-cigarette devices have evolved substantially over time, from early-generation 
cigalike e-cigarettes to more advanced modifiable tank-style versions. One of the 
latest products to be introduced on the market, initially in the USA, is the JUUL e-
cigarette (Truth Initiative, 2018). JUUL is a non-modifiable compacted closed 
system e-cigarette and represents one of a newer generation of pod devices (Figure 
2).  
 
Figure 2. JUUL e-cigarette 
 
JUUL has two basic components: the device, which includes the battery and 
temperature regulation system, and the prefilled e-liquid cartridge, called a ‘pod’, 
that comes in a variety of flavours (tobacco, mango, mint, and others). The original 
JUUL device pods contained 0.7 mL of e-liquid with 5% nicotine by weight, although 
lower strength nicotine options are now on the market, particularly in Europe.  
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The JUUL pods also serve as the mouthpiece for the product. JUUL is rechargeable 
by a USB port and is rectangular and small in size, fashioned to look like a computer 
flash drive (Kee, 2018).  
 
The characteristics that make JUUL different from its predecessors include its 
design (called the ‘iPhone of e-cigarettes’) (Radding., 2015), its high levels of 
nicotine (0.7 mL or 59 mg/mL per pod) and the use of a specific e-liquid formula, 
JUUL salts, based on the nicotine salts found in leaf-based tobacco rather than free-
based nicotine. JUUL provides a nicotine concentration comparable with a 
traditional cigarette, with the nicotine peaking in about five min., and delivers 
nicotine 1.25–2.7 times faster than competing e-cigarettes on the market (Brown & 
Xing, 2015; Lawler, 2018; Juulvapor, 2018).  
 
2.2.3 Existing evidence on e-cigarette harms and benefits 
Although e-cigarettes have only become widely used in the last few years, research 
evidence on these devices has been growing rapidly. This evidence is not always 
consistent and sometimes contradictory, but there is a growing consensus that 
these products are significantly less harmful than traditional cigarettes (Farsalinos 
& Polosa 2014; Nutt et al., 2016). That said, important research questions remain 
regarding any potential harms from use and also the potential benefits of use.  
These questions include, for example, whether these products are effective aids for 
smoking cessation, promote uptake by nontobacco users, sustain nicotine 
dependency via dual use, slow intentions to quit in dual users, or encourage relapse 
to cigarette use amongst former smokers (Glasser et al., 2017). 
 
E-cigarette use is a complex and dynamically evolving behaviour. To advance 
knowledge of the impact of e-cigarettes use on smoking status, it will be necessary 
to conduct prospective studies considering relevant descriptors of vaping behaviour 
such as frequency of use (e.g. focusing on daily users, and not just on those who 
are experimenting), reasons for using e-cigarettes (e.g. to quit smoking vs. out of 
curiosity), and product design (e.g. closed vs. open systems, nicotine containing vs, 
non-nicotine containing products, etc.). Reasons for vaping, the type of device and 
e-liquid, frequency of use, and the accompanying sensory and craving-control 
experiences may have some impact on smoking behaviours (Polosa et al., 2017). 
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E-cigarettes have ingredients that are not inert and are likely to have some potential 
health risks. While traditional cigarette combustion generates toxic substances 
correlated with cancers, respiratory disorders and CVDs, e-cigarettes usage 
delivers potentially toxic substances involving fine particulate matter, metals that are 
known to probably determine adverse health effects related to cancers, respiratory 
disorders and CVDs.  
 
2.2.3.1 Recent studies on relative risks in comparison with smoking 
E-cigarette-related toxicants and carcinogens: A number of studies have tried to 
assess the RRs of e-cigarette use compared with tobacco smoking, in particular, 
the extent to which there is any reduction in exposure to harmful toxicants as 
compared with smoking traditional cigarettes.  
 
For example, in one study, a research group provided 40 smokers with e-cigarettes 
in a choice of eight flavours with 12 mg or 24 mg of nicotine. The researchers 
collected urinary cotinine, the tobacco-specific carcinogen 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanol (NNAL), and eight volatile organic compounds at BL visit and 
a four week follow-up visit. They observed that CO (p < .001), NNAL (p <.01), and 
metabolites of benzene (p < .01) and acrylonitrile (p = .001) decreased significantly 
in smokers who switched to e-cigarettes (Pulvers et al., 2016). Another recent study 
(Shahab et al., 2017) compared, in 37 participants of traditional cigarette-only 
smokers, and in 72 smokers and 72 ex-smokers with long-term e-cigarette use or 
with use of NRT, the exposure to nicotine, tobacco-related carcinogens and 
toxicants. Urine and saliva samples were collected and there were no differences in 
salivary or urinary biomarkers of nicotine intake after controlling for confounders. 
The study found lower carcinogen and toxicant levels in participants who had 
switched completely from smoking to either exclusively e-cigarettes or NRT use. 
However, both of the studies, conducted by Pulvers et al. and Shahab et al., used 
samples too small to assess the potential association of different types of e-
cigarettes, did not assess indirect exposure and were limited by the number of 
biomarkers available. 
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A large study used data from 5,105 of the U.S. adults participating in the Population 
Assessment of Tobacco and Health (PATH) study and compared exposure to 
toxicants amongst e-cigarettes users, non-smokers and smokers. This study 
examined urine samples for key biomarkers of exposure to harmful chemicals, 
tobacco-specific nitrosamines (TSNAs), metals, polycyclic aromatic hydrocarbons 
(PAHs), and volatile organic compounds (VOCs), and suggested possible benefits 
for smokers who totally switched to e-cigarettes.   
Exclusive users of e-cigarettes were exposed to more toxicants than people who 
did not use any form of traditional cigarette, but at significantly lower levels than 
smokers (Goniewicz et al., 2018). 
 
E-cigarette use and cancer risk: The cancer risk related to e-cigarette usage 
would be expected to be less than traditional cigarettes based on the fact that e-
cigarettes include nicotine but not many of the other toxicants in traditional 
combusted cigarettes.  
On this basis their use should result in a reduced burden of carcinogens compared 
with smoking (Chen et al., 2017; Stephens, 2018).  
A small number of studies to date have focused on e-cigarette users and cancer. 
For example, in a study conducted by Franco et al. (2016), oral cells were collected 
by scraping the oral mucosa from a population of 65 participants from three groups: 
traditional cigarette smokers (n = 23); e-cigarette users (n = 22); and non-smokers 
or users of traditional cigarettes and e-cigarettes (n = 20).  
Their findings showed that compared with non-smokers of traditional cigarettes and 
non-users of e-cigarettes, the mean number of micronucleated cells/1,000 cells and 
the measure of total micronuclei/1,000 cells was respectively 160% and 633% 
higher in traditional cigarette smokers and 21% and 133% higher in e-cigarette 
users.   
This study, despite not presenting any evidence on the reliability of the micronucleus 
assay, nor reporting all important p-values, or several potential confounding factors 
(e.g. age, or age at smoke initiation), showed that the average micronuclei burden 
was high in e-cigarette users compared with never smokers, and was higher in 
traditional cigarette smokers compared with e-cigarette users and never smokers.  
 
A further study assessing RRs compared with smoking was conducted by Manzoli 
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et al. (2017). They enrolled 932 participants at BL assessment with the following 
sample sizes at the end of the 24-month follow-up: 363 smokers of only traditional 
cigarettes throughout follow-up, 97 users of only e-cigarettes throughout follow-up, 
and 37 dual users of both traditional and e-cigarettes. This study reported the 
definition “any cancer” as one of the possible serious adverse events (SAEs) in 
participants with this distribution: 0.8% (3/363) in traditional cigarettes users, 2.1% 
(2/97) in e-cigarettes users and 0% (0/37) in dual users. The risk ratios calculated 
from these data, using traditional cigarettes as the referent category, were 2.49 
(95% CI 0.42-14.72) for e-cigarettes only and 0 (95% CI not estimable) for dual use. 
Considering that all participants were previous traditional cigarette users, the 
findings did not provide any indication of elevated cancer risk from sole use of e-
cigarettes. However, the study did have limitations including: the absence of 
consideration of traditional cigarette smoking history, a small sample size to 
evaluate the endpoint of cancer, and self-reported cancer data.  
Studies in humans focusing on cancer and e-cigarette use are relatively few in 
number, and to date there are no epidemiological studies on the possible 
association between e-cigarette use and cancer in humans. This makes it difficult 
to draw definitive conclusions about any association between e-cigarette use and 
risk of cancer in human populations. However, a joint statement on e-cigarettes by 
Public Health England and other UK public health organisations (PHE, 2016) 
developed a shared agreement document stating that e-cigarettes are significantly 
less harmful than smoking. A recent study conducted by Stephens (2018) measured 
emissions from cigarettes and e-cigarettes, calculating lifetime cancer risk using 
daily consumption estimates, and calculated that e-cigarette cancer potencies were 
largely found to be only a small fraction of those of smoking (0.4%). 
E-cigarette use, respiratory and heart conditions:  A different body of research 
has focused on e-cigarettes’ effects on users of traditional cigarettes with or without 
pre-existing respiratory conditions such as COPD or asthma. These studies in 
humans examine the effect of switching to e-cigarettes (single or dual use), examine 
health effects of e-cigarettes compared with traditional cigarette usage, and overall 
suggest that smokers with pre-existing respiratory conditions such as asthma and 
COPD may experience some benefits from switching to e-cigarettes (Polosa et al., 
2014 a, b, 2016 a,b; Campagna et al., 2016; Cibella et al., 2016). Our research 
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group in Italy has contributed to this literature on respiratory health and e-cigarettes. 
In a one-year RCT of healthy smokers who abstained from cigarette smoking and 
switched to e-cigarette use, we observed improvements in their exhaled breath 
measurements, including fractional nitric oxide concentration in exhaled breath 
(FeNO) and exhaled carbon monoxide (eCO) (Campagna et al., 2016). A 24-month 
prospective study (Polosa et al., 2016) demonstrated improved respiratory 
symptoms and lung function in 16 former smokers who switched to e-cigarettes, 
suggesting that e-cigarette use could potentially contribute to reversing the harm 
from combustible tobacco in smokers with asthma. Polosa et al. (2017), conducted 
a study with young-adult never-smoking, daily e-cigarette users who were followed 
up for at least 3½ years by our research group. No worsening in spirometric indices 
(i.e. lung function), no development of respiratory symptoms, no changes in markers 
of lung inflammation in exhaled air, and no signs of early lung damage on high 
resolution computed tomography (HRCT) were detected. However, a limitation of 
these studies is that they were conducted in a small number of smokers selected 
retrospectively from the same region and primarily from a single study research 
group, which limits generalizability of the results. Different findings come from a 
high-quality RCT with large sample size, where Cravo et al. (2016) reported no 
difference in lung function in smokers who switched to e-cigarettes. In this study 
smokers with respiratory conditions were excluded and two cohorts of smokers were 
randomised to either change to e-cigarettes with nicotine or continue smoking 
traditional cigarettes. The authors reported no significant positive or negative 
changes in pulmonary function tests after 12 weeks between the two groups (Cravo 
et al., 2016). Several recent studies have evaluated acute cardiovascular effects 
such as modifications in blood pressure (BP) levels and HR (HR) following e-
cigarette use.  Studies investigated modifications in BP levels after e-cigarette use 
(Farsalinos et al., 2014a; Szołtysek-Bołdys et al., 2014; Yan and D’Ruiz, 2015; 
Cooke et al., 2015; Fogt et al., 2016; Moheimani et al., 2017). These studies had 
some inconsistent results, with the majority finding weak positive increases or no 
modifications and harms using e-cigarettes. Previous studies, using first and second 
generation e-cigarettes, found no changes in HR following e-cigarette use 
(Vansickel et al., 2010; Farsalinos et al., 2014a; Szołtysek-Bołdys et al., 2014) but 
these were conducted with devices characterized by slight or no increase in blood 
nicotine levels. In one prospective study, using first and second generation e-
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cigarettes and conducted by our team in Italy, systolic BP was significantly reduced 
at week 52 compared with BL (132.4 +/- 12.0 vs. 141.2 +/- 10.5 mmHg, p < 0.00) 
amongst participants who had reduced smoking (>50% reduction) and in those who 
had quit smoking with the use of e-cigarettes. These findings suggest that e-
cigarette use does not elevate BP (Farsalinos et al., 2016). This study did not find 
any changes in BP when assessing all participants, because the vast majority 
initially had normal BP and no change in this parameter was expected to occur within 
the 12-month duration of the survey. The interest was directed towards the 
population with an initially high BP (high-normal or higher, as defined by the 
European Society of Cardiology). The reduction in BP was evident even after 
adjusting for confounders such as age, gender and weight gain. However, these 
early studies may not reflect the effects of newer devices. Some more recent 
research using third generation devices, which increase blood nicotine levels, has 
identified some increase in HR just after e-cigarette use (Cooke et al., 2015; Spindle 
et al., 2017; St. Helen et al., 2017). A key factor to consider when drawing any 
conclusions about potential health risks from e-cigarettes is the extent to which 
studies directly compare vaping with tobacco smoking. Those studies that have 
aimed to directly compare the two have fairly consistently found reduced levels of 
harm if participants switch completely to vaping from smoking. Looking across the 
body of literature, there is convincing evidence that vaping amongst ex-smokers 
reduces exposure to toxicants that are carcinogenic and may increase the risk of 
cancer. In addition, there is now good evidence that risks to both cardiovascular 
(Yan and D’Ruiz, 2015; D’Ruiz et al., 2017) and respiratory health (Polosa et al., 
2014a,b; 2016b,c) are reduced when smokers switch from using combustible 
tobacco to vaping.  
 
2.3 E-cigarette use and craving  
Smokers with considerable histories of cigarette usage report using e-cigarettes to 
alleviate nicotine withdrawal generated by smoking cessation or to satisfy cravings 
for these traditional cigarettes (Etter and Bullen, 2014).  
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An RCT (Adriaens et al., 2014) on smoking behaviour and use e-cigarettes in 48 
traditional cigarettes smokers randomised partcipants into two e-cigarette groups 
and one control group.  
One of the researchers' objectives was to assess whether e-cigarettes decreased 
craving in the short term, and during the laboratory studies in the first two-month 
period of the study, researchers assessed craving and found that e-cigarettes 
proved to be just as effective in suppressing the craving for smoking as traditional 
tobacco cigarettes.  
 
Dawkins and Corcoran (2014) enrolled 14 experienced vapers and asked them to 
abstain overnight from their traditional cigarettes. In the morning, they were 
presented with a first-generation e-cigarette with 18 mg/mL nicotine, from which they 
were invited to take 10 puffs. As a result, the nicotine craving and urge to smoke 
were significantly reduced in these participants. In a second study, Dawkins et al. 
(2016) presented 63 abstinent smokers who were not current e-cigarette users with 
either a red or a white first generation e-cigarette containing 18 mg/mL of nicotine 
in the form of “tobacco” flavored e-liquid after a 10-hour abstinence period. Their 
results suggest that the visual appearance of an e-cigarette has an effect on 
cigarette craving reduction. These researchers found that the more the e-cigarette 
resembled a traditional cigarette, the stronger the craving reduction.  
Another study focused on e-cigarettes’ flavour (Goldenson et al., 2016) and showed 
that nicotine-free and nicotine-containing e-cigarettes produced greater appeal 
when containing sweet flavours than when containing non-sweet flavours or no 
flavour. 
 
2.4 E-cigarettes and smoking cessation  
Smoking is a difficult addiction to break and many smokers persist in tobacco use 
for numerous years, typically cycling through multiple periods of remission and 
relapse (Caponnetto et al., 2013a; Caponnetto et al., 2013b). Yet, while complete 
cessation of any nicotine use may be the most desirable final outcome, substitution 
of traditional cigarettes with alternative non-combusted forms of nicotine delivery, 
such as e-cigarettes, is now a relatively new option available to smokers. Surveys 
of e-cigarette users have examined reasons for use and, overall, these suggest that 
users report using them to help quit smoking, to reduce cigarette consumption, to 
66 
 
relieve tobacco withdrawal symptoms, and to continue some of the behavioural 
aspects of smoking with perceived reduced risks to (Etter, 2010). 
 
2.4.1 Early studies of e-cigarettes for smoking cessation  
The first RCT examining the impact of e-cigarettes on smoking behaviour was 
conducted by the research team at the Centro per la Prevenzione e Cura del 
Tabagismo-University of Catania (CPCT), Italy, led by Professor Riccardo Polosa 
and including the PhD candidate. This study found that smokers not immediately 
willing to quit who used e-cigarettes substantially decreased daily cigarette 
consumption without significant side effects (Caponnetto et al., 2013c). The trial 
involved 300 smokers without mental health conditions recruited from 
advertisements in a local newspaper in Catania.  This double blind RCT examined 
the effects of using a 7.2 mg nicotine e-cigarette, hereafter referred to as Group A; 
7.2 mg for six weeks, then transition to 5.4 mg nicotine e-cigarettes, hereafter 
referred to as Group B; and nicotine-free e-cigarettes, hereafter referred to as Group 
C, on smoking reduction/cessation and adverse effects. The primary outcome of the 
study was >50% reduction in cigarettes/day (CPD) at the 52-week study visit from 
BL.  The secondary outcome was sustained smoking abstinence at the 52-week 
study visit.  
 
The eligibility for study inclusion was adult smokers in good health, age 18-70 yrs., 
using ≥10 factory-made CPD for at least the past five years, not attempting /wishing 
to quit in the next 30 days. Exclusion criteria for the study were symptomatic CVD, 
symptomatic respiratory disease, regular psychotropic medication use, current or 
past history of alcohol abuse, use of smokeless tobacco or NRT, pregnancy or 
breastfeeding. Participants were not encouraged or given any motivation to cease 
smoking. Study participants were instructed to use the product ad libitum throughout 
the day, not to exceed a four cartridge/day maximum as recommended by the 
manufacturer of the product. Participants attended follow-up visits at 2, 4, 6, 8, 10, 
12, 24, and 52 weeks.  At each of these visits, participant eCO levels were recorded, 
study diaries were given to study personnel, and unused study products were turned 
in. After 12 weeks, no additional cartridges were provided to the participants.  
However, participants were told they could continue to use the e-cigarettes. Saliva 
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cotinine levels were measured at six and 12 weeks in participants who reported no 
smoking and had an eCO ≤ seven ppm.   
 
Loss to follow-up was 35/100 (35%) in Group A, 37/100 (37%) in Group B, and 
45/100 (45%) in Group C.  All patients were analyzed in the group to which they 
were first allocated with an intention to treat philosophy. At week 52, 10/100 (10%) 
of those allocated to Group A, 9/100 (9%) of those allocated to Group B and 12/100 
(12%) of those allocated to Group C had reduced their CPD by ≥ 50%, p = 0.24. At 
week 52, 13/100 (13%) of those allocated to Group A, 9/100 (9%) of those allocated 
to Group B and 4/100 (4%) of those allocated to Group C had achieved smoking 
abstinence and had eCO concentrations of ≤ seven ppm, p = 0.24. Self-reported 
adverse effects amongst the remaining 183 participants of the study at 52 weeks 
included: throat irritation 37/183 (20.2%), mouth irritation 34/183 (18.6), dry cough 
37/183 (20.2%), headache 5/183 (2.7%), shortness of breath 15/183 (8.1%). No 
SAEs (that is, major depression, abnormal behaviour or any event requiring an 
unscheduled visit to the family practitioner or hospitalization) occurred during the 
study.  
 
The second RCT examining the impact of e-cigarette use on smoking behaviour 
was conducted by the research team at the National Institute for Health Innovation, 
University of Auckland and Health New Zealand, Christchurch, led by Professor 
Chris Bullen (2013). This research evaluated the quitting efficacy, acceptability, and 
adverse effects of e-cigarettes, comparing active (16 mg nicotine) e-cigarettes with 
nicotine patch and placebo (0 mg nicotine) e-cigarettes. The trial was a three-arm 
parallel group RCT. A total of 657 smokers were randomised into one of three 
groups: a group who used active e-cigarettes for 12 weeks after quitting, a group 
using nicotine patches for 12 weeks, or a group using placebo e-cigarettes for 12 
weeks. Quit rates were assessed at three and six months after the quit date. The 
primary outcome was the proportion of smokers who maintained sustained 
continuous abstinence from smoking for six months after their quit day. Secondary 
outcomes were: continuous abstinence at one and three months, seven-day point 
prevalence, proportion of participants who significantly reduced daily cigarette 
smoking by at least 25% in terms of numbers of CPD, and AEs.  
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Those eligibility for study inclusion were adult smokers in good health, age ≥18 yrs, 
who had smoked at least 10 cigarettes per day for the past year and were motivated 
to stop smoking. Exclusion criteria for the study were: having had a heart attack, 
stroke or severe angina in the previous two weeks; poorly controlled asthma or other 
airway disease from self-report; poorly controlled diabetes mellitus; severe allergies; 
poorly controlled psychiatric disorders; or current drug dependence other than that 
involving nicotine. Pregnant and breastfeeding women were excluded. 
 
At six months, the verified continuous abstinence was 7.3% (21 of 289) with nicotine 
e-cigarettes, 5.8% (17 of 295) with nicotine patches, and 4.1% (three of 73) with no-
nicotine e-cigarettes. No significant difference between e-cigarette users compared 
with nicotine patch users was found in six-month abstinence rates (RR 1.26, 95% 
CI = 0.68 to 2.34).  
 
A significantly higher proportion of e-cigarettes users, compared with nicotine patch 
users, achieved a 50% or more reduction in traditional cigarette use (57% vs 41%; 
RR 1.41, 95% CI 1.20 to 1.67). The first group reduced traditional cigarette 
consumption by an average of 9.7 (SE 0.4) CPD, compared with a reduction of 7.7 
(SE 0.4) showed by nicotine patch users (P = 0.002). The authors noted no evidence 
of an association between AEs or SAEs and products used in their study. 
 
There are also non-randomised studies of e-cigarettes for smoking cessation and 
this literature is too extensive to summarise those here.  
 
2.4.2 Systematic reviews of e-cigarettes for smoking cessation 
Following these early studies, a large number of subsequent studies have been 
published focusing on e-cigarettes for smoking cessation. These have been 
summarized and assessed in a number of systematic reviews; in fact, there are 22 
systematic reviews of e-cigarettes for smoking cessation published to date.  
 
The most robust of these is the Cochrane review of e-cigarettes for smoking 
cessation, first published in 2014 and subsequently updated in 2016. In this 
Cochrane review of the effect of e-cigarettes on smoking cessation, Hartmann-
Boyce et al. (2016) identified 24 studies: two RCTs that followed participants for at 
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least six months (described in section 2.3.1 above) and 22 observational studies 
which followed participants for less than six months or did not put people into 
treatment groups so could not directly compare e-cigarettes with something else. 
The authors also identified 15 ongoing trials. The two RCTs compared e-cigarettes 
with and without nicotine and had a combined sample size of 662 participants 
(Bullen et al., 2013; Caponnetto et al., 2013c). One trial included minimal telephone 
support, one recruited smokers not intending to quit, and both used early e-cigarette 
models with low nicotine content and poor battery life. In the meta-analysis of the 
two trials, e-cigarettes had a higher smoking cessation rate compared with placebo 
e-cigarettes. Nine percent of participants using an e-cigarette containing nicotine 
successfully quit for at least six months compared with 4% of participants using a 
placebo e-cigarette (RR 2.29, 95% CI 1.05 to 4.96). Also, in this review, none of the 
studies found that smokers who used e-cigarettes short- to mid-term (for two years 
or less) had an increased health risk compared with smokers who did not use e-
cigarettes. 
 
Hartmann-Boyce et al. (2016) judged the RCTs to be at low risk of bias, though they 
rated the overall quality of the evidence as ‘low’ or ‘very low’, because of imprecision 
due to the small number of trials. According to the Grading of Recommendations, 
Assessment, Development and Evaluations (GRADE) system used in Cochrane 
reviews, a ‘low’ grade means that further research is very likely to have an important 
impact on the confidence in the estimate of effect and is likely to change the 
estimate. A ‘very low’ grade means there is uncertainty about the estimate.  
 
The WHO commissioned El Dib et al. (2017) to conduct a systematic review and 
meta-analysis of the effect of e-cigarettes on traditional cigarette use amongst 
smokers. This research compared e-cigarettes with nicotine with e-cigarettes 
without nicotine and two independent reviewers, who also extracted data and 
assessed the studies’ risk of bias, independently evaluated prospective 
observational studies published up to December 2015. Three eligible randomised 
trials were considered, with 1,007 participants, but the third randomised trial was 
excluded because the effect of e-cigarettes versus no e-cigarettes couldn’t be 
compared for 24 weeks; hence, a total sample of 481 participants were considered. 
These researchers also identified nine eligible cohort studies with 13,115 
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participants but concluded overall that there was still limited evidence about the 
effectiveness of e-cigarettes for smoking cessation. 
 
These two systematic reviews considered a similar group of studies and arrived at 
similar conclusions: that the available studies are few and that additional evidence 
is needed to provide a definitive conclusion. However, the reviews differed slightly 
in their interpretation. The Hartmann-Boyce (2016) systematic review found a 
statistically significant effect of nicotine e-cigarettes compared with e-cigarettes 
without nicotine and considered this an important effect of e-cigarettes on quitting, 
and El Dib et al. (2017), using the same studies, were more cautious in their 
conclusions. 
 
Kalkhoran and Glantz (2016) conducted a systematic review and meta-analysis and 
identified 38 eligible studies about the impact of e-cigarette use on smoking 
cessation amongst adult smokers. In this systematic review and meta-analysis, the 
authors included cohort studies, cross sectional studies, and randomised and non-
randomised clinical trials published up to December 2015 and concluded that e-
cigarettes are associated with significantly less quitting amongst smokers 
(Kalkhoran & Glantz, 2016).  
 
Khoudigian et al. (2016) published a systematic review and meta-analysis of RCTs 
and observational studies about smoking cessation for at least 24 weeks after the 
start of e-cigarette adoption. These authors observed that despite their findings, 
which suggested that e-cigarettes with nicotine increased the proportion of smokers 
who quit (RR of 2.02 (95% CI = 0.97-4.21), this change was not statistically 
significant in their meta-analysis. Consequently, the authors concluded that several 
larger high-quality studies are needed to inform policy decisions. 
 
In conclusion, the existing systematic reviews on e-cigarettes for smoking cessation 
have inconsistent results. However, all identify the need for further research, in 
particular further RCTs. 
 
2.4.3 More recent studies of e-cigarettes for smoking cessation 
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Since the trials, observational studies and systematic reviews mentioned above 
were conducted, there have been furthermore recent studies on e-cigarettes for 
smoking cessation. In particular, three recent population-based, cross sectional 
studies have been conducted that identify promising smoking cessation rates, 
particularly amongst more frequent e-cigarette users (Levy et al., 2017; Zhu et al., 
2017; Giovenco & Delnevo, 2018).  
 
Firstly, Giovenco & Delnevo (2018) conducted a retrospective cohort study by 
including smokers and former smokers who quit in 2010 or later. Amongst these 
participants daily e-cigarette users and former smokers were 52%, daily e-cigarette 
users and never e-cigarette users were 28%, (adjusted prevalence ratio (aPR) 3.15, 
95% CI = 2.66, 3.73). Compared with participants who never used e-cigarettes (aPR 
0.38, 95% CI = 0.32, 0.47), those who previously used e-cigarettes but did not use 
them currently and those who used them on only some days were less likely to be 
former smokers (aPR 0.67, 95% CI = 0.61, 0.75). 
 
In addition, Levy et al. (2017) retrospectively generated a cohort of smokers who 
were using traditional cigarettes one year prior to their survey. This research 
focused on the association between e-cigarette use and having made a quit attempt 
in the past year, and having been abstinent from traditional cigarettes for a minimum 
of 12 weeks after a quit attempt. By using multiple logistic regression analysis, their 
findings suggested that: quit attempt in the past year was related to previous or 
current e-cigarettes usage and that the probability of smoking cessation for 12 
weeks or more was significantly associated with e-cigarette use.  
 
Finally, in terms of the most recent studies, Zhu et al. (2017) examined data from 
the large U.S. Current Population Survey-Tobacco Use Supplement (CPS-TUS). 
The researchers drew on survey data from more than 160,000 respondents to 
generate a retrospective cohort of participants who reported having been smokers 
of traditional cigarettes one year prior to the survey. They examined the population-
level rates of making a quit attempt in the past year and of quitting smoking. 
Smokers who used e-cigarettes during 2014-15 were more likely than non-users to 
make a quit attempt and obtain complete smoking cessation. The analysis verified 
that the quit rates between smokers of traditional cigarettes who used or had ever 
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used an e-cigarette showed a smoking cessation rate increased by 1.1 percentage 
points between 2010-2011 and 2014-2015.  This happened in coincidence with the 
increase of e-cigarette use amongst smokers of traditional cigarettes. Hence, in this 
study e-cigarettes appear to have helped to improve smoking cessation rates. 
All three of these more recent studies have significant limitations. They are 
observational in nature and thus cannot determine causality. In addition, there was 
likely to be recall bias amongst participants in relation to both the extent of e-
cigarette use and quit attempts. Finally, there may be confounders not assessed in 
the studies, including lack of information on previous quit attempts, the type of e-
cigarette used, motivation to quit and reasons for e-cigarette use, for example.  
 
In a very recent fourth study, e-cigarettes usage was almost twice as effective as 
NRT to help smokers of traditional cigarettes quit smoking (Hajek et al., 2019). This 
multicentre randomised trial of e-cigarettes versus NRT involved 886 adults 
attending smoking cessation services in England. The smokers were randomised 
with 447 individuals assigned to a NRT group and 439 assigned to an e-cigarette 
group. Both groups received one-on-one behavioural counselling each week for four 
weeks and were biochemically tested at the end of the year to assure they had 
stopped smoking. Smokers in the e-cigarette group were given a starter pack, a 30 
mL bottle of tobacco flavoured e-liquid with a nicotine concentration of 18 mg per 
mL, and instructions on how to use the device. Participants were encouraged to use 
different flavoured e-liquids with different concentrations of nicotine. Participants in 
the NRT group were offered a several products including patches, gum, lozenges, 
nasal or mouth sprays, inhalers, mouth strips, or microtabs and they were 
encouraged to choose a combination of products. 
 
The primary outcome was sustained smoking abstinence for one year, which was 
biochemically validated during the final visit of the trial. Secondary outcomes 
included participant-reported treatment usage and respiratory symptoms. The 
researchers observed a one-year abstinence rate of 18.0% in the e-cigarette group 
compared with 9.9% in the NRT group. This study found that 80% of participants in 
the e-cigarette group were more likely to continue using their product at one year 
compared with 9.0% in the NRT group.This study had several strong points, 
including long-term outcomes with a large sample size, a real life setting, 
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researchers who let participants choose their e-liquid and their NRT, biochemical 
verification of smoking cessation outcomes, and rigorous data analysis but it's 
uncertain if the results would generalize to other populations of smokers. It is also 
not possible to affirm that these discoveries would apply to other e-cigarette devices, 
or away from the setting of a controlled study and lacking behavioural counselling.  
 
2.5 E-cigarettes for smoking cessation in people with schizophrenia spectrum 
disorders 
 
While the number of studies examining e-cigarettes for smoking cessation in the 
general population is now fairly substantial, despite mixed conclusions, there are far 
fewer studies relevant to this topic that have been conducted with priority groups for 
smoking cessation. This includes people with schizophrenia spectrum disorders: the 
population that is the focus of this thesis. This section reviews the existing published 
literature on this topic, firstly outlining findings of studies that have examined e-
cigarettes as an intervention for smoking cessation in this group, and secondly 
outlining the prevalence and attitudes of people with schizophrenia spectrum 
disorder regarding e-cigarettes.  
 
2.5.1 Interventional studies 
When initial work on this PhD thesis began, there was almost no available literature 
on e-cigarettes for smoking cessation for smokers with schizophrenia. The 
exception was a small uncontrolled study conducted at CPCT, where the PhD 
candidate is based. This was the first study in the world to investigate the efficacy 
of e-cigarettes for smoking cessation/reduction in people with schizophrenia.  
 
In this early study, 14 smokers with schizophrenia spectrum disorders not motivated 
to quit smoking were recruited. Fourteen smokers were provided with an electronic 
cigarette kit and enough cartridges to last up to12 weeks. They were advised to use 
the product ad libitum throughout the day, not to exceed a four cartridge/day 
maximum as recommended by the manufacturer of the product, a first generation 
“Categoria” e-cigarette, (Arbi Group Srl, Milano, Italy) loaded with 7.4 mg nicotine 
cartridges called “Original” cartridges.  Participants were followed-up for one year. 
At each visit, participant eCO levels were recorded, study diaries were given to study 
personnel and unused study products were turned in.  Overall, this study found that 
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at the 52-week visit, 50% of smokers with schizophrenia who were provided with e-
cigarettes for 12 weeks had reduced their smoking by 50%, and a further 14% had 
quit smoking completely with no increases in psychiatric symptoms (Caponnetto et 
al., 2013d). These preliminary findings are noteworthy because none of the 
participants initially sought treatment for smoking. However, the study had a 
significant number of limitations, including the absence of a control group and a very 
small sample size. 
 
Subsequently, Pratt et al. (2016) enrolled 21 outpatients with serious mental illness 
(schizophrenia, schizoaffective disorder, or bipolar disorder) who smoked at least 
10 CPD, had a history of failed treatment-facilitated quit attempts, and were not 
involved in smoking cessation treatment. Participants were given second generation 
e-cigarettes (N-Joy brand) based on each participant’s level of use of traditional 
cigarettes and directions on how to use them, and were evaluated weekly for one 
month. Authors declared that each e-cigarette cartridge was approximately 
equivalent to two packs of traditional cigarettes but they didn’t mention the nicotine 
strength of the cartridges used in the study. Nineteen participants completed the 
study visit (10 with schizophrenia spectrum disorders, nine with bipolar disorder). 
The study found a significant smoking reduction with a mean self-reported decline 
in use of traditional cigarette from 192 to 67 cigarettes/week confirmed by CO 
reduction from 27 ppm to 15 ppm. There were some AEs reported: 58% of 
participants experienced mild and transitory side effects, including cough, dry/sore 
throat, nausea and dizziness. The study also examined participant’s perceptions. In 
answer to open-ended questions, these smokers perceived e-cigarettes as 
enjoyable and satisfying, and they were willing to buy e-cigarettes; they also 
perceived e-cigarettes as healthier, useful to help them feel more accepted by non-
smokers, and useful to avoid the unpleasant odor of burned cigarettes. In their 
conclusions Pratt et al. suggested that people with serious mental illness may find 
e-cigarettes an appealing alternative to traditional cigarettes but recommended that 
further RCTs with longstanding mental health conditions were needed.  
 
In a more recent study, Hickling et al. (2018) conducted a 24-week pilot study to 
investigate the efficacy of a six-week free first-generation e-cigarette treatment to 
reduce traditional cigarette consumption in 50 smokers with severe mental illness 
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not motivated to quit, including 42 (84%) participants with schizophrenia spectrum 
disorders. These smokers were offered free NJOY disposable e-cigarettes with 
4.5% nicotine and were encouraged to replace traditional cigarettes with e-
cigarettes as much as possible. A final follow-up visit for assessment was scheduled 
at week 24. At the end of the six-week free e-cigarette phase, 37% of participants 
had reduced their tobacco consumption and 7% had stopped smoking. Four weeks 
post this phase 26% of participants had reduced their tobacco consumption and 5% 
had quit to smoke traditional cigarettes. At final follow up (24 weeks), 25% of 
participants had reduced their tobacco consumption and 2% had quit to smoke 
traditional cigarettes. This study found good product acceptability and no negative 
impact on participants’ mental health or significant AEs. However, the study had 
limitations, including that 16% of participants with bipolar disorder had their 
psychopathological changes assessed by the PANSS scale, which is designed to 
assess schizophrenia spectrum disorder symptoms and not bipolar disorder 
symptoms. In addition, as the authors acknowledged, the study was also limited by 
the fact that it involved the use of a first-generation e-cigarette, considered less 
effective in terms of blood nicotine delivery, and the use of a self-report method for 
various measures. 
 
2.5.2 Prevalence and attitudes towards e-cigarettes in people with 
schizophrenia spectrum disorders  
In addition to a small number of intervention studies, there are also some data 
available on the extent to which schizophrenic smokers use e-cigarettes and their 
attitudes towards these products. For example, Miller et al. (2017) investigated the 
prevalence and attitudes of e-cigarette use in the USA amongst 60 inpatients and 
outpatients with schizophrenia or schizoaffective disorder diagnosis.  
Participants completed an anonymous, 10-minute, pencil-and-paper survey to 
evaluate the prevalence of and attitudes toward e-cigarette use, and use of e-
cigarettes to help or hinder their psychopathology. The majority (70%) of participants 
were current smokers, of whom 83% smoked a mean of 15 CPD; 90% percent of 
participants were aware of e-cigarettes, 37% had used them, 7% were current users 
and 24% of never-users were considering using e-cigarette in the future. Thirty four 
percent of surveyed smokers believed that the health effects of e-cigarettes were 
less harmful than traditional cigarettes.  
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Cost was the most frequently mentioned potential disadvantage of e-cigarettes 
(33%) and health improvements (39%), smoking reduction (37%), and quitting 
(37%) were the most commonly mentioned potential benefits.  
Smokers who were ever-users stated that traditional cigarettes were significantly 
more useful in reducing paranoia, anxiety, depression, and reduced concentration, 
than e-cigarettes.  
The authors suggested that e-cigarettes have modest significance to smoking 
cessation in smokers with schizophrenia spectrum disorders and concluded that 
their preliminary findings should be investigated in larger samples. 
 
Chen et al. (2016) conducted a survey of smoking cessation treatment with 231 
smokers with serious mental illness (33% with schizophrenia/schizoaffective 
disorders, 63% with mood disorders, 11% with post-traumatic stress disorder and 
eight percent with borderline personality disorder), 45 psychiatrists and 97 case 
workers in four community mental health centers in the USA.  
Fifty percent of smokers showed an interest in using e-cigarettes to quit smoking 
and 22% reported current e-cigarette use. There were differences between patient 
and provider perspectives: despite 82% of patients reporting wanting to quit or 
reduce traditional cigarette smoking, 91% of psychiatrists and 84% of case workers 
stated that their patients were not interested in quitting; hence, psychiatric treatment 
providers perceive their patients to have no motivation to quit smoking.   
In contrast, their patients reported motivation to use and active use of e-cigarettes 
to quit smoking. 
 
Sharma et al. (2017a) conducted a qualitative study to analyze Reddit online lay 
discussions and assess motivations and limitations associated with e-cigarette use 
amongst people with self-reported mental Illness, including nine smokers with 
schizophrenia. Their thematic analysis included 3,263 comments from 133 
discussion threads.   
Motivations to use e-cigarettes amongst people with mental illness included self-
medication, quitting smoking, freedom and control, as a hobby, for social 
connectedness and in response to caregivers and online communities. Some 
limitations of e-cigarettes use included that they were perceived to be an 
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unsatisfactory substitute for traditional cigarettes and psychiatric medicines, drug 
interactions, nicotine addiction, risks of e-liquid, practical difficulties and cost.  
 
2.6 Summary and conclusion 
Following on from the introductory chapter, this second chapter has reviewed further 
relevant literature to provide context for the thesis. It began by describing the 
concept of THR and then discussed the development of e-cigarettes and their 
characteristics. The chapter also summarised and critically reviewed studies on the 
RRs of e-cigarette use compared with smoking as well as available literature on 
vaping as a smoking cessation strategy in the general population and then for 
smokers with schizophrenia spectrum disorders.  
  
Although e-cigarettes have not been proven to be totally safe, evidence reviewed in 
this chapter suggests that they may be less harmful alternatives to combustible 
cigarette smoking. Consequently, e-cigarettes could be considered as an applicable 
instrument for THR. This chapter also outlined the history, evolution and marketing 
of e-cigarettes and existing evidence on e-cigarette harms and benefits. While tests 
of e-cigarette constituents, in vitro toxicological tests, and short-term research in 
humans suggest that e-cigarettes are likely to be less harmful than traditional 
cigarettes, due to absence of long-term epidemiological research and large clinical 
trials, the consequences for long-term effects on health and death are not yet clear. 
As a result, the safety of e-cigarette use cannot be definitely assessed at this time.  
 
A further directly relevant theme for this thesis, however, is whether the existing 
literature suggests that e-cigarettes can help smokers to quit. Systematic reviews of 
e-cigarettes for smoking cessation in the general population suggest mixed results, 
but the best quality review (Cochrane) and one other show promising findings. 
These need to be confirmed in future trials. Smokers with schizophrenia spectrum 
disorders and new routes to smoking cessation are the main focus of this thesis. 
Overall, there are very few studies of e-cigarettes for smoking cessation in patients 
with schizophrenia and these studies are very small. They have promising results, 
but more research is needed. The findings from these studies, conducted with first 
generation and second-generation e-cigarettes, suggests that the provision of e-
cigarettes can significantly reduce traditional cigarette consumption and CO expired 
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breath without significant variations of psychopathological signs and symptoms and 
without showing significant and serious AEs. There is little research about  the views 
and perceptions of this group of people regarding e-cigarettes as an acceptable aid 
to quitting or reducing smoking  The next chapter describes a qualitative study of 
people with schizophrenia spectrum disorders who smoke and their views about 
traditional cigarettes compared with e-cigarettes and the appeal of licensed 
cessation aids compared with e-cigarettes for smoking cessation or smoking 
reduction.  
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CHAPTER 3: QUALITATIVE STUDY  
 
3.1 Study title: A qualitative study of the views about smoking, licensed 
cessation aids and e-cigarettes in people with schizophrenia spectrum 
disorders 
 
3.2 Chapter overview  
This chapter presents a qualitative study which explored the perspectives of 30 
participants with schizophrenia spectrum disorders about traditional cigarettes 
compared with e-cigarettes, and licensed cessation aids and e-cigarettes for 
smoking cessation or smoking reduction. Half of the participants were motivated to 
quit and half unmotivated to quit. This chapter includes a description of the purpose 
of the study, research questions, methods, findings and interpretation. I have used 
the principles of the Standards for Reporting Qualitative Research (SRQR) 
guidelines to structure this chapter. 
 
3.3 Purpose of the study 
This is the first qualitative study to explore the perspectives about traditional 
cigarettes compared with e-cigarettes and the views about licenced cessation aids 
and e-cigarettes for smoking cessation or smoking reduction in an exclusive sample 
of participants with a DSM-V diagnosis of schizophrenia spectrum disorders.  It is 
also the first to explore the similarities and differences amongst this group according 
to their motivation to quit. Views about smoking cessation treatments may be 
different according to motivation.  It is arguably important to understand this through 
a comparative combined analysis between motivated and not motivated smokers in 
order to improve and tailor interventions and inform the protocol for a future RCT 
(Chapter 5). There are several qualitative studies about the experience of smoking, 
smoking cessation or reduction and smoking cessation aids in people with 
schizophrenia spectrum disorders (Knowles et al., 2016; Rae et al., 2015; Esterberg 
& Compton, 2005), all discussed in Chapter 1. When my PhD studies began, there 
were no published qualitative studies of adult smokers with schizophrenia spectrum 
disorders regarding e-cigarettes for smoking cessation or smoking reduction. Since 
then, Sharma et al. (2017a) has conducted a thematic analysis about the motivation 
to use e-cigarettes and their limitations using postings made by 1,681 people with 
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mental illnesses on the Redditt website. These authors analysed 3,263 comments 
from 133 discussion threads, of which 2.1% (n = 9) were made by people who self-
reported they had schizophrenia.   
 
3.4 Research questions 
Research questions included the following: 
• How do people with schizophrenia spectrum disorders perceive traditional 
cigarettes compared with e-cigarettes? 
• How appealing are licenced cessation aids for smoking cessation or 
reduction? 
• How appealing are e-cigarettes for smoking cessation or reduction? 
 
3.5 Methodology 
A qualitative approach was used for this study allowing for the exploration of the 
meaning of smoking, licenced medications and e-cigarettes for smoking cessation 
and reduction, through personal description of experiences and perspectives (Flick, 
2006). 
 
Qualitative research is a method of enquiry, based on the report of events gained 
through observation or interaction with participants, to gain an in-depth 
understanding of human behaviour. It draws from the situation in which events occur 
and attempts to “describe occurrences, as a means of determining the process in 
which events are embedded and the perspectives of those participating in the 
events, using induction to derive possible explanations based on observed 
phenomena” (Gorman, 2005, p.3).  
 
Qualitative information is collected by audio recording, video recording, and 
transcribed texts from interviews with single participants or focus groups. Induction, 
the method of understanding and interpreting information, and the presentation of 
participants’ viewpoints are created after data and evidence have been collected 
(Braun, 2006). 
 
There are various methodological approaches for conducting qualitative research, 
depending on the purpose of the study and the research questions. A 
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phenomenological approach served as a guiding methodology in the development 
of this study, having considered other common methodologies, described in Table 
1. A phenomenological approach seeks to discover how individuals construct 
meaning of the human experience (Moerer-Urdahl & Creswell, 2004) and represents 
the lived experiences of those being interviewed. Discovering the essence of the 
respondents’ perspective improves accuracy in representing the phenomenon 
(Moustakas, 1994). During the process of qualitative research, the researcher is 
obliged to develop a broad foundation of relative knowledge in order to examine 
adequately the developing themes (Strauss & Corbin, 1998). 
 
Table 1: Examples of qualitative methodologies 
 
Methodology Brief description 
Phenomenology 
 
Describes the "lived experience" of a phenomenon and the 
meaning, structure and essence of the lived experience. 
The researcher tries to gain access to an individual’s 
world, i.e., their world of experiences, which is where 
consciousness exists (Moerer-Urdahl & Creswell, 2004).  
Grounded Theory 
 
The development of inductive “bottom-up” theory that is 
grounded directly in the empirical data. Each new 
individual observation is compared with existing data to 
identify similarities and differences (Charmaz, 2006).  
Ethnography 
 
Ethnography is the study of behaviours, social 
connections, and perceptions that naturally occur within 
groups or communities. The principal aim is to provide in-
depth insights into people’s views and actions by collecting 
detailed observations and interviews (Hammersley & 
Atkinson, 2007).  
 
This qualitative study is based on an interpretive paradigm, which advocates from a 
theoretical perspective the study of research participants’ experiences, which are 
taken at face value. Behaviours that stem from experiences help describe reality. 
Interpretation can be achieved by exploration of recordings or quotations through 
the formulation of categories against which a text is analysed (Gorman, 2005). The 
interpretive paradigm sees each experience and situation as unique with its 
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meaning being an outcome of the circumstances as well as the individuals involved 
(Moustakas, 1994). Moustakas (1994) identified seven common qualities of an 
interpretive paradigm.  These are:  
 
1.  Focusing on the wholeness of an experience instead of its parts. 
2.  Formulating questions and problems that reflect the interest, involvement, 
and interpersonal and personal commitments of the researcher. 
3.  Obtaining first person accounts of experiences through (in)formal 
discussions and interviews. 
4.  Putting value on qualitative designs and methodologies as approaches to 
human experiences. 
5.  The day-to-day experience is imperative to understanding human 
behaviour and can be used as evidence for scientific research. 
6. Searching for underlying meanings of experiences rather than simple 
measurements or explanations. 
7.  Experience is integrated into an inseparable relationship between subjects 
and objects either in part or whole. 
 
3.6 Methods 
The following sections provide an account of the eligibility criteria, and methods for 
recruiting participants and collecting data. Thematic analysis was used to analyse, 
synthesise and interpret the data.  
 
3.6.1 Eligibility criteria 
Participants were eligible for the study if they 
1. Had a diagnosis of schizophrenia spectrum disorder according to DSM-
V criteria, with first or multiple episodes. A homogenous diagnostic 
sample (i.e. only people with schizophrenia) was preferred to a 
heterogenous one (e.g. people with bipolar disorder, depression and 
anxiety) because people with schizophrenia have similar patterns of 
thinking, emotion and behaviour compared with people with other mental 
disorders. People with schizophrenia also have a higher co-morbidity 
between smoking and schizophrenia compared to other mental disorders 
(de Leon and Diaz, 2005).  
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2. Were outpatients who were in the stable phase of illness (no relapse or 
hospitalization in the previous three months and/or need to change 
psychopharmacological treatment in the previous month (Mendrek et 
al.2012)), to ensure a state of absence of psychopathological 
exacerbation in line with studies conducted in people with schizophrenia 
(Potvin et al., 2013; Bourque et al., 2013).  
3. Were current smokers of ≥10 CPD for at least the past five years. My 
research group in Catania has used this criterion in previous studies with 
e-cigarettes (Caponnetto et al., 2013c, Russo et al., 2016). Our rationale 
for this criterion in these two Italian studies was influenced by our 
intention to provide help for the ‘average Italian smoker’ and provide a 
potentially effective intervention generalizable to all smokers. We 
therefore used the data from the Statistical Observatory on Smoking in 
Italy; the average daily number of cigarettes per Italian smokers was 13, 
with higher prevalence from 25 to 65 years and an average age at 
initiation of 18 (OSSFAD, 2012).  
4. Were aged 18 to 65 years. 
5. Had not used licenced smoking cessation aids or e-cigarettes as part of 
an intention to modify their daily cigarette consumption (to a quit or 
reduce) in the previous 12 months. The rationale for this eligibility 
criterion is based on the evidence that recent use of cessation aids could 
in some way significantly change their appeal and perception (Perez 
Mata et al., 2017). Product usage may influence attachment to the 
product and its associated appeal and perception (Klein & Baker, 2004; 
Ball & Tasaki, 1992). Product attachment has been defined as “the 
emotional bond a consumer experiences with a product” (Schifferstein & 
Zwartkruis-Pelgrim, 2008). Norman (2004) holds that the attachment 
between the user and product is formed by product appearance and 
aesthetic appeal, behavioural-product in use, effectiveness and pleasure 
of use and personal satisfaction of using it. A study showed that recently 
acquired and used products (under one year) have a high level of 
attachment for users (Schifferstein & Zwartkruis-Pelgrim, 2008). Use and 
frequency of e-cigarettes was assessed following recommendations by 
Pearson et al. (2017). 
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Motivation to quit was assessed by two answers of the Motivation to Stop Scale 
(MTSS) (Kotz et al., 2013). The MTSS consisted of one item and participants were 
asked “Which of the following describes you?”  
 
The seven answers of the MTSS offer a dimensional vision of the motivation to quit 
smoking, from 1=lowest to 7=highest level of motivation to stop (1. "I don't want to 
stop smoking"; 2. "I think I should stop smoking but don't really want to"; 3. "I want 
to stop smoking but haven't thought about when"; 4. "I really want to stop smoking 
but I don't know when I will"; 5. "I want to stop smoking and hope to soon"; 6. "I really 
want to stop smoking and intend to in the next three months"; 7. "I really want to 
stop smoking and intend to in the next month"), but not a categorical one and do not 
allow a precise demarcation or cut-off between those who are motivated and those 
who are not motivated to quit. Hence, I identified participants clearly not motivated 
to quit to be people who answered “I don’t want to stop smoking”. I considered 
participants clearly motivated to quit as people who answered “I really want to stop 
smoking and intend to in the next month”. The first answer correlates with the 
absence of any belief or desire to quit, the second answer correlates with a strong 
desire and short-term intention to quit (Kotz et al., 2013). I explored the perception 
of motivated participants and unmotivated participants to understand the 
commonalities and differences between the two groups and the possible implication 
for smoking cessation and/or THR.  
 
3.6.2 Setting  
All interviews were conducted at Catania Schizophrenia Center, Department of 
Mental Health. The Department of Mental Health is part of the Italian National Health 
System (SSN) and is responsible for prevention, psychiatric diagnosis, care and 
rehabilitation and for the organisation of interventions aimed at safeguarding the 
mental health of the local population. The Department of Mental Health aims to 
eliminate any form of discrimination, stigma and exclusion directed at persons with 
a mental disorder or condition, and actively promotes the full and complete rights of 
citizenship of such persons. The Department of Mental Health guarantees that the 
mental health services and structures operating within the SSN constitute a single 
and unified organisational structure. Further, the Catania Schizophrenia Centre 
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ensures the close coordination between its services and other SSN districts. This 
Centre cares for people who are outpatients. I carried out the qualitative study 
between October 2016 and January 2017 prior to the single arm pilot study (Chapter 
4).  
 
3.6.3 Sampling and recruitment strategy 
In this study, I used two non-probability sampling techniques, namely purposive 
sampling and quota sampling, which complemented each other. 
 
Purposeful sampling is widely used in qualitative research (Patton, 2002). In this 
type of sampling, participants are selected or sought after according to pre-selected 
criteria based on the research question (i.e. the eligibility criteria). Quota sampling 
is a sampling technique whereby a participant quota is pre-set prior to sampling (an 
equal number of motivated and unmotivated participants). The sample size was 
predetermined: 30 smokers with schizophrenia were recruited according to their 
motivation to quit smoking. According to Creswell (1998) five to 25 participants are 
required for qualitative phenomenological studies; as I had two subgroups, I chose 
to recruit 15 participants for each group. I also aimed to capture both breadth and 
depth of understanding from men and women. Fifty-five people were referred for 
assessment for inclusion in the study, 10 were excluded because they did not meet 
the eligibility criteria (smoked fewer than 10 CPD), and 15 were excluded because 
they scored in the middle range of MTSS. It was easier and quicker to recruit clearly 
unmotivated than clearly motivated participants and as such, these participants 
were enrolled first in the study. 
 
3.6.4 Ethical issues 
The qualitative study was approved by the University of Stirling ethics committee on 
24 October 2016 (Appendix 1). Participants gave written informed consent prior to 
participation in the study. The recruitment and informed consent process was 
consistent with that for clinical research (Appendix 2, Appendix 3). Clinicians 
(psychiatrists, clinical psychologists, nurses, and clinical social workers) from the 
Schizophrenia Center informed current patients about the study and if agreeable 
arranged a suitable time for interview with the researcher. I enrolled them into the 
study if they met the eligibility criteria and informed consent was then taken by the 
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researcher before the interview began. This means that the referring clinician had 
no knowledge of whether the person he or she nominated participated or not.   
 
Participant data were stored securely on a University password protected computer. 
Interview recordings were transcribed verbatim and anonymised, with participants 
identified by a unique identification number. Audio recordings will be retained for at 
least three years after the completion of the research (and stored in a locked filing 
cabinet). Only anonymous versions of transcripts were shared with the PhD 
supervisors, to help guide plans for the analysis. This qualitative study considered 
the dimensions of non-biological risk (e.g., psychosocial, anxiety-related, 
confidentiality, disclosure, stigmatization, and legal issues) that are associated with 
taking part in this research. It was important that study participants with 
schizophrenia (who were all volunteers) had an intellectual understanding of the 
overall goals of the research. I also considered the phenomenon of ‘‘respondent 
burden’’ (e.g. time, energy, and emotional expenditure of participants). The 
recruitment and informed consent process presented in the next section describes 
how I considered ethical issues and the strategy to mitigate any risks. With any 
interview there is a small risk that the participant may disclose information that 
causes the researcher concern for the participant’s safety or that of someone else. 
It was not anticipated that interviews would precipitate potentially sensitive content; 
however, it was made clear when obtaining informed consent that participants could 
refuse to answer any questions they wished and could terminate the interview at 
any time (with no reason necessary).  If during the interview the participant became 
distressed, he or she was offered a break, offered to terminate the interview or 
steered to discuss another topic. It was made clear that everything he or she said 
was confidential unless he or she disclosed to the researcher something that caused 
concern for his or her own safety or others’ safety. I used a structured topic guide 
and took care to direct the conversation back to this if the participant discussed 
something that was not relevant or particularity sensitive.  
 
3.6.5 Data collection and processing 
Individual structured interviews were used to collect data, conducted by two trained 
clinical psychologists at a Schizophrenia Center. This included me (the PhD student) 
and another colleague (Dr Marilena Maglia), who interviewed some female patients 
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who were more comfortable with a female interviewer. Neither of us had any 
previous knowledge or clinical relationship with any of the participants. I chose to 
use a structured interview to facilitate data collection. People with schizophrenia 
spectrum disorders may be suspicious, have difficulty with attention and 
concentration, or have poverty of thought or in some cases logorrhoea; a structured 
approach provides more focus for both interviewer and interviewee compared with 
an unstructured or semi-structured approach. The interviews followed a structured 
topic guide developed by me with input from my supervisors (Appendix 4) and 
covered the following aspects: smoking history; mental health experience; views 
about the taste, satisfaction and cost of traditional cigarettes and e-cigarettes; the 
perceived impact of both on their health; their knowledge and experience of NRT, 
varenicline and bupropion; and the appeal of e-cigarettes and licenced cessation 
aids for smoking cessation or reduction. 
 
A topic guide is a structured series of topics which reflect the objectives of the 
interview. During the creation of this topic guide, I kept in mind the specific research 
questions and I followed guidelines by Ulin et al. (2004) for constructing a topic 
guide.  As suggested by King and Horrocks (2010), in constructing this topic guide 
I used my own personal experience in the research area and consulted the research 
literature on the subject. Hence, as the first step I identified topics and subtopics. 
The key topics were extracted from the original research questions and these were 
broken down into subtopics. As a second step, I chose the sequence of the topics 
and subtopics to direct the natural flow of the conversation. As the final step, I 
prepared opening and closing statements.  
 
Interviews took place during working hours at the Schizophrenia Center in a private 
room where no one else was present; all interviews were recorded. The duration of 
the interviews ranged from 10 minutes to one hour and the average length of 
interviews was approximately 15 minutes (some participants became distressed or 
were easily fatigued, which influenced the length of the interview). I transcribed all 
interviews verbatim within one week of each interview. It took an average of two to 
four hours to transcribe each interview script. Transcription can be problematic 
because, depending on the length of the interview, nuance can be lost via the 
omission of non-verbal cues such as pauses, laughter, anger and pitch which can 
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be important aspects of the analysis (Cohen et al., 2011). The use of a tape recorder 
was very helpful in this regard as it gave me the opportunity to consider these para-
verbal cues more fully when transcribing. I initially transcribed the interviews in 
Italian and then translated the transcripts into English. Several of the participants 
had opted to use Sicilian or both Italian and Sicilian language during the interviews, 
which made the transcription and translation complex at times, especially as I had 
to ensure that I did not distort any of the information presented by the participants. 
 
3.6.6 Analysis 
I approached this study using thematic analysis, which involved multiple angles and 
iterations of studying the participants’ views. Braun & Clarke (2006) describe 
thematic analysis as “a method for identifying, analyzing and reporting patterns 
(themes) within data” (Braun and Clarke, 2006, p. 6). They also describe it as a 
flexible and useful research tool that provides a rich and detailed, yet complex, 
account of the data (Braun & Clarke, 2006). Thematic analysis involves the search 
for and identification of common threads that extend across an entire interview or 
set of interviews (DeSantis & Noel Ugarriza, 2000) in which a ‘theme’ is the main 
product of data analysis (Green et al., 2007).  
Thematic analysis is different from other qualitative methods of analysis in that 
“thematic analysis is not wedded to any pre-existing theoretical framework and 
therefore it can be used within different theoretical frameworks” (Braun & Clarke, 
2006 p. 9). Following the six-phased guide suggested by Braun & Clarke (2006) 
(Figure 3), the first step in thematic analysis involves becoming closely familiar with 
the data by reading and re-reading the interview transcripts. This included my 
translation of the transcriptions from Italian into English, validating the transcriptions 
through reading a translated transcript and listening to its corresponding audio 
recording. The English transcriptions were sent to my second supervisor (Dr 
Deborah Robson) for independent reading. I then studied the transcripts one at a 
time (Appendix 5), actively engaging the text through highlighting and memoing 
different sections, and then generating one- to two-page summaries on each 
smoker.  
 
Following the close reading phase, my second supervisor and I independently made 
notes and developed a coding system that comprised deductive codes derived from 
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the topic guide (e.g. financial cost of smoking) and inductive codes that emerged 
from the interview data (e.g. the experience of time). This involved examining the 
data while keeping the research question at the forefront of my mind, noting down 
additional material that might not be directly related to the question but that provided 
a context to understanding the participant’s experiences. Using NVivo software, we 
coded sections of text in the transcript that aligned with the descriptions of the code 
as well as the surrounding context. In this process, we regarded our codes as filters 
for the large amounts of textual data in that they organized sections of text around 
a common description. Once the codes were applied to all of the transcripts, we re-
organized the codes into themes. 
 
In thematic analysis a theme is defined as “a pattern found in the information that at 
a minimum describes and organises the possible observations and at a maximum 
interprets aspects of the phenomenon” (Boyatizis,1998, p. 4). Four broad themes 
were identified and related to the original research question: 1) reasons for starting 
to smoke; 2) perceptions of traditional cigarettes compared with e-cigarettes; 3) 
perceptions and appeal of licensed medications for smoking cessation or reduction; 
and 4) the appeal of e-cigarettes for smoking cessation or reduction.  
 
While all transcript data are required in order to arrive at the themes, it is not 
necessary to use all the data to illustrate the theme. The quotations used need to 
capture discrete aspects of the themes. The presentation of each theme requires a 
process of writing and re-writing. The final phase can be described as the process 
of synthesis (Braun and Clarke, 2006). Once each theme was clearly defined and 
described, I illustrated the theme with reference to the transcripts using extracts of 
verbatim quotations and photographs of study participants in order to capture the 
essence of the theme.  
 
Figure 3. Six-phased guide suggested by Braun & Clarke 
 
90 
 
 
3.6.7 Data Management 
I began arranging data in a systematic manner whilst still conducting field work. I 
typed my field notes every day, transcribed the interviews, downloaded photographs 
from my camera and attached memos accordingly. I used NVivo 11, a Computer 
Aided Qualitative Data Analysis Software (CAQDAS) programme, to manage the 
data. The use of the NVivo software facilitated the process of organising, re-
arranging and managing the considerable amount of data. The interview transcripts 
were formatted in Microsoft Word to facilitate importing the transcripts into NVivo.  
Importing transcripts into NVivo, resulted in the questions being displayed in the 
content panel in the NVivo explorer. Hence, when selecting a question, it was 
possible to jump to this section in the interview transcript. After coding the interviews 
in NVivo, all passages assigned to a specific code were viewed on screen and 
printed. I also had access to each participant’s biographical data and these were 
kept under a node classification file. An advantageous feature of NVivo is that the 
software keeps a log of all data that were entered, which means that all codes and 
memos were automatically assigned a date and time stamp. This feature helped to 
trace the development of codes. I took photographs (with the participants’ consent) 
with the intention of using them to enrich the illustration of potential themes. These 
were stored in a password protected external file. 
 
3.7 Findings 
This section begins with a description of the participants’ characteristics, then gives 
a tabulated overview of the themes followed by a more detailed synthesis. 
 
3.7.1 Participant characteristics Thirty interviews were conducted with 20 male 
and 10 female participants; their characteristics are presented in Table 2. Fifteen 
participants were not motivated to quit smoking and 15 participants were motivated 
to quit smoking.  
 
Table 2: Characteristics of participants  
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Total 
(n=30) 
Not 
motivated 
to quit 
(n=15) 
Motivated 
to quit 
(n=15) 
Gender male: n (%) 
 
20 (67%) 10 (67%) 10 (67%) 
Gender female: n (%) 10 (33%) 5 (33%) 5 (33%) 
Age: mean years (SD)    46.4 (12.2) 49.3 (10.5) 43.4 (13.2) 
Age of onset of schizophrenia spectrum 
disorders: mean years (SD)    
19.2 (1.8) 19.5 (1.7) 18.9 (1.9) 
CPD: mean (SD)    25.1 (11.1) 23.8 (12.4) 26.3 (10.4) 
Age of onset of smoking: mean years 
(SD)  
17.1 (5.2) 17.5 (4.4) 16.6 (5.9) 
Length of time smoking: mean years 
(SD)    
30.3 (13.4) 33.7 (12.8) 26.3 (13.7) 
Packs/year: mean (SD)    37.8 (22.9) 39.5 (25.1) 36.1 (25.2) 
Participants who have previously tried 
to quit: n (%) 
9 (30%) 1 (6.7%) 8 (54.4%) 
Ever e-cigarette users: n (%) 15(50%) 6 (40%) 9(60%) 
Former daily e-cigarette users: n (%) 10 (33.3%) 4 (27.2%) 6 (40%) 
Previously ever used a licenced 
cessation aid: n (%) 
1 (3.3%) 0 1 (6.6%) 
NRT 1 (3.3%) 0 1 (6.6%) 
Varenicline 0 0 0 
Bupropion 0 0 0 
 
Participants who were not motivated to quit had similar smoking and clinical 
characteristics for gender and age of smoking initiation, were slightly older and had 
smoked for longer compared with those who were motivated to quit. People who 
were motivated to quit smoked more CPD and had previously tried to quit more 
times than those who were not motivated to quit smoking.  Half of the total sample 
had a history of ever e-cigarette use (according to the definition by Pearson et al., 
2017), with slightly more participants from the motivated group having ever used 
them. A third of the total sample were classified as former daily e-cigarette users 
(according to Pearson et al., 2018), again slightly more in the motivated group.  Only 
one participant (from the motivated group) had ever previously used NRT as a 
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licensed cessation aid. No one had previous experience of using varenicline or 
bupropion for cessation. 
 
3.7.2 Themes 
Participants’ views were synthesised into four themes and related codes (Table 3).  
 
Table 3: Themes and codes 
 
Theme Codes 
Reasons for starting to smoke 
 
• Age initiation 
• Social context 
• Why start smoking? 
Perceptions of traditional cigarettes 
compared with e-cigarettes 
 
• Taste 
• Satisfaction 
• Enjoyment 
• Financial cost 
• The experience of time 
• Perceived impact of traditional 
and e-cigarettes on health 
Perceptions and appeal of licensed 
medication for smoking cessation or 
reduction 
 
• Experiences of NRT for quitting 
or reduction 
• Experiences of Varenicline for 
quitting or reduction 
• Experiences of Bupropion for 
quitting or reduction   
• Intention for future use 
The appeal of e-cigarettes for smoking 
cessation or reduction 
• Experience of e-cigarette use for 
quiiting  
• Experience of e-cigarette use for 
reduction 
• Percentions of harm Intentions 
for future use  
 
3.7.2.1 Theme 1: Reasons for starting to smoke 
Participants in both groups started to smoke when they were teenagers and before 
their diagnoses of schizophrenia spectrum disorders. When asked to recall their 
reasons for smoking initiation, only two participants could not remember why they 
started. Many participants said they started smoking with friends (n = 11) whilst still 
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at school or with family members (n = 4). They started smoking to rebel, feel like an 
adult, be cool, or be attractive, or during a period of sadness. 
 
REASONS FOR STARTING TO SMOKE 
Not motivated to quit smoking Motivated to quit smoking 
“I started smoking because everyone 
smoked, my mother too.” 
(Cetty, female, aged 58) 
“I started to smoke during a sad 
period” 
(Mela, female, aged 55). 
“I started smoking to be cool” 
 (Sharon 60, female, aged 39) 
“I started smoking because i felt bad, i 
felt sad. I wanted to be a rebell” 
(Gino, male, aged 29) 
 
3.7.2.2 Theme 2: Perceptions of traditional cigarettes compared with e-
cigarettes 
Participants were asked about their views about traditional cigarettes and e-
cigarettes in relation to the taste, satisfaction, enjoyment, cost, experience of time, 
and impact on their health and wellbeing. 
 
Taste, satisfaction and enjoyment 
The two groups held mixed opinions about the taste and satisfaction of traditional 
cigarettes. Compared with the motivated participants, participants who were not 
motivated to quit considered the taste of traditional cigarettes as an important part 
of their smoking experience and they preferred particular brands over others.  The 
majority (n = 13) of the unmotivated participants enjoyed the taste of traditional 
cigarettes and found them satisfying compared with a minority of the motivated 
group (n = 4). Most participants in the motivated group no longer experienced 
satisfaction from smoking; they reported they smoked because they were addicted 
to tobacco and found it too difficult to quit. 
 
 
 
 
 
 
TASTE, SATISFACTION AND ENJOYMENT OF TRADITIONAL CIGARETTES 
Not motivated to quit smoking Motivated to quit smoking 
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“ohh….It's a big part of my life..…if It 
wasn't for the cigarettes, I could not do 
anything in the day” 
(Glenda, female, aged 55) 
“Smoking is an addiction, not a 
satisfaction”  
(Bruno, male, aged 57) 
“I don’t like the taste of the cigarette 
filter, I take out the filter to feel the 
taste of cigarettes” (Julietta, female, 
aged 25) 
“Though it’s a bad habit, smoking is 
nice” 
 (Tony, male, aged 37) 
 
Participants had a range of experiences with regards to e-cigarette use.  Half the 
total sample had never used an e-cigarette and therefore were not asked about the 
experience of taste and satisfaction. The 15 participants who had ever used an e-
cigarette (six from the unmotivated group and nine from the motivated group) 
expressed different opinions about e-cigarettes. Very few participants in both groups 
who had previous experience of having tried an e-cigarette liked the sweet taste of 
some products, though one person preferred tobacco flavor. The majority across 
both groups said either they did not like the taste of e-cigarettes or preferred the 
taste of traditional cigarettes. A minority across both groups were satisfied by their 
previous e-cigarette use.  Another aspect they emphasized was the complexity of 
using an e-cigarette compared with a traditional cigarette and the effort required.  
 
TASTE, SATISFACTION AND ENJOYMENTOF E-CIGARETTES 
Not motivated to quit smoking Motivated to quit smoking 
“I only smoked the e-cigarettes for two 
days, it’s ok, you can choose from 
different flavors such as vanilla, 
cinnamon, and it smells good…. but it 
doesn't give you the same satisfaction 
as normal cigarettes” 
(Glenda, female, aged 55) 
“I've tried an e-cigarette for a while but 
I sometimes broke the atomizer…e- 
cigarettes take long time to charge and 
only five minutes to smoke so I had a 
complicated relationship with them.  
(Giorgia, female, aged 44). 
“It’s less powerful than my cigarettes”  
(Ugo, male, aged 55)   
I used them in the past and it was 
satisfying” (Natale, male, aged 28) 
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Financial cost  
The majority of participants in the motivated-to-quit group reported that they thought 
traditional cigarettes were too expensive, whereas only half of the unmotivated 
group believed they were expensive and the other half were not worried about the 
cost. Some participants bought hand rolled tobacco as a way to save money. The 
30 participants spent approximately €216 (SD 91.6) per month on traditional 
cigarettes. In Italy people with schizophrenia receive approximately €250 per month 
from the National Institute of Health (SSI). Therefore, smokers with schizophrenia 
spend the majority of the money they receive from the SSI to buy cigarettes. 
 
COST OF TRADITIONAL CIGARETTES 
Not motivated to quit smoking Motivated to quit smoking 
“Yes, they are expensive, I spend 
€300 a month” 
(Enrico, male, aged 43) 
 
“I think they are too expensive, they 
cost €20 euro…one packet of 20 
cigarettes, you can't buy anything else” 
(Carla, male, aged 58) 
“The costs are not a problem, but now 
they are increasing” 
(Julietta, female, aged 25) 
“Now cigarettes are more expensive 
than before….. the cost is increased. I 
started smoking hand rolled tobacco, 
that is more cheap than traditional 
cigarettes” 
(Gino, male, aged 29) 
 
All participants were asked their opinion about the cost of e-cigarettes and their 
views varied. Eleven participants (five from the unmotivated group and six from the 
motivated group) considered e-cigarettes to be less expensive than traditional 
cigarettes. Nine participants (five from the unmotivated group and four from the 
motivated group) did not know how much e-cigarettes cost and the remainder 
thought they were more expensive (one from the unmotivated group and four from 
the motivated group) or a similar cost. The majority of those who had no previous 
experience of e-cigarette use were unaware of the costs. 
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COST OF E-CIGARETTES 
Not motivated to quit smoking Motivated to quit smoking 
“E-cigarettes are more 
expensive…they are waste of money” 
(Ugo, male, aged 55) 
“I know that the price is around 50-60 
euros” 
(Rosa, female, aged 39) 
“Considering the battery cost, 
considering the e-liquid cost, the 
overall costs are the same more or 
less, with little differences 
(Enrico, male aged 43) 
“They are a waste of money and time”  
(Giorgia, female, aged 44)  
 
The experience of time 
Smoking traditional cigarettes was seen as a way to structure time and occupy the 
day. Participants reported that other people were less likely to interrupt you whilst 
you were smoking and respected their personal time compared with time spent 
vaping; they suggested that other people were more likely to interrupt you or ask 
you to do something while vaping and assume that you could re-start vaping any 
time. 
 
TRADITIONAL AND E-CIGARETTES AND THE EXPERIENCE OF TIME  
Not motivated to quit smoking Motivated to quit smoking 
“With a cigarette there is a beginning 
and an end…. you must finish a 
cigarette. The e-cigarette finishes 
when I finish the liquid… and at the 
end with a normal cigarette I can 
understand where my time goes…and 
this doesn’t happen using an electronic 
cigarette” 
(Juliette, female, aged 25) 
“A positive thing about (traditional) 
cigarettes is that it punctuates the 
times of my days..…With the cigarettes 
you have 5 minutes to yourself and no 
one disturbs you, you have a break 
from the rest of the world, others only 
disturb you if there is an important 
situation…..when you are using the e-
cigarette other people disturb you for 
minor things, this does not happen 
when you smoke cigarette” 
(Pippo, male, aged 27)  
 
Perceived impact of traditional and e-cigarettes on health 
Participants in both groups were aware that smoking traditional cigarettes causes 
several diseases. The group who were not motivated to quit perceived traditional 
cigarettes as damaging to their physical health but did not express concern; instead 
they described smoking as helpful, calming and as a way to cope with negative 
emotions. This is in contrast to the group who were motivated to quit, who were 
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concerned that smoking might damage their physical health, for example by causing 
respiratory problems such as cough, sore throat, catarrh and bronchitis or cancers. 
 
The majority of participants from the unmotivated group (n = 9) were not aware of 
the impact of vaping on health. Three participants considered e-cigarettes safer than 
traditional cigarettes and three participants considered them dangerous for their 
health.  In the group who were motivated to quit, many (n = 8) considered e-
cigarettes safer than traditional cigarettes for their health and the remainder either 
believed e-cigarettes were dangerous or not useful to improve their health or were 
unaware. Participants reported that smoking traditional cigarettes had a positive 
effect on their mental health, helping them feel less anxious and depressed and 
relieving stress. None of the participants from either group mentioned a similar effect 
from an e-cigarette.   
 
I interviewed exclusively smokers of traditional cigarettes. On the other hand, if I had 
interviewed a group of daily vapers, they may have said that e-cigarettes had a 
positive effect on their mental health. 
 
PERCEIVED IMPACT OF TRADITIONAL AND E-CIGARETTES ON HEALTH  
Not motivated to quit smoking Motivated to quit smoking 
“Smoking is dangerous, we all know 
this, but I have a personal trick, I don’t 
breathe in the smoke, I just taste the 
tobacco…If you breathe in the smoke 
it will go into your lungs and be 
dangerous for you” 
(Sara, female, aged 58) 
“Normal cigarettes give you a lot of 
body illness for example cancer, but 
with the help of the modern science 
you can get rid of this…. but it would 
be better to not smoke at all” 
(Natale, male, aged 28) 
 
“I smoked four packs a day in the past 
then I felt sick and I had a cardiac 
arrest…. I started to smoke again but 
not as much as before”,  
(Sharon female, aged 60) 
“A few months ago, I suffered with 
bronchitis and stopped for three weeks, 
but I started again”  
(Grace, female, aged 65) 
 
“Smoking helps me with my 
depression, (traditional) cigarettes 
make me feel better”   
(Sara, female, aged 58) 
“I obviously think it’s is a bad thing, it's 
supposed to help your stress, but 
actually it ends up making stress 
worse, it’s very bad for you” 
(Pippo, male, aged 27) 
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3.7.2.3 Theme 3: Perceptions and appeal of licensed medication for smoking 
cessation or reduction 
Participants were asked to describe their perceptions of NRT, varenicline and 
bupropion. Ten motivated-to-quit participants compared with nine non-motivated 
participants had heard of NRT patches and gum but all participants in both groups 
were not aware of varenicline and bupropion. Three participants from the motivated 
group had heard about some other approaches to help smokers quit other than 
pharmacotherapies. One participant had heard about psychotherapy, another 
suggested acupuncture and a third participant was aware of liquorice sticks (an 
alternative therapy).  
 
Nicotine replacement therapy 
The majority (n = 19) were aware of NRT but only one participant had ever tried it 
in the past. A similar number of participants in both groups were aware of NRT (10 
in the motivated group and nine in the unmotivated group); however, most 
participants in both groups believed NRT was ineffective for helping smokers quit 
smoking or reduce cigarette consumption. Participants in the motivated group had 
a variety of views; one participant reported that when using NRT previously that 
participant had experienced nausea, gastritis and headaches. Other participants 
believed that NRT was only helpful for occasional smokers and not regular smokers, 
was too expensive and only benefitted pharmaceutical companies. Participants in 
the unmotivated group suggested that NRT was only effective for a brief period of 
time and others thought it increased the amount one smoked.  
 
One participant in the motivated group expressed an interest in using NRT in the 
future to help quit and two to help reduce their cigarette consumption. Most were 
interested in using a nicotine patch, gum or mouth spray and their choice was 
influenced by either the cost of the product or what they had seen on TV. One 
participant in the unmotivated group expressed curiosity about the possible effects 
of the mouth spray.  
 
 
  
99 
 
 
PERCEPTION AND APPEAL OF NRT 
Not motivated to quit smoking Motivated to quit smoking 
“NRT helps you to quit for a very brief 
period of time, for example for an hour” 
(Glenda, female, aged 55) 
 “I’ve never used a nicotine patch 
because I was worried about the cost” 
(Giorgia, female, aged 44) 
“Many smokers who use the patch 
smoked even more. I have never tried 
them” 
(Enrico, male, aged 43) 
 
“The patches satisfy half of your 
nicotine needs and are good for 
occasional smokers and not for regular 
smokers, because it cannot satisfy 
their nicotine needs” (Nino, male, aged 
38)  
 
Bupropion 
None of the participants had heard of bupropion. After I gave them brief information 
about it as a licensed smoking cessation aid, no participants in the unmotivated 
group wanted to use it to quit or reduce smoking. The information below was 
provided according to principles of the “Standard Treatment Programme: A guide to 
behavioural support for smoking cessation” (McEwen, 2014). 
 
“Bupropion was the first non-nicotine medication available to smokers and research 
shows that, like NRT, it doubles your chances of successfully stopping. Bupropion 
is an antidepressant tablet that works by reducing urges to smoke and other 
withdrawal symptoms once you have stopped smoking. It does have some common 
minor side effects that include headache, difficulty sleeping and dry mouth; and 
some more serious side effects”.  
 
Four participants in the motivated group expressed an interest in bupropion as a 
smoking cessation tool because they believed bupropion’s antidepressant effects 
might help them with their mood problems; however, they were also slightly 
concerned about the possible adverse effects. An additional participant in the 
motivated group expressed an interest in using bupropion to reduce cigarette 
consumption. 
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PERCEPTION AND APPEAL OF BUPROPION 
Not motivated to quit smoking Motivated to quit smoking 
“No, I don’t want to spend more money 
and I don’t want to quit” 
(Julietta, female, aged 25) 
“Yes, I would use it to quit tobacco 
smoking because it is an 
antidepressant too”  (Mela, female, 
aged 55)  
“I only want to smoke my cigarettes, I 
don’t want to smoke bupropion”  
(Marco, male, aged 50) 
“If it doesn’t give me physical 
problems, I would use it” 
(Rosa, female, aged 39) 
 
Varenicline 
None of the participants had heard of varenicline. After I gave them brief information 
about it as a licensed smoking cessation aid, no participants in the unmotivated 
group wanted to use it to quit or reduce smoking. The information below was 
provided according to principles of the “Standard Treatment Programme: A guide to 
behavioural support for smoking cessation” (McEwen, 2014). 
 
“Varenicline has been specifically designed to help smokers to stop smoking and 
initial evidence suggests that it might be the most effective of the three medications. 
Champix is a tablet that works by reducing urges to smoke and other withdrawal 
symptoms once you have stopped smoking. It also blocks the ability of nicotine to 
stimulate the brain which is why many smokers using varenicline do not feel 
‘satisfied’ should they have a cigarette. Varenicline has some common minor side 
effects that include nausea, headache, difficulty sleeping and abnormal dreams”.   
 
Only one participant from the motivated group considered it might be helpful in the 
future for quitting and another participant for future use for smoking reduction. One 
participant from the unmotivated group did not want to spend money to quit smoking; 
others were concerned about the effect of varenicline on their health or did not want 
to take additional medication on top of their psychiatric medication.  
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PERCEPTION AND APPEAL OF VARENICLINE 
Not motivated to quit smoking Motivated to quit smoking 
“No I’ never heard about them”  
(Salvo, male, aged 50) 
“I don't think drugs will help, I already 
take a lot of drugs daily I would not 
take more in order to quit smoking” 
(Natale, male, aged 28) 
“They are not effective to help you to 
quit”  
(Angelo, male, aged 30)  
“If it’s safe I will use it”  
(Mela, female, aged 55) 
 
3.7.2.4 Theme 4: The appeal of e-cigarettes for smoking cessation or reduction 
As discussed above, only half the participants had ever used an e-cigarette 
previously, six in the group who were not motivated and nine in those motivated to 
quit (and not in the past 12 months). The total sample was ambivalent about the 
potential appeal of e-cigarettes as a smoking cessation or reduction tool. In the 
group not motivated to quit smoking, one participant believed that e-cigarettes were 
potentially useful for quitting and three for reduction.  The general view of the 
remaining 11 participants in this group was that they are not an effective solution for 
changing their own or others’ smoking behaviour. One reason given for their appeal 
was to save money, and another to “detox the body from nicotine”.   
 
Twelve participants from the motivated group believed that e-cigarettes were 
potentially useful for quitting or reducing smoking (nine for quitting, three for 
reducing). The remaining three participants did not find e-cigarettes (or a licensed 
product) appealing for either cessation or reduction. 
 
In participants who were former daily e-cigarette users (n = 10), e-cigarettes were 
appealing to nine participants, six in the motivated and three in the unmotivated 
group. Participants who reported that they might be appealing for cessation or 
reduction believed they were less risky for one’s health and they enabled switching 
from a “bad habit” to a “good habit.” They reported that the physical and behavioural 
experience of vaping was similar to smoking in terms of the hand to mouth action 
and were cheaper.  Participants who did not consider e-cigarette use appealing had 
been influenced by their physician or from negative experiences of others or what 
they had learned from the TV and media.  
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THE APPEAL OF E-CIGARETTES FOR SMOKING CESSATION 
Not motivated to quit smoking Motivated to quit smoking 
“They can help people that smoke a 
few cigarettes, not people like me that 
smoke a lot of cigarettes per day“ 
(Ugo, male, aged 55) 
“In my opinion it is not good, they are 
worse than normal cigarettes, my 
doctor told me”  
(Davide, male, aged 25)  
“The pharmacist told me if I smoke a 
cigarette and an e-cigarette together, I 
could go into a coma because e-
cigarettes are a harmful drug”  
(Angelo, male, aged 30)  
“I need the same gesture to satisfy 
me……you have many options but my 
favorite is the sweet taste”    
(Natale, male, aged 28) 
 
THE APPEAL OF E-CIGARETTES FOR SMOKING REDUCTION 
Not motivated to quit smoking Motivated to quit smoking 
“Because with the cigarette you can 
smoke easily, instead with the 
electronic ones you have to always 
suck harder.…the e-cigarettes are not 
strong enough”  
(Pietro, male, aged 57) 
“They will help to save money and I will 
do less damage to myself”  
(Sara, female, aged 58)  
“They both are both addictive but e-
cigarettes are more addictive”  
(Angelo, male, aged 30) 
“Of course, I would you use one if it’s a 
cure” 
(Mela, female, aged 55) 
 
3.8 Discussion 
This is the first qualitative study of an exclusive group of people with schizophrenia 
spectrum disorders and an exploration of their views about smoking and licenced 
smoking cessation aids compared with e-cigarettes. Structured interviews were 
conducted with 30 people with schizophrenia spectrum disorders who were current 
smokers, half of whom were motivated and the other half not motivated to quit. A 
thematic analysis was conducted from responses to questions about the reasons 
for starting smoking and experience of traditional cigarettes compared with e-
cigarettes, in addition to the appeal of licensed cessation aids or e-cigarettes for 
smoking cessation or smoking reduction. 
 
Reasons for starting to smoke 
The majority of participants started to smoke for similar reasons as people without 
a mental health condition report. Adolescents’ perceptions about smoking by peers 
and role models play a fundamental role in smoking initiation and positive 
associations to smoking, including the perception of smoking of role models (e.g. 
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adults and friends) and social acceptability, has been suggested as predictors for 
adolescents' reasons to start to smoke (Wiium et al., 2006).  The same reasons 
were reported in a recent Italian study (Backhaus et al., 2017). Following the social 
cognitive theory, adolescents shape their behaviour based on people whom they 
consider worthy (Bandura, 1963), and adolescents who observe role models 
smoking have a higher probability of smoking initiation (Poulsen et al., 2002).  
 
A study conducted by Gonzales et al. (2008), showed that people usually smoke to 
decrease their stress, keep calm, feel comfortable in social situations, sustain 
concentration, and balance their mood. In another study conducted by Barr et al. 
(2008b), patients with schizophrenia believed the stimulant properties of cigarettes 
were very important, suggesting they associate smoking with relief from negative 
symptoms of schizophrenia or, more likely, from medication side effects. 
 
Their average age of onset was approximately the same age as the general 
population in Italy (18.1 years) (OSSFAD, 2016). However, some international 
studies show most smokers with schizophrenia report they begin smoking slightly 
later than healthy controls. De Leon et al. (2002) compared 66 patients with 
schizophrenia and 51 patients with a mood disorder with 404 control subjects from 
a community sample. Before the age of 20, the three populations appeared to have 
had a similar risk of smoking initiation. However, after the age of 20, the initiation 
rate of daily smoking for patients with schizophrenia was higher than in patients with 
a mood disorder or controls. 
 
Perceptions of traditional cigarettes compared with e-cigarettes 
Sensory characteristics of smoking such as the sense of smoke in the throat, the 
taste and smell, and the physical acts that are integral to smoking, such as 
unwrapping, sharing or handling cigarettes, are important determinants of the 
maintenance of smoking and therefore reinforcement and dependence (Carpenter 
et al., 2007; Rees et al., 2012). Participants across the two groups showed different 
opinions about the taste and satisfaction from smoking cigarettes; participants in the 
group not motivated to quit considered the taste of tobacco smoke fundamental for 
their smoking behaviour, whereas a minority of participants who were motivated to 
quit enjoyed the taste. Studies conducted with healthy smokers showed that 
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sensorial and motor stimuli as well as flavour cues and the visual appearance of an 
e-cigarette may contribute to the effectiveness of e-cigarettes for craving reduction 
(Dawkins et al., 2016; Goldenson et al., 2016). E-cigarettes retain several important 
features of smoking (other than the delivery of nicotine), including similar hand-to-
mouth action, behavioural rituals, and an inhaled sensory stimulus. These 
characteristics may make e-cigarettes potentially attractive to smokers with 
schizophrenia (RCP, 2016).  
 
The costs of traditional cigarettes are relatively similar to each other (e.g. a packet 
of 20 cigarettes in Italy ranges between €5 and €5.50). The cost of e-cigarettes 
devices and e-liquid bottles/cartridges varies between manufacturers and products 
(e.g. in Italy costs of e-cigarette devices range from €15 for a “cigalike” model, to 
€50 for a personal vaporizer model, to €150 for a third generation model; whereas 
a 10 ml bottle of e-liquid costs approximately €4 to €6 on the basis of brand used). 
A third of the study sample were unaware of how much e-cigarettes cost, with the 
other two thirds relatively equally split as to whether they thought they were more or 
less expensive. It is important to understand if smokers know the average cost of e-
cigarettes and how they perceive the cost; if smokers believe they are too expensive 
this may be barrier to future use or of attractiveness/appeal. In a recent study 
conducted in USA by Miller et al. (2017), sixty inpatients and outpatients aged 18 to 
70 with schizophrenia completed a brief survey on e-cigarette use and reported that 
e-cigarette cost was the most commonly endorsed potential disadvantage 
associated with e-cigarettes use. 
 
Health risk perceptions of cigarette smoking is associated with motivation to quit and 
cessation in non-mentally ill and mentally ill smokers (White et al., 2014; Williams et 
al., 2011; Filia et al., 2014). However, despite acknowledging that smoking is 
dangerous for their health many were not motivated to quit for health reasons. A US 
study assembled cohorts of 174,277 individuals with ICD-9 (ICD, Ninth Revision) 
diagnoses of schizophrenia spectrum disorders, provided mortality estimates for 
conditions causally related to tobacco use in California from 1990 to 2005, and 
showed that smoking-related conditions may be responsible for 50% of the deaths 
in smokers with schizophrenia spectrum disorders (Callaghan et al., 2014).  
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An alternative perspective has been demonstrated in a recent study conducted by 
Kowalczyk et al. (2017), where a health risk subscale from the Smoking 
Consequences Questionnaire was used to measure health risk perception in 67 
smokers with schizophrenia and 100 smokers without schizophrenia. This study 
reported that smokers with schizophrenia were less likely to completely recognize 
the health risks of smoking than smokers without schizophrenia, despite having 
higher average daily cigarette use and significantly higher rates of existing 
pulmonary disease.  
Our participants reported that smoking cigarettes had a positive effect on their 
mental health status (e.g. helping them feel less anxious/depressed, relieving 
stress) and this is in line with the study conducted by Miller et al. (2017) where 60 
inpatients and outpatients with schizophrenia or schizoaffective disorder who were 
current or former users of e-cigarettes were recruited to complete an anonymous, 
10-minute, pencil-and-paper survey to examine their prevalence of and attitudes 
toward e-cigarette use, and reported that their experience with tobacco cigarettes 
were significantly more helpful with reducing depression/anxiety, impaired 
concentration, and paranoia than e-cigarettes. 
 
Our participants reported that smoking traditional cigarettes helped to structure time 
and occupy the day and that e-cigarettes were unable to replicate this function. 
Previous studies including individuals with severe and persistent mental illnesses 
have also found that traditional cigarettes were used to structure time and formed 
the core of one’s daily routine (York, 1997).  
 
The National Centre for Smoking Cessation and Training (NCSCT) briefing on e-
cigarettes was created to help stop smoking services support smokers who want to 
use e-cigarettes for quitting and included the following anecdotal quotes as 
examples of differences in the experience of time when using traditional cigarettes 
smoking compared with vaping (McEwan & McRobbie, 2016). 
 
“It’s not like a cigarette, which you would smoke from start to finish, with an e-
cigarette you can sip on it once or twice, and then put it away”. 
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“Using an e-cigarette is different to smoking a cigarette. This usually involves taking 
slower and longer puffs over a longer period of time….. You may feel the need to 
take a few puffs on an e-cigarette at times when you would not have smoked; this 
is nothing to worry about and your pattern of e-cigarette use will develop over time” 
 
“Smokers binge on nicotine, vapers graze” 
 
Perceptions and appeal of licensed medication for smoking cessation or 
reduction 
In healthy population smokers, licensed pharmacological treatments for smoking 
cessation, varenicline, bupropion and NRT, are associated with increased cessation 
rates compared with placebo (Cahil et al., 2014). The EAGLES study showed for 
the first time that the efficacy of these medications in terms of ORs was similar for 
smokers with or without psychiatric disorders (Anthenelli et al., 2016) and in the 
same study varenicline appears to be the most effective pharmacological aid for 
smoking cessation in smokers with schizophrenia spectrum disorders. Despite 
these evidence-based findings, all participants in this qualitative study had never 
heard of varenicline and bupropion, though many participants (n = 19) were aware 
of NRT patches and gum. The qualitative results indicate the need for interventions 
to improve awareness of licensed aids (particularly varenicline and bupropion) in 
this group of smokers. 
 
The appeal of e-cigarettes for smoking cessation or reduction 
A recent intervention study on the appeal of e-cigarettes in smokers with serious 
mental illnesses conducted by Pratt et al. (2016), provides evidence that e-
cigarettes may be appealing for smokers with schizophrenia spectrum disorders A 
recent patient survey conducted by Chen et al. (2016) showed that half of smokers 
with mental illnesses reported interest in using e-cigarettes to quit smoking. This 
finding is similar to our results, in which about half of participants in whole sample 
(16 of 30) reported interest in using e-cigarettes to quit or reduce smoking. Of these 
16 participants, 12 were from the motivated group and four were from the not 
motivated group. 
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Some participants who reported that e-cigarettes may be appealing for cessation or 
reduction perceived e-cigarettes to be less risky for their health compared with 
traditional cigarettes. Research about perceptions and reasons for e-cigarette use 
in healthy smokers has previously demonstrated that users believe e-cigarettes are 
less harmful than traditional cigarettes (Tan et al., 2014; Rass et al., 2015; Pepper 
et al., 2015) but in other studies, conducted with smokers and non-smokers, 
participants considered e-cigarettes just as harmful as traditional cigarettes (Majeed 
et al., 2017; Timothy et al., 2017; Brose et al., 2015). 
 
In the study conducted by Miller et al. (2017), 34% (n=18) of surveyed patients with 
schizophrenia believed that e-cigarettes were less harmful than traditional 
cigarettes. In a recent study by Spears et al. (2018), conducted with 550 adult 
current e-cigarette users, associations between self-reported mental health 
illnesses and motives for e-cigarette use and risk perceptions were explored and 
stratified according to smoking status. Current smokers with a self-reported mental 
health condition indicated thinking more about how e-cigarettes might improve their 
health, whereas former smokers indicated thinking less about how e-cigarettes 
might harm their health and rated several reasons for e-cigarettes use (e.g. less 
harmful than traditional cigarettes and useful to quit smoking).  
 
Several participants in the current study reported that physicians and pharmacists 
had told them that e-cigarettes were dangerous or just as harmful as traditional 
cigarettes. Harm perceptions of health professionals may influence the health 
behaviours of patients (Pawlikowska et al., 2012; Osuna et al., 2018), and in my 
opinion all health professionals should be informed about and trained in e-cigarette 
use in order to avoid giving misleading information to their patients.  
 
Motivation to quit or reduce smoking in smokers with schizophrenia spectrum 
disorders 
This is the first qualitative study to compare perceptions about traditional cigarettes 
and e-cigarettes in smokers with schizophrenia spectrum disorders motivated and 
not motivated to quit. In this research, participants in both groups showed similar 
reasons for starting to smoke traditional cigarettes. The majority of participants in 
both groups said they either did not like the taste of e-cigarettes or preferred the 
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taste of traditional cigarettes. More smokers who were not motivated considered the 
taste of traditional cigarettes to be an important part of their smoking dependence 
and enjoyed the taste of traditional cigarettes compared with the motivated group. 
Hence, for an e-cigarette to be appealing to smokers, it should be at least as tasty 
as traditional cigarettes, and this should apply especially to unmotivated smokers. 
 
Both groups, motivated and not motivated, reported that using an e-cigarette was 
much more complicated than using traditional cigarettes. Hence, for smokers with 
schizophrenia spectrum disorders, motivated and not motivated to quit, an e-
cigarette that is simple and easy to use might be more acceptable. 
 
Differences between both groups were observed about traditional cigarette costs.  
More participants in the motivated to quit group considered traditional cigarettes to 
be too expensive, compared with the unmotivated group. The group not motivated 
to quit, in contrast with the motivated group, reported absence of concern about 
smoking traditional cigarettes and described smoking traditional cigarettes as 
helpful, calming and a way to cope with negative emotions.  For this reason, a high-
performing e-cigarette might be as close to the smoking experience as possible and 
be particularly useful for smokers who are unmotivated to quit.  Many participants 
of the unmotivated group considered e-cigarettes to be safer than traditional 
cigarettes for their health.  
 
On the other hand, motivated-to-quit participants were concerned that smoking 
traditional cigarettes might damage their physical health and the majority reported 
that they didn’t know about the possible impact of e-cigarettes on their health.   
 
There is not a definitive consensus on whether smokers with schizophrenia 
spectrum disorders are less likely than those without schizophrenia spectrum 
disorders to want to quit smoking traditional cigarettes. One perspective is that these 
smokers belong to a category of so-called ‘hardcore’ smokers, defined as daily, 
long-term traditional cigarette smokers who, despite extensive knowledge of the 
health risks of smoking, are not motivated to quit (Warner & Burns, 2003).  
An alternative perspective suggests that there is some evidence that smokers with 
schizophrenia spectrum disorders are as motivated to quit as the general population 
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(Lawn et al., 2002). However, these smokers have in the past been less likely to 
receive smoking cessation interventions (Siru et al., 2009). Ideally, we should 
include motivated and not motivated smokers in future quantitative studies but 
current ethics arrangements in Italy make this difficult because e-cigarettes are not 
licensed for smoking cessation.  If a person is motivated to quit smoking, in Italy it 
is ethically correct to suggest licensed smoking cessation aids, and so we would not 
easily be able to get ethical approval for a new study using e-cigarettes.   
 
Limitations 
The findings of this qualitative study are limited for a number of reasons. The sample 
was relatively small and comprised smokers with schizophrenia spectrum disorders 
motivated and not motivated to quit (total = 30 participants) drawn from the Catania 
Schizophrenia Center, Department of Mental Health. Furthermore, interviews were 
limited in length because most participants showed signs of distress, irritability and 
fatigue after approximately 15 minutes of interview, and this in turn limited the depth 
of the data. All participants were currently receiving mental health treatment and 
were in a stable clinical condition at the time of interview.  
 
Overall, the sample characteristics suggest that the views elicited in the interviews 
may not be representative of the broader population of smokers with schizophrenia 
spectrum disorders, which therefore limits the generalizability of findings derived 
here. The findings of this study are applicable to smokers with schizophrenia who 
are in a stable phase of their illness.  As different settings and different 
psychopathological conditions may have different effects on individuals, the findings 
from this study should not be generalized to participants in other settings and with 
other stable psychopathological conditions. Findings were founded on respondents’ 
subjective perceptions of the topic and on the researcher’s subjective interpretation 
of these perceptions. 
 
Thematic analysis as a method is not free from criticism: some of the literature posits 
that this type of analysis lacks a theoretical base when compared with other 
strategies (Cohen et al., 2011; Brayman, 2012).  
The absence of substantial literature on thematic analysis compared with grounded 
theory, ethnography, and phenomenology, for example, may concern novice 
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researchers about how to conduct a rigorous thematic analysis (Novelli et al., 2017). 
Thematic analysis is disadvantaged when compared with other methods, as it does 
not allow the researcher to make claims about language use (Braun & Clarke, 2006). 
While thematic analysis is flexible, this flexibility can lead to inconsistency and a lack 
of coherence when developing themes derived from the research data (Holloway & 
Todres, 2003).  
 
In spite of these limitations, the information provided by the current research could 
provide a useful starting point for further research into this neglected area of tobacco 
control by developing smoking cessation studies and interventions tailored to these 
populations’ needs.  
 
3.9 Reflexivity 
My personal influence on interpreting and constructing themes should be also 
considered. In qualitative studies such as this, the interviewer and participant can 
co-generate a dataset through the process of interviewing. The next paragraph 
explains how my past knowledge and experience may have influenced the content 
of my interview questions and interpretation of findings.  
 
Regarding my past knowledge, I obtained my second degree in Clinical and 
Community Psychology in 2001 at the University of Rome “La Sapienza”, with a 
dissertation thesis on schizophrenia spectrum disorders, and started my study and 
clinical practice in this field a month later, when I was  a clinical psychologist in a 
small hospital dedicated to research and treatment of schizophrenia spectrum 
disorders. At that time, I also started my work as a researcher and psychologist at a 
smoking cessation clinic of the University of Catania directed by Prof Riccardo 
Polosa. So, for more than 15 years my research and clinical work has been 
dedicated to tobacco addiction, smoking cessation and schizophrenic spectrum 
disorders and my curiosity to do this research stems from the desire to be able to 
help these people to reduce the risks associated with smoking.  
 
During the interviews, I attempted to recognize my own biases by using reflective 
thinking and by writing down my impressions of each single interview instantly 
following that interview. I always introduced myself as a PhD student and licensed 
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clinical psychologist, although I was conscious of the fact that such an introduction 
might create an association with my role of a professional healthcare worker that 
could potentially influence participant responses. 
 
Regarding my past work experience, in 15 years I've seen many people die or get 
sick due to their smoking behaviour. Many patients died not because of 
schizophrenia but because of smoking and this made me feel always very helpless. 
My existing expertise in these two fields (tobacco addiction and schizophrenia) 
helped me in recruiting participants in terms of knowing where I could best recruit 
eligible participants. Despite this, it took longer than expected to recruit patients 
because many people with schizophrenia tend to avoid interpersonal contact and 
meeting new people. In addition, the paranoid delusions experienced by some 
patients with schizophrenia made it difficult to complete the audio recording and to 
develop a deep rapport with the interviewer. Asociality and alogia, with reduction in 
speech, meant that the qualitative interviews were much briefer than would be the 
case in interviews with adults without schizophrenia. Interviewees also had 
disorganized speech (formal thought disorder) with incoherence and inability to 
organize ideas, loose associations (derailment) and rambling. They had difficulty 
sticking to one topic and it was occasionally challenging to follow their trains of 
thought. All these signs and symptoms are the essence of schizophrenia disease.  
 
My experience in this area helped me to establish a therapeutic alliance with 
interviewees and I was able to minimize any distress, which enabled participants to 
share with me their experiences, and they were sufficiently cooperative. They often 
left sentences unfinished, acting under the assumption that ‘you know how …’ (e.g. 
how schizophrenia spectrum disorders are treated at both inpatient and outpatient 
levels). Because of my position, I had to be constantly alert and rigorously reflect on 
how my presence shaped the conversation as well as explain to interviewees that 
while I may have helped several smokers with and without schizophrenia spectrum 
disorders and several people with or without smoking addiction, during the 
interviews it was different for each, and I wanted to learn from their unique 
experience.  
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Finally, my experience equipped me with insights and the ability to understand 
implied content, and I was sensitized to certain dimensions of the data. I was familiar 
with the “typical” language of people with schizophrenia spectrum disorders and 
aware of potential sensitivities; thus, I knew what to ask and how to ask it as well as 
understanding the responses in a nuanced and multileveled way. I was able to hear 
the unsaid, probe more efficiently, and understand hints that others might miss. 
While listening to their stories and later analysing them, in my mind I thought about 
how much I wanted to help them quit or reduce smoking and protect them from the 
harmful effects of smoking and how I felt may influence the delivery, analysis and 
interpretation of my further quantitative studies. 
 
In relation to my experience within this qualitative study, it was imperative for me to 
allow interviewees to tell their stories rather than ‘push’ them in certain directions, 
to hear what was said rather than ignore potentially painful content, and to check 
how I filtered what I heard through the lens of my experience and refrain from 
insinuation (Padgett, 2008). However, reflecting on this study has revealed other 
questions. For example, my hesitation to ask intimate and deep questions became 
clear in the reflective process. In order to respect the time and needs of the 
participants, I avoided very intimate and profound questions and respected their 
need for silence and their strange and bizarre language and behaviour including 
their desire to end the interview as soon as possible. 
 
During the interviews, thanks to this qualitative research I was able to know new 
aspects of both the methodology of research and the experience of the patients 
interviewed. I last undertook qualitative research when I was at the University of 
Rome, about teenagers falling in love. Since then I have only conducted quantitative 
research and have published about 70 scientific “quantitative” articles. The first thing 
I noticed is that qualitative research takes a long time and it is time with a human 
dimension, of a man or woman and of his/her dignity and personal quality. 
Compared with the initial interview scheme, which assumed about an hour per 
interview, the actual answers were frequently very, very short; however, I thought 
that the strength of qualitative research was precisely this, to get out of my schemas 
derived from years in quantitative research and to welcome the interviewees in their 
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natural quality, without imposing presetting grids, so as to uncover patients’ real 
needs, demands and expectations. 
 
Another feature that concerned me, but I think it is in total harmony with the 
pathology from which the respondents suffer, was the extreme inconsistency in 
some answers where an interviewee often said everything and the opposite of 
everything on the same subject.  This incoherence at times made it difficult to 
understand and interpret what really mattered to the patient. During the interviews 
it was important to respect the psychic balance of the patient: I had to be able to 
obtain information without stressing the patient with excessive intrusiveness that 
would cause them agitation or disturbed thoughts. Another thing that struck me is 
that patients often did not want to talk or tended to give short and stereotypical 
answers because they said they were in a hurry to go to smoke. It became important 
to be extremely delicate with these patients to avoid being intrusive and to respect 
them in their unrest, in their dependence, in their equilibrium when entering their 
world. I was also very concerned about the non-compliance of the smoking rules by 
the participants, who tended to smoke even in closed places, and the extreme 
tolerance of the carers of these patients in allowing them to smoke, but I thought 
this was extremely unfair and discriminatory towards these patients because they 
removed the possibility of avoiding smoking-related diseases. So, it’s very important 
to improve smoking cessation interventions for this vulnerable population. I was very 
concerned, perceiving that many were poor and despite this they spent all the state 
aid in buying cigarettes, just as I was very concerned to see their fingers and lips 
burned by cigarettes, their teeth stained by smoke and some clothing that carried 
the typical signs of cigarette burning.  With permission from the subjects, I took some 
photos to further illustrate my findings. 
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                 Smoker’s Fingers               Smoker’s Clothing 
 
             
 
 
Even the environments, such fundamental elements of our well-being, appeared 
dirty and contaminated by cigarettes. The outside garden was full of cigarette butts 
and some patients picked them up from the ground to smoke them. Also, the lounge 
of the waiting room and the tent had unmistakable signs of cigarette burning and 
this made me think about how many risks of fires are generated by cigarettes. 
 
Garden at the Schizophrenia Center        Stairs at the Schizophrenia Center 
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Waiting room at the Schizophrenia Center (1) 
 
 
 
 
Waiting room at the Schizophrenia Center (2)    Curtain of the waiting room 
 
            
 
In relation to the effects of the qualitative study on myself and on participants, in my 
opinion complete smoking cessation or switching to low risk products such as an e-
cigarette could be a solution to the above problems. This was one of my opinions 
prior to conducting this study. I think that this experience has made me so 
appreciative of qualitative research that it is now my intention to include a qualitative 
part in all my future research.  
 
As a final point, I feel it is significant to point out the effects of the research process 
on the participants. For several participants, talking about cigarette dependence 
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created curiosity about possible solutions to quit or reduce smoking and the 
resources available to do so. 
 
3.10 Conclusion 
This qualitative study aimed to explore perspectives about traditional cigarettes 
compared with e-cigarettes, in addition to licenced cessation aids or e-cigarettes for 
smoking cessation or smoking reduction, in 30 participants with schizophrenia 
spectrum disorders, 50% motivated to quit and 50% unmotivated to quit. The 
findings could provide useful information and direction to augment the existing body 
of knowledge on smoking and vaping behaviour of smokers with schizophrenia 
spectrum disorders. They could also help to inform the study design of a single arm 
pilot study of smokers with schizophrenia not motivated to quit, the results potentially 
building on those of a previous study with first generation e-cigarettes also amongst 
smokers with schizophrenia not motivated to quit (Caponnetto et al., 2013d).  In Italy 
the e-cigarette is not an approved cessation aid and Italian national guidelines 
recommend that if a person is motivated to quit smoking it is ethically correct to 
suggest licensed smoking cessation aids approved by the guidelines of the Italian 
ministry of health to quit smoking (OSSFAD, 2008). Also, if a treatment proves to be 
effective for those unmotivated to quit, it may be more likely to be equally or even 
more effective for those motivated to quit.  
 
Findings from this qualitative study suggest that e-cigarettes may be an appealing 
smoking cessation or reduction strategy. A high-performing e-cigarette, as close to 
the traditional smoking experience as possible, easy to use and loaded with tobacco 
flavor similar to traditional cigarettes, may be helpful for this group of smokers. The 
next chapter describes a pilot study to test the feasibility of providing such an e-
cigarette device to a group of smokers with schizophrenia spectrum disorders who 
are not motivated to quit smoking. Ideally, we would include motivated smokers but 
current ethics arrangements in Italy make this difficult because e-cigarettes are not 
licensed for smoking cessation.  
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CHAPTER 4: FEASIBILITY AND SINGLE ARM PILOT 
STUDY 
 
4.1 Study title: Role of an electronic cigarette in smoking cessation or 
reduction for smokers with schizophrenia spectrum disorders: a feasibility 
and pilot single arm study  
This chapter describes study procedures, methods, results and discussion of a 
feasibility, single arm pilot study conducted with 40 smokers with schizophrenia 
spectrum disorders. The limitations of this study and suggestions for future research 
are also included. 
 
4.2 Background and objectives 
At the start of this PhD research, there was almost no literature on e-cigarettes for 
smoking cessation for smokers with schizophrenia. There was just one small 
uncontrolled study conducted at CPCT by my own research team. This was the first 
study in the world investigating the effectiveness of e-cigarettes for smoking 
cessation/reduction in people with schizophrenia. This study found that 50% of 
smokers with schizophrenia who were provided with e-cigarettes for 12 weeks 
reduced their smoking by 50%, and 14% quit, with no increases in psychiatric 
symptoms (Caponnetto et al., 2013d). These preliminary findings are noteworthy, 
because none of the participants was initially seeking treatment for smoking. 
However, the study had several limitations including the absence of a control group, 
use of first-generation e-cigarettes model and a small sample (14 subjects). 
 
Following this study, a protocol for a large three-armed RCT was prepared and 
published in the journal Trials in 2014 (Caponnetto et al., 2014). This outlined plans 
for a large multi-center study to assess changes in smoking behaviour in a group of 
153 psychiatrically stable individuals with schizophrenia who would be offered 
second generation personal vaporizers to reduce the risk of their tobacco smoking. 
It was to be known as the SCARIS study. 
 
The SCARIS study wasn’t conducted (Caponnetto et al., 2014) because after a 
series of meetings with international experts in this field it became apparent that the 
study might be more complicated than originally envisaged. Colleagues raised 
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concerns about respondent burden (e.g., time, energy, and emotional expenditure 
by participants) given the number of questionnaires and measures to be used. There 
were also queries about the third arm of the trial, which was intended to include use 
of a plastic cigarette ‘paipo’, and it was suggested instead that e-cigarettes without 
nicotine could be used in the control group. 
 
Before being able to proceed with the modified SCARIS study, reviewers and PhD 
supervisors suggested that more preliminary research was needed. This preliminary 
research is the focus of this chapter of the dissertation. The intention is that this 
early work will inform a future larger trial to be completed following the PhD and the 
protocol for this future trial is included in the Chapter 5. The study design was a 
single-arm pilot trial with the overall objective of evaluating the feasibility and 
preliminary effectiveness of e-cigarettes for smoking cessation. The design was 
informed by a conceptual framework for defining feasibility and pilot studies 
developed by Eldridge and colleagues. They argue that pilot studies are a subset of 
feasibility studies, rather than the two being mutually exclusive (Eldridge et al., 
2016), and that single arm pilot studies (as in the current research) can still answer 
feasibility questions.  Therefore, this single arm pilot study aimed to determine if and 
how the proposed intervention could be delivered in practice and how to proceed 
with testing the intervention in a future, larger study. Non-randomised single arm 
pilot studies are similar to randomised pilot studies except they do not include 
randomisation of study participants and they use a single arm. They are studies in 
which all or part of the intervention to be evaluated, and other processes to be 
undertaken in a future trial, are carried out (piloted) but without randomisation of 
participants (Eldridge et al., 2016).  
In line with the objectives to pilot and assess feasibility, the study described in this 
chapter was designed to monitor possible modifications in the smoking behavior of 
a group of regular smokers with schizophrenia using a new generation e-cigarette 
(JUUL). The study also included assessments for body weight and users’ 
perceptions of psychological reward, craving reduction, aversions, enjoyment and 
satisfaction. When this study began, JUUL e-cigarettes were not available in Italy 
and the EU. Other common devices used in Italy were considered for this study, like 
the Just Fog or the Blu cigalike, but we adopted the JUUL for its specific 
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characteristics of new generation e-cigarettes, previously explained in Chapter 2 
(Section 2.2.2). Considering the lack of availability, the producers donated the 
product for use in the study, and also agreed to supply cartridges/pods for a further 
three months after the end of the pilot to participants who expressed a wish to 
continue using them.    
 
4.3 Research questions 
There are three main research questions for this single arm pilot study: 
1.  Will the participants quit smoking if they use this e-cigarette? 
2.  Will the participants reduce the number of cigarettes smoked if they use 
this e-cigarette? 
3.  Are the study procedures feasible, and are they acceptable to 
participants? 
 
4.4 Methods 
4.4.1 Study design  
This was a 3-month single arm pilot study to observe cigarette use behaviour 
amongst a group of regular smokers with a schizophrenia spectrum disorder 
diagnosis who smoked traditional cigarettes, did not intend to reduce or quit 
smoking, and were invited to use an e-cigarette. We were interested to know if e-
cigarette use is associated with cigarette smoking cessation. Cessation is defined 
as switching from traditional cigarettes to e-cigarettes. The e-cigarettes were offered 
to participants as an alternative to traditional cigarettes. Participants were not 
mandated to switch to e-cigarettes for the study. Other assessments included the 
extent of e-cigarette use, the stability of symptoms of schizophrenia, possible AEs 
associated with e-cigarette use, the effects of e-cigarette use on enjoyment of 
respiratory tract sensations, psychological reward and satisfaction, and the extent 
of acceptability of study procedures and e-cigarettes as substitutes for traditional 
cigarettes.  
 
4.4.2 Study team 
Although the research itself was conducted by the PhD candidate, the study 
benefited from the support and advice of colleagues in several institutions in addition 
to support from the PhD supervisors. Additional input was provided by Dr Jason Kim 
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from the Weill Cornell Medical College Clinical and Translational Science Center 
(CTSC) and Professor Jennifer DiPiazza from the Hunter Bellevue School of 
Nursing at Hunter College (HBSON) as well as Professor Riccardo Polosa from the 
University of Catania, Italy. 
 
At the start of the study, it was intended that data would be collected in both Italy 
and the USA, with the Italian data to form part of the candidate’s PhD. However, 
data collection did not proceed as planned in the USA. This was because the US 
researchers at the CTSC experienced several difficulties in enrolling the participants 
for this study that will be further explained in the discussion section of this chapter. 
 
4.4.3 Ethics 
Ethical approval for the single arm pilot study was obtained for both the Italian site 
and the proposed USA site from the relevant committees in both areas. These 
approvals along with the full protocol were also submitted to the University of Stirling 
ethics committee which approved the ethics application on 27 September 2017 
(Appendix 6). 
 
No separate funding was secured for the study. However, the e-cigarettes used in 
the study were donated by the manufacturer, an independent company (Pax Labs) 
that, at the time of the research, was not part-owned by the tobacco industry. 
 
4.4.4 Participants 
Forty participants were recruited between 29 September and 07 October, 2017 at CPCT, 
University of Catania, Italy. 
 
4.4.5 Inclusion criteria 
The participants were: 
1.  adult non-hospitalized daily smokers of 20 or more traditional CPD in order to 
compare the results with those of a previous study that enrolled heavy 
smokers (Evins et al., 2004) with schizophrenia spectrum disorders who 
smoked 20 or more traditional CPD (Caponnetto et al., 2013d). 
2.  aged 21 to 65 years. 
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3.  not intending to reduce or quit smoking, firstly because Italian smoking 
cessation guidelines stipulate offering only approved therapies (varenicline, 
bupropion, NRT) and therefore it would be ethically incorrect to propose e-
cigarettes for smoking cessation in Italy and secondly to compare the results 
with those of the same previous study (Caponnetto et al., 2013d) in which we 
enrolled, for the reason cited before, smokers not motivated to quit. 
4.  able to provide written informed consent, and read, write and communicate in 
Italian proficiently. 
5.  able to meet the criteria for a schizophrenia spectrum disorder diagnosis 
without evidence of current exacerbation of illness, defined as “no relapse to 
hospitalization within the last three months and no change antipsychotic 
treatment within the last month” (Mendrek, 2012).  
In terms of this last inclusion criterion, a clinical psychologist or a psychiatrist not involved 
in the study made the diagnosis based on criteria from the DSM-V (APA, 2013), which 
was confirmed by electronic health records.  
 
4.4.6 Exclusion criteria 
Exclusion criteria were: 1) pregnancy, 2) breastfeeding, 3) myocardial infarction or angina 
pectoris within the past three months, 4) current poorly controlled asthma or COPD, 4) 
use of smokeless tobacco or any other tobacco products, 5) use of NRT or other smoking 
cessation therapies within the last three months. 
 
4.4.7 Recruitment 
A “Dear Provider Letter” was sent to physicians, psychiatrists and other health care 
providers to inform them about the study (Appendix 7). Flyers (Appendix 8) were 
posted within and outside of the CPCT, University of Catania, at the Policlinico 
Vittorio Emanuele. Participants were recruited from Catania outpatient psychiatric 
clinics by researchers of CPCT, University of Catania at the Policlinico Vittorio 
Emanuele. Clinicians from outpatient psychiatric clinics identified suitable 
participants and drew their attention to the study flyers. 
 
Clinicians asked permission from potential participants to pass their contact details 
to the PhD student and an assisting clinical researcher (Appendix 9). If participants 
agreed, their details were passed on. The assisting clinical researcher then made 
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the first approach to eligible patients after they had been identified by health 
professionals in the clinics. Patients were given full study information and participant 
information sheets (PIS) (Appendix 10). At least 48 hours passed between 
participants receiving the PIS and a request to sign the consent form (Appendix 10) 
and start the BL visit with the PhD candidate. 
 
4.4.8 Procedures  
Participants were screened at the BL visit (study visit one), where eligible participants 
were invited to use a JUUL e-cigarette and were followed prospectively for 12 weeks. It 
was mentioned that the product was less harmful than traditional cigarettes and could be 
used as a cigarette substitute as much as they liked. Participants attended a total of four 
study visits at the smoking cessation clinic where the PhD candidate is employed: CPCT, 
Università di Catania at the Policlinico Vittorio Emanuele, Catania, Italy.  
 
The BL visit and three follow-up visits at weeks four, eight, and 12 took place in the clinic. 
In between the BL and three study visits, participants were telephoned by the PhD 
candidate at weeks two, six, and 10 to confirm the next appointment and answer 
questions about product use.  
 
The following were recorded at BL (study visit one): demographics, smoking history 
and pack-years, eCO, vital signs and body weight, scores on the FTCD 
(Fagerström, 2012) (Appendix 11) and SANS (Andreasen, 1983) and SAPS 
(Andreasen, 1984), two of the most widely used scales to measure symptoms of 
schizophrenia (van Erp et al., 2014) (Appendices 12 and 13).  
 
To evaluate changes in symptoms of schizophrenia, the SANS and SAPS were 
repeated at each study visit by a qualified independent psychiatrist [Dr Roberta 
Auditore MD] not directly involved in the study and blinded to the study objectives. 
She used the REDCap system to administer the SANS and SAPS and data were 
inputted directly into the REDCap system. CO was measured by a portable device 
(Micro CO, Micro Medical Ltd, Kent, UK). 
   
Participants were given a free e-cigarette kit containing one JUUL device with a 
charger and 5% nicotine cartridges/pods with instructions on how to charge, activate 
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and use the e-cigarette. A full four-week supply of pods equivalent to their current 
cigarette smoking behaviour, according to the manufacturer’s guidelines, was given 
to each participant.  Phone numbers were provided for both technical and medical 
assistance. In between study visits participants were asked to maintain a daily study 
diary recording product use, number of tobacco cigarettes smoked, and AEs.  
 
To provide more information on the device used in the study, JUUL is an e-cigarette 
that has been created by Pax Labs. JUUL is a closed system ENDS product. The 
system consists of a device and closed pod. The pod contains 0.7 ml of e-liquid and 
up to 5% nicotine by weight. The e-liquid composition includes propylene glycol, 
glycerol, nicotine, benzoic acid, and flavouring. The product is charged via USB port. 
JUUL incorporates several key technological advances:  JUUL is breath actuated 
and has no user modifiable settings; the battery (200 mah) is not removable, and 
the electronics incorporate battery regulation features; a unique temperature 
regulation system has been demonstrated to maintain coil and wick temperatures 
below 300 degrees Celsius under a range of operating conditions (cigarettes can 
exceed 1000 degrees Celsius).  
 
At study visits two (week four), three (week eight), and four (week 12), participants 
were invited back for further assessments and to return unused study products, 
double check their study diary, and receive another four-week supply of 
pods/cartridges.  At these visits the following data were recorded: number of 
traditional cigarettes smoked and pods/cartridges used daily since the last visit, CO, 
vital signs and body weight, and scores from the SANS and SAPS to assess 
symptoms of schizophrenia.  
 
The Modified Cigarette Evaluation Questionnaire (mCEQ) (Cappellieri et al., 2007), 
adapted for e-cigarette (Steinberg et al., 2014), was used to examine acceptability 
(Appendix 14). For participants who used e-cigarettes, the mCEQ was used to 
assess effects of e-cigarette use on respiratory tract sensations, acceptability of e-
cigarettes as substitutes for traditional cigarettes, psychological reward, and 
satisfaction. Previous studies have used this questionnaire for e-cigarettes 
(Steinberg et al., 2014; Carpenter et al., 2017; St. Helen et al., 2017). The mCEQ 
assesses five domains of smoking behavior (craving reduction, aversion, 
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psychological reward, satisfaction, and enjoyment) and its reliability and validity 
have been confirmed. Smoking satisfaction and psychological reward domains 
showed a Cronbach's alpha for internal consistency reliability > 0.70, but < 0.70 for 
the aversion domain; test-retest reliability generally exceeded 0.70 on the three 
multi-item domains (smoking satisfaction, psychological reward, and aversion) and 
two single items (enjoyment of respiratory tract sensations and on craving 
reduction). The validity of this questionnaire is sustained by the analyses of three 
independent studies, with multi-item domains on satisfaction, psychological reward, 
and aversion, and single-item domains on enjoyment of respiratory tract sensations 
and craving reduction (Cappelleri et al., 2007).   
 
The mCEQ was used with participants who reported having tried the e-cigarette at 
least once. It is a self-administered questionnaire that contains 12 items covering 
both the reinforcing and the aversive effects of smoking. Participants were asked to 
rate the extent to which the e-cigarette they used was satisfying, tasted good, made 
them dizzy, calmed them down, helped them concentrate, made them feel more 
awake, reduced appetite, made them nauseated, decreased irritability, produced 
enjoyable sensations in the throat and chest, immediately reduced craving for 
cigarettes and was enjoyable to smoke. The items were rated on a seven-point scale 
of 1 (not at all), 2 (very little), 3 (a little), 4 (moderately), 5 (a lot), 6 (quite a lot), and 
7 (extremely). The mCEQ uses three multi-item domains (subscales) and two single 
items: "Smoking Satisfaction" (items 1, 2, plus item 12); "Psychological Reward" 
(items 4-8); "Aversion" (9, 10); "Enjoyment of Respiratory Tract Sensations" (item 
3); and "Craving Reduction" (item 11). Higher scores indicate greater intensity of 
each smoking effect with, for example, greater satisfaction or psychological reward 
after vaping. 
 
Participants who attended at least one study visit but missed the next study 
appointment were called by phone or sent an email (depending on participants’ 
preferred method of communication). Limited behavioural support was provided as 
part of the intervention. In terms of behaviour change techniques, these were limited 
to behaviour substitution of traditional cigarettes with e-cigarettes and self-
monitoring of traditional cigarette consumption through study diaries. Behaviour 
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substitution and self-monitoring are respectively coded as 8.2 and 2.3 in the 
Behavior Change Technique Taxonomy v1 (BCTTv1) (Michie et al., 2013).  
 
4.4.9 Outcomes 
Primary outcome 
The primary outcome or endpoint of this study was the proportion of study 
participants who self-reported that they had stopped smoking (not even a puff) for 
the 30-day period prior to the week 12 study visit, along with a confirmatory CO 
reading of ≤ 10 ppm (Kendrick, 2010) as recommended by the Russell standard 
(West et al., 2005). These participants are referred to as “Quitters”. 
 
Secondary outcomes 
1. Smoking reduction was defined as a reduction in cigarette consumption by 
≥ 50% in the number of traditional cigarettes smoked per day compared 
with BL for the 30-day period prior to the week 12 study visit. CO levels were 
measured to verify smoking status and confirm a reduction compared with 
BL. These participants were referred to as “Reducers”. No change was 
defined as participants with a self-reported no change in traditional 
cigarette smoking consumption. Smokers who failed to meet the above 
criteria at the final week-12 follow-up visit were categorized as “Continuous 
Smokers”. 
2. Adoption rate and adherence to product use as measured by 1) daily use 
of e-cigarettes during the 12 weeks of observation, and 2) ≥ 50% e-
cigarette use during the 12 weeks of observation. Participants were asked 
to keep track of the amount they used their e-cigarette using a study diary. 
The diary was reviewed with the participant by the researcher at each study 
visit. Participants who did not complete their diary in between study visits 
completed it during the study visit.  
3. Feasibility and acceptability as measured by participants’ vital signs, weight 
and psychopathological changes, reported AEs and subjective effects of 
using the e-cigarette.  Changes in vital signs (BP and HR) and weight were 
measured by difference between BL (visit1) and week 12 (visit 4). Changes 
in positive and negative symptoms of schizophrenia, were measured by the 
SANS and SAPS between BL (visit one) and week 12 (visit four). 
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Participants reported frequency and percent of AEs associated with e-
cigarette use (Appendix 15). They were asked to keep track of any AEs 
they felt may be associated with e-cigarette using the study diary. The diary 
was reviewed with the participant by the researcher at each study visit. 
Subjective effects were assessed by mCEQ scoring that reported 
frequency and percent of participants reporting a) enjoyment of respiratory 
tract sensations, b) psychological reward, and c) satisfaction, amongst 
users of e-cigarettes.  Acceptability of e-cigarettes as substitutes for 
traditional cigarettes was also assessed. 
  
4.4.10 Statistical analysis  
The primary outcome of this study was the proportion of study participants with self-
reported complete cessation from traditional cigarette smoking (“Quitters”) at each 
study visit, along with confirmatory CO values of ≤ 10 ppm taken at each study visit. 
Because this was a single arm pilot study, a formal sample size calculation was not 
required. However, with approximately 40 participants in the study, a 95% CI for the 
proportion of study participants with self-reported complete cessation from 
traditional cigarette smoking at each study visit could be constructed to be within ± 
17.6% of the true proportion of “Quitters”. This first calculation, during protocol study 
design, using our previous work on the impact of e-cigarettes on smoking reduction 
and cessation in smokers with schizophrenia (Caponnetto et al., 2013d), which 
assumed that approximately 20% of participants would have achieved complete 
cessation from traditional cigarette smoking during the entire study period. Up to 40 
participants were recruited at BL, as this study assumed a conservative attrition rate 
of 50%. Primary and secondary outcome measures were computed by including all 
enrolled participants assuming, on the basis of the intention-to-treat principle, that 
all individuals lost to follow-up would be classified as continuous smokers (West et 
al., 2005). Parametric and non-parametric data were expressed as mean (±SD) and 
median, interquartile range (IQR) respectively. The primary endpoint of the 
proportion of “Quitters” and CO values ≤ 10 ppm were reported descriptively.  
 
The secondary endpoint of self-reported ≥ 50% reduction in the number of traditional 
cigarettes smoked per day compared with BL for the 30-day period prior to the week 
12 study visit and confirmatory CO reduction were reported descriptively. The 
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change in the number of cigarettes smoked per day for each visit compared with BL 
was assessed with the Wilcoxon signed rank test. No adjustments for multiple 
comparisons were performed given the exploratory (i.e., hypothesis-generating) 
nature of this study. The secondary outcomes of adoption and product use of a) self-
reported daily e-cigarette use and b) ≥ 50% e-cigarette use during 12 weeks of 
observation were reported descriptively.  
 
Feasibility and acceptability measures (vital signs and weight, SAPS, SANS, AEs, 
SAEs, mCEQ) were reported descriptively. Descriptive statistics (including mean, 
standard deviation (SD), median, range, frequency, and percent) were calculated 
for patient demographics. All p-values were two-sided with statistical significance 
evaluated at the 0.05 alpha level. Analyses were performed in SPSS Version 23 
(Statistical Package for Social Sciences Program, IBM Corp., Armonk, N.Y., USA). 
 
4.5 Results 
4.5.1 Participant characteristics 
Fifty-six smokers with schizophrenia spectrum disorders responded to the study 
advert and were given the PIS. A total of 40 (M 26; F 14; mean (±SD) age of 48.3 
(±12.1) years) smokers (mean (±SD) pack/yrs of 45.4 (±23.9) consented to 
participate and were included in the study (Table 4, Figure 4).  
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Figure 4. Study flowchart 
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Table 4: Participants’ characteristics 
 
Socio-demographic characteristics at baseline n (%) 
Gender  
Male 
Female 
 
26 (65) 
14 (35) 
Age: mean (SD)    
 
Age range 
18-24  
25-44 
45-65  
48.3 (12.1) 
 
 
1 (2.5) 
13 (32.5) 
26 (65) 
Education: n (%) 
Middle school  
High school  
University 
 
22 (55) 
17 (42.5) 
1 (2.5) 
Ethnicity 
White Caucasian 
Asian 
African 
 
40 (100) 
0 (0) 
0 (0) 
Smoking History  
CPD: mean (SD)    28 (9) 
Age of onset of smoking: mean (SD)  15.4 (1.2) 
Length of time smoking: mean (SD)    33.5(12.2) 
Pack/years: mean (SD)    45.4 (23.9) 
Smokers who have made previous cessation attempts: n (%) 14 (35%) 
Smokers who had previously used an e cigarette, 
either regularly or tried: n (%) 
12 (30%) 
FTCD: mean (SD)    8.3 (1.8) 
Mental Health History and Status  
Age onset of schizophrenia spectrum disorders: mean (SD)    21.9 (2.8) 
SAPS at Baseline: mean (SD)    42.9 (23.7) 
SANS at Baseline: mean (SD)    43.3 (21.7) 
 
The retention rate was high, with 37 (92.5%) participants completing all study visits 
and attending their final follow-up visit at week 12. A drop-out rate of 7.5% (3 of 40 
participants) was observed. One participant chose not to participate after week two 
because he wanted to continue to smoke traditional cigarettes.  
 
Two participants dropped out of the study after week four because they did not find 
the e-cigarette acceptable and reported that it caused them to cough. BL 
characteristics of those who were lost to follow-up were not significantly different 
from participants who completed the study. Recruitment and follow up was shown 
in the study flowchart (Figure 3). 
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4.5.2 Changes in smoking behaviour 
Participants’ tobacco consumption at BL and at 12 weeks is shown in Table 5.  
 
Table 5. Participants’ traditional cigarette consumption at baseline and at 12 
weeks 
 
Event Name N Obs Variable Mean SD Median 
Baseline (visit 1) 40 Cigs number 
CO 
27.95 
34.03 
9.14 
10.95 
25.00 
30.00 
Baseline (visit 1) 
Participants completed the study 
37 Cigs number 
CO 
28.59 
33.23 
9.79 
10.97 
25.00 
30.00 
Week 12  
(visit 4) 
37 Cigs number 
CO 
6.38 
8.19 
6.89 
6.53 
6.00 
10.00 
 
4.5.2.1 Smoking cessation 
The Wilcoxon signed-rank test was used to test the difference in number of 
cigarettes smoked (self-report) between BL (visit 1) and 12 weeks follow up 12 (visit 
4). The difference (decrease in cigarettes smoked) was significant at <.001. 
Sustained smoking abstinence at week-12 from BL (quitters) was defined as 
sustained self- reported abstinence from tobacco smoking (not even a puff) for the 
30 days period prior to week-12 study visit. CO levels were measured to verify CO 
concentration of ≤10 ppm for the reducers/quitters as recommended by the Russell 
standard (West et al., 2005). There were 16/40 (40%) quitters in total, with 16/16 
(100%) still using their electronic cigarette by the end of the study (Table 6, Figure 
4).  
 
4.5.2.2 Smoking reduction 
Sustained 50% reduction in the number of CPD at week 12 was defined as 
sustained self-reported 50% reduction in the number of CPD compared with BL for 
the 30-day period prior to the week-12 study visit. CO levels were measured to verify 
smoking status and confirm a reduction compared with BL (Bolliger et al., 2000). A 
≥ 50% reduction in the number of traditional cigarettes smoked per day compared 
with BL for the 30-day period prior to the week-12 study visit and confirmatory CO 
reduction was found in 21/40 (52.5%) participants, with a median of 25 CPD at BL 
(IQR 20, 40) decreasing significantly to 10 CPD (IQR 8.5, 15) (p <0.001) (Table 6). 
 
131 
 
For the whole sample, an overall, sustained 50% reduction or smoking abstinence 
was shown in 37/40 (92.5%) participants. (Figure 4). Taking the cohort of 
participants as whole (n = 40), an overall 75% reduction in median CPD use from 
25 to six was observed by the end of the study (p < 0.001).  
 
Table 6: Smoking behaviour outcomes   
 
Parameter Baseline 12 weeks 
 
p-value‡ 
Quitters. 100% reduction in cigarette 
smoking (n=16)                                                               
     Age 
Pack Years 
CPD 
 
47.3(±9.7)† 
32.1(±14.5)† 
20 (20, 30)* 
 
 
 
 
0 (0,  0)* 
 
 
 
 
<0,001 
Reducers. 50% reduction in cigarette 
smoking (n=21)  
                                         Age 
Pack Years 
CPD 
 
 
49.3 (±14.1)† 
54.4 (±23.6)† 
25 (20,40)* 
 
 
 
 
10 (8.5, 15)* 
 
 
 
 
<0.001 
Abbreviations:  
‡p-value within group Wilcoxon signed-rank test 
† Parametric data expressed as mean (±SD) 
*Non-parametric data expressed as median (IQR) 
 
 
Figure 5. Changes in smoking behaviour at week 12 
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The Wilcoxon signed-rank test was used to test the difference in CO between BL 
visit and the final (12 week) visit. The observed difference (decrease in CO) was 
significant at < 0.001. 
 
4.5.3 Adoption rate and adherence to product use 
All participants that completed the full schedule of visits (n = 37) reported using the 
e-cigarette each day over the 12 weeks, with a median (IQR) amount of e-cigarettes’ 
cartridges/pods of one per day (1, 1) over the study duration.  
 
 
4.5.4 Acceptability 
This element of the study examined how smokers with schizophrenia spectrum 
disorders responded to the 12-week e-cigarette intervention. This research 
assessed participants’ responses objectively and subjectively. Objective 
assessments included vital signs (BP and HR) and weight changes, any 
psychopathological exacerbations (assessed by SAPS and SANS); and any 
reported AEs from using the e-cigarette. Subjective effects were assessed by the 
mCEQ questions as described in the methods. Thirty-seven of 40 participants 
completed visit four at 12 weeks and, as described above, all of these participants 
were classified as quitters or reducers. Participants’ vital signs, weight and 
psychopathological changes from BL to week 12 are shown in Table 7. 
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Table 7. Participants’ vital signs, weights and psychopathological changes 
from baseline to week 12 
Event 
Name 
N 
Obs Variable Mean SD Median 
Baseline 
(Visit 1) 
40 weight 
heart_rate 
bp_systolic 
bp_diastolic 
sans 
saps 
75.98 
80.13 
133.48 
76.73 
43.33 
42.90 
14.56 
9.32 
9.91 
7.20 
21.76 
23.74. 
73.75 
79.50 
135.00 
80.00 
41.00 
36.50 
12 
weeks 
(Visit 4) 
37 weight 
heart_rate 
bp_systolic 
bp_diasstolic 
sans 
saps 
74.67 
72.29 
121.41 
70.30 
44.89 
43.16 
14.22 
6.19 
8.59 
4.75 
21.33 
24.91 
71.00 
73.00 
123.00 
70.00 
44.00 
36.00 
 
 
4.5.4.1 Vital signs (BP and HR) and weights  
The Wilcoxon signed-rank test was used to test the difference in: 
• systolic BP between BL (visit one) and 12-week follow up (visit four). The 
difference was significant at < 0.0001.  
• diastolic BP between BL (visit one) and 12-week follow up (visit four). The 
difference was significant at < 0.0001. 
• patient HR between BL (visit one) and 12-week follow up (visit 4 four). Again, 
the trends indicated a decrease. The difference between BL and visit four 
was significant at p = < 0.0001. The trend indicated that the systolic BP and 
HR decreased over the study period.  
• patient weights between BL (visit one) and 12-week follow up (visit four). 
Again, the trends indicated a decrease. The difference between BL and visit 
four was significant at p = 0.0052. 
 
4.5.4.2 Psychopathological changes during e-cigarette use 
Positive and negative symptoms of schizophrenia were not significantly increased 
after using e-cigarettes from BL (visit one) to week 12 (visit four), suggesting 
absence of psychopathological exacerbation during the period when participants 
were e-cigarettes. The SANS difference between BL and visit 4 was not significant 
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at p = 0.932. The SAPS difference between BL and visit four was also not significant 
at p = 0.809. 
 
4.5.4.3 Adverse events 
Reported AEs amongst participants (Table 8) were dry cough (5.1 % at week four 
and 2,7% at week eight), headache (5,4% at week eight) and throat irritation (2.7% 
at week 12). These events were rare. Of note, typical withdrawal symptoms of 
smoking cessation were not reported (i.e. depression, anxiety, insomnia, irritability, 
hunger, constipation, weight gain). Moreover, there were no reported SAEs (i.e. 
events requiring unscheduled visit to the family practitioner or hospitalisation) during 
the study. 
 
Table 8. Adverse events reported by participants 
AEs Week four 
n/n (%) 
Week eight 
n/n (%) 
Week 12 
n/n (%) 
Dry cough 2/39 (5.1%) 
 
1/37 (2.7%) 0/37 (0%) 
Headache 0/39 (0%) 
 
2/37 (5.4%) 0/37 (0%) 
Throat Irritation 0/39 (0%) 
 
0/37 (0%) 1/37 (2.7%) 
 
4.5.4.4 Subjective effects 
The proportion and frequency of enjoyment of respiratory tract sensations, 
psychological reward and satisfaction amongst e-cigarettes users, and acceptability 
of e-cigarettes as substitutes for traditional cigarettes were assessed by mCEQ as 
illustrated below (Table 9). 
 
Participants’ responses to items related to the “smoking satisfaction” domain 
suggested that the majority of participants obtained satisfaction while using e-
cigarettes. Response to items relating to the “psychological reward” domain 
suggested that the majority of participants obtained low levels of psychological 
reward associated with e-cigarette use. In relation to the “aversion” domain, the 
majority of participants reported no aversion to e-cigarette use.  
 
Response to items related to the “enjoyment of respiratory tract sensations” domain 
suggested that the majority of participants reported moderate to significant 
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enjoyment (i.e obtaining a ‘throat hit’). In relation to the “craving reduction” domain, 
the majority of participants reported a moderate craving reduction associated with 
e-cigarette use (Table 9). 
 
Table 9. Subjective effects of e-cigarettes: Participant responses to mCEQ 
questions n (%) 
 
"SMOKING 
SATISFACTION" 
1 
not at 
all 
2 
very 
little 
3 
a little 
4 
moderately 
5 
a lot 
6 
quite a 
lot 
7 
extremely 
Q1 “Was using your 
e-cigarette 
satisfying? 
2 
(1.8%) 
6 
(5.3%) 
20 
(17.7) 
16 
(14.2%) 
46 
(40.7) 
19 
(16.8) 
4 
(3.5%) 
Q2 “Does the e-
cigarette taste 
good? 
4 
(3.5%) 
4 
(3.5%) 
7 
(6.2%) 
28 
(24.8%) 
58 
(51.3) 
11 
(9.7%) 
1 
(0.9%) 
Q12 “Do you enjoy 
using your e-
cigarette?” 
1 
(0.9%) 
2  
(1.8%) 
12 
(10.6) 
28 
(24.8%) 
44 
(38.9) 
15 
(13.3) 
11 
(9.7%) 
"PSYCHOLOGICAL 
REWARD" 
1 
not at 
all 
2 
very 
little 
3 
a little 
4 
moderately 
5 
a lot 
6 
quite a 
lot 
7 
extremely 
Q4 “Does using your 
e-cigarette calm you 
down?” 
14 
(12.4) 
10 
(8.8%) 
38 
(33.6) 
22 
(19.5%) 
20 
(17.7) 
8 
(7.1%) 
1 
(0.9%) 
Q5 “Does using your 
e-cigarette make 
you feel more 
awake?” 
25 
(22.1) 
20 
(17.7) 
36 
(31.9) 
18 
(15.9%) 
13 
(11.5) 
1 
(0.9%) 
0 
(0.0%) 
Q6 “Did using your 
e-cigarette make 
you feel less 
irritable?” 
16 
(14.2) 
18 
(15.9) 
33 
(29.2) 
26 
(23.0%) 
12 
(10.6) 
8 
(7.1%) 
0 
(0.0%) 
Q7 “Did using your 
e-cigarette help you 
concentrate?” 
21 
(18.6) 
13 
(11.5) 
41 
(36.3) 
16 
(14.2%) 
17 
(15.0) 
5 
(4.4%) 
0 
(0.0%) 
Q8 “Does using your 
e-cigarette reduce 
your hunger for 
food?” 
33 
(29.2) 
32 
(28.3) 
22 
(19.5) 
18 
(15.9%) 
6 
(5.3%) 
2 
(1.8%) 
0 
(0.0%) 
“AVERSION” 
1 
not at 
all 
2 
very 
little 
3 
a little 
4 
moderately 
5 
a lot 
6 
quite a 
lot 
7 
extremely 
Q9 “Does using your 
e-cigarette make 
you dizzy?” 
92 
(81.4) 
13 
(11.5) 
5 
(4.4%) 
0 
(0.0%) 
3 
(2.7%) 
0 
(0.0%) 
0 
(0.0%) 
Q10 “Does using 
your e-cigarette 
make you 
nauseous?” 
83 
(73.5) 
15 
(13.3%) 
13 
(11.5%) 
1 
(0.9%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(0.9%) 
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“ENJOYMENT OF 
RESPIRATORY 
TRACT 
SENSATIONS" 
1 
not at 
all 
2 
very 
little 
3 
a little 
4 
moderately 
5 
a lot 
6 
quite a 
lot 
7 
extremely 
Q3 “Do you enjoy 
the sensations in 
your throat and 
chest?” 
11 
(9.7%) 
2 
 (1.8%) 
14 
(12.4%) 
34 
(30.1%) 
32 
(28.3%) 
14 
(12.4%) 
6 
(5.3%) 
“CRAVING 
REDUCTION” 
1 
not at 
all 
2 
very 
little 
3 
a little 
4 
moderately 
5 
a lot 
6 
quite a 
lot 
7 
extremely 
Q11 “Does using 
your e-cigarette 
immediately reduce 
your craving for 
nicotine?” 
6 
(5.3%) 
5 
(4.4%) 
23 
(20.4%) 
34 
(30.1%) 
23 
(20.4%) 
18 
(15.9%) 
4 
(3.5%) 
 
 
4.6 Discussion 
Non-randomised or single arm pilot studies are an acceptable approach to testing 
the feasibility of interventions (Eldridge et al., 2016).  These types of studies 
constitute research in which all or part of an intervention is evaluated and other study 
procedures are piloted for a future definitive trial, but without randomisation of 
participants. These studies are used to determine whether an intervention is 
appropriate for further testing; in other words, they enable researchers to assess 
whether or not the ideas and findings can be shaped to be relevant and sustainable. 
Performing this kind of study may be indicated when there are few previously 
published studies or existing data using a specific intervention technique. Commonly 
a number of issues are examined in these studies: initial efficacy, acceptability, 
demand, implementation, practicality and adaption (Eldridge et al., 2016; Bowen et 
al., 2009). 
 
Given the very limited existing literature on the use of e-cigarettes for smoking 
reduction or cessation in adults with schizophrenia it was decided that a single arm 
pilot study would provide an achievable output as part of a PhD and could advance 
the field in terms of informing future research. For a single arm pilot study on this 
topic it was felt particularly important to assess demand (whether participants could 
be recruited and would consent to participate), test appropriate changes to smoking 
behaviour that could provide data to inform the design of a future trial, examine how 
feasible offering an e-cigarette was and whether participants with schizophrenia 
would use it, and also whether it was acceptable. More behavioural 
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support/counselling was not provided in this study because, although this may have 
been desirable the intention was to focus primarily on the e-cigarette elements of 
the intervention with a view to informing  a large RCT. Also time, resource and 
staffing constraints for this small study, conducted as part of a PhD, also limited 
what could be provided in terms of behavioural support. However, it should be noted 
that participants did request more counselling in future similar studies.  
 
Given this patient group it was also important to assess any changes in their mental 
health during the conduct of the study. This discussion section outlines: 
• Outcomes in relation to the three research questions generated for the study 
• The contribution of the PhD candidate 
• Limitations 
• Future research 
 
4.6.1 Outcomes in relation to the research questions 
This single arm pilot study had three main research questions as outlined above: 
 1. Will the participants quit smoking if they use this e-cigarette? 
2. Will the participants reduce the number of cigarettes smoked if they use 
this e-cigarette? 
 3. Are the study procedures feasible, and are they acceptable to 
participants? 
 
For research questions one and two, success rates in terms of complete smoking 
cessation or reduction of traditional cigarettes smoked at BL visit were observed. 
The majority of participants (92.5%) completed the study. At week 12, 16 of the 40 
heavy smokers enrolled in study (40% of participants) completely stopped smoking 
by continuing to use the e-cigarette product provided. This proportion is higher than 
that found in previous studies with similar patient groups. For example, in the first 
ever study of e-cigarettes with patients with schizophrenia spectrum disorders 
(Caponnetto et al., 2013d), at week 52, two of 14 (14%) smokers of at least 20 CPD 
enrolled stopped smoking completely by continuing to use the product provided. In 
a study in the USA (Pratt et al., 2016), two of 19 (10.5%) participants with serious 
mental illness (schizophrenia, schizoaffective disorder, or bipolar disorder) switched 
completely to e-cigarettes without using combustible cigarettes at the four-week 
138 
 
assessment. In a more recent study conducted in UK by Hickling et al. (2018), with 
50 smokers with severe mental illness (of which 42 (84%) had schizophrenia), by 
the end of the free e-cigarette phase at week six, 7% reported having stopped 
smoking traditional cigarettes. 
 
A further 52% of the participants (21 of 40 (37%), were able to sustain ≥ 50% 
cigarette reduction by the end of the study by continuing to use the JUUL product. 
This finding is similar to that in previous studies where available. For example, in 
the Italian study mentioned above (Caponnetto et al., 2013d), at week 52, seven of 
14 (50%) smokers were able to sustain ≥ 50% cigarette reduction by the end of the 
study and the same measure of CO showed a significant decrease. The USA study 
conducted reported a 65% reduction in cigarette use in their participants (Pratt et al. 
2016). In the recent UK study (Hickling et al., 2018), by the end of the free e-cigarette 
phase 37% of smokers had reduced the number of traditional CPD by ≥ 50%These 
preliminary findings are promising in view of the fact that all smokers in the research 
were, by eligibility criteria, not motivated to quit smoking. Moreover, though it is not 
directly comparable with standard smoking cessation and/or reduction studies 
because of its design, success rates in the present study are not only similar to 
those obtained with approved pharmaceutical products for the treatment of nicotine 
addiction (Bennet et al., 2013; Peckham et al., 2017), but also greater than those 
for first generation and second generation e-cigarettes with similar patient groups 
(Caponnetto et al., 2013d; Pratt et al., 2016; Hickling et al., 2018). 
 
This study showed that use of a new generation e-cigarette in heavy smokers not 
motivated to quit substantially decreased cigarette consumption without causing 
significant side effects. Although not specifically measured in this study, nicotine 
absorption using new-generation devices has been shown to be consistently 
superior compared with the first e-cigarette generation (Dawkins & Corcoran, 2014; 
Farsalinos et al., 2014a), which may form part of the explanation for higher quit rates 
than in studies using earlier generation devices. Considering its pharmacokinetic 
profile is similar to that of traditional cigarettes (Brown & Xing., 2015; Lawler., 2018) 
the e-cigarette used in this study may have provided a more ‘cigarette-like’ 
experience which may have promoted switching.  
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In terms of research question three, the study procedures appeared acceptable to 
participants. This is evidenced by the high retention rate.  Given that few problems 
were experienced in conducting the research, the study procedures were also 
feasible. Although the study was small in size, it progressed well and this provides 
some confidence that the approached used here could inform a protocol for a larger 
trial (see Chapter 5). There is also evidence of feasibility and acceptability in terms 
of the short-term markers of physical and mental health assessed during the study. 
Participants showed significant improvements in BP and HR without weight gain, 
SAEs or psychopathological exacerbation.  Other studies suggest that positive and 
negative symptoms of schizophrenia are not increased in patients using nicotine 
patches (Dalack et al., 1999; Dalack & Meador-Woodruff, 1999) bupropion (Evins 
et al., 2001) or early generation e-cigarettes (Caponnetto et al., 2013d). Specifically, 
in Caponnetto et al. (2013d), the same measures of positive and negative symptoms 
of schizophrenia (SAPS and SANS scales) were used without showing exacerbation 
of psychotic symptoms during the study. Some further evidence of acceptability 
relates to satisfaction with the performance of the e-cigarette used in the current 
research. Compared with the first pilot study conducted with 14 smokers with 
schizophrenia, which used a first-generation e-cigarette, in this study it was possible 
to observe improved product acceptance in terms of technological advancement, 
reliability of the product and the fact that participants remained in the study and 
continued to use the device. This is in marked contrast to the 2013 study in Italy in 
which the PhD candidate was involved. In that 2013 study, the patients used a five-
piece product that was complicated to use, vape and recharge; with batteries, 
rechargers and atomizing devices that were frequently broken and of low durability; 
and with cartridges that often leaked liquid into the mouth and needed frequent 
changing because the manufacturer recommended a certain number of filters to be 
used per day.  
 
In contrast, the e-cigarette used in this single arm pilot study is more advanced. For 
example, it is designed to avoid the “dry puff” phenomenon (Jensen, 2015), is breath 
actuated, and has no user modifiable settings. In addition, the battery is not 
removable, the electronics incorporate battery regulation features, and it has a 
unique temperature regulation system that has been demonstrated to maintain coil 
and wick temperatures below 300 degrees Celsius under a range of operating 
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conditions. Only three participants in the current study requested a new battery, and 
the single cartridge-pods per day were easy to use. The appearance of the product 
is also an improvement on the first generation “cigalike” used in the 2013 study 
(Figure 6).  
 
Figure 6. First generation e-cigarette versus JUUL e-cigarette 
 
 
 
The high level of satisfaction with the product under investigation is substantiated 
by the notion that 37 out of the 37 who attended the last study visit were still using 
their e-cigarette. This, together with the high retention rate and elevated rating in 
satisfaction scores, indicates that the quality and attractiveness of the study product 
may have played a vital role in attaining success rates. It is also interesting that 
other smokers who came into contact with the study participants, including some 
relatives and caregivers, a psychiatrist, several nurses and a psychologist, asked 
the study team where they could buy the product to quit or reduce their own cigarette 
smoking. 
 
4.6.2 Contribution of the PhD candidate 
The idea for this small trial was developed by the PhD candidate following the earlier 
work of our team in Italy. The trial was set up as a core part of the PhD and was 
intended from the beginning to form part of my thesis. Although this small trial should 
have enrolled 40 participants by a team in two countries (USA and Italy), as 
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discussed above the USA Center at NY Cornell University and City University of 
New York enrolled only one participant who immediately dropped out. Due to this 
and other challenges facing the US collaborators at the time, it was decided in 
discussion with the PhD supervisors to drop the US site. As a result, 40 participants 
were recruited in Italy only and the PhD candidate was responsible for all key 
aspects of the research. 
 
In terms of the conduct of the final study, the PhD candidate developed the study 
concept and protocol design, was involved in recruiting participants, and was 
responsible for data collection and interpretation and for drafting and revising this 
chapter. The PhD candidate conducted the data analysis with assistance from a 
more senior statistician.  A clinical research fellow assisted with recruiting 
participants and a psychiatrist was involved for SAPS and SANS assessments and 
their scoring. 
 
4.6.3 Limitations 
There were several limitations in this study. First, this was an uncontrolled study and 
the lack of a control group limits the internal validity and external validity of the 
findings. Confounding is usually a major threat to the validity of most associations 
based on uncontrolled data. Thus, the need for a future RCT, which is discussed in 
Chapter 5.  
 
Secondly, the study involved exclusively heavy smokers (Evins et al. 2004) who 
smoked at least 20 CPD and cannot therefore be assumed to apply to all smokers 
with schizophrenia.  
 
Thirdly, other characteristics of the sample and of the e-cigarette used limit the 
generalization of the findings: because of its unusual design (smokers not willing to 
quit) this was not an ordinary cessation study and therefore direct comparison with 
other smoking cessation studies involving smokers motivated to quit  cannot be 
made; direct comparison with other smoking cessation studies using different e-
cigarettes products cannot be made; all participants were outpatients and the 
findings reported from urban Sicilian residents in this study may not be valid for other 
population samples.  
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Lastly, because only a single nicotine strength (i.e. 5%) and a single aroma (i.e. 
tobacco flavour) were investigated in this study, it is possible that the study failed to 
provide options that could have increased cessation rates. Other research has 
suggested that unrestricted access to a wider selection of e-liquid nicotine strengths 
and flavours can play an important role in the attractiveness and success rates of 
these products (Farsalinos et al., 2014b). 
 
4.6.4 Future research 
Preliminary positive results from this single arm pilot study suggest that this 
intervention could be tested in an RCT. It will be important to discard or modify those 
interventions that do not seem to be feasible as a result of data collected during this 
early stage study. 
 
Considering a future RCT, this programme could be implemented, extending further 
use of e-cigarette pods/cartridges for a further three months and with a follow up of 
one year. In addition to this programme, a specific brief smoking cessation 
counselling intervention could be added to help smokers first to switch to the e-
cigarette and then to progressively become totally smoke and vape free. We could 
propose interventions with groups of smokers and the possibility of proposing this 
treatment in more centers where there are smokers affected by schizophrenia 
spectrum disorders (for example hospitals or departments of psychiatry, mental 
health units located in prisons). A future RCT could also include a study site in 
another country, such as the USA, to improve generalizability.  
 
Other considerations are relevant to future research and were identified during this 
single arm pilot study. A problem that was encountered was the long duration of the 
data collection visits due to the long administration of SAPS and SANS at each visit. 
In anticipation of an RCT, rather than carrying out these assessments at each visit, 
they could be carried out every three months. In addition, many participants asked 
if there was a chance to have the electronic cigarettes for another three months and 
more counselling to quit smoking. Both of these elements could be incorporated into 
a future RCT. 
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Considering that smokers with schizophrenic spectrum disorders are heavy 
smokers, we included smokers who smoked at least 20 CPD and we used a latest 
generation model e-cigarette with a pharmacokinetic profile similar to traditional 
cigarettes, which was easy to use and had good technological performance and 
reliability to avoid unnecessary stress to the participants. A future RCT could employ 
the same or similar device. With a view to extending and proposing this model of 
intervention or in order to conduct an RCT for healthy participants or participants 
with other pathologies, it would be necessary to include people who smoke from 10 
CPD and use cartridges/pods with lower nicotine levels, (e.g., allowing a maximum 
of 1.8% cartridge/pod nicotine levels in Europe). Any future studies conducted with 
healthy smokers could adapt specific diagnostic questionnaire tools depending on 
the disease group such as diabetes, COPD, alcohol or other substances 
dependence. Finally, a specific measure of possible dependence on e-cigarettes 
should be made at each follow up visit. 
 
4.7 Conclusion 
This study aimed to conduct preliminary research to begin to determine the 
effectiveness of an innovative smoking cessation intervention with an underserved 
population. The results provide useful information and direction to augment the 
existing body of knowledge on smoking cessation for people with schizophrenia 
spectrum disorders. If a future RCT is conducted and is successful, the findings 
could inform the roll-out of programmes or interventions to help reduce the number 
of people with schizophrenia who smoke.  
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CHAPTER 5: ROLE OF AN ELECTRONIC CIGARETTE IN 
SMOKING CESSATION OR REDUCTION FOR SMOKERS 
WITH SCHIZOPHRENIA SPECTRUM DISORDERS: A 
PROTOCOL FOR A LARGE MULTICENTER RANDOMISED 
CONTROLLED TRIAL 
 
This chapter includes a formal protocol for a future RCT of e-cigarettes for smoking 
cessation or reduction in smokers with schizophrenia. The protocol was developed 
following the earlier stages of the PhD including the qualitative research included in 
Chapter 3 and the single arm pilot study included in Chapter 4.  
 
The findings of both the qualitative research and the pilot study helped inform the 
protocol for future research. The relationship between key findings from each and 
how these findings influenced particular elements of the protocol is set out below in 
Table 10.  
 
Table 10: How key elements of the qualitative and single arm pilot study 
informed the protocol for a future RCT 
QUALITATIVE STUDY 
FINDINGS 
INFLUENCE ON RCT PROTOCOL 
Compared with the motivated 
participants, participants who were 
not motivated to stop smoking 
considered the taste of traditional 
cigarettes to be an important part 
of their smoking experience and 
they preferred particular brands 
over others.  
E-cigarette cartridges/pods with tobacco 
flavour, similar to traditional cigarettes, were 
used in the single arm pilot study and will 
also be used in a future RCT. 
The majority of participants in both 
groups said they either did not like 
the taste of e-cigarettes or 
preferred the taste of traditional 
cigarettes. 
As above, the selection of tobacco flavoured 
e-liquids seeks to address this finding.  
Participants reported that they felt 
that using an e-cigarette was 
much more complicated than 
smoking traditional cigarettes.  
The device used in the single arm pilot study 
(JUUL) is arguably one of the easiest to use 
on the market and the future RCT would also 
propose to use JUUL.  
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All participants were aware that 
smoking traditional cigarettes 
causes several diseases but 
expressed different opinions about 
the potential impact of e-cigarettes 
on their physical health. 
In order to examine perceptions of e-
cigarette use on participants’ physical health, 
two questions extracted from the interview 
used for the qualitative study will be included 
in follow-up questions to participants at 
weeks 12 and 24. 
Participants reported that 
smoking traditional cigarettes had 
a positive effect on their mental 
health, either helping them feel 
less anxious and depressed or 
relieving stress. None of the 
participants mentioned a similar 
effect from e-cigarettes (amongst 
those who had used them and 
were interviewed). 
For this reason, a high-performing electronic 
cigarette has been chosen for this trial to try 
and get as close to the smoking experience 
as possible. In addition, to examine the 
potential effect of e-cigarette use on 
participants’ mental health, two questions 
extracted from the interview used for the 
qualitative study will be included in follow up 
questions to participants at week 12 and 24. 
The qualitative results indicate that 
the intervention needs to improve 
awareness of licensed stop-
smoking aids (particularly 
varenicline and bupropion) in this 
group of smokers. 
Participants will have a screening visit, 
during which they will be informed about 
licensed smoking cessation aids in addition 
to the trial arrangements.  
About half of participants in the 
sample reported interest in using 
e-cigarettes to quit or reduce 
smoking. Of these 16 participants, 
12 were from the motivated group 
and four were from the not 
motivated group. 
Ideally, we would include motivated smokers 
in the RCT but current ethics arrangements 
in Italy make this difficult (unlike in the UK 
where the Medicines and Healthcare 
products Regulatory Agency has taken a 
more permissive view) because e-cigarettes 
are not licensed for smoking cessation. 
Thus, in the future RCT we propose to 
include only smokers not motivated to quit 
because we will not easily get ethical 
approval for a new Italian trial using e-
cigarettes for smokers motivated to quit.   
SINGLE ARM PILOT STUDY 
FINDINGS 
INFLUENCE ON RCT PROTOCOL 
At week 12, there were 16/40 
(40%) quitters in total. In addition, 
a sustained 50% reduction in the 
number of CPD was found in 
21/40 (52.5%) of participants. 
These are promising short-term results, but 
12 weeks is not an outcome commonly used 
in RCTs and is likely to be of insufficient 
duration. Thus, for a future RCT the primary 
outcome should be fixed at week 24. The 
cartridges/pods will be dispensed for 24 
weeks. Also 24 weeks equates to a 6-month 
follow up, which would allow a future RCT to 
be included in Cochrane reviews.  
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At week 12, the cessation and 
reduction rates, respectively 40% 
and 52%, were achieved by using 
a nicotine content of 5%. 
These are promising cessation and reduction 
rates, but it’s important to consider the 
cessation and reduction rates that could be 
archived by using the dosages allowed within 
the European Union and at the same time 
check the effect of the only e-cigarette factor 
in the absence of nicotine level impact. For 
these reasons a three-arm study with 5%, 
1.7% and 0% nicotine has been designed. 
The pilot study found that the 
study procedures (including the 
majority of the data collection 
instruments used) were 
acceptable to the patients and the 
e-cigarette device used was also 
acceptable.  
 
One exception to this was the 
burdensome frequency with which 
the SAPS and SANS data were 
collected.   
Given the high degree of acceptability, the 
same measures and same device could be 
used in an RCT for comparison. However, a 
problem that was encountered was the long 
duration of the data collection visits due to 
the administration of SAPS and SANS at 
each visit. Consequently, SAPS and SANS 
data will only be collected every three 
months. 
Many participants in the single arm 
pilot study asked to keep the e-
cigarette for another three months 
and receive more counselling to 
quit smoking.  
Both of these elements are incorporated in 
the RCT protocol. This also relates to the 
cost concern raised in the qualitative 
research. Longer-term provision of free 
support may enhance longer-term 
abstinence from smoking.  
 
The overall aim of this thesis was to develop an intervention to create a study 
protocol for an RCT on the role of e-cigarettes in smoking cessation or reduction for 
smokers with schizophrenia spectrum disorders. This chapter aims to address this 
aim directly, and the format of the chapter is the same as would be included in a 
formal protocol paper for submission to a journal. 
 
This will be a large trial focusing on effectiveness, safety and cost-effectiveness.  
Part of the structured interview used for the qualitative study (Chapter 3) will be 
included in this RCT.  A full process evaluation with an in-depth qualitative research 
element could be added but would require more funding and plans, which could be 
developed following the PhD and once a suitable funder had been identified.  
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5.1 Title and summary 
The title for the full protocol will be “New generation electronic cigarettes in smoking 
cessation or reduction for smokers with schizophrenia spectrum disorders (SCARIS 
1.0): Study protocol for a multicenter randomised control trial”. 
 
In summary, the protocol outlines the plan for an RCT investigating the 
effectiveness, safety and cost effectiveness of e-cigarettes. The intended study is a 
double-blind, placebo-controlled, randomised clinical trial designed to assess the 
effectiveness, safety and cost effectiveness of 5% nicotine new generation e-
cigarettes in comparison with 1.7% nicotine new generation e-cigarettes and 0% 
nicotine new generation e-cigarettes (placebo) for smoking cessation or reduction.  
 
The duration of active treatment will be 24 weeks. The primary endpoint of this study 
will be the proportion of study participants who self-report that they have stopped 
smoking (not even a puff) from the week-9 to the week-24 study visit, along with 
confirmatory CO readings of ≤10 ppm. These participants will be referred to as 
“Quitters”.  
 
The differences of continuous variables between the three groups will be evaluated 
with the Kruskal-Wallis Test, followed by the Dunn multiple comparison test. The 
differences between the three groups for normally distributed data will be evaluated 
with the one-way ANOVA test, followed by the Newman-Keuls multiple comparison 
test. The normality of the distribution will be evaluated with the Kolmogorov-Smirnov 
test. Any correlations between the variables under evaluation will be assessed by 
Spearman r correlation. To compare qualitative data measured on a nominal scale, 
the Chi-square test will be used.   
 
Objective: The primary objective is a comparison of 5% nicotine to 1.7% and 0% 
nicotine new generation e-cigarettes for smoking cessation efficacy after 24 weeks 
of treatment. 
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5.2 Methods 
5.2.1 Trial design 
The study will be a double-blind, three-arm parallel group, randomised controlled 
clinical trial designed to assess the efficacy and safety of e-cigarettes with 5% 
nicotine, e-cigarettes with 1.7% nicotine, and e-cigarettes with no nicotine.  
 
Three arms of the study are needed because in the first arm we will see the effects 
of factor e-cigarette plus the 5% nicotine level, in the second arm the effects of the 
e-cigarette plus nicotine level (1.7%), and in the third arm we will see only the effect 
of single factor e-cigarette with its sensorial and hand-to-mouth experience in the 
absence of nicotine release. The Consolidated Standards of Reporting Trials 
(CONSORT) guidelines will be adhered to in the reporting of the trial. 
 
5.2.2 Participants 
The participants will be adult non-hospitalized daily smokers (10 or more traditional 
CPD, for at least the past five years, age 18 to 65 years) not motivated to quit 
smoking, meeting criteria for a schizophrenia spectrum disorder diagnosis without 
evidence of current exacerbation of illness, defined as no relapse to hospitalization 
within the last three months and no change in antipsychotic treatment within the last 
month (Mendrek, 2012). 
 
A clinical psychologist or a psychiatrist not involved in the trial will make the 
diagnosis based on criteria from the DSM-V (APA, 2013), which will be confirmed 
by the electronic health record. The participant will be able to provide written 
informed consent and will be able to read, write and communicate in Italian 
proficiently. Motivation to quit will be assessed by the MTSS (Kotz et al., 2013). The 
MTSS has been chosen because it has been found to have a high correlation with 
other measures of current motivation to quit, and so it will provide a measure of 
motivation to quit smoking which would allow evaluation of all the most important 
aspects of motivation. This evaluation includes desire, intention and belief into one 
item with the expectation that this will guarantee the most cost-efficient assessment 
possible (Hummel et al., 2017). 
 
149 
 
Participants will be not eligible for the study in cases of pregnancy, breastfeeding, 
myocardial infarction or angina pectoris within the past three months, current poorly 
controlled asthma or COPD, and use of smokeless tobacco or any other tobacco 
products and/or use of NRT or other smoking cessation therapies within the past 
three months. 
 
Settings: 300 regular smokers with schizophrenia will be recruited from three 
outpatient mental health clinics/psychiatric practices in Italy, with the support of their 
medical providers, inviting them to try e-cigarettes to reduce the risk of tobacco 
smoking. The participants will have visits in an outpatient clinic setting. Participants 
will attend their study visits at each study center at approximately the same time of 
day. With the exception of the BL study day, most visits will take approximately 10 
to 15 minutes to complete. The flowcharts in Table 9 describe the procedures to be 
completed at each visit. 
 
5.2.3 Ethics 
This study must be conducted in compliance with Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) informed consent regulations, and 
International Committee on Harmonization (ICH), GCP (Good Clinical Practice) 
Guidelines. An ethics proposal will be submitted to the relevant ethics committee in 
Italy, should the plan for the trial proceed following the PhD. In addition, all local 
regulatory requirements will be adhered to, in particular those which afford greater 
protection to the safety of the trial participants. This study will be conducted in 
general according to the Declaration of Helsinki and with local laws and regulations.  
 
The investigator, or a person designated by the investigator, will explain the benefits 
and risks of participation in the study to each subject, the subject’s legally 
acceptable representative or an impartial witness and obtain written informed 
consent prior to the subject entering the study (before initiation of protocol-specified 
procedures). 
 
5.2.4 Interventions 
The study will involve a total of six onsite visits, a screening visit, a BL visit and four 
visits (at weeks four, eight, 12 and 24) and three telephone contacts will be 
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scheduled during the treatment phase (at weeks two, six, and 10) (Figure 7). A total 
of 300 participants will be randomised in three study conditions (A, B, and C), 90 for 
each condition. Participants randomised in study group A will receive 24 weeks of 
JUUL e-cigarettes loaded with 5% nicotine level virginia tobacco aroma cartridges 
and smoking cessation counselling; those in study group B, will receive 24 weeks 
of JUUL e-cigarettes loaded with 1.7% nicotine level virginia tobacco aroma 
cartridges and smoking cessation counselling; participants in study group C will 
receive 24 weeks of JUUL e-cigarettes loaded with 0% nicotine level virginia 
tobacco aroma cartridges and smoking cessation counseling. These three arms of 
the study are set at different levels of nicotine to see the effect of different dosages 
on the consumption of traditional cigarettes. 
 
Participants will receive 24 weeks of cartridges/pods because in the previous single 
arm pilot study most of the participants asked to have another three months of free 
products for these reasons: fear of traditional cigarette relapse, to try in the 
meantime to quit smoking traditional cigarettes, and to save money.  
 
This model of e-cigarette was chosen because: it has a nicotine concentration 
comparable with a traditional cigarette; is easy to use; mimics the flavour, length, 
and mouth-feel of traditional cigarettes; is produced by a company (JUUL) not 
owned by a tobacco company; and does not require charging or re-filling. In addition, 
JUUL was successfully used in the single arm pilot study that informs this RCT 
protocol.  
 
The JUUL is a cig-a-like that has been created by Pax Labs. JUUL is a closed 
system ENDS product.  The system consists of a device and closed pod.  The pod 
contains 0.7 ml of e-liquid and up to 5% nicotine by weight.  The e-liquid composition 
includes propylene glycol, glycerol, nicotine, benzoic acid, and flavouring. The 
product is charged via USB port. JUUL was designed as an alternative to traditional 
cigarettes for adult smokers. Central to this is the ability to provide cigarette-like 
satisfaction via a pharmacokinetic profile similar to that of cigarettes (Brown & Xing., 
2015; Lawler., 2018). JUUL incorporates several key technological advances:  JUUL 
is breath actuated and has no user modifiable settings; the battery (200 mah) is not 
removable, and the electronics incorporate battery regulation features; JUUL has a 
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unique temperature regulation system that has been demonstrated to maintain coil 
and wick temperatures below 300 degrees Celsius under a range of operating 
conditions (cigarettes can exceed 1000 degrees Celsius). Notably, JUUL was 
designed to avoid the “dry puff” phenomenon (Jensen, 2015). The aerosol profile of 
JUUL’s flavors in stock have been characterized by independent third-party labs 
using validated analytical methods. Multiple categories of harmful and potentially 
harmful constituents from an FDA panel of 31 chemicals were found to be below the 
level of quantification, including carbonyls such as diacetyl and formaldehyde, 
volatile organic compounds such as benzene (also reported by Pankow, et al., 
2017), and TSNAs such as NNN (nitrosonornicotine) and NNK (4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone). 
 
The ‘smoking cessation counselling’ protocol for the trial will follow a Standard 
Treatment Programme (McEwen, 2014), and specialty training modules and 
briefings for practitioners who help smokers with mental health problems to quit 
(Robson & Pots, 2014; Robson & McEwen, 2018). The involved researchers will 
provide support in the form of CBT through one-to-one sessions. CBT has been 
developed on the basis of Pavlov's, Skinner's and Beck’s theories. CBT is an 
evidence-based treatment that aims to sustain smokers to achieve specific 
objectives, such as smoking cessation, through focussing on the current situation 
rather than the past (Guichenez et al., 2007). 
 
Goal setting, review of behavioural goals, feedback on behaviour, self-monitoring, 
social support, information about health consequences, behaviour substitution, 
habit reversal, pros and cons, social reward, avoidance/reducing exposure to cues 
for the behavior, distraction, adding objects to the environment, and verbal 
persuasion about capability are the behaviour change techniques (BCTs) that will 
be used in this study. These BCTs are coded in Table 11 according to the Behavior 
Change Technique Taxonomy v1 (BCTTv1) (Michie et al., 2013).  
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Table 11: Behaviour change techniques applicated 
No. 
BCTs applicated 
1.1 Goal setting (behaviour) 
1.5 Review behavioural goal(s) 
2.2 Feedback on behaviour 
2.3 Self-monitoring of behaviour 
3.3 Social support (emotional) 
5.1 Information about health consequences 
8.2 Behaviour substitution 
8.4 Habit reversal 
9.2 Pros and Cons 
10.4 Social Reward 
12.3  Avoidance/reducing exposure to cues for the behaviour 
12.4 Distraction 
12.5 Adding objects to the environment 
15.1 Verbal persuasion about capability 
 
Participants will be seen in a screening visit, during which eligibility criteria will be 
reviewed and informed consent will be obtained prior to any study procedures. 
Participants will also be informed about licensed smoking cessation aids, and if they 
choose to use one of these methods, they will be directed to the smoking cessation 
center closest to their residence. 
The baseline visit will occur no less than three days and no more than two weeks 
after the screening visit. 
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Figure 7. Study diagram 
 
 
 
5.2.5 Study procedures 
The BL visit will be carried out within two weeks of the screening visit. At BL (study 
visit one), socio-demographic factors and detailed smoking history will be annotated 
and individual pack-years calculated, together with the ratings of positive and 
negative symptoms of schizophrenia, quality of life and neurocognitive functioning 
assessed by the SANS (Andreasen, 1983),  the SAPS (Andreasen, 1984), the EQ 
VAS, (Rabin & De Charro, 2001)  and BACS (Kefee RSE et al., 2004 ), respectively. 
SANS and SAPS have been chosen because, firstly, they are both used frequently 
in clinical and research settings and reliability and validity has been shown to be 
consistent in multiple cross-cultural settings (Andresen et al.,1991) and secondly, 
this enables comparison of the results with those obtained in the single arm pilot 
study.The EQ VAS is a valid and reliable measure in many disease areas (Wailoo 
et al., 2010) and  is the most widely used generic patient‐reported outcome 
questionnaire internationally (Devlin & Brooks, 2017). BACS has been chosen 
because it is designed to require about 30 minutes of testing time with minimal extra 
time for scoring and because is designed to be administered easily by a variety of 
testers, including research nurse, clinical social workers, nurse clinicians, 
psychologists, psychiatrists and other mental health professionals. 
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Cigarette dependence will be measured with the FTCD (Fagerström, 2012) to 
evaluate if there will be any differences linked to the initial cigarette dependency 
level measured through this test. 
 
The assessments at baseline and follow up will be carried out by a clinical 
psychologist or psychiatrist. Additionally, levels of CO in exhaled breath will be 
measured using a portable device (Micro CO, Micro Medical Ltd, Kent, UK). Vital 
signs (HR and BP, body weight) will also be recorded at BL. Participants will be 
asked not to smoke for at least 30 minutes prior to BL visit.  
 
Participants will be given a free supply of e-cigarettes for 24 weeks (on average, a 
4-week supply of e-cigarettes at a time) and instructed on how to use them. This 
visit will also cover general preparations for quitting and it should aim to enhance 
motivation and boost self-confidence throughout. Key trouble-shooting support will 
be provided and phone numbers will be supplied for medical assistance. 
 
A study diary recording will be used to check the daily cigarette and pod/cartridge 
consumption and most common AEs related to the use of e-cigarettes (for example, 
dry cough, mouth irritation, throat irritation, headache, shortness of breath, nausea) 
and monitor/report symptoms of drug toxicity related to reducing or eliminating 
tobacco toxicity. Participants will be instructed to return every four weeks to obtain 
their four-weekly supply of e-cigarette pods/cartridges. 
 
The BL (visit one) in brief is as follows: case report form (CRF) (physical 
examination, FTCD, EQ VAS, BACS, HR, BP, weight, CO, SAPS and SANS); 
randomisation into either study group A (e-cigarette 5% nicotine), B (e-cigarette 
1.7% nicotine), or C (e-cigarette 0% nicotine); dispense four-week supply of nicotine 
5% e-cigarette, nicotine 1.7% e-cigarette  or no-nicotine e-cigarette  (depending on 
the study-arm allocation); dispense four-week study diary; book for next 
appointment in four weeks (week four; study visit two).  
 
At week four (study visit two), and week eight (study visit three), participants will a) 
receive the study diaries for the residual study periods; b) have their cigarette and 
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e-cigarette consumption recorded, c) have their CO levels and vital signs recorded; 
d) return their completed study diaries and used study products, e) be assessed, 
using the mCEQ (Cappelleri et al., 2007), for enjoyment of respiratory tract 
sensations, craving reduction for cigarettes, psychological reward, aversions, and 
satisfaction will be assessed. The mCEQ has been chosen firstly, to compare the 
results with those obtained in the single arm pilot study and, secondly, to obtain self-
report measures in relation to behavioural preference of e-cigarettes varying in 
nicotine content. These visits will also cover strategies for avoiding cigarette 
smoking and should aim to enhance motivation and boost self-confidence 
throughout.  
 
Week four (visit two) in brief will be as follows: collect four-week study diary; CRF 
(number of CPD, number of cartridges/day, CO, HR, BP, mCEQ); record cigarette 
and e-cigarette consumption; dispense four-week supply of nicotine 5% e-cigarette, 
nicotine 1.7% e-cigarette or no-nicotine e-cigarette  (depending on the study-arm 
allocation); dispense next four-week study diary for AEs; book for next appointment 
in four weeks (week eight; study visit three). 
 
Week eight (visit three) in brief will be as follows: collect four-week study diary; CRF 
(number of CPD, number of cartridges/day, CO, HR, BP, mCEQ); dispense four-
week supply of nicotine 5% e-cigarette, nicotine 1.7% e-cigarette  or no-nicotine e-
cigarette (depending on the study-arm allocation); dispense next four-week study 
diary for AEs; book for next appointment in four weeks (week 12; study visit four). 
 
At week 12 (study visit four), and week 24 (study visit five), participants will a) 
receive the study diaries for the residual study periods; b) have their cigarettes and 
e-cigarettes consumption recorded; c) have their CO levels and vital signs and 
weight recorded; d) return their completed study diaries and used study products; 
e) be assessed using the mCEQ (Cappelleri et al., 2007) for enjoyment of respiratory 
tract sensations, craving reduction for cigarettes, psychological reward, aversions, 
and satisfaction; f) be measured for cigarette dependence with the FTCD 
(Fagerström, K, 2012); g) be rated for positive and negative symptoms of 
schizophrenia, quality of life and neurocognitive functioning by the SANS and the 
SAPS (Andreasen, 1982), EQ VAS (Rabin & De Charro, 2001)  and BACS (Kefee 
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RSE et al., 2004),  respectively; and h) be measured for e-cigarette dependence 
with the Penn State [Electronic] Cigarette Dependence Index (Foulds J, et al., 2015). 
The last questionnaire has been chosed to evaluate whether or not the use of the 
products under investigation can determine dependence in these population. 
 
These visits will also cover strategies for avoiding cigarette smoking and should aim 
to enhance motivation and boost self-confidence throughout. At the end of the week-
24 study visit, no more products will be provided by the investigators. The study will 
be conducted where the products under investigation are available on the market 
online and in retail outlets. Smoking cessation counselling will be offered during all 
planned visits. After closing the study, participants will be directed to the smoking 
cessation center nearest to their place of residence. 
 
Week 12 (visit four) in brief will be as follows: collect four-week study diary; CRF 
(number of CPD, number of cartridges/day; CO, HR, BP, weight; EQ VAS; SAPS, 
SANS; BACS; mCEQ; FTCD; Penn State [Electronic] Cigarette Dependence Index); 
brief structured interview about effects of smoking and/or vaping on mental and 
physical health; dispense 12-week supply of nicotine 5% e-cigarette, nicotine 1.7% 
e-cigarette  or no-nicotine e-cigarette  (depending on the study-arm allocation); book 
for next appointment in 12 weeks (week 24; study visit five). 
 
Week 24 (visit five) in brief is as follows: collect 12-week study diary for AEs; CRF 
(number of CPD, number of cartridges/day; CO, HR, BP, weight; EQ VAS; SAPS, 
SANS; BACS; mCEQ; FTCD; Penn State [Electronic] Cigarette Dependence Index); 
brief structured interview about the effects of smoking and/or vaping on mental and 
physical health. 
 
The early termination visit (ET; unscheduled visit) will involve: CRF (number of CPD; 
CO; HR; BP; weight; SAPS, SANS; BACS; EQ VAS; FTCD; Penn State [Electronic] 
Cigarette Dependence Index (Table 9). 
5.2.6 Study Discontinuation 
The proposed study will be stopped when required study numbers are achieved. 
Recruitment at a center may be stopped for reasons of low recruitment, protocol 
violation or inadequate data recording. 
157 
 
 
Table 12: Study Schedule/Flowchart 
 
PROCEDURE SCREENING 
 
VISIT 0 
BL 
VISIT 
1 
WK4 
VISIT 
2 
WK8 
VISIT 
3 
WK12 
VISIT 
4 
WK24 
VISIT 
5 
ET 
Eligibility criteria 
(review) 
x       
Informed consent  x      
Randomisation into 
either study group 
 x      
C
R
F
 
Socio-
demographic 
factors 
 x x     
Smoking 
history  
 x x     
Number of 
CPD 
 x x x x x x 
Number of 
cartridges/day 
  x x x x  
Physical 
examination 
 x      
Vital signs – 
BP & HR 
 x x x x x x 
Weight - kg  x   x x x 
AEs  x x x x x x 
FTCD  x   x x  
Penn state 
[electronic] 
cigarette 
dependence 
index 
    x x  
EQ VAS, 
BACS, SAPS 
SANS 
 x   x x x 
mCEQ   x x x x  
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Brief 
structured 
interview  
    x x x 
CO  x x x x x x 
Dispense study 
products and study 
diary 
 x x x x x  
Counselling  x x x x x  
 
 
5.2.7 Outcomes 
The primary outcome for the trial will be continuous abstinence from smoking at 
week 24. Participants will be classified as ‘quitters’ if they are able to maintain 
complete abstinence from cigarette smoking from week nine through week 24 with 
end-expiratory exhaled CO measurements ≤ 10 ppm. This outcome was chosen, 
firstly, to verify the efficacy of the e-cigarette at different levels of nicotine as a tool 
for smoking cessation and for a significant period of time (24 weeks), in this category 
of smokers typically difficult to help to quit smoking traditional cigarettes, and 
secondly, because measuring the primary outcome at 24 weeks will also allow 
inclusion in the Cochrane reviews. 
 
Secondary outcome measures will include:  
• continuous abstinence rate from week nine through week 12;  
• continuous reduction rate from week nine through week 12;  
• continuous reduction rate from week nine through week 24;  
• safety  
• cost effectiveness  
• change from baseline in results of SAPS, SANS, BACS, FTCD, Penn State 
[Electronic] Cigarette Dependence Index, and mCEQ 
Safety will be assessed by measuring and recording AEs including symptoms 
thought to be related to tobacco smoking and e-cigarette use and to withdrawal from 
nicotine. These will be annotated at BL and at each subsequent study visit on the 
AE page of the study diary. Vital signs (BP, HR) and body weight will be also 
recorded to help inform an assessment of safety.  
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Cost effectiveness will be assessed by an embedded economic evaluation. This will 
be carried out in the form of an incremental cost-effectiveness analysis over the 12-
month trial period. An experienced health economist will be included in the study 
team if the research proceeds as hoped, and any protocol developed for publication 
or for submission to a funder would include further details on the economic analysis 
provided by the health economist colleague.  Intervention costs will be recorded by 
the research team and include e-cigarette costs, insurance cost, training costs, 
delivery costs within the trial, coordination and supervision costs and appropriate 
capital costs. An adapted Health Economic and Service Utilisation Questionnaire 
and case notes will be used to count and evaluate human resources use. Resource 
units will be calculated by multiplying quantities by the associated market costs or 
local average unit costs. Health-related quality of life will be assessed using EQ VAS 
(Rabin & De Charro, 2001). Health advantages will be transformed into quality-
adjusted life years (QALYs), by obtaining the area under curve (Richardson & 
Manca, 2004). An incremental cost-effectiveness ratio (ICER) will be considered by 
linking variance in costs between groups and difference in QALYs between groups 
and related to the national willingness-to-pay threshold to determine cost-
effectiveness. 
 
5.2.8 Sample size 
This will be a large RCT that will use the JUUL e-cigarette with different nicotine 
levels (5%, 1.7% and 0%) in smokers with schizophrenia spectrum disorders, the 
first of its kind; hence, no previous data are available for an accurate power 
calculation. The six-month continuous abstinence rates used in estimating this 
sample size were extracted from the single arm pilot study protocol. Since there was 
no basis for assessing the long-term quit rate in the single arm pilot study, the 
assumption has been made that the rates and relative differences for this endpoint 
would be at least as good as the continuous abstinence through week 24. In our 
single arm pilot study, reported in Chapter 4, we used JUUL e-cigarettes in 40 
smokers with schizophrenia spectrum disorders, supplied with 5% nicotine 
cartridges/pods, and we reported a quit rate of 40% at three months in smokers not 
wishing to quit and with an observed attrition rate of 7.5%. Other previous research 
that is relevant was our first large long term RCT (Caponnetto et al., 2013c, 
conducted separately from and prior to the PhD), in which we used first generation 
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e-cigarettes in 300 smokers without schizophrenia spectrum disorders, 
experimenting with two different nicotine strengths compared with a non-nicotine 
choice, and we reported a quit rate respectively of 12%, 10% and 5% in arms with 
high, medium and no nicotine level and with an associated attrition rate respectively 
of 35%, 37% and 45%.   
 
A sample size of 213 subjects will be aimed for in this RCT following any drop out. 
The sample size was calculated in line with the following parameters: effect size 
medium in smoking abstinence = 0.18; alpha = 0.05; power (1-ß) = 0.80.  
 
Considering that the drop out rate could be higher in the group without nicotine, we 
have assumed a drop-out rate of 30%; hence, a total sample size of 300 smokers 
at recruitment will be needed. The smokers will be randomised into the three arms 
of our study protocol (i.e., 100 smokers for each arm).  
 
5.2.9 Randomisation 
At BL, participants will be randomised into three separate study groups. The 
randomisation sequence will be computer generated by using blocks of 15 with an 
allocation ratio of 5:5:5 for each of the three study conditions (A, B, and C). 
Participants randomised in study group A will receive a 24-week supply of the e-
cigarette with 5% of nicotine; those in study group B, a 24-week supply of the e-
cigarette with 1.7% of nicotine; participants in study group C will receive a 24-week 
supply of the e-cigarette with 0% of nicotine. Blinding will be ensured by the identical 
external appearance of the e-cigarettes and cartridges. The hospital pharmacy will 
be in charge of randomisation and packaging cartridges. At the initiation of the study, 
staff at the study site will be instructed on the method for blind breaking. The method 
will be either a manual or electronic process. Blinding codes should only be broken 
in emergency situations for reasons of subject safety. When a blinding code is 
broken, the reason must be fully documented. 
 
5.2.10 Statistical methods 
Statistical analysis will be performed with SPSS 23.0 (IBM). Continuous variables 
will be described as mean and SD (for normally distributed variables), or median 
and IQR (for not normally distributed variables). Categorical variables will be 
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described with percentages and absolute frequencies. The differences in 
continuous variables between the three groups will be evaluated by the Kruskal-
Wallis test followed by the Dunn multiple comparison test. The differences between 
the three groups for normally distributed data will be evaluated by one-way ANOVA 
followed by the Newman-Keuls multiple comparison test. The normality of the data 
distribution will be evaluated by means of the Kolmogorov-Smirnov test. Any 
correlation between the variables under evaluation will be assessed by Spearman r 
correlation. To analyze differences in frequency distribution of categorical variables 
we will use the Chi-square test with the Yates correction or the Fisher exact test. All 
statistical tests are two-tailed and are considered to be statistically significant at P < 
0.05. 
 
The consistency of effects for pre-specified subgroups will be assessed using tests 
for heterogeneity. Subgroups will be based on age, sex, education, and level of 
nicotine dependence. 
 
Smokers who leave the study before its completion due to lack of efficacy or poor 
tolerability of the product under investigation will be subject to an ET and will be 
defined as continuous smokers. AEs, including  symptoms thought to be related to 
tobacco smoking, e-cigarette use, and withdrawal from nicotine, will be annotated 
at each subsequent study visit to BL on the AE page of the study diary. The number 
and the percentage of subjects experiencing AEs, adverse reactions, SAEs and AEs 
leading to study withdrawal will be summarized by treatment group. AEs will also be 
summarized by system organ class and preferred term using the MedDRA 
dictionary. 
 
A logistic regression model will be fitted to binary endpoints and will include 
treatment and center as independent variables. Subjects who discontinue the study 
are assumed to be smokers for the remainder of the study. In responder rates, those 
subjects will be represented in the denominator but not the numerator. For 
continuous endpoints, a linear model including treatment and center will be used as 
the underlying model. 
 
5.2.11 Study plan 
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It is anticipated that it will take about three months to comply with all regulatory 
requirements (ethics committee review and approval). The study, from the 
enrollment to the study close out for all the patients at week 24 (follow-up), will have 
a total duration of 12 months.  
 
The enrollment period will last about six months with the support of a multi-channel 
advertising method. This will include location-based advertising on social networks, 
advertising in local media, and information days organized within the city. It will take 
about five months for data cleaning; data analysis; writing the draft, interim, and final 
reports; manuscript writing; and submission of a results paper to a peer-reviewed 
journal. 
 
Dissemination activities will be undertaken after the clinical study closes, that is, 
when all study visits have been completed by all the participants. The study results 
will be disseminated principally through peer reviewed academic publications and 
by way of dissemination events such as academic conferences. We will prioritise 
the use of open access channels in the course of dissemination activities. 
 
5.2.12 Next steps 
The study protocol, after adjustments following comments from the PhD examiners, 
and seeking additional external input on the health economics element, will be 
submitted to a peer reviewed scientific journal.  
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CHAPTER 6: DISCUSSION 
In this concluding chapter, the key findings of the research conducted for this thesis 
are discussed.  
 
The main aim of this thesis was to conduct preliminary research that would help 
inform the development of future research to assess the role of e-cigarettes in 
smoking cessation or reduction for smokers with schizophrenia spectrum disorders. 
The preliminary research was also intended to explore what would be acceptable 
and feasible for this target group and was underpinned by a robust theoretical basis. 
The final goal was to develop an intervention to reduce the risk of tobacco smoking, 
as a complementary tool to treat smokers with schizophrenia spectrum disorders. 
Specific objectives for the PhD were to: explore the perceptions of participants 
regarding e-cigarettes and licensed smoking cessation aids through a qualitative 
study; investigate the role of e-cigarettes on smoking cessation/reduction in 
smokers with schizophrenia through a prospective three-month single arm pilot 
study; and develop a protocol for a definitive trial to investigate the role of e-
cigarettes on smoking cessation in smokers with schizophrenia in a large multisite 
RCT with longer term follow up. 
 
Work towards this aim and these objectives was carried out using a mixed method 
approach based on a review of relevant literature, one qualitative study and one 
quantitative single arm pilot study. 
 
First the contents of the thesis and main findings of the empirical work are 
summarized. Secondly, the findings of this empirical work are revisited and reflected 
upon in the context of the wider literature. These reflections relate firstly to the three 
research questions developed for the qualitative research outlined in Chapter 3 and 
secondly to the three research questions developed for the single arm pilot outlined 
in Chapter 4. How the findings address these questions is discussed in the context 
of the wider literature. In the remaining sections of this chapter the strengths and 
limitations of the research conducted as part of this thesis are examined, as are the 
implications for clinical practice and future research. 
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6.1 Summary of the research 
Chapters 1 and 2 of this thesis reviewed the available literature in relation to: the 
epidemiology of tobacco smoking in people with schizophrenia; the relationship 
between smoking and mental health; harmful effects in patients with schizophrenia 
compared with the general population; the evidence base of the licensed smoking 
cessation treatments in the general population and in people with schizophrenia 
spectrum disorders; the concept of THR; and the description of e-cigarettes and 
relevant characteristics and potential application to improve health; and they also 
explored e-cigarettes for smokers  with schizophrenia spectrum disorders.  
 
Findings from the qualitative study reported in Chapter 3 suggested that smokers 
with schizophrenia spectrum disorders started to smoke for similar reasons to 
people without a mental health condition. In addition, they were aware of nicotine 
patches and nicotine gum as licensed smoking cessation aids, had never heard of 
varenicline and bupropion, and reported interest in using e-cigarettes to quit or 
reduce their consumption of traditional cigarettes. 
 
Findings from the quantitative single arm pilot study reported in Chapter 4 suggested 
that the components of the intervention were feasible and acceptable to this group 
of smokers. Potential barriers and facilitators were identified which could inform 
future research, and important elements to assess in future studies were identified 
including: assessing improvements to BP and HR without weight gain; monitoring 
SAEs, and monitoring psychopathological exacerbation. The process of conducting 
the single arm pilot study and its outcomes directly informed plans for a future larger 
study which are outlined in Chapter 5. This consisted of a draft protocol for an RCT 
of e-cigarettes for smoking cessation or reduction in smokers with schizophrenia.  
 
6.2 Perspectives on smoking and e-cigarettes amongst people with 
schizophrenia spectrum disorders  
This section revisits the three research questions developed for the qualitative study 
included in the thesis (Chapter 3, Section 3.4) and considers these in the light of 
relevant literature. 
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Question 1: How do participants perceive traditional cigarettes compared with 
e-cigarettes? 
The qualitative study found (Chapter 3) that around one in three study participants 
considered traditional cigarettes to be more expensive than e-cigarettes or with an 
equivalent cost. Similar proportions considered traditional cigarettes to be less 
expensive than e-cigarettes and were uninformed about e-cigarettes costs. Only 
one other previous study has explored these issues in smokers with schizophrenia 
spectrum disorders, and 32% of participants in that study (a similar proportion to the 
current results) expressed concern about the cost of e-cigarettes as a deterrent to 
use (Miller et al., 2017).  
The qualitative study participants reported preferences for the taste, satisfaction and 
enjoyment of their own traditional cigarettes compared with e-cigarettes. All smokers 
were aware that smoking cigarettes causes several illnesses, but those unmotivated 
to stop were ambivalent about some of the health consequences. Members of the 
group that was motivated to quit, in contrast, were particularly concerned that 
smoking cigarettes might damage their health. 
 
Smoking cigarettes for participants in the qualitative study was seen as a way to 
structure time and occupy the day. In a previous qualitative study conducted with 
psychiatric clients living in the community, including smokers with schizophrenia, 
participants reported smoking cigarettes gave them a sense of identity, and that 
traditional cigarettes were reported as the marker that kept all elements of their lives 
in control:  they regarded smoking as a symbol of control (Lawn et al., 2002).  
 
When comparing possible experiences from using an e-cigarette compared with 
smoking (other than health factors), views were similar amongst those interviewed. 
All participants described smoking as helpful, relaxing and ‘a friend’ available to 
cope with negative sensations that occurred as a result of their mental health 
condition. None of the participants from either group mentioned a similar effect from 
e-cigarettes. Another aspect they emphasized was the complexity of using e-
cigarettes compared with traditional cigarettes and the effort required. These 
findings are similar to previous studies, including qualitative research, which has 
found that smoking traditional cigarettes offers a sense of control of mental health 
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symptoms in smokers with serious mental illness (Lawn et al., 2002; Barr et al., 
2008b). 
 
Although smokers believe that smoking offers mental health benefits there is also a 
strong association between smoking and poor mental health (Taylor et al., 2014). 
Smoking and disturbed mental health results in smoking to regulate feelings such 
as low mood and anxiety (Khantzian, 1997). Smokers with mental health diseases 
might be less likely to stop if they believed their mental health would suffer, and 
health professionals are often reluctant to treat this target group of smokers because 
they believe that this might be detrimental to their mental health (Johnson et al., 
2010; Ratschen et al., 2009).  
In terms of vaping and health risks, most participants unmotivated to quit were not 
aware of the possible impact of vaping on their health, particularly in relation to risks 
relative to smoking.  Amongst those motivated to quit, interviewees considered e-
cigarettes to be safer than traditional cigarettes. A recent relevant survey found 
(Hefner et al., 2016) that, as in the general population, many individuals with mental 
conditions do believe that e-cigarettes are less harmful than traditional cigarettes. 
In relation to the findings on e-cigarette use, a recent study by Miller et al. (2017) 
asked their participants with schizophrenia spectrum disorders about the 
advantages/disadvantages of e-cigarette use. In this study, 23% reported that e-
cigarettes might taste better than traditional cigarettes and 10% that they might taste 
unpleasant; 27% reported that e-cigarettes might satisfy the desire to smoke and 
13% that they might not satisfy their desire to smoke. In the same survey, when 
comparing the health effects of smoking and vaping, e-cigarettes were considered 
more harmful by 17% of participants, equally harmful by 17% of participants, less 
harmful by 34% of participants and 32% reported ‘don’t know’ as their answer. 
Finally, relating to disadvantages of e-cigarette use, 17% reported that e-cigarettes 
might be inconvenient to use compared with smoking. 
 
Overall, the qualitative study conducted as part of this thesis resulted in findings 
consistent with the other limited literature on this topic. It found that smokers with 
schizophrenia spectrum disorders perceived traditional cigarettes quite differently 
from e-cigarettes. In particular, they reported that for them, tobacco cigarettes were 
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easy to use, tasty, enjoyable and satisfying, with a perceived positive effect on their 
psychological health and useful to structure their time during the day. In contrast, e-
cigarettes were perceived as not as easy to use, less enjoyable and satisfying 
compared with traditional cigarettes, but perceived as less harmful than smoking 
traditional cigarettes. 
Question 2: How appealing are licensed cessation aids for smoking cessation 
or reduction? 
Many participants had heard about only two types of NRT, specifically patches and 
gum, despite the evidence regarding efficacy of a wider range of licensed cessation 
aids for smokers with schizophrenia spectrum disorders (Cahil et al., 2014; 
Anthenelli et al., 2016). Most participants in both groups believed NRT was 
ineffective for helping them quit smoking or reduce cigarette consumption.  Similar 
findings are reported in a recent qualitative study conducted by Meurk et al. (2016). 
Despite this perception, most participants were interested in using a nicotine patch, 
gum or mouth spray and reported their choice was influenced by either the cost of 
the product or what they had seen on TV. 
 
All participants in both groups were not aware of varenicline or bupropion. The 
qualitative findings indicate the importance of improving activities to progress 
awareness of licensed medications to stop smoking in Italian smokers with 
schizophrenia spectrum disorders. Findings from this study (given the gaps in 
knowledge and awareness) also suggest that smokers with schizophrenia spectrum 
disorders should receive more smoking cessation advice. Other recent research has 
suggested that they do not receive information about smoking cessation aids 
(Mitchell et al., 2015) and a survey of US psychiatrists reported that they routinely 
deliver smoking cessation advice to only 12.5% of their patients (Himelhoch & 
Daumit, 2003). 
 
Question 3, How appealing are e-cigarettes for smoking cessation or 
reduction? 
The qualitative study findings suggested that smokers’ views regarding the appeal 
of e-cigarettes were complex, but that they could be promising for modifying 
smoking behaviour. Finding from the qualitative study were that e-cigarettes 
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specifically for smoking cessation or reduction were appealing for about half of the 
participants in the whole sample (16 of 30) and principally in the majority (12) of 
participants who were from the group motivated to stop smoking. It emerged that 
smokers with schizophrenia spectrum disorders who reported that e-cigarettes 
might be appealing for cessation or reduction believed that they were safer for their 
own health compared with traditional cigarettes and were interested in switching. 
Thus, compared with licensed aids for smoking cessation and reduction, e-
cigarettes may have greater appeal. This should be taken into account in order to 
assist people with schizophrenia to quit or reduce smoking. 
 
This finding is supported by recent results from other studies that suggest that in 
individuals with serious mental illness, including schizophrenia spectrum disorders, 
e-cigarettes may appeal as a possible alternative to smoking (Hefner et al., 2016). 
Other studies have also found that mental health patients perceive e-cigarettes as 
a viable aid to smoking cessation and/or reducing traditional daily cigarettes 
consumption (Cummins et al., 2014; Hefner et al., 2017; Pratt et al., 2016). 
 
6.3 E-cigarettes for smoking cessation and reduction in people with 
schizophrenia spectrum disorders  
This section revisits the three research questions developed to inform the design 
and conduct of the single arm pilot study included in Chapter 4 and reflects on 
findings in the context of the wider literature. Each of the original research questions 
is discussed in turn. 
 
Question 1: Will the participants quit smoking if they use this e-cigarette? 
The single arm pilot study outlined in Chapter 4 demonstrated that the use of e-
cigarettes in this study were feasible and acceptable for promoting smoking 
cessation amongst participants. In addition, vaping for smoking cessation appeared 
effective, at least in terms of very preliminary findings from this small study. Here 
smoking abstinence was defined as sustained self-reported abstinence from 
tobacco smoking for the 30-day period prior to the last three-month study visit. CO 
levels were measured to verify CO concentration of ≤10 ppm for the quitters 
according to the Russell standard (West et al., 2005). Sixteen participants (40%) 
completely switched to e-cigarettes and stopped smoking.  
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These promising findings on the possible effectiveness of vaping for smoking 
cessation in this population add to the existing, but very sparse, literature on this 
topic. Few and small studies offer relevant and recent data about the effectiveness 
of e-cigarettes for smoking cessation in smokers with schizophrenia spectrum 
disorders. For example, a recent study comparing nicotine patch and e-cigarettes in 
smokers with mental illnesses showed similar effectiveness of e-cigarettes and 
nicotine patch for smoking cessation in 24 smokers who reported use of 
antipsychotic drugs (O’Brien et al., 2015). Amongst this subgroup, differences 
between treatments were not statistically significant for cessation (patch 14% [5/35], 
16 mg e-cigarette 5% [2/39], 0 mg e-cigarette 0% [0/12], p = 0.245), AEs or relapse 
rates. This was a secondary analysis of data from the ASCEND trial in New Zealand 
involving 657 dependent adult smokers motivated to quit, randomised to 16 mg 
nicotine e-cigarette, 21 mg nicotine patch, or 0 mg nicotine e-cigarette, where the 
authors identified 86 participants with mental illnesses by using self-reported 
medication use and the Anatomical Therapeutic Chemical Classification System, of 
which 28% (24/86) reported use of antipsychotics. 
A second study found that in 21 smokers with serious mental illnesses who were 
offered an e-cigarette for four weeks, two participants self-reported abstinence from 
traditional cigarettes (Pratt et al., 2016). In a more recent study, Hickling et al. (2018) 
reported that at the 24-weeksfollow up visit, only one of 50 participants enrolled this 
study quit smoking. The current study adds to a promising literature, therefore, in 
studies with a high priority group for smoking cessation. E-cigarettes may be 
effective for smoking cessation in this target group, but the impact of e-cigarettes 
for smoking cessation needs to be explored by additional well-controlled studies 
with larger sample sizes. 
 
Question 2: Will the participants reduce the number of cigarettes smoked if 
they use this e-cigarette? 
In the single arm pilot study, e-cigarette use facilitated smoking reduction amongst 
patients who didn’t want to quit smoking and was related to changes in their smoking 
behaviour such as 50% or greater reduction in their daily cigarette consumption. We 
observed a sustained 50% reduction, CO verified, in the number of traditional 
cigarettes smoked per day at week-12 amongst 52.5% (21/40) of participants. 
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Amongst 17 participants (excluding quitters), Pratt et al. (2016) reported a significant 
decrease in cigarettes per week between BL (204.5) and the end of the FOUR-week 
supply of e-cigarettes (75) and in the study conducted by Hickling et al. (2018) 10 
participants (25%) achieved ≥ 50% reduction in CPD.  
 
Smoking is well documented to be associated with a host of illnesses, including 
hypertension, CVDs, cancer, and COPD. These results, associated with other data 
indicating that 86.2% of those with mental illness who used e-cigarettes were also 
using traditional cigarettes (Hefner et al., 2016), support the possibility that dual 
usage may be more prevalent in adults with mental illnesses than in the general 
population (Berg et al., 2015; Dawkins et al., 2013). However, it is also important to 
consider that a recent study of Shahab et al. (2017), discussed in more depth in 
Chapter 2 of this thesis, did not support dual use for harm reduction. 
 
A recent Cochrane review found that in the general population, e-cigarettes may 
help smokers reduce the number of traditional CPD compared with placebo 
(McRobbie et al., 2014). Reducing the number of traditional cigarettes smoked may 
be a strategy (or pathway) towards future complete cessation and may lead to less 
exposure to dangerous toxicants than continued smoking of traditional cigarettes 
(Lindson-Hawley et al., 2012). However, this hypothesis remains to be tested.  
In another study, smokers who used e-cigarettes as part of smoking cessation 
treatment, and who failed in their attempt to quit smoking but reduced their daily 
cigarette consumption and continued to use e-cigarettes, were exposed to fewer 
toxicants compared with those who continued to smoke only traditional cigarettes, 
suggesting that the smoking reduction was associated with harm reduction 
(McRobbie et al., 2015). In the current single arm pilot study, we could not quantify 
harm reduction from cutting down the number of CPD while using an e-cigarette, 
but this is a viable area for future research with patients with schizophrenia. 
 
Question 3: Are the study procedures feasible, and are they acceptable to 
participants? 
To answer this question, the focus of the current research was on the acceptability 
and feasibility of the intervention for smokers with schizophrenia spectrum 
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disorders. In terms of feasibility, the research found the study procedures were 
acceptable to the smokers because negative impacts on the physical and mental 
health of participants following e-cigarette use (based on the measures we were 
able to collect) were not observed. In addition, early signs of harm reduction in term 
of BP, HR and CO reduction were promising. 
In detail, fully described in the Chapter 4 of this thesis (Section 4.5.4), participants 
who completed the study showed improvements in BP and HR without weight gain. 
AEs typical of smoking withdrawal symptoms such as depression, anxiety, 
insomnia, irritability, hunger, and constipation were not reported. Also, there were 
no reported SAEs during the study. Another explanation for the relative acceptability 
may be attributed to the satisfaction related to the e-cigarette used in this study as 
assessed by mCEQ. 
Psychopathological exacerbations (assessed by the SAPS and SANS scales) 
during the study procedures were not observed and positive and negative symptoms 
of schizophrenia maintained their stability during the study procedures. Participants 
also reported that using the e-cigarettes provided satisfaction. The e-cigarette 
(JUUL) was easy and simple to use. The device is breath actuated, has no user 
modifiable settings, has a fixed battery with battery regulation features, has a 
nicotine pharmacokinetic profile similar to traditional cigarettes, and its technology 
avoids the “dry puff” phenomenon (Jensen, 2015).  
Previous research has suggested that adherence to an intervention is more likely if 
the products used are acceptable to participants. Considering that attrition rates in 
smoking cessation studies have been found to be particularly high (Belita & Sidani, 
2015), the low attrition rate observed in the current study conducted as part of this 
PhD research could be considered as a further sign of the study’s acceptability. 
 
6.4 Reflections on the qualitative and quantitative research and implications 
for the proposed future RCT  
The extant literature on e-cigarette use amongst adults with schizophrenia spectrum 
disorders is limited, yet gradually growing. E-cigarettes have sparked a debate 
within the public health community as to their potential benefits as a tool for 
cessation and/or harm reduction (Wagener et al., 2012). 
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Each study (qualitative and quantitative) conducted as a part of this dissertation 
provided findings that can be used to inform public health professionals and 
researchers regarding perceptions of e-cigarette products held by smokers with 
schizophrenia. In addition, the findings provide insight into the complex relationship 
between e-cigarette use and traditional cigarette smoking. Again, both the 
qualitative study (Chapter 3) and quantitative study (Chapter 4) combined to inform 
the protocol for a future trial (Chapter 5). 
In the qualitative study, amongst smokers not motivated to quit, the taste of 
traditional cigarettes was considered fundamental to their smoking experience. 
Tobacco flavor cartridges/pods were used in the single arm pilot study with a good 
level of acceptability and satisfaction and the same flavour was maintained for the 
RCT protocol. A third of the qualitative study sample were unaware of how much e-
cigarettes cost, with the other two thirds relatively equally split as to whether they 
thought they were more or less expensive compared with traditional cigarettes. It is 
important to understand if smokers know the average cost of e-cigarettes (and how 
they perceive the cost) and know how much money they spend per week to smoke 
their traditional cigarettes; if smokers believe e-cigarettes are too expensive, this 
may be a barrier to future use or attractiveness/appeal. It is also important to 
consider that continuous use of the e-cigarette used in this study can in the long run 
be more expensive than e-cigarettes with liquid, but the JUUL model is certainly 
simpler and easier to use and does not waste time or require complicated operations 
to change components. We used an affordable product for the single arm pilot study, 
and its suggested effectiveness led us to include it in the RCT protocol. The starter 
kit costs about 45 euros and each pod/cartridge about three euros. Considering that 
our participants smoked about 30 cigarettes per day and that cigarettes in Italy cost 
about 5.50 euros, our participants would have spent about 460 euros in 12 weeks. 
In contrast, those who quit smoking traditional cigarettes used e-cigarettes to an 
economic value of about 295 euros, saving hypothetically 165 euro in 12 weeks. 
However, longitudinal research with longer term follow-up is needed to confirm this.  
The first study qualitatively explored the relationship with the participants’ own 
traditional cigarette smoking and findings from this study support the notion that for 
smokers with schizophrenia spectrum disorders, smoking their own traditional 
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cigarettes provided a perceived positive effect on their mental health status, for 
example by helping them feel less anxious, depressed, and stressed, and smoking 
their own traditional cigarettes was also perceived as an aid to structuring their time 
and occupying the day. For these reasons it was decided to include in the RCT study 
protocol brief counseling support at each study visit, to help these smokers manage 
and better deal with the aspects highlighted above. 
In the quantitative study all participants who had stopped or reduced smoking 
traditional cigarettes continued to use e-cigarettes for three months. However, the 
short duration of the single arm pilot study did not allow investigation of further 
changes in traditional cigarette smoking in the case of extended use of e-cigarettes, 
for example for an additional three months. In addition, many participants asked to 
have e-cigarettes for a further three months and more counselling to quit smoking. 
As a result, the RCT protocol proposed a programme with e-cigarette 
pods/cartridges provided for a total of 24 weeks, with follow-up until one year (52 
weeks). This would have the aim of measuring the long-term impact on the variation 
in quality of life, possible development of dependence on e-cigarettes, and possible 
harm reduction effects by variation in cardiovascular parameters (BP and HR) and 
weight gain. In addition, a brief smoking cessation counselling intervention would be 
added to help smokers first to switch to the e-cigarette and progressively to become 
totally smoke and vape free.  
Other reflections are relevant to future research and were identified during the 
quantitative study. A problem that was encountered was the long duration of the 
data collection visits due to the administration of SAPS and SANS at each visit. As 
a result, in the RCT protocol the two scales would be carried out every three months. 
In the quantitative study we included smokers who smoked at least 20 cigarettes 
daily, excluding many potential smokers who smoke fewer than 20 cigarettes daily; 
for this reason, the RCT protocol includes people who smoke 10 or more CPD. 
Limitations exist in both the qualitative and quantitative studies, particularly 
regarding the representativeness of the sample, as in the current work this was 
limited to Italian smokers with schizophrenia spectrum disorders. Considering this 
aspect, the RCT protocol has been designed as a multisite international study. 
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Finally, in the single arm pilot study, participants expressed positive attitudes 
towards e-cigarettes. During this study, many smokers with and without mental 
health illness were intrigued by this new form of e-cigarette. The researcher 
observed satisfaction in those who used it and that participants stopped smoking or 
significantly reduced the number of traditional cigarettes smoked per day. Also 
several people who referred our participants to these studies, including relatives, 
caregivers, psychiatrist, nurses and psychologists, asked where they could buy the 
product and use it to quit or reduce their traditional cigarette smoking. Considering 
all these elements, it would be worth considering whether the proposed RCT 
protocol as outlined in Chapter 6 would benefit from the addition of an embedded 
qualitative process evaluation. 
With this in mind, future work could examine differences in attitudes and beliefs 
about e-cigarettes by users of different types of devices, for example. This could 
include participants who use products that closely resemble cigarette products 
(“cigalikes”) versus those who use more customizable devices (“tank systems” or 
“mods”) or even the new RRP (Reduced risks products): heat-not-burn products. 
These device types can differ in significant ways that affect users’ experience (e.g., 
availability of flavors; effective delivery of nicotine) which, in turn, might affect 
behaviour, acceptability, appeal, attitudes, and beliefs about the products. The 
existence of multiple user groups may have implications for the public health impact 
of e-cigarette use, RRP use and marketing. 
A further area for consideration in future RCTs is economic analysis. It is well known 
that the costs of smoking fall on many different parts of society, especially on 
individuals with schizophrenia and their families and caregivers (Andrew et al., 
2012). In terms of economic evaluation, few analyses have specifically addressed 
the question of the economic benefits and consequences of treatments intended to 
help people with schizophrenia spectrum disorders to quit or reduce smoking. In the 
framework of healthcare, an economic evaluation is just the comparison of two 
clinical interventions, for example usual care current practice versus a proposed 
replacement/alternative, in terms of costs and consequences (Drummond et al., 
1997). The method in which consequences are measured would determine whether 
an economic evaluation is a cost effectiveness analysis (CEA: outcome generally 
measured in natural units such as number of hospital days avoided or life years 
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gained), a cost-utility analysis (CUA: outcome measured in terms of health-related 
utility), or a cost-benefit analysis (CBA: outcome measured in monetary terms). 
Schizophrenia spectrum disorders and tobacco addictions have very significant 
economic consequences.  
A recent and instructive analysis used a Markov model to provide an economic 
evaluation of two months’ treatment of bupropion and co-interventions (group 
therapy either alone or in combination with NRT) and compared this to co-
interventions only. The model estimated that the incremental cost-effectiveness ratio 
of the combined intervention was £385 per QALY, well below NICE’s recommended 
threshold for cost effectiveness. The model predicted that there was a 95% chance 
that the combined intervention was more cost-effective than the co-interventions 
alone (Winterbourne, 2012). Furthermore, a recent study Barnett et al. (2015) 
estimated that smokers the psychiatric illnesses who quit smoking at 41 years of 
age will realize a discounted gain of 0.83 QALYs or 1.14 life-years. This advantage 
is lower than the typical value of two QALYs per quit benefit calculated for smokers 
without mental health illnesses (Song et al., 2002; Godfrey et al., 2005), reflecting 
the higher non-smoking mortality hazard and lower health-related quality of life 
associated with serious mental diseases. Although these authors estimated the 
benefit per quit to be to be lower in smokers with mental health disorders than in 
smokers generally, this study showed that the intervention was still highly cost-
effective. 
Thus overall, an expanded protocol for a future RCT could consider an embedded 
additional process evaluation and could include an economic evaluation. An 
amended RCT protocol could emerge following the PhD.  
 
6.4.1 Emerging implications 
This PhD research has implications for future research and public health 
interventions, as well as for informing the debate surrounding e-cigarette products. 
Additionally, this dissertation research highlights the value of mixed methods 
approaches given that, looked at in isolation, the findings from the quantitative or 
qualitative studies could lead to very different conclusions. For example, based on 
the qualitative findings amongst not motivated-to-quit smokers, we might not expect 
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the high success rates that were observed in the quantitative results as a result of 
e-cigarette use.  
 
Lastly, smokers with schizophrenia spectrum disorders in the qualitative study 
reported a lack of information about varenicline and bupropion as licensed smoking 
cessation aids. Beyond the proposed future research on e-cigarettes for smoking 
cessation amongst patients with schizophrenia, there would be merit in future 
research on these licensed medications with this group. 
 
6.5 Strengths and limitations 
Considering the chapters presented within this thesis as a collective body of work, 
some strengths and limitations should be recognized when evaluating the results 
and the implications of the findings. 
 
6.5.1 Strengths 
A multidimensional approach was used throughout this thesis: reviews of literature 
in multiple disciplines followed by a mixed-methods approach with three empirical 
studies, one qualitative study, one quantitative single arm pilot study, a structured 
protocol for a large RCT.  
 
The study has an international and multi-disciplinary collaboration because it 
involved experts from five European and US universities with training deriving from 
psychology, medicine, public health and nursing. 
 
The methodology used to develop the protocol for the large RCT has been reported 
in a transparent manner. The benefit of this is the mixture of the individual strengths 
of these methods. Many chapters reached similar conclusions despite the different 
methods used in each chapter. Each chapter provides new information to the body 
of research about e-cigarettes for smokers with schizophrenia spectrum disorders. 
Perception, appeal, acceptability and feasibility of e-cigarettes for smoking 
cessation or reduction for smokers with schizophrenia spectrum disorders have 
been tested in the qualitative and quantitative research phases of the development 
of this e-cigarette intervention.  
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The interactive essence of the development process means that findings from 
Chapters 3 and 4 can be applied to modify and improve the study protocol and the 
content of the intervention for a future large RCT.  
 
This is the first qualitative study evaluating the perception of licensed smoking 
cessation therapies and e-cigarettes in smokers with schizophrenia spectrum 
disorders motivated and not motivated to quit.  
 
Finally, this is the first behavioural study using JUUL and, with the exception of the 
Hickling et al. study (2018), the largest smoking cessation/reduction study of e-
cigarettes in people with schizophrenia spectrum disorders.  
 
6.5.2 Limitations 
A number of limitations arise from the research in this thesis. First, the presentation 
of findings and results in the two studies (qualitative and quantitative) should only 
be taken as descriptions of selected representative samples of smokers with 
schizophrenia spectrum disorders from a specific geographic area of Sicily in Italy. 
This means the results may not be applicable to comparable populations elsewhere.  
 
Secondly, using JUUL can also be  a limitation for several reasons: it’s unlike other 
e-cigarette models so the findings may not generalise to other devices; it’s available 
only in the US, Canada, Israel, Switzerland, Russia, UK and Germany at the time of 
writing, and ongoing costs seem likely to be higher than for refillable e-cigarettes. 
 
Third, a very important limitation is that this thesis represents a preliminary stage in 
introducing a complex intervention (replacing one socially constructed behaviour, 
and product, with another) with patients with schizophrenia. 
 
A further limitation is that the included research cannot comment on the efficacy of 
an e-cigarette intervention for smoking cessation and reduction for smokers with 
schizophrenia spectrum disorders. The results were preliminary and involved 
qualitative research and a single arm pilot study. Hence, issues relating to the 
sample recruited for the qualitative study and for the single arm pilot quantitative 
study need to be addressed. In particular, a small sample means that findings would 
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not be generalizable to a larger population. This limitation has been highlighted in 
Chapter 4 and the larger trial proposed in Chapter 5, could help address this.  
 
6.6 Reflection on my role in the research 
As a PhD student preparing this thesis, I designed and carried out the studies. Thus, 
at this stage, I think it is important to outline my personal background and the 
perspective from which I managed this thesis.  
 
Prior to beginning this PhD, I worked in research and clinical practice regarding 
schizophrenia, smoking addiction, e-cigarettes and harm reduction. Specifically, It 
is important to note that while completing the PhD (which was part-time for the first 
two years) I worked as clinical psychologist/psychotherapist and researcher at the 
smoking cessation research center of the University of Catania and at the 
department of mental health with patients with schizophrenia from 2004.  
As consequence, I had access to support from other staff and a good site for 
recruitment. 
 
My qualifications are in clinical psychology and psychotherapy. Reflecting on the 
advantages that background brought to the thesis, it meant that I already had some 
relevant expertise in the topic.  
My approach to the thesis was undoubtedly shaped by my prior experience, either 
in research or with the target population. However, some aspects of the research 
were new to me. For example, I had not been involved in qualitative studies before. 
I therefore found the interviewing process a bit challenging. I experienced barriers 
in speaking to participants as they exhibited typical signs of schizophrenia syndrome 
which can make conversation (interviews) difficult.  
Support from my supervisors assisted in developing my interviewing skills and also 
in interpreting the findings of my interviews. In contrast, however, the fact that I was 
familiar with the target group and the smoking cessation center setting facilitated 
recruitment. 
 
179 
 
6.7 Implications for the intervention by a large multisite randomised controlled 
trial with long-term follow-up and for clinical practice 
Generally, results of the single arm pilot study show potential for investigating the 
effects of the intervention in a larger sample and in a real-life setting. The smoking 
cessation/reduction intervention looks to be acceptable to smokers with 
schizophrenia spectrum disorders and is feasible in practice. Further multisite RCT 
research with long-term follow up is needed to test if the intervention has the 
intended positive effect on smokers with schizophrenia spectrum disorders and 
could inform health authorities about the possibility of considering e-cigarettes as 
licensed smoking cessation/reduction aids. 
 
According to the guidelines of the Italian Ministry of Health to quit smoking 
(OSSFAD, 2008), smokers with schizophrenia should be advised to stop smoking 
using licensed aids such as NRT, varenicline or bupropion in combination with 
behavioural individual or group support. However, this does not always happen in 
practice. Beyond official guidelines, other researchers (i.e. Sharma et al., 2017b) 
have suggested that smokers with schizophrenia spectrum disorders who are not 
motivated to quit smoking traditional cigarettes by using licensed aids or who 
communicate interest in using e-cigarettes should be provided with full information.  
 
This should include smoking cessation counselling that includes information about 
the pros and cons of switching to e-cigarettes, and support in their attempts to do 
so. However again, in Italy, this rarely happens in practice at the current time.  
 
6.8 Implications for future research 
The limited studies to date, including those in this PhD thesis, suggest that e-
cigarettes can help smokers with schizophrenia spectrum disorders to quit or 
significantly reduce their smoking consumption without serious adverse effects, 
even in those not ready to quit (Caponnetto et al., 2013d; Sharma et al., 2017a; 
Pratt et al., 2016). 
 
Considering the increased exposure to traditional cigarette use, high nicotine 
dependence, and difficulty quitting amongst this target group, greater attention and 
effort is warranted in future studies that assess the following: 1) harm reduction by 
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switching from traditional cigarettes to e-cigarettes or other RRP, 2) the role of 
nicotine level/preferences in initiation and maintenance of e-cigarette use, 3) the 
role of flavour preferences in initiation and maintenance of e-cigarette use, 4) the 
longitudinal physical and psychological impact of e-cigarette single use or  dual use, 
5) the variability in e-cigarette use and appeal across different diagnostic groups 
(e.g affective disorders, personality disorders, anxiety and obsessive disorders, 
substance abuse disorders, ADHD), 6) the impact of switching from traditional 
cigarettes to e-cigarettes in neurocognitive performance, 7) the impact of switching 
from traditional cigarettes to e-cigarettes on quality of life, 8) assessment of possible 
e-cigarette dependence development, 9) the impact of switching from traditional 
cigarettes to e-cigarettes on pharmacological and psychosocial treatments, 10) 
combining smoking cessation counselling and e-cigarettes and 11) strategies to 
improve smoking cessation activities delivered by health professionals involved in 
schizophrenia spectrum disorders rehabilitation. 
 
Future interventions can draw on the body of information in this thesis. Arguably, 
the evidence is not only relevant for interventions to promote smoking cessation and 
smoking reduction for smokers with schizophrenia spectrum disorders, but 
potentially relevant for a wide range of smoking populations.  
 
Principally, the use of new generation e-cigarettes combined with smoking cessation 
counselling could be applied to promote health empowerment in inveterate smokers 
not motivated to quit or who have failed to quit with other smoking cessation 
treatments.  
 
Evidence gathered in Chapter 3 regarding smokers’ perceptions of traditional 
cigarettes, e-cigarettes and licensed smoking cessation/reduction aids, and 
evidence gathered in Chapter 4 regarding the feasibility and acceptability of an e-
cigarette intervention for  smokers with schizophrenia spectrum disorders not 
motivated to quit, may be relevant for future e-cigarette interventions delivered with 
smokers motivated to quit with or without schizophrenia. 
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6.9 Conclusion 
In this thesis, I have: reviewed the scientific literature; consulted smokers with 
schizophrenia spectrum disorders in order to develop an effective, safe and 
acceptable intervention; and tested this intervention in a preliminary study leading 
to plans for future research.  
 
This preliminary research indicates that the smoking cessation/reduction 
intervention using a new generation e-cigarette for smokers with schizophrenia 
spectrum disorders is: feasible; acceptable; and supports the body of theory and 
evidence described in this thesis. The work also highlights the need for a robust, 
well-controlled, large, multisite RCT with long-term follow-up.  
 
Effective approaches are urgently needed to address the persistently high smoking 
rates in smokers with schizophrenia spectrum disorders. THR and potential health 
empowerment by switching to e-cigarettes could help to further reduce the health, 
financial and psychosocial parity gap experienced by this population. 
 
Finally, it is worth emphasising the strengths of the intervention itself. E-cigarettes 
are a promising technology that replaces smoking with a less harmful alternative 
(based on the research to date) that still provides nicotine but with fewer or far lower 
levels of toxicants. Given the low success rates for smoking cessation in people with 
schizophrenia, alternatives are urgently needed. In addition, combining e-cigarettes 
with smoking cessation counselling that motivates people to change and sustain 
healthy behaviours has great potential. 
 
The potential promise of this approach can be summarised by an unexpected finding 
outlined at the end of Chapter 5. This was that several individuals connected to our 
single arm pilot study participants (including relatives, caregivers, psychiatrists, 
nurses and psychologists) asked where they could buy the e-cigarette to use 
themselves to stop or reduce cigarette smoking. This suggests that during the 
process of researching an intervention to try to improve the health of a priority group 
for smoking cessation, wider benefits may have been achieved, even including 
prompting quit attempts in other associated populations.  
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APPENDIX 2 
Information sheet for patients, qualitative study 
 
I would like to invite you to take part in our research study. Before you decide, it is 
important that you understand why the research is being done.  Please take the time 
to read through the information here and contact me to discuss any questions you 
may have, or if anything is not clear. This information sheet tells you the purpose of 
the study and what will happen to you if you take part. 
 
What is the purpose of the study? 
I’m a researcher undertaking doctoral studies at the University of Stirling, UK and I 
working on smoking behaviour and schizophrenia. This is a project to (1) examine 
sensations of e-cigarettes compared to traditional cigarettes; (2) examine 
sensations of approved smoking cessation aids; (3) examine the appeal for initiating 
and using e-cigarettes as smoking cessation/reduction method; (4) examine the 
appeal for initiating and using approved smoking cessation aids as smoking 
cessation/reduction method 
  
Why I’m invited? 
As part of this research I would like to talk to people with schizophrenia who have 
been selected by their clinicians at Schizophrenia center for participation at this 
project and invite you to complete an interview.  
 
What will happen if I take part? 
Your will be invited to take part in a face to face interview which will be completed 
during office hours. The interview will take about 60 minutes. Participation is 
voluntary and you can withdraw at any time either before, during or after the 
interview. The interview will be audio-recorded and will be conducted in 
conversational in style. 
 
Will the data you collect be confidential? 
What you tells me will be completely confidential unless they tell me something that 
makes me concerned for their safety or that of someone else. I will follow ethical 
and legal practice for the protection of your data. No-one except the research team 
will find out what you say and your participation in the study will not affect your care 
in the Centre at all. Interview data will be stored anonymously and held securely on 
a University password protected computer   that can only be accessed by authorised 
members of the research team. You will not be named or identified in any way in the 
results from the study such as reports or presentations. The results will be a series 
of information on traditional cigarette and e-cigarette use derived by interviews 
recorded and transcribed verbatim. 
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Before any research goes ahead it has to be approved by a Research Ethics 
Committee. This project has been approved by the University of Stirling Research 
Ethics Committee. 
 
What happens if I have some questions?  
If you have any questions please speak to me, your teacher or a Professor from the 
University using the contact details below.    
 
I hope you are happy to participate. If you are, you do NOT need to do anything. If 
you have any questions or concerns about any aspect of the study please contact 
Dr Pasquale Caponnetto (78, S.Sofia street,  95100 Catania, telephone:  095 
3781537  email: pasquale.caponnetto@stir.ac.uk) or Prof Riccardo Polosa (78, 
S.Sofia street  95100 Catania, telephone:  095 3781583  email: polosa@unict.it). If 
you would like to speak to someone independent of the research team at the 
University of Stirling – please please contact Professor Jayne Donaldson, Dean of 
Faculty of Health Sciences & Sport (telephone:  0044 1786 466345  email: 
jayne.donaldson@stir.ac.uk). 
 
If you’re happy to take part in an interview, please tick each box below 
a) I am interested in taking part in this study.⎕ 
b) I am happy for the researcher to contact me and arrange ⎕ 
a time to discuss what would be involved prior to arranging an interview 
 
Signed……………………………..…………….Date……………………………………. 
 
Many thanks for your time, 
 
Pasquale Caponnetto,  
 
Phd Students, Stirling University 
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APPENDIX 3 
Participant consent form, qualitative study 
Version 2 DATE 01.10.2016 
 
Please refer to the study information sheet or contact the research team 
(0953781537 pasquale.caponnetto@stir.ac.uk) if you would like further details 
about the study or if you have any questions.  
 
Please note that your participation is entirely voluntary and you are free to 
withdraw at any time, without giving any reason. The information you provide will 
be confidential and will be securely stored. Only the research team will have 
access to it and your name will not be in any outputs from the research. 
 
This research study involves: 
• One 60-minute face to face interview. 
Please initial the boxes and sign your name if you agree to take part in this 
research 
I agree to take part in the research  
I confirm that I have read and 
understood the information sheet. If I 
had any questions, I have discussed 
these with the researcher and these 
have been answered satisfactorily.  
 
I understand that my participation is 
voluntary and I am free to withdraw at 
any time without giving a reason. 
 
I understand that the information I 
provide may be used in publications, 
reports and presentations 
 
I understand that any information that 
can identify me will not appear in 
publications, reports or presentations 
and that my name will be anonymised 
 
 
Name of Participant Date Signature 
 
______________________ _________________ ______________ 
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APPENDIX 4 
Structured interview 
 
Interview schedule/topic guide for smokers with schizophrenia 
INSTRUCTIONS FOR RESEARCH WORKER Aims   
(1) Examine perceptions of e-cigarettes compared to traditional cigarettes; (2) 
examine perceptions of approved cessation aids; (3) examine the appeal for 
initiating and using e-cigarettes as smoking cessation/reduction tool; (4) examine 
the appeal for initiating and using approved cessation aids as smoking 
cessation/reduction tool 
 
a) Introduction and consent  
Aim: To introduce the research, clarify the content of the interview, explain 
confidentiality and gain consent.   
The interview will last up to an hour with an additional fifteen minutes to complete 
consent and respondent demographic data.   
• Introduce yourself 
• Introduce research  
• Participation is voluntary and participant can withdraw at any time either before, 
during or after the interview  
• Explain confidentiality (confidential unless participant report anything which may 
indicate harm to themselves or others)  
• Recording (to gain accurate record of discussion, allow interviewer to focus on 
what respondent is saying, only research team will hear it)  
• Length (about 60 minutes with breaks if needed)  
• Nature of discussion (conversational in style with specific topics to be addressed)  
• Place of interview (need for private space to conduct the interview)  
• Reporting and data storage (no-one identified in final report, data stored securely 
under  
Data Protection legislation – can only be used for purpose collected by law, e.g. 
transcripts kept in locked cabinets, not shared with anyone outside research team) 
 • Address any questions  
• Gain written consent    
b) Sociodemographic form  
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Aim: To gain background information about the interviewee. 
 
INTERVIEW QUESTIONS  
Introduction (5-10 minutes) 
START RECORDING Aim: To find out a little bit about the person and to help build 
rapport in the interview   
Tell me a little bit about yourself 
Prompts:  
o Tell me a little bit about yourself and your experiences 
o Tell me a little bit about your smoking history   
o Story of their mental health experience  
 
Section 1: e-cigarettes and traditional cigarettes (7 - 12 mins) 
Aim: To find out about the individual’s perceptions of e-cigarettes compared to 
traditional cigarettes.   
What do you think about classic cigarette? (e.g., taste, satisfaction, cost, impact on 
health............................) 
What do you think about the electronic cigarette? (e.g., taste, satisfaction, cost, 
impact on health, impact on quitting................)  
Prompt:   
o can you tell me what you feel similar?   
o can you tell me what you feel different? 
 
Section 2: approved smoking cessation aids (7 - 12 mins) 
Aim: To find out about the individual’s perceptions of approved smoking cessation 
aids. 
What treatments do you know about that help people stop smoking? 
Prompt:   
o can you tell me what you think about NRT?   
o can you tell me what you think about bupropion?  
o can you tell me what you think about varenicline? 
 
 
Section 3:  e-cigarettes smoking cessation/reduction (7 - 12 mins)  
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Aim: To find out about the appeal of e-cigarettes (initiation and  as a smoking 
cessation/reduction tool) 
Would you use an electronic cigarette to quit tobacco smoking?  
Please explain why 
Would you use an electronic cigarette to reduce tobacco smoking? 
Please explain why 
 
Section 4:  approved smoking cessation aids cessation/reduction (7 - 12 mins)  
Aim: To find out about the appeal of using approved smoking cessation aids 
 
Would you use NRT to quit tobacco smoking? 
Please explain why 
Would you use NRT to reduce tobacco smoking? 
Please explain why 
Would you use Bupropion to quit tobacco smoking? ask 2 separate question  
Please explain why 
You would use Bupropion to reduce tobacco smoking? 
Please explain why 
Would you use Varenicline to quit tobacco smoking? ask 2 separate question  
Please explain why 
You would use Varenicline to reduce tobacco smoking? 
Please explain why 
 
Ask for any other comments. 
End of interview. Thank respondent and close interview. 
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APPENDIX 5  
Example of transcript and coding 
 
(NINO, MASCHIO, ETÀ 38) 
Se le va mi parla un pò di lei? 
Ma che programma è questo? 
Buonasera, mi chiamo Nino ed ho 38 anni mi trovo in trattamento per esattamente 
un intoppo nella vita considerando che io sia stato sempre un ragazzo molto vivo 
allegro gioviale e soprattutto con tanta voglia di fare per una serie di eventi correlati 
a dei lutti, non probabilmente non molto elaborati mi sono trovato ad avere un 
periodo un po’ negativo. 
Considerato il fatto che io nella mia vita ho avuto sempre delle basi che sono quelle 
della famiglia quindi non parliamo del fatto che mio padre possa essere stato un 
grande imprenditore o che mio padre poteva essere un muratore o che mio padre 
poteva essere quello che era e mia mamma viceversa, comunque una solidale 
famiglia porta il benessere di un ragazzo nel senso che se hai un problema sai a chi 
rivolgerti se stai male sai a chi rivolgerti. 
Considerando il fatto che mia madre mi ha insegnato che poi a un certo punto i 
problemi dovevo risolverli da solo cioè mi ha insegnato se ti senti male ti nni vai dal 
medico, nel senso però un ragazzo con certezze ben assolute quindi per un certo 
punto queste mie certezze ben assolute, quindi per un certo punto queste mie 
certezze sono crollate. 
Possono essere quelle affettive, quelle possono essere, sono state anche lavorative 
perché mi trovavo in una situazione lavorativa molto favorevole che 
improvvisamente è diventata stop. Diciamo che non è stato non proprio favorevole 
però come un ragazzo che ha sempre vissuto la sua vita pienamente cerca di 
riprendersi la sua vita in un moto che sia comunque soddisfacente anche per il 
proseguo della sua vita. Per quanto concerne il fumare se v’interessa veramente, 
non m’interessa fumare, se v’interessa veramente non m’interessa fumare, però in 
questo momento è semplicemente una piccola valvola di sfogo che non è avere una 
ragazza o non avere un gruppo di amici, ma la cosa importante è essere un ragazzo 
solido forte e sicuro di sè. 
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Poi tutto il resto viene da solo gli amici le fidanzate tutto quello che concerne la vita 
nel senso proprio quando tu sei sereno tranquillo poi tutto il resto viene da solo 
senza problemi, poi la gente si avvicina senza che tu te ne accorga.  
 
Raccontami un po’ la tua storia da fumatore Ma dottore io non ho mai fumato in 
modo eccessivo nel senso ho iniziato a fumare a 16 anni quando sono stato insieme 
con gli amici, poi in questo periodo ho fumato un po’ di più perché ho avuto una 
valvola di sfogo. 
 
Raccontami un pò della tua esperienza nell’ambito della salute mentale  
Allora rispetto al mio equilibrio psichico mi trovo meglio, il problema sa qual è nasce 
dal fatto che per un ragazzo che non ha mai avuto un problema del genere di vita, 
avere un problema e non averne un supporto familiare adeguato e trovare un 
medico che ti sappia sopportare per come un ragazzo vuole essere sopportato non 
è stato neanche semplice. Perché il primo medico dice passerà, il secondo medico 
dice fa passare un po’ di tempo, poi passano gli anni fondamentalmente non ti 
riprendi e quanto meno non è che non ti riprendi perché fisicamente poi 
automaticamente scattano le difese di automeccanismo però conoscendo il tuo 
corpo sai che lavorare al 20 per cento rispetto al 100 per cento. Che tu non vuoi 
dare e per un ragazzo cioè per lo meno per la mia personalità non è propriamente 
buono  quindi trovare un medico di riferimento, non è proprio semplicissimo nel 
senso se tu non hai grosse aspettative nella vita vai da un medico, vivi giorno per 
giorno, poi quello che ti succede succede, io non sono fatto proprio così quindi se 
tu hai un medico che ti sappia riprendere ha senso, cioè ovvio il passato non lo puoi 
riprendere o quanto meno devi avere un futuro che sia degno del passato o per lo 
meno degno per te, cioè non per gli altri che  probabilmente se ne stanno fregando. 
 
Quali sono i tuoi pensieri rispetto alle sigarette classiche? 
E’ veramente stupida (risponde alla domanda sulla sigaretta classica) non ha 
nessun senso è semplicemente un palliativo che non ha assolutamente un senso 
logico cioè la nicotina è la nicotina, non c’è niente che fare cioè io ho provato la 
sigaretta elettronica ma la nicotina è la nicotina. Ah io stavo parlando avevo capito 
sigaretta elettronica. La sigaretta classica mi da soddisfazione. 
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La sigaretta classica è importante perché è vero la nicotina, il tabacco fanno certo 
come posso dire… devi andare dal dentista ogni sei mesi  
Cioè devi curare quell’aspetto che non è proprio facile della sigaretta, no? E quindi 
però sicuramente nel momento di benessere io non voglio utilizzare sigarette perché 
non ne avevo nessun motivo ma nel momento di malessere è un piccolo palliativo.  
Diciamo che ho scoperto nella vita l’affetto della propria madre, o l’affetto in generale 
della famiglia, a un certo punto della vita è mancato e quindi mi sono reso conto 
cioè nel senso un affetto di una famiglia compatta può portarti tante cose positive e 
quindi ti può evirate tante altre cose negative tipo la sigaretta, nel senso la sigaretta, 
nel senso la sigaretta, in questo momento è un palliativo perché non hai uno sfogo 
ben preciso cioè nel senso in questo momento stai lavorando, potrei tornare in 
ufficio ma non è più per come lo immaginavo io . 
Quindi se non lavori e ti senti diciamo, non ti senti potente cioè questo voglio dire 
se non ti senti con le palle quadrate, tendi a fumare, io questo l’ho visto su di me 
nella mia gioventù mi sentivo con le palle quadrate quindi non avevo bisogno di 
fumare. 
Un senso cioè, un senso probabilmente lo poteva avere lo spinello, come amico mio 
a livello di amicizia tipo tra me e la sigaretta di per sè a meno che c’è gente che ha 
il vizio ma fondamentalmente non lo puoi creare. 
Vabbè il costo di una sigaretta non è così disabilitante cioè voglio dire 5 euro a 
settimana 5-10 euro non è che sono una cosa pazzesca 
Si il costo di una sigaretta di 5-10 euro a settimana non è così esorbitante voglio 
dire 5-10 euro a settimanali puoi spendere per la sigaretta, ne puoi spendere anche 
di più, però voglio dire parliamo della sigaretta come esempio da seguire nella mia 
vita, è un esempio sbagliato. Ha problemi finiamo? domani? no prego. 
 
Cosa pensa della sigaretta classica in termini di impatto sulla salute? 
Non penso faccia tanto bene alla salute, l’incidenza tumorale è abbastanza alta e 
anche le malattie cardiovascolari sono molto frequenti! Sono informato su questo 
perché ho avuto esperienza con mio padre e so che più o meno nel 70% dei casi, il 
cancro è dovuto al fumo, oltre il fattore ereditario o altro. 
 
Cosa ne pensi della sigaretta elettronica? 
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La sigaretta elettronica è una grandissima stupidaggine, un palliativo ed è anche 
più costosa della sigaretta normale, l’unica cosa positiva forse è che per la salute è 
un po’ meglio, e che è più economica rispetto alle sigarette, ma la verità è che si 
dovrebbe smettere e basta! 
 
Per quanto riguarda il gusto della sigaretta elettronica cosa ne pensi? 
La sigaretta ha il sapore della sigaretta mentre la sigaretta elettronica ha sapore di 
fragola o di cocco ecc.  Se tu devi fumare fumi la sigaretta normale altrimenti non 
fumi! 
 
Cosa pensi del grado di soddisfazione della sigaretta elettronica? 
Non mi dà soddisfazione, per chi fuma una boccata di sigaretta normale è una cosa 
differente! 
 
Quali somiglianze percepisci tra sigarette normali e sigarette elettroniche? 
nessuna! 
 
E quali differenze? 
Quella normale è sigaretta, quella elettronica è un’altra cosa… si capisce! 
 
Quali trattamenti conosci per smettere di fumare? 
Il primo? La volontà!  
Non conosco altre cure 
 
Cosa pensi dei sono i sostitutivi nicotinici? 
Ho avuto esperienze indiretta riguardo a questi! Per me la sigaretta è come una 
droga perché la nicotina ti crea dipendenza e i cerotti che hanno un impatto non 
superiore al 50% sul fisico, per un fumatore occasionale non servirebbe neanche 
ma basterebbe avere una distrazione; mentre per il fumatore abituale la quantità di 
nicotina del cerotto non può sopperire al bisogno di nicotina dell’organismo. 
Secondo me chi vuole smettere di fumare o lo fa dopo aver preso un grosso 
spavento tipo un TIA o un infarto cardiaco, oppure deve essere spinto dalla propria 
volontà! Cerotti o sigarette elettroniche hanno poca influenza e non hanno nessun 
senso! 
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Potresti dirmi cosa pensi del bupropione? 
No! Non so cosa sia  
 
Potresti dirmi cosa pensi della vareniclina?  
Non ho mai sentito parlarne 
E’ un farmaco che agisce sulle stesse aree che sono occupate dalla nicotina, ma 
non è nicotina ed è forse il più efficace tra i farmaci per smettere di fumare!  
 
Vorresti utilizzare la sigaretta elettronica per smettere di fumare? 
No!  
 
Perché 
Non mi soddisfazione 
 
Vorresti utilizzare la sigaretta elettronica per ridurre? 
No!  
 
Perché 
Non mi soddisfazione 
 
Vorresti utilizzare i sostitutivi nicotinici per smettere di fumare? 
No!  
Se volessi smettere di fumare inizierei a fumare il tabacco per due motivazioni: 
innanzitutto perché il tabacco macchia le dita e questa è una cosa brutta dal punto 
di vista estetico e potrebbe essere un incentivo a smettere; da un punto di vista 
pratico poi è più complicato da utilizzare perché bisogna comprare tabacco, cartine 
e assemblare la sigaretta e questo potrebbe portare a far stancare. 
 
Vorresti utilizzare i sostitutivi nicotinici per ridurre? 
No!  
 
Perché 
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Non servono. I cerotti soddisfano metà del bisogno di nicotina e sono buoni per 
fumatori occasionali e non per I fumatori regolari perchè non soddisfano il loro 
bisogno nicotinico. 
 
Vorresti utilizzare Bupropione per smettere di fumare? 
No!  
 
Perché 
L’unica cura è la forza di volontà 
 
Vorresti utilizzare Bupropione per ridurre? 
No!  
 
Perché 
L’unica cura è la forza di volontà 
 
Vorresti utilizzare Vareniclina per smettere di fumare? 
No!  
 
Perché 
L’unica cura è la forza di volontà 
 
Vorresti utilizzare Vareniclina per ridurre? 
No!  
 
Perché 
L’unica cura è la forza di volontà 
 
Hai altri commenti o altre cose da dire rispetto all’argomento? 
La sigaretta elettronica ti permette di avere solo la sensazione della boccata di 
sigaretta… però se prendiamo un campione di 100 fumatori 10 fumano la sigaretta 
elettronica e 90 la sigaretta normale… 
Per esempio in un periodo come questo per un ragazzo che frequenta il centro per 
la cura della schizofrenia, la sigaretta è l’unico passatempo reale e quindi secondo 
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me, per quanto mi riguarda, questa vita da questo punto di vista non aiuta, perché 
quando avevo una vita normale e frequentavo i miei amici un pacchetto di sigarette 
mi durava due giorni, quindi anche la costrizione in un luogo crea abitudini che tu 
nella vita non ha mai avuto. Probabilmente se tu vivi all’aria aperta, sei più sereno 
e sei felice e non hai bisogno di doverti organizzare la giornata, giorno per giorno… 
quindi secondo me il centro per la cura della schizofrenia non aiuta!  
 
E’ tutto?  
Si!  
 
Ti ringrazio! 
 
 
NINO, MALE, AGED 38 
If you want, tell me a little bit about yourself.  
But what is this program? 
Good evening my name is Nino and I'm 38 years old, I’m in treatment for exactly a 
hitch in life considering that I've always been a very happy, jovial, and most of all 
like to do for a series of mournful events, probably not not very elaborate I found to 
have a somewhat negative period. 
Considering the fact that I always had bases in my life that are family ones so we 
do not talk about the fact that my father may have been a great businessman or that 
my father could be a bricklayer or that my father could be what he was and My mom 
vice-versa, however, a solid family brings a boy's well-being in the sense that if you 
have a problem you know who to turn to you if you're sick you know whom to turn. 
Considering that my mother taught me that then at some point I had to solve the 
problems on their own, that is, she taught me if you feel bad about you go to the 
doctor in the sense, but a guy with certain assurances so for a while these my, so 
certain assurances therefore for some time these my certainties have collapsed. 
They may be those affective, they may be, they were also working because I was in 
a very favorable working situation that suddenly stopped. We say that it was not 
quite favorable, however, as a boy who has always lived his life fully tries to recover 
his life in a motion that is still satisfactory even for the continuation of his life. With 
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regard to smoking if you really care, I'm not interested in smoking, if I'm really 
interested, I'm not interested in smoking, but at this time it's just a small relief valve 
that's not having a girlfriend or having a group of friends but the important thing is to 
be a strong and strong guy of sure of himself. 
Then everything else comes from friends alone, friends all about life in the right 
sense, when you are quite calm then everything else comes alone without any 
problems, then people get close without you noticing it. 
 
Tell me a little bit about your smoking history   
But doctor I have never smoked excessively, in the sense I started to smoke when 
I was 16 with my friends, then this time I smoked a bit more because I had a vent 
valve. 
 
Tell me a little bit about story of your mental health experience 
So, with respect to my psychic balance, I find myself better, the problem is what is 
the fact that for a boy who has never had a life-style problem, have a problem and 
do not have adequate family support and find a doctor who knowing how to endure 
how a boy wants to be born was not even simple. Because the first doctor says it 
will pass, the second doctor says it takes some time, then the years basically do not 
take you back and at least it's just that you do not resume it because physically then 
automatically take the defences of self-mechanics but knowing your body, you know 
you work at 20 percent compared to 100 percent. That you do not want to give and 
for a guy ie at least for my personality is not really good so find a referral doctor, it's 
not very simple in the sense if you do not have big expectations in life go to a doctor, 
live day to day, then what happens to you happens, I'm not doing it so so, if you 
have a doctor who knows how to resume it makes sense, ie obviously you cannot 
resume the past or at least you have a future that is worthy of the past or for the 
least worthy of you, that is, not for others who are likely to be frigging. 
 
What do you think about classic cigarette? 
It's really stupid (he is answering the question about classic cigarette) does not make 
any sense is just a palliative that has absolutely no logical meaning that nicotine is 
nicotine, there is nothing to do, I tried the electronic cigarette but the Nicotine is 
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nicotine. Ah I was talking about electronic cigarette. Classic cigarette give me 
satisfaction. 
The classic cigarette is important because nicotine is true, tobacco is certain as I 
can say ... you have to go to the dentist every six months 
That is, you have to cure that aspect that is not easy for the cigarette, right? And 
then surely at the moment of well-being I do not want to use cigarettes because I 
had no reason but at the time of illness is a small palliative. 
Let's say that I have discovered in the life the affection of one's mother, or the 
general affection of the family, at some point in life is missing and so I realized that 
in the sense a companion's affection can bring you many positive things So you can 
see so many other negative things like cigarettes, in the sense of the cigarette, in 
the sense of the cigarette, at this time it is a palliative because you do not have a 
very precise venture ie in the sense at this time you are working, I could go back to 
the office but not Is more about how I imagined it. So if you do not work and you feel 
we say, you do not feel powerful ie that I mean if you do not feel yourself with square 
balls, you smoke, I saw this on me in my youth I felt myself with square balls so I 
did not need to smoke. 
One sense, that is, a sense probably could have the spinel, as a friend of mine in 
the kind of friendship between me and the cigarette by itself unless there are people 
who have the vice but basically you cannot create it. 
Well the cost of a cigarette is not so disabling ie it means 5 euros a week, 5-10 euro 
is not a crazy thing 
The cost of a cigarette of 5-10 euros a week is not so exorbitant I mean 5-10 euros 
per week you can spend on the cigarette, you can spend even more, but I mean we 
talk about cigarettes as an example to follow in my Life, it is a wrong example. It has 
problems we end up? Tomorrow? No thanks. 
 
What do you think of classic cigarette in terms of impact on health? 
It is dangerous for health, cancer incidence is high in smokers, and cardiovascular 
disease is also very common in smokers! I am informed about this because I have 
had experience with my father and I know that more or less in 70% of cases is due 
to smoke beyond the hereditary factor or other. 
 
What do you think about the electronic cigarette?  
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The electronic cigarette is a very stupid, is a palliative and is also more expensive 
than normal cigarettes, the only positive thing is that health is a bit betterbut the truth 
is that you should quit enough! 
 
What do you think about the taste of the electronic cigarette? 
The cigarette has the cigarette flavor while the electronic cigarette has strawberry 
or coconut flavor and so on. If you have to smoke, smoke the normal cigarette 
otherwise it will not smoke! 
 
What do you think about the satisfaction of the electronic cigarette? 
It does not give me satisfaction, for those who smoke a normal cigarette puff is a 
different thing! 
 
Can you tell me what you feel similar between normal cigarettes and 
electronic cigarettes? 
None! 
 
Can you tell me what you feel different? 
The normal one is cigarette, the electronic one is another thing ... you understand! 
 
What treatments do you know about that help people stop smoking? 
The first one? The willpower! 
I don’t know other treatment 
 
Can you tell me what you think about nicotine replacement therapy? 
I had indirect experiences about these! For me the cigarette is like a drug because 
nicotine adds to you, for an occasional smoker the patches that have an impact no 
more than 50% on the physical,are not effective, but it would be enough to have a 
distraction; While for the regular smoker the amount of nicotine in the patch cannot 
overcome the need for nicotine in the body. In my opinion, anyone who wants to quit 
smoking or does so after taking a big scare like a TIA or a heart attack, or has to be 
driven by his own will! Nicotine patches ore-cigarettes have little influence and do 
not make any sense! 
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Can you tell me what you think about bupropion? 
No! I don’t know what is. 
 
Can you tell me what you think about varenicline? 
No, I ever heard of varenicline? 
 
It is a drug that acts on the same areas that are occupied by nicotine, but it is 
not nicotine and is perhaps the most effective drug to stop smoking!  
 
Would you use an electronic cigarette to stop smoking tobacco? 
No! 
 
Please explain why 
It does not give me satisfaction 
 
Would you use and electronic cigarette to reduce tobacco smoking? 
No! 
 
Please explain why 
It does not give me satisfaction  
 
Would you use NRT to quit tobacco smoking? 
No! 
 
Please explain why 
If I want to quit smoking I would start smoking hand rolled tobacco for two reasons: 
first of all, because the tobacco spots your fingers and this is a bad thing from the 
aesthetic point of view and it could be an incentive to stop; from a practical point of 
view it is more complicated to use because you need to buy tobacco, map and 
assemble the cigarette and this could make you tired. 
 
Would you use NRT to reduce tobacco smoking? 
No! 
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Please explain why 
They are not effective. The patches satisfy half of your nicotine needs and are good 
for occasional smokers and not for regular smokers, because it cannot satisfy their 
nicotine needs 
 
Would you use Bupropion to quit tobacco smoking? 
No! 
 
Please explain why 
The only therapy is the willpower 
 
Would you use Bupropion to reduce tobacco smoking? 
No! 
 
Please explain why 
The only therapy is the willpower 
 
Would you use Varenicline to quit tobacco smoking? 
No! 
 
Please explain why 
The only therapy is the willpower 
 
Would you use Varenicline to reduce tobacco smoking? 
No! 
 
Please explain why 
The only therapy is the willpower 
 
Do you have any other comments? 
The electronic cigarette allows you to have only the feel of the cigarette mouth ... 
but if we take a sample of 100 smokers, 10 smoke the electronic cigarette and 90 
the normal cigarette ...For example, at a time like this for a boy treated in a 
schizophrenia center, cigarette is the only real pastime and so in my opinion, 
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schizophrenia center from this point of view does not help because when I had a 
normal life, and attended my friends, a packet of cigarettes duration was about two 
days, so also constraint in a place creates habits that you have never had in life. 
Probably if you live in the open air, you are more serene and you are happy and you 
do not need to organize your day, day after day ... so I think the schizophrenia center 
does not help! 
 
Is it all? 
Yes! 
Thank you! 
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APPENDIX 6 
Ethics approval, quantitative study 
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APPENDIX 7 
Health care provider contact record, quantitative study 
Participant ID: 
Provider/s Contacted (Name/address/phone/email): 
Date of Contact 
Confirm the following eligibility criteria 
Diagnosis 
No relapse to hospitalization within the past 3 months 
No change in anti-psychotic treatment within the last month 
Smokers  20 cigarettes day 
Not motivated to quit smoking 
Confirm the participant does not meet the following exclusion criteria 
Myocardial infarction of angina pectoris within the past 3 months or current poorly 
controlled asthma 
Use of nicotine replacement therapy or other smoking cessation therapies within 
the last 3 months 
Pregnancy or breastfeeding 
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APPENDIX 8 
Flyer, quantitative study 
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APPENDIX 9 
Health provider information, quantitative study 
By signing below, I give the members of the research team permission to contact 
my medical and or mental health providers, the research team, to confirm eligibility 
to participate in this study, to inform my providers of my participation in this study, 
or for any other matter related to this study and my well-being. 
Participant ID: 
Print Participant Name: 
Sign Participant Name:       Date: 
Primary Care/Medical Provider 
Name: 
Phone: 
Address: 
Mental Health Provider 
Name: 
Phone: 
Address: 
Other Health Provider 
Name: 
Phone: 
Address:  
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APPENDIX 10 
Patient information sheet and consent form, quantitative study (Italy and US 
sites) 
 
CENTRO PER LA 
PREVENZIONE E CURA 
DEL TABAGISMO 
MODULO PER L’INFORMAZIONE E IL 
CONSENSO INFORMATO 
Studio :SchizEcig-P 
 
EudraCT N.:(obbligatorio per le 
sperimentazioni cliniche con 
medicinali): 
Paziente N.: 
 
 
 
Titolo dello studio: 
TITOLO: Ruolo della sigaretta elettronica nella cessazione da fumo di sigaretta in 
fumatori con schizofrenia: Studio pilota prospettico a 3 mesi 
 
Gentile paziente, la presente nota informativa Le viene presentata per darLe 
tutti gli elementi di conoscenza necessari per la Sua partecipazione allo studio 
clinico in oggetto. 
 
INTRODUZIONE   
Obiettivi. 
Lo scopo di questo studio è quello di vedere se fumatori di sigarette di tabacco con dia
gnosi di disturbo appartenente 
allo spettro di schizofrenico passano dalla sigaretta classica alla 
sigaretta elettronica quando sono invitati a provare l’elettronica. Siamo anche 
interessati a conoscere la vostra esperienza utilizzando la e-cigarette, come si sente 
quando la fuma, il grado di soddisfazione e la sua accettabilità per sostituire le 
sigarette classiche e se causa fastidi, 
come ad esempio la bocca asciutta.  Questo studio di ricerca è stato fatto perché le sig
arette 
elettroniche sono oramai ampiamente utilizzate e sappiamo molto poco su fumatori co
n disturbi appartenenti allo spettro di schizofrenico che utilizzano la e-cigarette. 
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DESCRIZIONE DELLO STUDIO  
Che cosa deve sapere riguardo la “e-cigarette”. La “e-cigarette” è un dispositivo 
elettronico a batteria che rilascia nicotina e che ricorda da vicino la forma di una 
sigaretta classica. La batteria al litio ha una capacità di 250 mAh e verrà 
completamente caricata prima dell'uso. I cartomizzatori saranno riempiti con circa 1 
ml di liquido. Questi saranno forniti gratuitamente dal fabbricante. 
Come e dove verrà condotto questo studio clinico?Questo studio clinico verrà 
condotto presso il CENTRO PER LA PREVENZIONE E CURA DEL TABAGISMO, 
A.O.U “Policlinico-V. Emanuele”, Pad n°4, piano 0, stanza 2,Via S. Sofia 78, 95100 
Catania.Venti fumatori riceveranno fornitura gratuita per 12 settimane di cigarette 
elettroniche modello “cigalike”.Si ricordi che è molto importante che Lei si impegni a 
presentarsi a tutte le visite presso l’ospedale e che segua le istruzioni fornite. Le 
affinché lo studio possa andare bene. 
Che cosa dovrò fare nel corso di questo studio clinico? Ci saranno un totale di 
4 visite presso l’ospedale. Ogni visita richiederà approssimativamente 15 minuti per 
il completamento. Se Lei acconsente a partecipare allo studio, per prima cosa 
entrerà in una fase di screening che ha lo scopo di identificare se Lei soddisfa i 
criteri per la partecipazione allo studio. Nel corso dello studio inoltre, i ricercatori Le 
chiederanno se ha avuto degli effetti indesiderati. Per la prima visita verranno 
raccolti i dati socio-demografici, verrà dettagliatamente analizzata la dipendenza da 
nicotina. La dipendenza dalla sigaretta sarà misurata con il Fagerström Test for 
Cigarette Dependence (FTCD). Inoltre, i livelli di monossido di carbonio nell’aria 
espirata (eCo) saranno misurati utilizzando un dispositivo portatile (Micro CO, Micro 
Medical Ltd, UK). Verranno anche registrati alla baseline i parametri vitali di 
pressione arteriosa, frequenza cardiaca (HR e BP) e peso corporeo. Verranno 
inoltre valutati i sintomi positive e negati della Schizofrenia attraverso le scale Scale 
for the Assessment of Negative symptoms of Schizophrenia (SANS), Scale for the 
Assessment of Positive symptoms of Schizophrenia (SAPS). Lei sarà inoltre invitato 
a compilare un diario giornaliero per registrare la sua esperienza con la sigaretta 
elettronica. Alla settimana 4- (visita di studio 2), settimana-8 (visita di studio 3), 
settimana-12 (visita di studio 4), i partecipanti mostreranno i diari, b) saranno 
registrati i loro livelli di eCo, segni vitali, peso, punteggi ai test SAPS, SANS e 
“Modified Cigarette Evaluation Questionnaire (mCEQ)”.  Conservi le sigarette 
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elettroniche che le sono state date durante le visite dello studio in un posto sicuro, 
e le tenga al di fuori della portata dei bambini o di altre persone che non possano 
comprendere il rischio potenziale del fumo. Non deve dare la sigaretta elettronica a 
nessun altro. Si ricordi inoltre di restituire sia le sigarette elettroniche utilizzate che 
quelle non utilizzate ai ricercatori dello studio ad ogni visita presso l’ospedale. Si 
raccomanda di aspirare lentamente e di non compiere più di tre, quattro boccate 
consecutive, per evitare il surriscaldamento del vaporizzatore e/o la fuoriuscita del 
liquido. Il dispositivo non é impermeabile. Evitare che si bagni. Non lasciare il 
dispositivo in ambienti particolarmente caldi o freddi. Temperature troppo elevate o 
troppo basse possono danneggiare e ridurre la durata dei circuiti elettrici e delle 
batterie. Il Suo medico dello studio dovrà essere informato riguardo ai farmaci che sta 
assumendo, incluse tutte le medicine che può comprare liberamente, senza l’obbligo 
di prescrizione (la ricetta del medico), in modo che possa controllare se va bene che 
Lei continui ad assumerle mentre partecipa allo studio. È inoltre importante che non 
assuma altre medicine per il trattamento antifumo mentre partecipa a questo studio. 
Se darà il Suo consenso, i ricercatori dello studio informeranno il Suo medico di 
medicina generale (medico di famiglia) che Lei sta partecipando a questo studio 
clinico. Nel caso in cui Lei cambi indirizzo durante lo studio, informi cortesemente i 
ricercatori dello studio. 
 
RISCHI ED INCONVENIENTI POTENZIALI  
Quali sono i rischi correlati a questo studio clinico?  L’uso della sigaretta 
elettronica può dare degli effetti indesiderati. Gli effetti indesiderati più ricorrenti sono 
irritazione della bocca e della gola, tosse. 
BENEFICI 
La sigaretta elettronica può rappresentare un'alternativa a basso rischio rispetto al 
fumo di sigaretta tradizionale.  
 
PARTECIPAZIONE ALLO STUDIO 
La Sua partecipazione allo studio è totalmente volontaria; un Suo eventuale rifiuto non 
influirà in alcun modo sulla qualità dell'assistenza e dei trattamenti medici ritenuti 
opportuni per il Suo caso. Se successivamente alla firma di questo consenso informato 
si rendessero disponibili nuove informazioni sulla sigaretta elettronica, sullo studio a 
cui sta partecipando o sulla tipologia di dati da raccogliere, Le saranno 
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tempestivamente comunicate dal medico sperimentatore. Lei sarà comunque libero di 
ritirare il Suo consenso in qualsiasi momento, senza che ciò comprometta le cure che 
Lei riceverà in seguito. D'altra parte Lei potrà essere escluso dallo studio in ogni 
momento, anche contro la Sua volontà, qualora lo sperimentatore lo ritenga 
necessario per la Sua salute o per la corretta conduzione dello studio. Lo studio è stato 
approvato dalle Autorità competenti e sarà condotto in accordo alle normative vigenti 
in materia di ricerca clinica. 
Posso ritirarmi da questo studio? Le ricordiamo che la Sua partecipazione a questo 
studio clinico è volontaria, quindi può ritirare il Suo consenso alla partecipazione in 
qualsiasi momento, senza dover dare alcuna motivazione. Nel caso in cui Lei decida 
di ritirarsi in anticipo dallo studio o la Sua partecipazione è interrotta, è importante, per 
la Sua sicurezza, che effettui un’ultima visita presso l’ospedale. 
SPERIMENTAZIONE CHE PREVEDE: x Sostitutivo Nicotinico (Sigaretta 
Elettronica)           
Ai sensi e per gli effetti dell’Art 10 della L. 675/96, io sottoscritto/a………………dichiaro 
di essere stato informato in modo chiaro e comprensibile che per la sperimentazione a 
cui volontariamente mi sottopongo presso il Centro Universitario per la Prevenzione e 
Cura del Tabagismo è necessario l’uso per un totale di 3 mesi della sigaretta 
elettronica.  
Di tale sperimentazione mi sono stati spiegati l’obiettivo ed i possibili effetti collaterali.  
Dichiaro di acconsentire al trattamento proposto 
• Sono stato/a informato/a degli effetti collaterali che la l’uso della sigaretta 
elettronica potrebbe indurre. 
• Confermo di aver informato il medico di ogni mia patologia o condizione passata 
e presente e di ogni trattamento farmacologico e/o psicoterapico effettuato. 
• Confermo di voler sottopormi alla sperimentazione di mia spontanea volontà, 
senza alcuna compulsione fisica o morale. 
Nome e Cognome...............................................Indirizzo..…..................... 
Tel..................………Firma del paziente.…………................................................. 
Il sottoscritto Dott.................................................. confermo di aver illustrato in 
dettaglio la natura, lo scopo e i possibili rischi delle tecniche in oggetto al paziente 
sopra indicato, che ha dato il proprio consenso a sottoporsi al trattamento. 
Nome e Cognome ................................Firma ..................................................... 
Data….../…….../........... 
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ALL. 1 - G.P. del. 24/07/08 
INFORMATIVA E MANIFESTAZIONE DEL CONSENSO AL TRATTAMENTO DEI 
DATI PERSONALI 1 
 
Titolari del trattamento e relative finalità 
Il Centro per la Prevenzione e Cura del Tabagismo (C.P.C,T.) A.O.U “Policlinico 
Vittorio Emanuele”, U.O.C. di Medicina Interna e Medicina d’Urgenza, promotore 
dello studio che Le è stato descritto, in accordo alle responsabilità previste dalle 
norme della buona pratica clinica (decreto-legge n. 211/2003), tratteranno i Suoi dati 
personali, in particolare quelli sulla salute e, soltanto nella misura in cui sono 
indispensabili in relazione all’obiettivo dello studio, altri dati relativi alla Sua origine 
e ai Suoi stili di vita esclusivamente in funzione della realizzazione dello studio. A tal 
fine i dati indicati saranno raccolti dal Centro di sperimentazione. Il trattamento dei 
dati personali relativi alla Sua salute è indispensabile allo svolgimento dello studio: 
il rifiuto di conferirli non Le consentirà di parteciparvi. 
Natura dei dati 
Il medico che La seguirà nello studio La identificherà con un codice. I dati che La 
riguardano raccolti nel corso dello studio, ad eccezione del Suo nominativo, saranno 
registrati, elaborati e conservati unitamente a tale codice, alla Sua data di nascita, 
al sesso, al Suo peso, alla Sua statura, alla Sua attività lavorativa e sportiva, alla 
Sua salute. Soltanto il medico e i soggetti autorizzati potranno collegare questo 
codice al Suo nominativo. 
Modalità del trattamento 
I dati, trattati mediante strumenti anche elettronici, saranno diffusi solo in forma 
rigorosamente anonima, ad esempio attraverso pubblicazioni scientifiche, 
statistiche e convegni scientifici. La Sua partecipazione allo studio implica che, in 
conformità alla normativa sulle sperimentazioni cliniche dei medicinali, il personale 
del Centro Prevenzione e Cura del Tabagismo, il Comitato etico e le autorità 
sanitarie italiane e straniere potranno conoscere i dati che La riguardano, contenuti 
anche nella Sua documentazione clinica originale, con modalità tali da garantire la 
riservatezza della Sua identità. 
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Esercizio dei diritti 
Potrà esercitare i diritti di cui all’art. 7 del Codice (es. accedere ai Suoi dati personali, 
integrarli, aggiornarli, rettificarli, opporsi al loro trattamento per motivi legittimi, ecc.) 
rivolgendosi direttamente al centro di sperimentazione (Il Centro per la Prevenzione 
e Cura del Tabagismo (C.P.C,T.) A.O.U “Policlinico-V. Emanuele”, Pad n°4, piano 
0, stanza 2, Via S. Sofia 78, 95100 Catania, tel 095.3781537; Fax 095.7435083). 
Potrà interrompere in ogni momento e senza fornire alcuna giustificazione la Sua 
partecipazione allo studio: in tal caso, i campioni biologici a Lei correlati verranno 
distrutti.  
Non saranno inoltre raccolti ulteriori dati che La riguardano, ferma restando 
l’utilizzazione di quelli eventualmente già raccolti per determinare, senza alterarli, i 
risultati della ricerca.  
 
Aspetti economici 
Lei non dovrà sostenere nessun costo per le visite, prescrizioni mediche, analisi di 
laboratorio o altre procedure previste dallo studio in quanto a carico dell’azienda 
promotrice. 
 
Consenso 
Sottoscrivendo tale modulo acconsento al trattamento dei miei dati personali per gli 
scopi della ricerca nei limiti e con le modalità indicate nell’informativa fornitami con 
il presente documento. 
 
Nome e Cognome dell’interessato (in stampatello)_______________________ 
 
Firma dell’interessato_______________________________________________ 
 
Data__________ 
 
ULTERIORI INFORMAZIONI 
Per qualunque domanda, richiesta di chiarimento o problema riguardo al presente 
studio non esiti a contattare il medico qui di seguito indicato: 
 
 Dott. _________________________________________Tel. N° 0953781537 
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Indirizzo Centro per la Prevenzione e Cura del Tabagismo (C.P.C,T.) A.O.U 
“Policlinico-V. Emanuele”, Pad n°4, piano 0, stanza 2, Via S. Sofia 78, 95100 
Catania. 
 
1 Da sottoporre agli interessati unitamente al modulo di con senso informato che 
descrive le caratteristiche scientifiche dello studio, anche mediante integrazione 
dello stesso. 
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WEILL CORNELL MEDICAL COLLEGE 
Informed Consent and HIPAA Authorization for Clinical Investigation 
 
Project Title: 
Role of an electronic cigarette on smoking displacement in 
smokers with  
 schizophrenia: A prospective 3-month pilot study 
Research 
Project #: 
1607017418 
Principal 
Investigator: 
Jason Kim, MD  
 
INSTITUTION:                Weill Cornell Medical College and Hunter Bellevue School of Nursing 
at Hunter College, City University of New York. 
INTRODUCTION 
You are invited to consider participating in a research study.  You were selected as a 
possible participant in this study because you are a cigarette smoker with a diagnosis of 
a schizophrenia spectrum disorder.  
Please take your time to make your decision.  It is important that you read and 
understand several general principles that apply to all who take part in our studies: 
(a) Taking part in the study is entirely voluntary.    
(b) Personal benefit to you may or may not result from taking part in the study, but 
knowledge gained from your participation may benefit others.  
(c) You may decide not to participate in the study or you may decide to stop participating 
in the study at any time without loss of any benefits to which you are entitled.   
The purpose and nature of the study, possible benefits, risks, and discomforts, other 
options, your rights as a participant, and other information about the study are discussed 
below. Any new information discovered which might affect your decision to participate 
or remain in the study will be provided to you while you are a participant in this study.  
You are urged to ask any questions you have about this study with members of the 
research team. You should take whatever time you need to discuss the study with your 
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physician and family.  The decision to participate or not is yours.  If you decide to 
participate, please sign and date where indicated at the end of this form.   
The study will take place at the Weill Cornell Medical College Clinical and 
Translational Science Center Adult Outpatient Clinic located at 525 East 68th Street, 
New York, NY 10065. This study is a collaboration between researchers at the Weill 
Cornell Medical College and Hunter Bellevue School of Nursing (HBSON).  Funding 
to run this study is provided from a CTSC-HBSON grant.  The recipient of the grant 
is Jennifer DiPiazza, PMHNP-BC Assistant Professor at HBSON, who will be a co-
investigator in this study. 
WHY IS THE STUDY BEING DONE?  
The purpose of this study is to see if tobacco cigarette smokers with a schizophrenia 
spectrum disorder diagnosis switch from tobacco cigarettes to electronic cigarettes 
(e-cigarettes) when they are invited to try an e-cigarette. We are also interested in 
their experiences using the e-cigarette, such as how an e-cigarette feels when it is 
inhaled, the extent of satisfaction and acceptability of e-cigarettes as substitutes for 
tobacco cigarettes, and if they feel e-cigarette use is causing any discomfort, for 
example a dry mouth.  This research study is being done because e-cigarettes are 
becoming widely used and we know very little about cigarette smokers with 
schizophrenia, interested in trying an e-cigarette, and their experiences when using 
an e-cigarette.   
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
About 40 participants will take part in this study. 
WHAT IS INVOLVED IN THE STUDY? 
If you take part in this study, you will participate in a variety of procedures and 
assessments.  The table below reflects the assessments and procedures that will 
occur during each visit, as indicated by an ‘x.’  
Procedure Visit 
1  
Visit 
2 
Visit 
3 
Visit 
4 
Contact Information form x    
Health Care Provider Information Form x    
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Demographic and Smoking History Status form 
(DSH) 
x    
Vital signs and weight x x x x 
Exhaled Carbon Monoxide (eCO) x x x x 
Fagerström Test for Nicotine Dependence-
Revised (FTND-R) 
x    
Scale for the Assessment of Negative symptoms 
of Schizophrenia (SANS) 
x x x x 
Scale for the Assessment of Positive symptoms of 
Schizophrenia (SAPS) 
x x x x 
Modified Cigarette Evaluation Questionnaire 
(mCEQ) 
 x x x 
Study diary  x x x 
Dispense supply of e-cigarettes x x x  
Collect unused e-cigarettes    x 
 
Description of Assessments and Procedures 
DSH: The purpose of the DSH is to learn more about you. For example, you will be 
asked your age and the amount of cigarettes you smoke daily.  
Vital signs: The purpose of assessing your vital signs is to establish a baseline from 
which to refer back to at each study visit.  If there is a dramatic change in your vital 
signs this will alert us to refer you to your medical provider for further assessment. 
eCO: The purpose of measuring eCO (expired carbon monoxide) is to assess the 
level of carbon monoxide in your exhaled breath. Cigarette smoking typically 
increase the level of CO and stopping or reducing smoking typically decreases 
levels of CO. To measure eCO you will be asked to breathe one or more times into 
a tube. A reading of your eCO level will appear on the device. 
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FTND-R:  The purpose of completing the 6 question FTND-R is to estimate your 
level of nicotine dependence.  For example, you will be asked how soon after waking 
you smoke your first cigarette. 
SANS:  The SANS is an assessment for symptoms of schizophrenia. The purpose 
of completing this assessment is to establish a baseline of symptoms from which to 
refer back to at each study visit. If there are a dramatic change in symptoms this will 
alert us to refer you to your medical provider for further assessment.  For example, 
during this assessment you will be asked about your interest in social activities, your 
speech will be observed, and you will be asked about your feeling of well-being. 
SAPS:  The SAPS is an assessment for symptoms of schizophrenia.  The purpose 
of completing this assessment is to establish a baseline of symptoms from which to 
refer back to at each study. If there are dramatic changes in symptoms this will alert 
us to refer you to your medical provider for further assessment.  For example, during 
this assessment you will be asked if you have heard voices or other sounds when 
no one is around or if you are experiencing thoughts that do not seem to be your 
own.  
mCEQ: The purpose of completing the 12 question mCEQ is to learn about your 
experience using the e-cigarette. For example, you will be asked if you enjoyed the 
sensations in your throat and chest, if you enjoyed smoking the e-cigarette, and if 
smoking the e-cigarette reduced your craving to smoke cigarettes. 
Study Diary:  The purpose of the diary is to track number of cigarettes you smoke 
on a daily basis, the number of e-cigarette pods used on a daily basis, and any 
adverse events you feel may be attributed to e-cigarette use. 
Dispense supply of e-cig and instructions on how to use e-cigarette: At each 
study visit you will be given the amount of e-cigarettes that are equivalent to your 
current smoking status. You will receive enough e-cigarettes to last until your next 
study visit. At each study visit the research staff will review the instructions for use 
of the e-cigarette and answer any questions.   
Collect Unused E-Cigarettes:  At the last study visit you will be asked to return 
unused e-cigarettes. 
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Please advise the researchers of any medications you are taking.  In addition, if you 
are taking any over-the-counter drugs or herbal supplements which you have 
obtained from the drug store, grocery store, etc., you should advise the researchers. 
HOW LONG WILL I BE IN THE STUDY? 
We think you will be in the study for 16-18 weeks. You will be required to make four in-
person visits in the first 12 weeks, and we will follow up with you via telephone or email 
4-6 weeks after your last visit. You will also be contacted by phone or email to remind 
you of upcoming study visits, if you miss a study visit, or if you decide to withdraw from 
the study. In the first 12 weeks, you may be emailed an online survey for your study 
diary every day, if you decide to complete your diary via REDCap. The follow-up is to 
enquire of any changes in your cigarette use behavior, and e-cigarette use, after the end 
of the study. You can stop participating at any time.  However, if you decide to stop 
participating in the study, we encourage you to talk to the researcher and your regular 
doctor first. 
If you choose to not participate in the study or to leave the study, your regular care will 
not be affected nor will your relations with WCMC, NewYork-Presbyterian Hospital, your 
physicians, or other personnel. In addition, you will not lose any of the benefits to which 
you are entitled. 
Withdrawal by investigator, physician, or sponsor 
The investigators, physicians or sponsors may stop the study or take you out of the 
study at any time should they judge that it is in your best interest to do so, if you 
experience a study-related injury, if you need additional or different medication, or if 
you do not comply with the study plan. They may remove you from the study for 
various other administrative and medical reasons. They can do this without your 
consent. 
WHAT ARE THE RISKS OF THE STUDY? 
E-cigarette devices may impose a risk. Since the research is still being established it 
is difficult to say for sure if and which side-effects you may experience and the 
overall effect-to your health with e-cigarette use. Side effects may include increased 
addiction to nicotine, nicotine poisoning, changes in heart rate, heart palpitations, 
coughing, congestion, phlegm, sputum and throat clearing, enhanced sense of taste 
or smell, unusual gastrointestinal movements, wild/strange dreams, symptoms of 
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common cold, acne, mouth ulcers, canker sores, hiccups, heartburn, headaches, 
nausea, shaking, sleeplessness, dizziness, prickly, tingly or itchy skin, muscle 
cramps, spasms and/or aches, gas, diarrhea, and lipoid pneumonia (a rare form of 
pneumonia caused by inhalation of a fatty substance).  There may also be side 
effects, other than listed above that we cannot predict. There are also documented 
reports to the US Food and Drug Administration (FDA) from consumers about 
devices malfunctioning causing harm to the user. 
E-cigarettes deliver nicotine and other chemicals to the lungs. The maximum 
exposure of e-cigarettes will be the approximately equivalent to your current tobacco 
smoking status for 12 weeks. This is important for you to understand since nicotine 
is an addictive substance and theoretically participation in this study might lead you 
to “crave” more nicotine.  
Research procedures described above may involve risks that cannot be anticipated 
at this time. If we learn of anything that may affect your decision to participate, we 
will inform you as soon as possible. You will then have a chance to reconsider your 
continuing participation in the research. 
In considering your risks in this study it is also important to know that in 2016, The 
FDA finalized a rule extending regulatory authority to all tobacco products, including 
e-cigarettes. FDA now regulates the manufacture, import, packaging, labeling, 
advertising, promotion, sale, and distribution of e-cigarettes.  However, to date e-
cigarettes are not currently approved by the FDA, but they are available for purchase 
to the general public. This means that e-cigarettes, are not currently subject to the 
FDA review requirements of the Tobacco Control Act, however e-cigarette 
manufacturers are now required to meet timelines for adhering to FDA regulations. 
ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? 
We cannot and do not guarantee that you will receive any benefits from this study. We 
hope the information learned from this study will benefit other cigarette smokers with 
a schizophrenia spectrum disorder diagnosis who wish to try an e-cigarette as an 
alternative to cigarettes smoking. 
WHAT OTHER OPTIONS ARE THERE? 
Instead of being in this study, you may choose not to participate in this study. 
Confidentiality 
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Efforts will be made to protect your medical records and other personal information to 
the extent allowed by law. However, we cannot guarantee absolute confidentiality.  
Records of study participants are stored and kept according to legal requirements and 
may be part of your medial record. You will not be identified personally in any reports or 
publications resulting from this study. Organizations that may request to inspect and/or 
copy your research and medical records for quality assurance and data analysis include 
groups such as: 
o Weill Cornell Medical College and NewYork-Presbyterian Hospital 
o The Institutional Review Board (IRB) 
o The Office of Human Research Protection (OHRP) 
o Department of Health and Human Services and National Institutes of Health 
o The Food and Drug Administration (FDA) and/or their representatives 
o Hunter Bellevue School of Nursing at Hunter College will also be consenting 
participants for this study 
o University of Stirling 
By signing this consent form, you authorize access to this confidential information. 
You also authorize the release of your medical records to Weill Cornell Medical 
College and NewYork-Presbyterian Hospital by any other hospitals or institutions 
where you might receive medical care of any kind while you are participating in this 
study. In case of reported or observed adverse event, you give the principal 
investigator and members of the study team permission to consult with your medical 
or mental health provider. 
If information about your participation in this study is stored in a computer, we will 
take the following precautions to protect it from unauthorized disclosure, tampering, 
or damage by requiring a unique ID and password to log into the database: We will 
protect your confidentiality by 1) using REDCap a secure data management system 
to collect all data, 2) assigning a code to your name and contact information and 
stored in a password protected computer database, 3) identifying your information 
using the code assigned throughout the study, without revealing your actual identity, 
4) giving access to your data (study specific records in the database and your 
personal information) only to research personnel directly involved in this study. 
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HIPAA AUTHORIZATION TO USE or DISCLOSE PROTECTED HEALTH 
INFORMATION FOR RESEARCH 
Purposes for Using or Sharing Protected Health Information: If you decide to 
join this study, WCMC researchers need your permission to use your protected 
health information.  If you give permission, Weill Cornell Medical College (WCMC) 
and/or NewYork-Presbyterian Hospital (NYPH) researchers may use your 
information or share (disclose) information about you for their research that is 
considered to be protected health information.  
Voluntary Choice: The choice to give WCMC and/or NYPH researcher’s permission 
to use or share your protected health information for their research is voluntary.  It is 
completely up to you.  No one can force you to give permission.  However, you must 
give permission for WCMC and/or NYPH researchers to use or share your protected 
health information if you want to participate in the study. If you decline to sign this 
form, you cannot participate in this study, because the researchers will not be able 
to obtain and/or use the information they need in order to conduct their research. 
Refusing to give permission will not affect your ability to get usual treatment, or health 
care from WCMC and/or NYPH. 
Protected Health Information To Be Used or Shared:   Your personal health 
information will be used to ensure that you meet the eligibility criteria. If you are not 
a patient at WCMC your current medical providers will be contacted and asked for 
your personal health information to ensure that you meet the eligibility criteria. To 
support safe participation in the study throughout the investigation, the research staff 
will review a variety of measures as outlined above in the “procedures and 
assessments” section of this consent form. These measures include Scale for the 
Assessment of Negative Symptoms of Schizophrenia (SANS), Scale for the 
Assessment of Positive Symptoms of Schizophrenia (SAPS), and the study diary.  
Other Use and Sharing of Protected Health Information: 
Your information will not be shared with the company that is supplying the e-
cigarette, Pax Labs, Inc. 
CANCELING AUTHORIZATION  
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Canceling Permission:  If you give the WCMC and/or NYPH researchers 
permission to use or share your protected health information, you have the right to 
cancel your permission whenever you want. However, canceling your permission 
will not apply to information that the researchers have already used or shared. 
 
If you wish to cancel your permission, you may do so at any time by writing to: 
Privacy Officer 
1300 York Avenue, Box 303 
New York, NY 10065 
 
If you have questions about this, call: (212) 746-1179 or e-mail: 
privacy@med.cornell.edu 
End of Permission: Unless you cancel it, permission for WCMC and/or NYPH 
researchers to use or share your protected health information for their research will 
never end. 
ACCESS TO RESEARCH RECORDS  
During the course of this study, you will have access to see or copy your 
protected health information as described in this authorization form in accordance 
with Weill Cornell Medical College (WCMC) and/or New York-Presbyterian Hospital 
(NYPH) policies. During your participation in this study, you will have access to your 
research record and any study information that is part of that record.   
WHAT ARE THE COSTS? 
There will be no costs to you for your participation. The e-cigarette device will be 
provided free of charge by Pax Labs, Inc.  
POLICY/PROCEDURES FOR RESEARCH RELATED INJURY 
You will not be compensated for research related injury. 
The Policy and Procedure for Weill Cornell Medical College are as follows: We are 
obligated to inform you about WCMC’s policy in the event injury occurs.  If, as a result 
of your participation, you experience injury from known or unknown risks of the research 
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procedures as described, immediate medical care and treatment, including 
hospitalization, if necessary, will be available at the usual charge for such treatment.  No 
monetary compensation is available from WCMC or NewYork-Presbyterian Hospital.  
Further information can be obtained by calling the Institutional Review Board at (646) 
962-8200. 
COMPENSATION FOR PARTICIPATION 
You will not receive compensation for participating in this study. You should not 
expect anyone to pay you for pain, worry, lost income, or non-medical care costs that 
occur from taking part in this research study. 
COMMERCIAL INTEREST 
There are no commercial interests in this study. 
WHAT ARE MY RIGHTS AS A PARTICIPANT? 
Taking part in this study is voluntary. You may choose to not take part in the study or to 
leave the study at any time. If you choose to not participate in the study or to leave the 
study, your regular care will not be affected nor will your relations with the Weill Cornell 
Medical College, New York-Presbyterian Hospital, your physicians, or other personnel.  
In addition, you will not lose any of the benefits to which you are entitled.   
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
For questions about the study, a research-related injury, any problems, unexpected 
physical or psychological discomforts, or if you think that something unusual or 
unexpected is happening, call the investigator, Dr. Jason Kim, directly at (212)821-0712, 
or the Department of Psychiatry emergency room at Cornell Medical Center, 
(212)746-0711, or the Adult Emergency Department at (212)746-5050/5026.  
Please inform the emergency room physician about their participation in the study.  
If you have questions about your rights as a research participant, contact the WCMC 
IRB Office.  Direct your questions to: 
Institutional Review Board at: 
 Address:  1300 York Avenue               Telephone:  (646) 962-8200 
 Box 89, New York, New York 10065  
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Consent for Research Study 
Project Title: Role of an electronic cigarette on smoking displacement in smokers 
with schizophrenia: A prospective 3-month pilot study 
Principal Investigator: Jason Kim, M.D. 
RESEARCHER’S STATEMENT 
I have fully explained this study to the participant. As a representative of this study, I 
have explained the purpose, the procedures, the benefits and risks that are involved in 
this research study. Any questions that have been raised have been answered to the 
individual’s satisfaction. 
Signature of person obtaining the consent 
 Print Name of Person                  Date 
(Principal Investigator or Co-investigator) 
PARTICIPANT’S STATEMENT 
I, the undersigned, have been informed about this study’s purpose, procedures, possible 
benefits and risks, and I have received a copy of this consent. I have been given the 
opportunity to ask questions before I sign, and I have been told that I can ask other 
questions at any time. I voluntarily agree to participate in this study. I am free to withdraw 
from the study at any time without need to justify my decision. This withdrawal will not in 
any way affect my future treatment or medical management and I will not lose any 
benefits to which I otherwise am entitled. I agree to cooperate with Jennifer DiPiazza, 
PhD, PMHNP-BCand the research staff and to inform them immediately if I experience 
any unexpected or unusual symptoms. 
 
Signature of Participant Print Name of Participant                  Date 
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APPENDIX 11 
Fagerström Test for Cigarette Dependence – Revised (FTCD) 
 
Items  Scoring criteria  
 
1. How many cigarettes did you smoke?  
 
 
0 = less than 10  
1 = 11 – 20  
2 = 21 – 30  
3 = 31 +  
 
2. Do you smoke more in the morning 
than the rest of the day?  
 
 
0 = never  
1 = sometimes  
2 = most of the time  
3 = always  
 
3. How soon after you wake up do you 
have your first cigarette?  
 
 
3 = within 5 minutes  
2 = 6 – 30 minutes  
1 = 21 – 30 minutes  
0 = after 60 minutes  
 
4. Cigarette most hate to give up  
 
 
1 = first in the morning  
0 = all others  
 
5. Do you find it hard to refrain from 
smoking in places where it is forbidden, 
for example, in church, at the library, in 
the cinema, etc.?  
 
 
0 = never  
1 = sometimes  
2 = most of the time  
3 = always  
 
6. Do you smoke if you are so ill that 
you are in bed most of the day?  
 
 
0 = never  
1 = sometimes  
2 = most of the time  
3 = always  
 
Scoring   
Score of 1 – 2. A patient who scores between 1 and 2 on the Fagerstom Test for 
Nicotine Dependence is classified as having a low dependence on nicotine.  
 
Score of 3 – 4. A patient who scores between 3 and 4 would be considered to 
have low to moderate dependence on nicotine.  
 
Score 5 – 7. A patient who scores between 5 and 7 would be considered to have a 
moderate dependence on nicotine.  
 
Score 8 and over. A patient who scores 8 and over would be considered highly 
dependent on nicotine. 
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APPENDIX 12 
Scale for the Assessment of Negative Symptoms (SANS) 
Nancy C. Andreasen, M.D., Ph.D. Department of Psychiatry College of 
Medicine, The University of Iowa, Iowa City, Iowa 52242. Copyright by Nancy 
C. Andreasen, 1984 
1) AFFECTIVE FLATTENING OR BLUNTING 
Affective flattening or blunting manifests itself as a characteristic 
impoverishment of emotional expression, reactivity, and feeling. Affective 
flattening can be evaluated by observation of the subject's behavior and 
responsiveness during a routine interview. The rating of some items may be 
affected by drugs, since the Parkinsonian side-effect of phenothiazines may 
lead to mask-like facies and diminished associated movements. Other 
aspects of affect, such as responsivity or appropriateness, will not be 
affected, however. 
Unchanging Facial Expression. The subject's face appears wooden, 
mechanical, frozen. It does not change expression, or changes less than 
normally expected, as the emotional content of discourse changes. Since 
phenothiazines may partially mimic this effect, the interviewer should be 
careful to note whether or not the subject is on medication, but should not try 
to "correct" the rating accordingly. 
Not at all: Subject is normal or labile 0  
Questionable decrease 1 
Mild: Occasionally the subject's expression is not as full as expected 2 
Moderate: Subject's expressions are dulled overall, but not absent 3 
Marked: Subject's face has a flat "set" look, but flickers of affect arise 
occasionally 4 
Severe: Subject's face looks "wooden" and changes little, if at all throughout 
the interview 5 
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Decreased Spontaneous Movements. The subject sits quietly 
throughout the interview and shows few or no spontaneous movements. He 
does not shift position, move his legs, move his hands, etc., or does so less 
than normally expected. 
Not at all: Subject moves normally or is overactive 0  
Questionable decrease 1 
Mild: Some decrease in spontaneous movements 2 
Moderate: Subject moves three or four times during the interview 3 
Marked: Subject moves once or twice during the interview 4 
Severe: Subject sits immobile throughout the interview 5 
 
Paucity of Expressive Gestures. The subject does not use his body as 
an aid in expressing his ideas, through such means as hand gestures, sitting 
forward in his chair when intent on a subject, leaning back when relaxed, etc. 
This may occur in addition to decreased spontaneous movements. 
Not at all: Subject uses expressive gestures normally or excessively  
Questionable decrease 1 
Mild: Some decrease in expressive gestures 2 
Moderate: Subject uses body as an aid in expression at least three or four 
times 3 
Marked: Subject uses body as an aid in expression only once or twice 4 
Severe: Subject never uses body as an aid in expression 5 
 
 
Poor Eye Contact. The subject avoids looking at others or using his eyes 
as an aid in expression. He appears to be staring into space even when he is 
talking. 
Not at all: Good eye contact and expression 0 SS14 
Questionable decrease 1 
Mild: Some decrease in eye contact and eye expression 2 
Moderate: Subject's eye contact is decreased by at least half of normal 3 
Marked: Subject's eye contact is very infrequent 4 
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Severe: Subject almost never looks at interviewer 5 
 
 
Affective Non responsivity. Failure to smile or laugh when prompted may 
be tested by smiling or joking in a way which would usually elicit a smile from 
a normal individual. The examiner may also ask, "Have you forgotten how to 
smile?" while smiling himself. 
Not at all 0 
Questionable decrease 1 
Mild: Slight but definite lack in responsivity 2 
Moderate: Subject occasionally seems to miss the cues to respond 3 
Marked: Subject seems to miss the cues to respond most of the time 4 
Severe: Subject is essentially unresponsive, even on prompting 5 
 
 
Lack of Vocal Inflections. While speaking the subject fails to show normal 
vocal emphasis patterns. Speech has a monotonic quality, and important 
words are not emphasized through changes in pitch or volume. Subject also 
may fail to change volume with changes of subject so that he does not drop 
his voice when discussing private topics nor raise it as he discusses things 
which are exciting or for which louder speech might be appropriate. 
Not at all: Normal vocal Inflections 0  
Questionable decrease 1  
Mild: slight decrease in vocal inflections 2  
Moderate: Interview notices several instances of flattened vocal inflections 3  
Marked: Obvious decrease in vocal inflections 4  
Sever: Subject’s speech is a continuous monotone 5 
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Global Rating of Affective Flattening. The global rating should focus on 
overall severity of affective flattening or blunting. Special emphasis should be 
given to such core features as unresponsiveness, inappropriateness, and an 
overall decrease in emotional intensity. 
No flattening: Normal affect 0  
Questionable affective flattening 1 
Mild affective flattening 2 
Moderate affective flattening 3 
Marked affective flattening 4 
Severe affective flattening 5Inappropriate Affect. Affect expressed is 
inappropriate or incongruous, not simply flat or blunted. Most typically, this 
manifestation of affective disturbance takes the form of smiling or assuming 
a silly facial expression while talking about a serious or sad subject. 
(Occasionally subjects may smile or laugh when talking about a serious 
subject which they find uncomfortable or embarrassing. Although their 
smiling may seem inappropriate, it is due to anxiety and therefore should not 
be rated as inappropriate affect.) Do not rate affective flattening or blunting as 
inappropriate. (This item was in the original SANS. However, subsequent 
analyses have shown that it loads on a disorganized dimension in factor 
analyses. Consequently, it should not be used as part of the global rating of 
affective flattening or in the sum of negative symptoms if three dimensions of 
psychopathology are being examined.) 
Not at all: Affect is not inappropriate 0  
Questionable 1 
Mild: At least one instance of inappropriate smiling or other inappropriate 
affect 2 
Moderate: Subject exhibits two to four instances of inappropriate affect 3 
Marked: Subject exhibits five to ten instances of inappropriate affect 4 
Severe: Subject's affect is inappropriate most of the time 5 
 
 
263 
 
 
2) ALOGIA 
Alogia is a general term coined to refer to the impoverished thinking and 
cognition that often occur in subjects with schizophrenia (Greek a = no, none; 
logos = mind, thought). Subjects with alogia have thinking processes that 
seem empty, turgid, or slow. Since thinking cannot be observed directly, it is 
inferred from the subject's speech. The two major manifestations of alogia are 
nonfluent empty speech (poverty of speech) and fluent empty speech (poverty 
of content of speech). Blocking and increased latency or response may also 
reflect alogia. 
Poverty of Speech. Restriction in the amount of spontaneous speech, so 
that replies to questions tend to be brief, concrete, and unelaborated. 
Unprompted additional information is rarely provided. Replies may be 
monosyllabic, and some questions may be left unanswered altogether. When 
confronted with this speech pattern, the interviewer may find himself 
frequently prompting the subject in order to encourage elaboration of replies. 
To elicit this finding, the examiner must allow the subject adequate time to 
answer and to elaborate his answer. 
No poverty of speech: A substantial and appropriate number of replies to 
questions include additional information 0 SS19 
Questionable poverty of speech 1 
Mild: Occasional replies do not include elaborated information even though 
this is appropriate 2 
Moderate: Some replies do not include appropriately elaborated information, 
and some replies are monosyllabic or very brief--("Yes." "No." "Maybe." "I 
don't know." "Last week.") 3 
Marked: Answers are rarely more than a sentence or a few words in length 4 
Severe: Subject says almost nothing and occasionally fails to answer 
questions 5 
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Poverty of Content of Speech. Although replies are long enough so that 
speech is adequate in amount, it conveys little information. Language tends 
to be vague, often over-abstract or over-concrete, repetitive, and stereotyped. 
The interviewer may recognize this finding by observing that the subject has 
spoken at some length but has not given adequate information to answer the 
question. Alternatively, the subject may provide enough information, but 
require many words to do so, so that a lengthy reply can be summarized in a 
sentence or two. Sometimes the interviewer may characterize the speech as 
"empty philosophizing." 
Exclusions: This finding differs from circumstantiality in that the 
circumstantial subject tends to provide a wealth of detail. 
Example: Interviewer: "Why is it, do you think, that people believe in God?" 
Subject: "Well, first of all because he uh, he are the person that is their 
personal savior. He walks with me and talks with me. And uh, the 
understanding that I have, um, a lot of peoples, they don't really, uh, know 
they own personal self. Because, uh, they ain't, they all, just don't know they 
personal self. They don't, know that he uh, seemed like to me, a lot of 'em 
don't understand that he walks and talks with them." 
No poverty of content 0  
Questionable 1 
Mild: Occasional replies are too vague to be comprehensible or can be 
markedly condensed 2 
Moderate: Frequent replies which are vague or can be markedly condensed 
to make up at least a quarter of the interview 3 
Marked: At least half of the subject's speech is composed of vague or 
incomprehensible replies 4 
Severe: Nearly all the speech is vague, incomprehensible, or can be markedly 
condensed 5 
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Blocking. Interruption of a train of speech before a thought or idea has been 
completed. After a period of silence which may last from a few seconds to 
minutes, the person indicates that she/he cannot recall what he had been 
saying or meant to say. Blocking should only be judged to be present if a 
person voluntarily describes losing his thought or if, upon questioning by the 
interviewer, the person indicates that that was the reason for pausing. 
No blocking 0  
Questionable 1 
Mild: A single instance noted during a forty-five minute period 2 
Moderate: Occurs twice during forty-five minutes 3 
Marked: Occurs three or four times during forty-five minutes 4 
Severe: Occurs more than four times in forty-five minutes 5 
Increased Latency of Response. The subject takes a longer time to reply 
to questions than is usually considered normal. He may seem "distant" and 
sometimes the examiner may wonder if he has even heard the question. 
Prompting usually indicates that the subject is aware of the question, but has 
been having difficulty in formulating his thoughts in order to make an 
appropriate reply. 
Not at all 0  
Questionable 1 
Mild: Occasional brief pauses before replying 2 
Moderate: Often pauses several seconds before replying 3 
Marked: Usually pauses at least ten to fifteen seconds before replying 4 
Severe: Long pauses prior to nearly all replies. 5 
Global Rating of Alogia. Since the core features of alogia are poverty of 
speech and poverty of content of speech, the global rating should place 
particular emphasis on them. 
No alogia 0  
Questionable 1 
Mild: Mild but definite impoverishment in thinking 2 
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Moderate: Significant evidence for impoverished thinking 3 
Marked: Subject's thinking seems impoverished much of the time 4 
Severe: Subject's thinking seems impoverished nearly all of the time 5 
3) AVOLITION-APATHY  
Avolition manifests itself as a characteristic lack of energy, drive, and interest. 
Subjects are unable to mobilize themselves to initiate or persist in completing 
many different kinds of tasks. Unlike the diminished energy or interest of 
depression, the avolitional symptom complex in schizophrenia is usually not 
accompanied by saddened or depressed affect. The avolitional symptom 
complex often leads to severe social and economic impairment. 
Grooming and Hygiene. The subject displays less attention to grooming 
and hygiene than normal. Clothing may appear sloppy, outdated, or soiled. 
The subject may bathe infrequently and not care for hair, nails, or teeth--
leading to such manifestations as greasy or uncombed hair, dirty hands, body 
odor, or unclean teeth and bad breath. Overall, the appearance is dilapidated 
and disheveled. In extreme cases, the subject may even have poor toilet 
habits. 
 
How often do you bathe or shower? 
Do you change your clothes every day? 
How often do you do laundry? 
No evidence of poor grooming and hygiene 0 SS24 
Questionable 1 
Mild: Some slight but definite indication of inattention to appearance, i.e., 
messy hair or disheveled clothes 2 
Moderate: Appearance is somewhat disheveled, i.e., greasy hair, dirty clothes 
3 
Marked: Subject's attempts to keep up grooming or hygiene are minimal 4 
Severe: Subject's clothes, body and environment are dirty and smelly 5 
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Impersistence at Work or School. The subject has had difficulty in 
seeking or maintaining employment (or schoolwork) as appropriate for his or 
her age and sex. If a student, he/she does not do homework and may even fail 
to attend class. Grades will tend to reflect this. If a college student, there may 
be a pattern of registering for courses, but having to drop several or all of 
them before the semester is completed. If of working age, the subject may 
have found it difficult to work at a job because of inability to persist in 
completing tasks and apparent irresponsibility. He may go to work irregularly, 
wander away early, complete them in a disorganized manner. He may simply 
sit around the house and not seek any employment or seek it only in an 
infrequent and desultory manner. If a housewife or retired person, the subject 
may fail to complete chores, such as shopping or cleaning, or complete them 
in an apparently careless and half-hearted way. 
 
Have you been having any problems at (work, school)? 
Do you ever start some project and just never get around to finishing it? 
No evidence of impersistence at work or school 0  
Questionable 1 
Mild: Slight indications of impersistence, i.e., missing a couple days of school 
or work 2 
Moderate: Subject often has poor performance at work or school 3 
Marked: Subject has much difficulty maintaining even a below normal level of 
work or school 4 
Severe: Subject consistently fails to maintain a record at work or school 5 
268 
 
Physical Anergia. The subject tends to be physically inert. He may sit in a 
chair for hours at a time and not initiate any spontaneous activity. If 
encouraged to become involved in an activity, he may participate only briefly 
and then wander away or disengage himself and return to sitting alone. He 
may spend large amounts of time in some relatively mindless and physically 
inactive task such as watching TV or playing solitaire. His family may report 
that he spends most of his time at home "doing nothing except sitting 
around". Either at home or in an inpatient setting he may spend much of his 
time sitting in his room. 
Are there times when you lie or sit around most of the day? 
(Does this ever last longer than one day?) 
No Evidence of Physical Anergia 0  
Questionable 1 
Mild Anergia 2 
Moderate: Subject lies in bed or sits immobile at least a quarter of normal 
waking hours 3 
Marked: Subject lies in bed or sits immobile at least half of normal waking 
hours 4 
Severe: Subject lies in bed or sits immobile for most of the day 5 
Global Rating of Avolition – Apathy. The global rating should reflect the 
overall severity of the avolition symptoms, given expectational norms for the 
subject's age and social status or origin. In making the global rating, strong 
weight may be given to only one or two prominent symptoms if they are 
particularly striking. 
No Avolition 0  
Questionable 1 
Mild, But Definitely Present 2 
Moderate Avolition 3 
Marked Avolition 4 
Severe Avolition 5 
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4) ANHEDONIA-ASOCIALITY 
This symptom complex encompasses the schizophrenic subject's difficulties 
in experiencing interest or pleasure. It may express itself as a loss of interest 
in pleasurable activities, an inability to experience pleasure when 
participating in activities normally considered pleasurable, or a lack of 
involvement in social relationships of various kinds. 
Recreational Interests and Activities. The subject may have few or no 
interests, activities, or hobbies. Although this symptom may begin insidiously 
or slowly, there will usually be some obvious decline from an earlier level of 
interest and activity. Subjects with relatively milder loss of interest will engage 
in some activities which are passive or non-demanding, such as watching TV, 
or will show only occasional or sporadic interest. Subjects with the most 
extreme loss will appear to have a complete and intractible inability to become 
involved in or enjoy activities. The rating in this area should take both the 
quality and quantity of recreational interests into account. 
Have you felt interested in the things you usually enjoy? 
(Have they been as fun as usual?) 
Have you been watching TV or listening to the radio? 
No Inability to Enjoy Recreational Interests or Activities 0  
Questionable 1 
Mild Inability to Enjoy Recreational Activities 2 
Moderate: Subject often is not "up" for recreational activities 3 
Marked: Subject has little interest in and derives only mild pleasure from 
recreational activities 4 
Severe: Subject has no interest in and derives no pleasure from recreational 
activities 5 
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Sexual Interest and Activity. The subject may show a decrement in sexual 
interest and activity, as judged by what would be normal for the subject's age 
and marital status. Individuals who are married may manifest disinterest in 
sex or may engage in intercourse only at the partner's request. In extreme 
cases, the subject may not engage in any sex at all. Single subjects may go 
for long periods of time without sexual involvement and make no effort to 
satisfy this drive. Whether married or single, they may report that they 
subjectively feel only minimal sex drive or that they take little enjoyment in 
sexual intercourse or in masturbatory activity even when they engage in it. 
Have you noticed any changes in your sex drive? 
No Inability to Enjoy Sexual Activities 0 
Questionable Decrement in Sexual Interest and Activity 1 
Mild Decrement in Sexual Interest and Activity 2 
Moderate: Subject occasionally has noticed decreased interests in and/or 
enjoyment from sexual activities 3 
Marked: Subject has little interest in and/or derives little pleasure from sexual 
activities 4 
Severe: Subject has no interest in and/or derives no pleasure from sexual 
activities 5 
Ability to Feel Intimacy and Closeness. The subject may display an 
inability to form close and intimate relationships of a type appropriate for his 
age, sex, and family status. In the case of a younger person, this area should 
be rated in terms of relationships with the opposite sex and with parents and 
siblings. In the case of an older person who is married, the relationship with 
spouse and with children should be evaluated, while older unmarried 
individuals should be judged in terms of relationships with the opposite sex 
and any family members who live nearby. Subjects may display few or no 
feelings of affection to available family members. Or they may have arranged 
their lives so that they are completely isolated from any intimate relationships, 
living alone and making no effort to initiate contacts with family or members 
of the opposite sex. 
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Have you been having any problems with your (family, spouse)? 
How would you feel about visiting with your (family, parents, spouse, etc.)? 
No Inability to Feel Intimacy and Closeness 0  
Questionable Inability 1 
Mild, But Definite Inability to Feel Intimacy and Closeness 2 
Moderate: Subject appears to enjoy family or significant others but does not 
appear to "look forward" to visits 3 
Marked: Subject appears neutral toward visits from family or significant 
others. Brightens only mildly 4 
Severe: Subject prefers no contact with or is hostile toward family or 
significant others 5 
Relationships with Friends and Peers. Subjects may also be relatively 
restricted in their relationships with friends and peers of either sex. They may 
have few or no friends, make little or no effort to develop such relationships, 
and choose to spend all or most of their time alone. 
 
Have you been spending much time with friends? 
Do you enjoy spending time alone, or would you rather have more friends? 
No Inability to Form Close Friendships 0 
Questionable Inability to Form Friendships 1 
Mild, But Definite Inability to Form Friendships 2 
Moderate: Subject able to interact, but sees friends/acquaintances only two 
to three times per month 3 
Marked: Subject has difficulty forming and/or keeping friendships. Sees 
friends/acquaintances only one to two times per month 4 
Severe: Subject has no friends and no interest in developing any social ties 5 
Global Rating of Anhedonia-Asociality. The global rating should reflect 
the overall severity of the anhedonia-asociality complex, taking into account 
the norms appropriate for the subject's age, sex, and family status. 
No Evidence of Anhedonia-Asociality 0 
Questionable Evidence of Anhedonia-Asociality 1 
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Mild, But Definite Evidence of Anhedonia-Asociality 2 
Moderate Evidence of Anhedonia-Asociality 3 
Marked Evidence of Anhedonia-Asociality 4 
Severe Evidence of Anhedonia-Asociality 5 
5) ATTENTION 
Attention is often poor in schizophrenics. The subject may have trouble 
focusing his attention, or he may only be able to focus sporadically and 
erratically. He may ignore attempts to converse with him, wander away while 
in the middle of an activity or task, or appear to be inattentive when engaged 
in formal testing or interviewing. He may or may not be aware of his difficulty 
in focusing his attention. 
In some factor analyses, attentional impairment loads on the disorganized 
dimension, when three dimensions of psychopathology emerge. 
Consequently, analyses that examine three dimensions may choose to place 
this item in the disorganized dimension rather than the negative dimension. 
Social Inattentiveness. While involved in social situations or activities, the 
subject appears inattentive. He looks away during conversations, does not 
pick up the topic during a discussion, or appears uninvolved or unengaged. 
He may abruptly terminate a discussion or a task without any apparent 
reason. He may seem "spacy" or "out of it". He may seem to have poor 
concentration when playing games, reading, or watching TV. 
No Indication of Inattentiveness 0  
Questionable Signs 1 
Mild, But Definite Signs of Inattentiveness 2 
Moderate: Subject occasionally misses what is happening in the environment 
3 
Marked: Subject often misses what is happening in the environment; has 
trouble with reading comprehension 4 
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Severe: Subject unable to follow conversation, remember what he's read, or 
follow TV plot 5 
Inattentiveness During Mental Status Testing. The subject may 
perform poorly on simple tests of intellectual functioning in spite of adequate 
education and intellectual ability. This should be assessed by having the 
subject spell "world" backwards and by serial 7's (at least a tenth grade 
education) or serial 3's (at least a sixth grade education) for a series of five 
subtractions. A perfect score is 10. 
Questionable: No errors but subject performs in a halting manner or 
makes/corrects an error 1 
Mild, But Definite (One Error) 2 
Moderate (Two Errors) 3 
Marked (Three Errors) 4 
Severe (More Than Three Errors) 5 
Global Rating of Attention. This rating should assess the subject's overall 
ability to attend or concentrate, and include both clinical appearance and 
performance on tasks. 
No Indications of Inattentiveness 0  
Questionable 1 
Mild, But Definite Inattentiveness 2 
Moderate Inattentiveness 3 
Marked Inattentiveness 4 
Severe Inattentiveness 5 
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APPENDIX 13 
Scale for the Assessment of Positive Symptoms (SAPS) 
 
Nancy C. Andreasen, M.D., Ph.D. Department of Psychiatry, College of 
Medicine, The University of Iowa, Iowa City, Iowa 52242. Copyright by Nancy 
C. Andreasen, 1984 (SAS Variable Name edition: 2000) 
 
INTRODUCTION  
This scale is designed to assess positive symptoms, principally those that 
occur in schizophrenia. It is intended to serve as a complementary instrument 
to the Scale for the Assessment of Negative Symptoms (SANS). These 
positive symptoms include hallucinations, delusions, bizarre behavior, and 
positive formal thought disorder.  
As in the case of the SANS, the investigator using this instrument will need to 
decide on an appropriate "time set". The instrument was developed with the 
exception that, in general, the time set will cover the past month as in the case 
of SANS. This scale can also be used in psychopharmacologic research in 
order to make weekly ratings and chart the subject's response to treatment.  
Investigators using this instrument, particularly in combination with the 
SANS, will need to use a standard clinical interview in order to evaluate the 
subject's symptoms. Since positive formal thought disorder is an important 
positive symptom, it is recommended that, in doing this interview, the 
investigator begin talking with the subject on a relatively neutral topic for five 
to ten minutes in order to observe the subject's manner of speaking and 
responding. Thereafter, he can begin to ask specific questions about the 
various positive symptoms. Suggested probes are provided in the interview 
guide.  
In addition to using a clinical interview, the investigator should also draw on 
other sources of information, such as direct observation, reports from the 
subject's family, reports from nurses, and reports from the subject himself. In 
general, the subject can usually be considered a relatively reliable informant 
concerning delusions and hallucinations if he is able to communicate clearly 
and will comply with a clinical interview. On the other hand, the interviewer 
275 
 
will usually have to rely on observation and reports from outside sources in 
order to evaluate bizarre behavior and positive formal thought disorder.  
 
1) HALLUCINATIONS  
Hallucinations represent an abnormality in perception. They are false 
perceptions occurring in the absence of some identifiable external stimulus. 
They may be experienced in any of the sensory modalities, including hearing, 
touch, taste, smell, and vision. True hallucinations should be distinguished 
from illusions (which involve a misperception of an external stimulus), 
hypnogogic and hypnopompic experiences (which occur when the subject is 
falling asleep or waking up), or normal thought processes that are 
exceptionally vivid. If the hallucinations have a religious quality, then they 
should be judged within the context of what is normal for the subject's social 
and cultural background. Hallucinations occurring under the immediate 
influence of alcohol, drugs, or serious physical illness should not be rated as 
present. The subject should always be requested to describe the hallucination 
in detail. 
 
 
Auditory Hallucinations. The subject has reported voices, noises, or sounds. 
The commonest auditory hallucinations involve hearing voices speaking to 
the subject or calling him names. The voices may be male or female, familiar 
or unfamiliar, and critical or complimentary. Typically, subjects suffering from 
schizophrenia experience the voices as unpleasant and negative. 
Hallucinations involving sounds rather than voices, such as noises or music, 
should be considered less characteristic and less severe.  
Have you ever heard voices or other sounds when no one is around?  
What did they say?  
None 0  
Questionable 1  
Mild: Subject hears noises or single words; they occur only occasionally 2  
Moderate: Clear evidence of voices; they have occurred at least weekly 3  
Marked: Clear evidence of voices which occur almost every day 4  
Severe: Voices occur often every day  
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Voices Commenting. Voices commenting are a particular type of auditory 
hallucination which phenomenologists as Kurt Schneider consider to be 
pathognomonic of schizophrenia, although some recent evidence contradicts 
this. These hallucinations involve hearing a voice that makes a running 
commentary on the subject's behavior or thought as it occurs. If this is the 
only type of auditory hallucination that the subject hears, it should be scored 
instead of auditory hallucinations (No. 1 above). Usually, however, voices 
commenting will occur in addition to other types of auditory hallucinations.  
Have you ever heard voices commenting on what you are thinking or doing? 
What do they say?  
None 0  
Questionable 1  
Mild: Subject hears noises or single words; they occur only occasionally 2  
Moderate: Clear evidence of voices; they have occurred at least weekly 3  
Marked: Clear evidence of voices which occur almost every day 4  
Severe: Voices occur often every day 5 
 
 
Voices Conversing. Like voices commenting, voices conversing are 
considered a Schneiderian first-rank symptom. They involve hearing two or 
more voices talking with one another, usually discussing something about the 
subject. As in the case of voices commenting, they should be scored 
independently of other auditory hallucinations.  
Have you heard two or more voices talking with each other?  
What did they say?  
None 0  
Questionable 1  
Mild: Subject hears noises or single words; they occur only occasionally 2  
Moderate: Clear evidence of voices; they have occurred at least weekly 3  
Marked: Clear evidence of voices which occur almost every day 4  
Severe: Voices occur often every day 5  
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Somatic or Tactile Hallucinations. These hallucinations involve 
experiencing peculiar physical sensations in the body. They include burning 
sensations, tingling, and perceptions that the body has changed in shape or 
size.  
Have you ever had burning sensations or other strange feelings in your body?  
What were they?  
Did your body ever appear to change in shape or size?  
None 0  
Questionable 1  
Mild: Subject experiences peculiar physical sensations; they occur only 
occasionally 2  
Moderate: Clear evidence of somatic or tactile hallucinations; they have 
occurred at least weekly 3  
Marked: Clear evidence of somatic or tactile hallucinations which occur 
almost every day 4  
Severe: Hallucinations occur often every day 5  
 
 
Olfactory Hallucinations. The subject experiences unusual smells which 
are typically quite unpleasant. Sometimes the subject may believe that he 
himself smells. This belief should be scored here if the subject can actually 
smell the odor himself, but should be scored among delusions if he only 
believes that others can smell the odor.  
Have you ever experienced any unusual smells or smells that others do not 
notice?  
What were they?  
None 0  
Questionable 1  
Mild: Subject experiences unusual smells; they occur only occasionally 2  
Moderate: Clear evidence of olfactory hallucinations; they have occurred at 
least weekly 3  
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Marked: Clear evidence of olfactory hallucinations; they occur almost every 
day 4  
Severe: Olfactory hallucinations occur often every day 5 
 
 
Visual Hallucinations. The subject sees shapes or people that are not 
actually present. Sometimes these are shapes or colors, but most typically 
they are figures of people or human-like objects. They may also be characters 
of a religious nature, such as the Devil or Christ. As always, visual 
hallucinations involving religious themes should be judged within the context 
of the subject's cultural background. Hypnogogic and hypnopompic visual 
hallucinations (which are relatively common) should be excluded, as should 
visual hallucinations occurring when the subject has been taking 
hallucinogenic drugs.  
Have you had visions or seen things that other people cannot?  
What did you see?  
Did this occur when you were falling asleep or waking up?  
None 0  
Questionable 1  
Mild: Subject experiences visual hallucinations; they occur only occasionally 
2  
Moderate: Clear evidence of visual hallucinations; they have occurred at least 
weekly 3  
Marked: Clear evidence of visual hallucinations which occur almost every day 
4  
Severe: Hallucinations occur often every day 5  
 
 
Global Rating of Severity of Hallucinations. This global rating should 
be based on the duration and severity of hallucinations, the extent of the 
subject's preoccupation with the hallucinations, his degree of conviction, and 
their effect on his actions. Also consider the extent to which the hallucinations 
279 
 
might be considered bizarre or unusual. Hallucinations not mentioned above, 
such as those involving taste, should be included in this rating.  
None 0  
Questionable 1  
Mild: Hallucinations definitely present, but occur infrequently; at times the 
subject may question their existence 2  
Moderate: Hallucinations are vivid and occur occasionally; they may bother 
him to some extent 3  
Marked: Hallucinations are quite vivid, occur frequently, and pervade his life 
4  
Severe: Hallucinations occur almost daily and are sometimes unusual or 
bizarre; they are very vivid and extremely troubling  
 
 
2) DELUSIONS  
Delusions represent an abnormality in content of thought. They are false 
beliefs that cannot be explained on the basis of the subject's cultural 
background. Although delusions are sometimes defined as "fixed false 
beliefs," in their mildest form delusions may persist only for weeks to months, 
and the subject may question his beliefs or doubt them. The subject's 
behavior may or may not be influenced by his delusions. The rating of severity 
of individual delusions and of the global severity of delusional thinking should 
take into account their persistence, their complexity, the extent to which the 
subject acts on them, the extent to which the subject doubts them, and the 
extent to which the beliefs deviate from those that normal people might have. 
For each positive rating, specific examples should be noted in the margin.  
 
Persecutory Delusions. People suffering from persecutory delusions 
believe that they are being conspired against or persecuted in some way. 
Common manifestations include the belief that one is being followed, that 
one's mail is being opened, that one's room or office is bugged, that the 
telephone is tapped, or that police, government officials, neighbors, or fellow 
workers are harassing the subject. Persecutory delusions are sometimes 
280 
 
relatively isolated or fragmented, but sometimes the subject has a complex 
set of delusions involving both a wide range of forms of persecution and a 
belief that there is a well-designed conspiracy behind them. For example, a 
subject may believe that his house is bugged and that he is being followed 
because the government wrongly considers him a secret agent for a foreign 
government; this delusion may be so complex that it explains almost 
everything that happens to him. The ratings of severity should be based on 
duration and complexity.  
Have people been bothering you in any way?  
Have you felt that people are against you?  
Has anyone been trying to harm you in any way?  
Has anyone been watching or monitoring you?  
None 0  
Questionable 1  
Mild: Delusional beliefs are simple and may be of several different types; 
subject may question them occasionally 2  
Moderate: Clear, consistent delusion that is firmly held 3  
Marked: Consistent, firmly-held delusion that the subject acts on 4  
Severe: Complex well-formed delusion that the subject acts on and that 
preoccupies him a great deal of the time; some aspects of the delusion or his 
reaction may seem quite bizarre 5 
 
 
Delusions of Jealousy. The subject believes that his/her mate is having an 
affair with someone. Miscellaneous bits of information are construed as 
"evidence". The person usually goes to great effort to prove the existence of 
the affair, searching for hair in the bedclothes, the odor of shaving lotion or 
smoke on clothing, or receipts or checks indicating a gift has been bought for 
the lover. Elaborate plans are often made in order to trap the two together.  
Have you ever worried that your husband (wife) might be unfaithful to you?  
What evidence do you have?  
None 0  
Questionable 1  
Mild: Delusion clearly present, but the subject may question it occasionally 2  
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Moderate: Clear consistent delusion that is firmly held 3  
Marked: Consistent, firmly-held delusion that the subject acts on 4  
Severe: Complex, well-formed delusion that the subject acts on and that 
preoccupies him a great deal of the time; some aspects of the delusion or his 
reaction may seem quite bizarre  
 
 
Delusions of Sin or Guilt. The subject believes that he has committed 
some terrible sin or done something unforgivable. Sometimes the subject is 
excessively or inappropriately preoccupied with things he did wrong as a 
child, such as masturbating. Sometimes the subject feels responsible for 
causing some disastrous event, such as a fire or accident, with which he in 
fact has no connection. Sometimes these delusions may have a religious 
flavor, involving the belief that the sin is unpardonable and that the subject 
will suffer eternal punishment from God. Sometimes the subject simply 
believes that he deserves punishment by society. The subject may spend a 
good deal of time confessing these sins to whomever will listen. Have you 
ever felt that you have done some terrible thing that you deserve to be 
punished for?  
None 0 
Questionable 1  
Mild: Delusional beliefs may be simple and may be of several different types; 
subject may question them occasionally 2  
Moderate: Clear, consistent delusion that is firmly held 3  
Marked: Consistent, firmly-held delusion that the subject acts on 4  
Severe: Complex, well-formed delusion that the subject acts on and that 
preoccupies him a great deal of the time; some aspects of the delusion or his 
reaction may seem quite bizarre  
 
 
Grandiose Delusions. The subject believes that he has special powers or 
abilities. He may think he is actually some famous personage, such as a rock 
star, Napoleon, or Christ. He may believe he is writing some definitive book, 
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composing a great piece of music, or developing some wonderful new 
invention. The subject is often suspicious that someone is trying to steal his 
ideas, and he may become quite irritable if his ideas are doubted.  
Do you have any special or unusual abilities or talents?  
Do you feel you are going to achieve great things?  
None 0   
Questionable 1  
Mild: Delusional beliefs may be simple and may be of several different types; 
subject may question them occasionally 2  
Moderate: Clear, consistent delusion that is firmly held 3  
Marked: Consistent, firmly-held delusion that the subject acts on 4  
Severe: Complex, well-formed delusion that the subject acts on and that 
preoccupies him a great deal of the time; some aspects of the delusion or his 
reaction may seem quite bizarre 5 
 
 
Religious Delusions. The subject is preoccupied with false beliefs of a 
religious nature. Sometimes these exist within the context of a conventional 
religious system, such as beliefs about the Second Coming, the Antichrist, or 
possession by the Devil. At other times, they may involve an entirely new 
religious system or a pastiche of beliefs from a variety of religions, 
particularly Eastern religions, such as ideas about reincarnation or Nirvana. 
Religious delusions may be combined with grandiose delusions (if the subject 
considers himself a religious leader), delusions of guilt, or delusions of being 
controlled. Religious delusions must be outside the range considered normal 
for the subject's cultural and religious background.  
Are you a religious person?  
Have you had any unusual religious experiences?  
What was your religious training as a child?  
None 0  
Questionable 1  
Mild: Delusional beliefs may be simple and may be of several different types; 
subject may question them occasionally 2  
Moderate: Clear, consistent delusion that is firmly held 3  
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Marked: Consistent, firmly-held delusion that the subject acts on 4  
Severe: Complex, well-formed delusion that the subject acts on and that 
preoccupies him a great deal of the time; some aspects of the delusion or his 
reaction may seem quite bizarre 5  
 
 
Somatic Delusions. The subject believes that somehow his body is 
diseased, abnormal, or changed. For example, he may believe that his 
stomach or brain is rotting, that his hands or penis have become enlarged, or 
that his facial features are unusual (dysmorphophobia). Sometimes somatic 
delusions are accompanied by tactile or other hallucinations, and when this 
occurs, both should be rated. (For example, the subject believes that he has 
ball bearings rolling around in his head, placed there by a dentist who filled 
his teeth, and can actually hear them clanking against one another.)  
Is there anything wrong with your body?  
Have you noticed any change in your appearance?  
None 0  
Questionable 1  
Mild: Delusional beliefs may be simple and may be of several different types; 
subject may question them occasionally 2  
Moderate: Clear, consistent delusion that is firmly held 3  
Marked: Consistent, firmly-held delusion that the subject acts on 4  
Severe: Complex, well-formed delusion that the subject acts on and that 
preoccupies him a great deal of the time; some aspects of the delusion or his 
reaction may seem quite bizarre 5 
 
 
Ideas and Delusions of Reference. The subject believes that 
insignificant remarks, statements, or events refer to him or have some special 
meaning for him. For example, the subject walks into a room, sees people 
laughing, and suspects that they were just talking about him and laughing at 
him. Sometimes items read in the paper, heard on the radio, or seen on 
television are considered to be special messages to the subject. In the case 
of ideas of reference, the subject is suspicious, but recognizes his idea is 
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erroneous. When the subject actually believes that the statements or events 
refer to him, then this is considered a delusion of reference.  
Have you ever walked into a room and thought people were talking about you 
or laughing at you?  
Have you seen things in magazines or on TV that seem to refer to you or 
contain a special message for you?  
Have people communicated with you in any unusual ways?  
None 0  
Questionable 1  
Mild: Occasional ideas of reference 2  
Moderate: Have occurred at least weekly 3  
Marked: Occurs at least two to four times weekly 4  
Severe: Occurs frequently 5  
 
 
Delusions of Being Controlled. The subject has a subjective experience 
that his feelings or actions are controlled by some outside force. The central 
requirement for this type of delusion is an actual strong subjective experience 
of being controlled. It does not include simple beliefs or ideas, such as that 
the subject is acting as an agent of God or that friends or parents are trying 
to coerce him to do something. Rather, the subject must describe, for 
example, that his body has been occupied by some alien force that is making 
it move in peculiar ways, or that messages are being sent to his brain by radio 
waves and causing him to experience particular feelings that he recognizes 
are not his own.  
Have you ever felt you were being controlled by some outside force?  
None 0  
Questionable 1  
Mild: Subject has experienced being controlled, but doubts it occasionally 2  
Moderate: Clear experience of control, which has occurred on two or three 
occasions in a week 3  
Marked: Clear experience of control, which occurs frequently; behavior may 
be affected 4  
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Severe: Clear experience of control which occurs frequently, pervades the 
subject's life, and often affects his behavior 5 
 
 
Delusions of Mind Reading. The subject believes that people can read his 
mind or know his thoughts. This is different than thought broadcasting (see 
below) in that it is a belief without a percept. That is, the subject subjectively 
experiences and recognizes that others know his thoughts, but he does not 
think that they can be heard out loud.  
Have you ever had the feeling that people could read your mind?  
None 0  
Questionable 1  
Mild: Subject has experienced mind reading, but doubts it occasionally 2  
Moderate: Clear experience of mind reading which has occurred on two or 
three occasions in a week 3  
Marked: Clear experience of mind reading which occurs frequently; behavior 
may be affected 4  
Severe: Clear experience of mind reading which occurs frequently, pervades 
the subject's life, and often affects his behavior 5 
 
 
Thought Broadcasting. The subject believes that his thoughts are 
broadcast so that he or others can hear them. Sometimes the subject 
experiences his thoughts as a voice outside his head; this is an auditory 
hallucination as well as a delusion. Sometimes the subject feels his thoughts 
are being broadcast although he cannot hear them himself. Sometimes he 
believes that his thoughts are picked up by a microphone and broadcast on 
the radio or television.  
Have you ever heard your own thoughts out loud, as if they were a voice 
outside your head?  
Have you ever felt your thoughts were broadcast so other people could hear 
them?  
None 0  
286 
 
Questionable 1  
Mild: Subject has experienced thought broadcasting, but doubts it 
occasionally 2  
Moderate: Clear experience of thought broadcasting which has occurred on 
two or three occasions in a week 3  
Marked: Clear experience of thought broadcasting which occurs frequently; 
behavior may be affected 4  
Severe: Clear experience of thought broadcasting which occurs frequently, 
pervades the subject's life, and often affects his behavior 5  
 
 
Thought Insertion. The subject believes that thoughts that are not his own 
have been inserted into his mind. For example, the subject may believe that a 
neighbor is practicing voodoo and planting alien sexual thoughts in his mind. 
This symptom should not be confused with experiencing unpleasant thoughts 
that the subject recognizes as his own, such as delusions of persecution or 
guilt.  
Have you ever felt that thoughts were being put into your head by some 
outside force?  
Have you ever experienced thoughts that didn't seem to be your own?  
None 0  
Questionable 1  
Mild: Subject has experienced thought insertion, but doubts it occasionally 2  
Moderate: Clear experience of thought insertion which has occurred on two 
or three occasions in a week 3  
Marked: Clear experience of thought insertion which occurs frequently; 
behavior may be affected 4  
Severe: Thought insertion which occurs frequently, pervades the subject's life 
and affects behavior 5 
 
 
Thought Withdrawal. The subject believes that thoughts have been taken 
away from his mind. He is able to describe a subjective experience of 
beginning a thought and then suddenly having it removed by some outside 
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force. This symptom does not include the mere subjective recognition of 
alogia.  
Have you ever felt your thoughts were taken away by some outside force?  
None 0  
Questionable 1  
Mild: Subject has experienced thought withdrawal, but doubts it occasionally 
2  
Moderate: Clear experience of thought withdrawal which has occurred on two 
or three occasions in a week 3  
Marked: Clear experience of thought withdrawal which occurs frequently; 
behavior may be affected 4  
Severe: Clear experience of thought withdrawal which occurs frequently, 
pervades the subject's life and often affects his behavior 5  
 
 
Global Rating of Severity of Delusions. The global rating should be 
based on duration and persistence of delusions, the extent of the subject's 
preoccupation with the delusions, his degree of conviction, and their effect 
on his actions. Also consider the extent to which the delusions might be 
considered bizarre or unusual. Delusions not mentioned above should be 
included in this rating.  
None 0  
Questionable 1  
Mild: Delusion definitely present but, at times, the subject questions the belief 
2  
Moderate: The subject is convinced of the belief, but it may occur infrequently 
and have little effect on his behavior 3  
Marked: The delusion is firmly held; it occurs frequently and affects the 
subject's behavior 4  
Severe: Delusions are complex, well-formed, and pervasive; they are firmly 
held and have a major effect on the subject's behavior; they may be somewhat 
bizarre or unusual 5 
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3) BIZARRE BEHAVIOR  
The subject's behavior is unusual, bizarre, or fantastic. For example, the 
subject may urinate in a sugar bowl, paint the two halves of his body different 
colors, or kill a litter of pigs by smashing their heads against a wall. The 
information for this item will sometimes come from the subject, sometimes 
from other sources, and sometimes from direct observation. Bizarre behavior 
due to the immediate effects of alcohol or drugs should be excluded. As 
always, social and cultural norms must be considered in making the ratings, 
and detailed examples should be elicited and noted. 
 
Clothing and Appearance. The subject dresses in an unusual manner or 
does other strange things to alter his appearance. For example, he may shave 
off all his hair or paint parts of his body different colors. His clothing may be 
quite unusual; for example, he may choose to wear some outfit that appears 
generally inappropriate and unacceptable, such as a baseball cap backwards 
with rubber galoshes and long underwear covered by denim overalls. He may 
dress in a fantastic costume representing some historical personage or a man 
from outer space. He may wear clothing completely inappropriate to the 
climatic conditions, such as heavy wools in the midst of summer.  
Has anyone made comments about your appearance?  
None 0  
Questionable 1  
Mild: Occasional oddities of dress or appearance 2  
Moderate: Appearance or apparel are clearly unusual and would attract 
attention 3  
Marked: Appearance or apparel are markedly odd 4  
Severe: Subject's appearance or apparel are very fantastic or bizarre 5  
 
 
Social and Sexual Behavior. The subject may do things that are 
considered inappropriate according to usual social norms. For example, he 
may masturbate in public, urinate or defecate in inappropriate receptacles, or 
exhibit his sex organs inappropriately. He may walk along the street muttering 
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to himself, or he may begin talking to people whom he has never met about 
his personal life (as when riding on a subway or standing in some public 
place). He may drop to his knees praying and shouting in the midst of a crowd 
of people, or he may suddenly sit in a yoga position while in the midst of a 
crowd. He may make inappropriate sexual overtures or remarks to strangers.  
Have you ever done anything that others might thing unusual or that has 
called attention to yourself?  
None 0  
Questionable 1  
Mild: Occasional instances of somewhat peculiar behavior 2  
Moderate: Frequent instances of odd behavior 3  
Marked: Very odd behavior 4  
Severe: Extremely odd behavior which may have a fantastic quality 5 
 
 
Aggressive and Agitated Behavior. The subject may behave in an 
aggressive, agitated manner, often quite unpredictably. He may start 
arguments inappropriately with friends or members of his family, or he may 
accost strangers on the street and begin haranguing them angrily. He may 
write letters of a threatening or angry nature to government officials or others 
with whom he has some quarrel. Occasionally, subjects may perform violent 
acts such as injuring or tormenting animals, or attempting to injure or kill 
human beings.  
Have you ever done anything to try to harm animals or people?  
Have you felt angry with anyone?  
How did you express your anger?  
None 0  
Questionable 1  
Mild: Occasional instances 2  
Moderate: For example, writing angry letters to strangers 3  
Marked: For example, threatening people, public harangues 4  
Severe: For example, mutilating animals, attacking people 5  
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Repetitive or Stereotyped Behavior. The subject may develop a set of 
repetitive actions or rituals that he must perform over and over. Frequently, 
he will attribute some symbolic significance to these actions and believe that 
they are either influencing others or preventing himself from being influenced. 
For example, he may eat jelly beans every night for dessert, assuming that 
different consequences will occur depending on the color of the jelly beans. 
He may have to eat foods in a particular order, wear particular clothes, or put 
them on in a certain order. He may have to write messages to himself or to 
others over and over; sometimes this will be in an unusual or occult language.  
Are there any things that you feel you have to do?  
None 0  
Questionable 1  
Mild: Occasional instances of ritualistic or stereotyped behavior 2  
Moderate: For example, eating or dressing rituals lacking symbolic 
significance 3  
Marked: For example, eating or dressing rituals with a symbolic significance 
4  
Severe: For example, keeping a diary in an incomprehensible language 5 
 
 
Global Rating of Severity of Bizarre Behavior. In making this rating, 
the interviewer should consider the type of behavior, the extent to which it 
deviates from social norms, the subject's awareness of the degree to which 
the behavior is deviant, and the extent to which it is obviously bizarre.  
None 0  
Questionable 1  
Mild: Occasional instances of unusual or apparently idiosyncratic behavior; 
subject usually has some insight 2  
Moderate: Behavior which is clearly deviant from social norms and seems 
somewhat bizarre; subject may have some insight 3  
Marked: Behavior which is markedly deviant from social norms and clearly 
bizarre; subject may have some insight 4  
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Severe: Behavior which is extremely bizarre or fantastic; may include a single 
extreme act, e.g., attempting murder; subject usually lacks insight. 5 
 
4) POSITIVE FORMAL THOUGHT DISORDER  
Positive formal thought disorder is fluent speech that tends to communicate 
poorly for a variety of reasons.  
The subject tends to skip from topic to topic without warning, to be distracted 
by events in the nearby environment, to join words together because they are 
semantically or phonologically alike even though they make no sense, or to 
ignore the question asked and ask another. This type of speech may be rapid, 
and it frequently seems quite disjointed. It has sometimes been referred to as 
"loose associations." Unlike alogia (negative formal thought disorder), a 
wealth of detail is provided, and the flow of speech tends to have an energetic, 
rather than an apathetic, quality to it.  
In order to evaluate thought disorder, the subject should be permitted to talk 
at length on some topic, particularly a topic unrelated to his psychopathology, 
for as long as five to ten minutes. The interviewer should observe closely the 
extent to which his sequencing of ideas is well connected. In addition, the 
interviewer should insist that he clarify or elaborate further if the ideas seem 
vague or incomprehensible. He should also pay close attention to how well 
the subject can reply to a variety of different types of questions, ranging from 
simple (Where were you born?) to more complicated (How do you think the 
present government is doing?)  
The anchor points for these ratings assume that the subject has been 
interviewed for a total of approximately forty-five minutes. If the interview is 
shorter, the ratings should be adjusted accordingly. 
 
 
Derailment (Loose Associations). A pattern of spontaneous speech in 
which the ideas slip off one track onto another which is clearly but obliquely 
related, or onto one which is completely unrelated. Things may be said in 
juxaposition which lack a meaningful relationship, or the subject may shift 
idiosyncratically from one frame of reference to another. At times there may 
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be a vague connection between the ideas, and at others none will be apparent. 
This pattern of speech is often characterized as sounding "disjointed." 
Perhaps the commonest manifestation of this disorder is a slow, steady 
slippage, with no single derailment being particularly severe, so that the 
speaker gets farther and farther off the track with each derailment without 
showing any awareness that his reply no longer has any connection with the 
question which was asked.  
This abnormality is often characterized by lack of cohesion between clauses 
and sentences and by unclear pronoun references.  
Example: Interviewer: "Did you enjoy college?" Subject: "Um-hum. Oh hey 
well, I oh, I really enjoyed some communities I tried it, and the, and the next 
day when I'd be going out, you know, um, I took control like uh, I put, um, 
bleach on my hair in, in California. My roommate was from Chicago, and she 
was going to the junior college. And we lived in the Y.M.C.A., so she wanted 
to put it, um, peroxide on my hair, and she did, and I got up and looked at the 
mirror and tears came to my eyes. Now do you understand it, I was fully aware 
of what was going on but why couldn't I, I . . . why, why the tears? I can't 
understand that, can you?"  
None 0  
Questionable 1  
Mild: Occasional instances of derailment, with only slight topic shifts 2  
Moderate: Several instances of derailment; subject is sometimes difficult to 
follow 3  
Marked: Frequent instances of derailment; subject is often difficult to follow 4  
Severe: Derailment so frequent and/or extreme that the subject's speech is 
almost incomprehensible 5 
 
 
Tangentiality. Replying to a question in an oblique, tangential or even 
irrelevant manner. The reply may be related to the question in some distant 
way. Or the reply may be unrelated and seem totally irrelevant. In the past 
tangentiality has sometimes been used as roughly equivalent to loose 
associations or derailment. The concept of tangentiality has been partially 
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redefined so that it refers only to answers to questions and not to transitions 
in spontaneous speech.  
Example: Interviewer: "What city are you from?" Subject: "That's a hard 
question to answer because my parents . . . I was born in Iowa, but I know that 
I'm white instead of black, so apparently I came from the North somewhere 
and I don't know where, you know, I really don't know whether I'm Irish or 
Scandinavian or I don't, I don't believe I'm Polish but I think I'm, I think I might 
be German or Welsh.  
None 0 
Questionable 1  
Mild: One or two oblique replies 2  
Moderate: Occasional oblique replies (three to four times) 3  
Marked: Frequent oblique replies (more than four times 4  
Severe: Tangentiality so severe that interviewing the subject is extremely 
difficult 5 
 
 
Incoherence (Word Salad, Schizophasia). A pattern of speech which is 
essentially incomprehensible at times. Incoherence is often accompanied by 
derailment. It differs from derailment in that in incoherence the abnormality 
occurs within the level of the sentence or clause, which contains words or 
phrases that are joined incoherently.  
The abnormality in derailment involves unclear or confusing connections 
between larger units, such as sentences or clauses.  
This type of language disorder is relatively rare. When it occurs, it tends to be 
severe or extreme, and mild forms are quite uncommon. It may sound quite 
similar to Wernicke's aphasia or jargon aphasia, and in these cases the 
disorder should only be called incoherence when history and laboratory data 
exclude the possibility of a past stroke, and formal testing for aphasia is 
negative.  
Exclusions: Mildly ungrammatical constructions or idiomatic usages 
characteristic of particular regional or ethnic backgrounds, lack of education, 
or low intelligence.  
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Example: Interviewer: "What do you think about current political issues like 
the energy crisis?" Subject: "They're destroying too many cattle and oil just 
to make soap. If we need soap when you can jump into a pool of water, and 
then when you go to buy your gasoline, my folks always thought they should, 
get pop but the best thing to get, is motor oil, and, money. May, may as well 
go there and, trade in some, pop caps and, uh, tires, and tractors to group, car 
garages, so they can pull cars away from wrecks, is what I believed in."  
None 0  
Questionable 1  
Mild: Occasional instances of incoherence 2  
Moderate: Frequent bursts of incoherence 3  
Marked: At least half of the subject's speech is incomprehensible 4  
Severe: Almost all of the subject's speech is incomprehensible 5 
 
 
Illogicality. A pattern of speech in which conclusions are reached which do 
not follow logically. This may take the form of non-sequiturs (= it does not 
follow), in which the subject makes a logical inference between two clauses 
which is unwarranted or illogical.  
It may take the form of faulty inductive inferences. It may also take the form 
of reaching conclusions based on faulty premises without any actual 
delusional thinking.  
Exclusions: Illogicality may either lead to or result from delusional beliefs. 
When illogical thinking occurs within the context of a delusional system, it 
should be subsumed under the concept of delusions and not considered a 
separate phenomenon representing a different type of thinking disorder. 
Illogical thinking which is clearly due to cultural or religious values or to 
intellectual deficit should also be excluded.  
Example: "Parents are the people that raise you. Anything that raises you can 
be a parent. Parents can be anything -- material, vegetable, or mineral -- that 
has taught you something. Parents would be the world of things that are alive, 
that are there. Rocks -- a person can look at a rock and learn something from 
it, so that would be a parent."  
None 0  
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Questionable 1  
Mild: Occasional instances of illogicality 2  
Moderate: Frequent instances of illogicality (three or four times) 3  
Marked: Much of the subject's speech is illogical (more than four times) 4  
Severe: Most of the subject's speech is illogical 5  
 
 
Circumstantiality. A pattern of speech which is very indirect and delayed 
in reaching its goal idea. In the process of explaining something, the speaker 
brings in many tedious details and sometimes makes parenthetical remarks. 
Circumstantial replies or statements may last for many minutes if the speaker 
is not interrupted and urged to get to the point. Interviewers will often 
recognize circumstantiality on the basis of needing to interrupt the speaker in 
order to complete the process of history-taking within an allotted time.  
When not called circumstantial, these people are often referred to as "long-
winded."  
Exclusions: Although it may coexist with instances of poverty of content of 
speech or loss of goal, it differs from poverty of content of speech in 
containing excessive amplifying or illustrative detail and from loss of goal in 
that the goal is eventually reached if the person is allowed to talk long enough. 
It differs from derailment in that the details presented are closely related to 
some particular goal or idea and that the particular goal or idea must be, by 
definition, eventually reached.  
None 0  
Questionable 1  
Mild: Occasional instances of circumstantiality 2  
Moderate: Frequent instances of circumstantiality 3  
Marked: At least half of subject's speech is circumstantial 4  
Severe: Most of the subject's speech is circumstantial 5 
 
Pressure of Speech. An increase in the amount of spontaneous speech as 
compared to what is considered ordinary or socially customary. The subject 
talks rapidly and is difficult to interrupt. Some sentences may be left 
uncompleted because of eagerness to get on to a new idea. Simple questions 
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which could be answered in only a few words or sentences are answered at 
great length so that the answer takes minutes rather than seconds and indeed 
may not stop at all if the speaker is not interrupted.  
Even when interrupted, the speaker often continues to talk. Speech tends to 
be loud and emphatic. Sometimes speakers with severe pressure will talk 
without any social stimulation and talk even though no one is listening. When 
subjects are receiving phenothiazines or lithium, their speech is often slowed 
down by medication, and then it can be judged only on the basis of amount, 
volume, and social appropriateness. If a quantitative measure is applied to the 
rate of speech, then a rate greater than 150 words per minute is usually 
considered rapid or pressured. This disorder may be accompanied by 
derailment, tangentiality, or incoherence, but it is distinct from them.  
None 0  
Questionable 1  
Mild: Slight pressure of speech; some slight increase in amount, speed, or 
loudness of speech 2  
Moderate: Usually takes several minutes to answer simple questions, may talk 
when no one is listening, and/or speaks loudly and rapidly 3  
Marked: Frequently talks as much as three minutes to answer simple 
questions; sometimes begins talking without social stimulation; difficult to 
interrupt 4  
Severe: Subject talks almost continually, cannot be interrupted at all, and/or 
may shout to drown out the speech of others 5  
 
 
Distractible Speech. During the course of a discussion or interview, the 
subject stops talking in the middle of a sentence or idea and changes the 
subject in response to a nearby stimulus, such as an object on a desk, the 
interviewer's clothing or appearance, etc.  
 
Example: "Then I left San Francisco and moved to . . . where did you get that 
tie? It looks like it's left over from the 50's. I like the warm weather in San 
Diego. Is that a conch shell on your desk? Have you ever gone scuba diving?  
None 0  
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Questionable 1  
Mild: Is distracted once during an interview 2  
Moderate: Is distracted from two to four times during an interview 3  
Marked: Is distracted from five to ten times during an interview 4  
Severe: Is distracted more than ten times during an interview 5 
 
 
Clanging. A pattern of speech in which sounds rather than meaningful 
relationships appear to govern word choice, so that the intelligibility of the 
speech is impaired and redundant words are introduced. In addition to 
rhyming relationships, this pattern of speech may also include punning 
associations, so that a word similar in sound brings in a new thought.  
 
Example: I'm not trying to make a noise. I'm trying to make sense. If you can 
make sense out of nonsense, well, have fun. I'm trying to make sense out of 
sense. I'm not making sense (cents) anymore. I have to make dollars."  
None 0  
Questionable 1  
Mild: Occurs once during an interview 2  
Moderate: Occurs from two to four times during an interview 3  
Marked: Occurs five to ten times during an interview 4  
Severe: Occurs more than ten times, or so frequently that the interview is 
incomprehensible.  
 
 
Global Rating of Positive Formal Thought Disorder. In making this 
rating, the interviewer should consider the type of abnormality, the degree to 
which it affects the subject's ability to communicate, the frequency with which 
abnormal speech occurs, and its degree of severity.  
None 0  
Questionable 1  
Mild: Occasional instances of disorder; subject's speech is understandable 2  
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Moderate: Frequent instances of disorder; subject is sometimes hard to 
understand 3  
Marked: Subject is often difficult to understand 4  
Severe: Subject is incomprehensible 5 
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APPENDIX 14 
Modified Cigarette Evaluation Questionnaire (mCEQ) adapted for e-cigarette 
users  
 
Instructions: Please read each item below and mark the number that best 
represents how using your e-cigarette or vaping made you feel.  
 
1- not at all, 2-very little, 3-a little, 4-moderately, 5-a lot, 6-quite a lot, 7 extremely  
 
1. Was using your e-cigarette satisfying? 1 2 3 4 5 6 7  
2. Did the e-cigarette taste good? 1 2 3 4 5 6 7  
3. Did you enjoy the sensations in your throat and chest?  1 2 3 4 5 6 7  
4. Did using your e-cigarette calm you down? 1 2 3 4 5 6 7  
5. Did using your e-cigarette make you feel more awake? 1 2 3 4 5 6 7  
6. Did using your e-cigarette make you feel less irritable? 1 2 3 4 5 6 7  
7. Did using your e-cigarette help you to concentrate? 1 2 3 4 5 6 7  
8. Did using your e-cigarette reduce your hunger for food? 1 2 3 4 5 6 7  
9. Did using your e-cigarette make you dizzy? 1 2 3 4 5 6 7  
10. Did using your e-cigarette make you nauseous? 1 2 3 4 5 6 7  
11. Did using your e-cigarette immediately reduce your craving for nicotine? 1 2 3 4 
5 6 7  
12. Did you enjoy using your e-cigarette? 1 2 3 4 5 6 7  
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APPENDIX 15 
Symptoms and adverse events (AE) form:   
Ask and checking the box for the presence of AEs at each study visit.   Report the 
severity of AEs by using the AE-VAS Scale. Then, report the grade of the severity 
below the listed AE 
 
 BL Visit 
1 
Visit 
2 
Visit 
3 
1 Nausea  ⁪ ⁪ ⁪ 
2 Vomiting  ⁪ ⁪ ⁪ 
3 Dry mouth  ⁪ ⁪ ⁪ 
4 Constipation  ⁪ ⁪ ⁪ 
5 Diarrea  ⁪ ⁪ ⁪ 
6 Increase in appetite  ⁪ ⁪ ⁪ 
7 Anxiety  ⁪ ⁪ ⁪ 
8 Depression  ⁪ ⁪ ⁪ 
9 Dyspepsia  ⁪ ⁪ ⁪ 
10 Palpitations  ⁪ ⁪ ⁪ 
11 Insomnia  ⁪ ⁪ ⁪ 
12 Irritability  ⁪ ⁪ ⁪ 
13 Abnormal dreams  ⁪ ⁪ ⁪ 
14 Headache  ⁪ ⁪ ⁪ 
15 Dizziness  ⁪ ⁪ ⁪ 
16 Fatigue  ⁪ ⁪ ⁪ 
17 Vertigo  ⁪ ⁪ ⁪ 
18 Sweating  ⁪ ⁪ ⁪ 
19 Skin rashes  ⁪ ⁪ ⁪ 
20 Influenza-like illness  ⁪ ⁪ ⁪ 
21 Respiratory tract infection  ⁪ ⁪ ⁪ 
22. Cough  ⁪ ⁪ ⁪ 
23. Shortness of breath     
24. Throat irritation  ⁪ ⁪ ⁪ 
25. Mouth rritation     
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26. Other     
27. …………………………………………………..     
28. …………………………………………………..     
29. …………………………………………………..     
30. …………………………………………………..     
 
Adverse Event-Visual Analog Scale (AE-VAS) 
 
 
 
KEY 
Mild (Grade 1): Mildly symptomatic, no medical intervention needed 
Moderate (Grade 2): Moderately symptomatic, evaluation by PI to determine if 
medical intervention is necesary 
Severe (Grade 3): Medically signficant but not life threatening cause for an 
immediate referral for a medical and/or psychiatric evaluation 
Significant (Grade 4): Potentially life threatening, urgent intervention needed 
Death (Grade 5): Results in death; Is life-threatening; Results in inpatient 
hospitalization or prolongation of existing hospitalization; Results in a persistent or 
significant disability/incapacity. 
 
Mild 
(Grade 1) 
 
Moderate 
(Grade 2) 
 
Severe 
 (Grade 3) 
 
 
Significant 
 (Grade 4) 
 
Serious 
(Grade 5) 
 
 
    
